(AZA)indole-,benzothiophene-, and benzofuran-3-sulfonamides

LAP668AUndetermined Publication Date: 2026-01-23UCB PHARMA GMBH
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
LAP668
Authority / Receiving Office
LA · LA
Patent Type
Applications
Current Assignee / Owner
Filing Date
2017-12-27
Publication Date
2026-01-23

AI Technical Summary

Technical Problem

Current treatments for myelination disorders, such as multiple sclerosis, lack effective and safe oral medications that can reverse demyelination or promote remyelination, with existing GPR17 modulators having low affinity and stability issues, and existing drugs primarily addressing inflammation rather than demyelination.

Method used

Development of a class of chemical compounds that act as negative GPR17 modulators, specifically designed to decrease GPR17 receptor activity, with a general structure that includes various substituents allowing for potent and selective inhibition, suitable for oral administration.

Benefits of technology

These compounds effectively stimulate myelin formation, enhance myelin sheath length, and improve myelin protein expression, demonstrating potential for treating myelination disorders by promoting remyelination and reducing demyelination.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
Patent Text Reader

Abstract

Disclosed are sulfonamide compounds with GPR17 modulating properties, which are useful for treating or preventing a variety of CNS and other diseases, in particular for preventing and treating myelinating diseases or disorders.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] (AZA)INDOLE-, BENZOTHIOPHENE-, AND BENZOFURAN-3-SULFONAMIDES

[0002] Background

[0003] G-protein coupled receptors (GPCRs) constitute the largest family of membrane receptors in the cell. They transduce extracellular signals to intracellular effector systems and are involved in a large variety of physiological phenomena, therefore representing the most common targets of pharmaceutical drugs although only a small percentage of GPCRs are targeted by current therapies.

[0004] GPCRs respond to a wide range of ligands. Due to the progress in human genome sequencing, for about 25% out of the more than 400 GPCRs (not including the olfactory

[0005] GPCRs) that have been identified, a defined physiologically relevant ligand is still lacking.

[0006] These receptors are known as "orphan GPCRs". "Deorphanization" and identification of their in vivo roles is expected to clarify novel regulatory mechanisms and, therefore, to disclose novel drug targets. Whether GPR17 is such an orphan receptor is still a matter of debate. Phylogenetically, GPR17 is closely related to the nucleotide P2Y receptors and the cysteinylleukotriene (CysLTI , CysLT2) receptors, with an amino acid sequence identity of between about 30 and about 35%, respectively.

[0007] Multiple-tissue Northern blot and RT-PCR analyses indicate a predominant expression of GPR17 in the central nervous system (CNS) (Ciana et al., 2006, EMBO J 25(19): 4615; Blasius et al., 1998, J Neurochem 70(4): 1357) and additionally in heart and kidney, i.e. organs typically undergoing ischemic damage. Two human GPR17 isoforms have been identified differing only by the length of their N-terminus. The short GPR17 isoform encodes a 339 amino acid-residue protein with typical rhodopsin type-seven

[0008] transmembrane motifs. The long isoform encodes a receptor with a 28 amino acid longer N-terminus (Blasius et al., 1998). GPR17 is highly conserved among vertebrate species (~ 90% identity of amino acid sequence to both mouse and rat orthologs), which may constitute an advantageous feature for development of small molecule ligands and animal models in a drug discovery context.

[0009] In the original deorphaning report, GPR17 was identified as a dual receptor for uracil nucleotides and cysteinyl-leukotrienes (cysLTs) LTC4 and LTD4, respectively based on35SGTPvS binding and cAMP inhibition assays as well as single cell calcium imaging (Ciana et al., 2006, ibid). Evidence for GPR17 functionality was provided in different cellular backgrounds such as 1321 N1 , COS7, CHO, and HEK293 cells (Ciana et al., 2006, ibid). Subsequently, an independent study confirmed activation of GPR17 by uracil nucleotides but failed to recapitulate activation by CysLTs (Benned-Jensen and Rosenkilde, 2010, Br J Pharmacol , 159(5): 1092). Yet recent independent reports (Maekawa et al., 2009, PNAS 106(28), 1 1685; Qi et al., 2013, J Pharmacol Ther 347,1 , 38; Hennen et al.,2013, Sci Signal 6, 298) suggested lack of GPR17 responsiveness to both uracil nucleotides and CysLTs across different cellular backgrounds stably expressing GPR17 (1321 N1 , CHO, HEK293 cells). A novel regulatory role for GPR17 has also been proposed: GPR17 - upon coexpression with the CysLTI receptor- rendered the CysLTI receptor unresponsive to its endogenous lipid mediators LTC4 and LTD4. Clearly, additional in vitro investigations are required to probe GPR17 pharmacology and function in more depth.

[0010] Drugs modulating the GPR17 activity may have neuroprotective, anti-inflammatory and anti-ischemic effects and may thus be useful for the treatment of cerebral, cardiac and renal ischemia, and stroke (WO 2006 / 045476), and / or for improving the recovery from these events (Bonfanti et al, Cell Death and Disease, 2017, 8, e2871 ).

[0011] GPR17 modulators are also thought to be involved in food uptake, insulin and leptin responses and are thus claimed to have a role in obesity treatment (WO 201 1 / 1 13032).

[0012] Moreover, there is strong evidence that GPR17 is involved in myelination processes and that negative GPR17 modulators (antagonists or inverse agonists) can be valuable drugs for the treatment or alleviation of myelination disorders such as multiple sclerosis or spinal cord injury (Chen et al, Nature neuroscience 2009, 12(1 1 ):1398-406; Ceruti et al; Brain: a journal of neurology 2009 132(Pt 8):2206-18; Hennen et al, Sci Signal, 6, 2013, 298;

[0013] Simon et al J Biol Chem 291 , 2016, 705; Fumagalli et al, Neuropharmacology 104, 2016, 82). Activation of GPR17 has been shown to inhibit oligodendrocyte precursor cells (OPCs) maturation thus preventing effective myelination (Simon et al, supra). The identification of potent and selective GPR17 antagonists or inverse agonists would thus be of significant relevance in the treatment of myelination disorders.

[0014] Several serious myelination diseases are known to be caused by disturbances in myelination, either by a loss of myelin (usually called demyelination), and / or by a failure of the body to properly form myelin (sometimes called dysmyelination). The myelination diseases may be idiopathic or secondary to certain trigger events like e.g. traumatic brain injury or viral infection. Myelination diseases may primarily affect the central nervous system (CNS) but may also concern the peripheral nervous system. Myelination diseases include, inter alia, multiple sclerosis, neuromyelitis optica (also known as Devic's disease), leucodystrophies, Guillain-Barre syndrome, and many other diseases as described in more detail further below (see also e.g. Love, J Clin Pathol, 59, 2006, 1 151 , Fumagalli et al, supra). Neurodegenerative diseases such as Alzheimer's Disease, Huntington's Disease, Parkinson's Disease, amyotropic lateral sclerosis (ALS) and multiple system atrophy (MSA) have been also strongly associated with decreased myelination recently (see e.g. Ettle et al, Mol Neurobiol 53, 2016, 3046; Jellinger and Welling, Movement Disorders, 31 , 2016; 1767; Kang et al, Nature Neurosci 6, 2013, 571 ; Bartzokis,

[0015] Neurochem Res (2007) 32:1655).

[0016] Multiple Sclerosis (MS) is a chronic progressive disorder. It is an inflammatory

[0017] autoimmune disease causing oligodendrocyte damage, demyelination and ultimately axonal loss, thus leading to a broad spectrum of signs and symptoms of a severe neurological disease, like e.g. fatigue, dizziness, mobility and walking issues, speech and swallowing difficulties, pain and others. MS takes several forms, with new symptoms either occurring in isolated attacks (relapsing forms) or building up over time (progressive forms). While certain symptoms may disappear completely between isolated attacks, severe neurological problems often remain, especially as the disease advances to a more progressive form. According to the Multiple Sclerosis Association of America,

[0018] approximately 400,000 individuals have been diagnosed with MS in the United States and as many as 2.5 million worldwide, with an estimated 10,000 new cases diagnosed in the United States annually. Multiple sclerosis is two to three times more common in women than in men.

[0019] There is no known causal treatment or cure for multiple sclerosis, or many other myelination diseases. Treatments are usually symptomatic and try to improve function after an attack and prevent new attacks, by addressing the inflammatory component of the disease. Such immunomodulatory drugs are usually only modestly effective, in particular if the disease is progressed, but can have side effects and be poorly tolerated. Moreover, most of the available drugs, like β-interferons, glatiramer acetate, or therapeutic antibodies are only available in injectable form and / or only address the inflammatory component of the disease but not demyelination directly Others drugs, like corticosteroids, show rather unspecific anti-inflammatory and immunosupressive effects thus potentially leading to chronic side effects, such as manifested in Cushing's syndrome, for example.

[0020] A strong need therefore exists for a safe and effective drug for the treatment of myelination diseases, like MS, preferably for a drug that is suitable for oral administration. Ideally such a drug would reverse the demyelination process by decreasing demyelination and / or by promoting remyelination of the impacted neurons. A chemical compound which effectively decreases the GPR17 receptor activity could fulfil these requirements.

[0021] However, only few chemical compounds are known that effectively modulate GPR17 activity. WO 2005 / 103291 suggests the endogenous molecules 5 amino levulinic acid (5-ALA) and porphobilinogen (PBG) as activating ligands for GPR17, discloses analgesic effects of a GPR17 agonist and proposes the use of GPR17 agonists for treating neuropathic pain and as tools in GPR17 screening assays. However, the reported affinity of 5-ALA and PBG is quite low and the amounts needed in the assays are significant, namely in the three digit micromolar range for 5-ALA or even in the mM range for PBG, which make both compounds not well suited for use in routine screening assays or even for therapy. Moreover, PBG is a chemically unstable, reactive compound which rapidly decomposes after exposure to air and light, making it impractical to handle on a routine basis. Hence, these compounds do not offer a promising starting point to develop therapeutically effective negative GPR17 modulators.

[0022] Montelukast and pranlukast were originally developed as leukotriene receptor antagonists and were recently found to act on the GPR17 receptor as well (Ciana et al, EMBO J. 2006, 25, 4615-4627). However, subsequent results in a functional assay were contradictory for montekulast (Hennen et al, 2013, ibid), while pharmacological inhibition of GPR17 with pranlukast promotes differentiation of primary mouse (Hennen et al., 2013, ibid) and rat (Ou et al., J. Neurosci. 36, 2016, 10560-10573) oligodendrocytes. Pranlukast even phenocopies the effect of GPR17 depression in a lysolecithin model of focal demyelination because both GPR17 knock-out and pranlukast-treated wild-type mice show an earlier onset of remyelination (Ou, ibid). These results strongly support the hypothesis that GPR17 inhibitors offer potential for the treatment of human demyelinating diseases.

[0023] However, the affinity of montekulast and prankulast to GPR17 is only in the high micromolar range (Kose et al, ACS Med. Chem. Lett. 2014, 5, 326-330). Given the high protein binding of both compounds and their poor brain penetration, it is unlikely that they could reach high enough free concentrations to bind to GPR17 receptors in amounts suitable for human therapy. In addition, results obtained in vivo with these compounds are difficult to interpret due to their confounding high affinity for CYSLT1 receptors.

[0024] US 8,623,593 discloses certain indole-2-carboxylic acids as GPR17 agonists and their use in screening assays. However, these derivatives are all potent agonists and are not suited to down-regulate GPR17 activity as needed in the treatment of myelination disorders such as MS. Moreover, this class of GPR17 activators does not sufficiently pass the blood-brain barrier due to their easily ionizable carboxyl groups, and were thus no suitable lead compounds to develop negative GPR17 modulators. See also Baqi et al, Med. Chem. Commun., 2014, 5, 86 and Kose et al, 2014, ibid.

[0025] WO 2013 / 167177 suggests certain phenyltriazole and benzodiazepine compounds as GPR17 antagonists. However, the disclosed compounds were selected solely based on in- silico screening results and no biological data at all was provided. The inventors of the present application were unable to confirm the GPR17 antagonist modulating activity of any of purported ligands proposed by the authors of this former patent application so far.

[0026] A need therefore exists to identify potent modulators, preferably negative modulators, of GPR17 which are capable of effectively decreasing the GPR17 activity, preferably upon oral administration.

[0027] Mehra et al (Eur J Med Chem, 92, 2015, 78-90) disclose a variety of compounds with EColi acetyltransferase inhibiting activity, including four phenyl-substituted pyrrolo[2,3- b]pyridine-3-sulfonamides (compounds 20 [N-(3,4-difluorophenyl 1 H-pyrrolo[2,3-b] pyridine-3-sulfonamide], 32 [N-(3,5-dimethoxyphenyl 1 H-pyrrolo[2,3-b]pyridine-3- sulfonamide],37 [N-(2,5-difluorophenyl 1 H-pyrrolo[2,3-b]pyridine-3-sulfonamide] and 43 [N-(3,5-difluorophenyl 1 H-pyrrolo[2,3-b]pyridine-3-sulfonamide] of Table S7). These four azaindole compounds distinguish structurally from the presently disclosed compounds in that the azaindole core in Mehra is not further substituted. Moreover, Mehra et al do not suggest any GPR17 inhibiting property of these compounds and / or any utility of their compounds for treating a myelination disorder. Instead, Mehra et al disclose compounds as potential antibiotics.

[0028] Figures:

[0029] Figure 1 shows the expression of melin basic protein (MBP) as a marker of

[0030] oligodendrocyte maturation in a Western Blot assay. After administration to

[0031] oligodendrocyte progenitor cells (OPCs), the compounds of the present invention, in particular compounds 1-1 12, 1-185, 1-108 and 1-1 16, stimulated the MBP expression compared to vehicle alone.

[0032] Figure 2 shows the effect of a compound of the present invention (1-1 16) on the length of myelin sheats expressed by OPCs. After administration to OPCs, compound 1-1 16 induced the formation of longer myelin sheats compared to OPS after addition of a vehicle alone.

[0033] Figure 3 shows the plasma and brain exposure of a compound of the present invention, I- 1 , after intraperitoneal administration in mice.

[0034] Figure 4 illustrates the distribution of PLP, a myelin marker, in two relevant regions of the mice brain, Region 1 (Figure 4.1 ) and Region 2 (Figure 4.2), after immunhistochemical staining with anti PLP-antibodies. This setup was used to measure the effects of compounds of the present invention in the cuprizone model (results shown in Figure 5). Figure 5 shows the effect of a compound of the present invention (1-228) on the expression of PLP in mice during recovery from cuprizone treatment, as measured by immunhistochemical staining. Following oral administration of 1-228 at doses of 6mg / kg and 20 mg / kg to mice, the myelin-associated protein PLP reappeared significantly quicker in certain mice brain regions than after administration of vehicle only.

[0035] Description of the Invention

[0036] The present invention relates to a class of chemical compounds which are negative GPR17 modulators.

[0037] These compounds have a general structure according to Formula I:

[0038] wherein

[0039] X1 is N or C(R7),

[0040] X2 is NH, S or O,

[0041] X3 is N or C(R12),

[0042] R4 is selected from hydrogen, methoxy and halogen including fluoro, and is preferably hydrogen,

[0043] R5 is selected from hydrogen, halogen, cyano, Ci-s alkyl, C2-3 alkenyl, C2-3 alkynyl, Ci-s alkoxy, C1-3 alkylcarbonyl, Ci-3 alkoxycarbonyl, C1-3 alkylsulfinyl, and Ci-3alkylsulfonyl, wherein each alkyl or alkoxy may optionally be substituted one or more times selected from halogen, C1-3 alkoxy, cyano, azido, hydroxyl, Ci-3alkylamino and di(Ci-3alkyl)amino, and C1-3 alkylaminocarbonyl (with preferred optional substitutions of said alkyl and alkoxy groups being halogen and Ci-s alkoxy), or R5 forms a ring together with R6 as described herein,

[0044] R6 is selected from hydrogen, hydroxy, halogen, cyano, azido, nitro, C1-6 alkyl, C2-6alkenyl, C2-6 alkynyl, C1-6 alkoxy, C3-7 cycloalkyi, C3-6 cycloalkenyl, C3-7 heterocycloalkyi, C3- 7 heterocycloalkenyl, phenyl, C5-10 heteroaryl, Cs-io heterocyclyl , -ORx, -SRx, -SORx, S02Rx, -pentafluorosulfanyl , NRyRzz, -NRyCORx,-NRyC02Rx, -NRxCONRyRz, - NRySORx,-NRyS02Rx, -CORx, -C02Rx,-CONRyRz, wherein each alkyl, alkenyl, alkynyl, alkoxy, cycloalkyi, heterocycloalkyi, cycloalkenyl, phenyl, heteroaryl or heterocyclyl group in R6 can be unsubstituted or substituted with one or more residue preferably selected from halogen, hydroxyl, oxo, cyano, azido, nitro, Ci-s alkyl, halo(Ci-6)alkyl, Ci-6 alkoxy(Ci- 3)alkyl , C3-7 cycloalkyi, C3-7 heterocycloalkyi, phenyl, Cs-io (preferably C5-6) heteroaryl, ORx, -SRx, -SORx, S02Rx, -pentafluorosulfanyl, NRyRz, -NRyCORx,-NRyC02Rx, - CORx, -C02Rx,-CONRyRz,

[0045] wherein Rx, Ry, Rz and Rzz are independently selected from hydrogen, Ci-s alkyl, C3-7 cycloalkyi, C3-6 cycloalkenyl, C3-7 cycloalkyl(Ci-6)alkyl, phenyl, phenyl(Ci-6)alkyl, C3-7 heterocycloalkyi, C3-7 heterocycloalkyl(Ci-6)alkyl, C5-6 heteroaryl or heteroaryl(Ci-6)alkyl, any of which groups can be unsubstituted or substituted with one or more substituents, selected from those described above, and wherein Rzz is preferably different from hydrogen,

[0046] or Ry and Rz, or Ry and Rzz together with the amino atom to which they are both attached may form an aromatic or non aromatic, unsubstituted or substituted C5-6 heterocycle, wherein any substituent is selected from the substituents described above, or R6 forms together with R5 or R7 and the carbon atoms to which they are attached a 5 or 6 membered aromatic or non-aromatic ring which may optionally contain one or more heteroatoms selected from S, O, and N, and wherein said ring can be unsubstituted or substituted with one or more substituents,

[0047] wherein preferably (i) R6 forms together with R7 and the carbon atoms to which R6 and R7 are attached, an unsubstituted or substituted phenyl, unsubstituted or substituted pyridyl, unsubstituted or substituted cyclopentyl or unsubstituted or substituted cyclohexyl, wherein each substitution, if present, of a ring formed by R6 and R7, is preferably selected from halogen, hydroxy, cyano, Ci-s alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-7 cycloalkyi, C3-7 cycloalkyl(Ci-3)alkyl, C3-7 heterocycloalkyl(Ci-3)alkyl and Ci-s alkoxy, wherein each alkyl or alkoxy can be unsubstituted or substituted with one or more substituents selected from halogen, hydroxy, and unsubstituted or fluorinated C1-3 alkoxy, C3-7 cycloalkyi, and C3-7 heterocycloalkyi, wherein any substitution of phenyl, pyridyl, cyclopentyl and cyclohexyl are preferably selected from fluoro, chloro, cyano, hydroxy, methyl, fluoromethyl, methoxy and fluoromethoxy,

[0048] or (ii) R6 forms together with R5 and the carbon atoms to which R6 and R5 are attached, a 1 ,3-dioxolane which may be unsubstituted or substituted with one or two substituents selected from fluoro and methyl, or

[0049] R7, if present, is selected from hydrogen, halogen, cyano, azido, nitro, amino, Ci-6 alkyl, Ci-6 alkoxy, C2-6 alkynyl, C2-6 alkenyl, Ci-6 alkylcarbonyl, Ci-6 alkoxycarbonyl, C1-6

[0050] alkylsulfonyl, C1-6 alkylsulfinyl, C1-6 alkylthio, Ci-3 alkylcarbonylamino, C1-6

[0051] alkylaminocarbonyl, di(Ci-3)alkylaminocarbonyl, C3-7 cycloalkyl, C3-7 cycloalkoxy, C3-7 heterocycloalkyl, C3-6 heterocycloalkoxy, phenyl, phenyloxy, phenyl(Ci-2)alkyl, phenyl(Ci- 2)alkoxy, phenylsulfonyl, phenylsulfinyl, C5-6 heteroaryl, C5-6 heteroaryloxy, C5-6 heteroaryl(Ci-3)alkyl, C5-6 heteroaryl(Ci-3) alkoxy, C3-6cycloalkyl(Ci-2)alkyl, C3-6

[0052] cycloalkyl(Ci-3)alkoxy, C3-6 heterocycloalkyl(Ci-2)alkyl, C3-6 heterocycloalkyl(Ci-2)alkoxy, and, wherein each group in R7, in particular each alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, heterocycloalkyl, phenyl or heteroaryl group, can be unsubstituted or substituted with one or more substituents selected from halogen, hydroxy, cyano, unsubstituted or halogenated Ci-s alkyl and unsubstituted or halogenated Ci-s alkoxy,

[0053] R8 is selected from hydrogen, Ci-s alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, Ci-3alkylsulfinyl, Ci-3alkylsulfonyl, C1.3alkylt.hio, cyano, and halogen, wherein each alkyl or alkoxy can be unsubstituted or substituted with one or more substituents selected from halogen and unsubstituted or fluorinated C1-3 alkoxy, or forms a ring system together with R9, as described herein,

[0054] R9 is selected from hydrogen, halogen, cyano, azido, C1-6 alkyl, C1-6 alkoxy, C2-6 alkenyl, C2-6 alkynyl and halogen, wherein each alkyl or alkoxy can be unsubstituted or substituted with one or more substituents selected from halogen and unsubstituted or fluorinated C1-3 alkoxy,

[0055] or R9 forms together with R8 or R10 and the C atoms to which they are attached a 5 or 6 membered ring which can optionally be further substituted and which may contain one or more ring forming heteroatoms selected from N, S, O, and Se;

[0056] wherein the ring formed by R9 together with R8 or R10 and the ring to which they are attached form a bicyclic ring system preferably selected from (a) 2, 1 ,3-benzothiadiazole, (b) 2, 1 ,3-benzoselenadiazole, (c) 2,1 ,3-benzoxadiazole, (d) 1 ,3-benzothiazole, (e)1 ,3- benzoxazole which may be unsubstituted or may be partially hydrogenated and unsubstituted or substituted with oxo, (f) 1 ,3-benzodioxole which may be unsubstituted or substituted with one or two substituents selected from fluoro and methyl, (g) benzothiophene, which may be unsubstituted or may be partially hydrogenated and unsubstituted or substituted with one or two substituents selected from oxo, methyl or fluoro, wherein the benzothiophene is preferably partially hydrogenated to 1 ,3-dihydro-2- benzothiophen which is preferably substituted with two oxos to form 1 , 1 -dioxido-2,3- dihydro-1 -benzothiophen, which may be optionally further substituted, (h) benzofuran, which may be unsubstituted or may be partially hydrogenated and unsubstituted or substituted with one or two groups selected from oxo, fluoro and methyl, preferably with one oxo group, wherein the benzofuran is preferably partially hydrogenated to 1 ,3- dihydro-2-benzofuran which is preferably substituted with oxo to form 3-oxo-1 ,3 dihydrobenzofuran, which may be optionally further substituted, e.g. with a methyl group, and (i) 2,3-dihydro-1 H-isoindol, which is preferably substituted with oxo to give 3-oxo-2,3- dihydro-1 H-isoindol, which may be optionally further substituted.

[0057] R10 is selected from hydrogen, halogen, Ci-s alkyl, Ci-6alkoxy, C2-6 alkenyl, C2-6 alkynyl, cyano, cyano(Ci-6)alkyl, cyano(Ci-6)alkyloxy,Ci-6 alkylcarbonyl, Ci-6 alkoxycarbonyl, Ci-s alkylsulfonyl, C1-6 alkylsulfinyl, C1-6 alkylthio, C3-6cycloalkyl, C3-6 cycloalkyloxy, C3-6hetero cycloalkyl, C3-6heterocycloalkyloxy, amino, azido, pentafluorosulfanyl, nitro, C1-5

[0058] alkylcarbonylamino, d-s alkylaminocarbonyl, di(Ci-3)alkylaminocarbonyl, C1-3 alkylsulfinyl and C1-3 alkylsulfonyl, wherein each alkyl, alkenyl, alkynyl or alkoxy can be unsubstituted or substituted with one or more substituents selected from halogen,Ci-6 alkoxy, halo(Ci- 6)alkoxyhydroxy(Ci-6)alkoxy, optionally halogenated C1-6 alkylthio, optionally halogenated C1-3 alkylcarbonyl, optionally halogenated Ci-3 alkyloxycarbonyl, optionally halogenated Ci- 3 alkylsulfonyl, optionally halogenated C1-3 alkylsulfinyl, C1-3 alkylcarbonylamino, C1-3 alkylaminocarbonyl, di(Ci-3)alkylaminocarbonyl, hydroxy, cyano, nitro, oxo, C3-6cycloalkyl, C3-6cycloalkoxy, C3-6heterocycloalkyl, C3-6heterocycloalkoxy, phenyl, phenyloxy, and C5- 6heteroaryl, wherein any C3-6cycloalkyl, C3-6cycloalkoxy, C3-6heterocycloalkyl, C3-

[0059] 6heterocycloalkoxy, phenyl and heteroaryl may be unsubstituted or substituted with one or more residues selected from halogen, hydroxy, hydroxymethyl, oxo, cyano, nitro, amino, optionally halogenated or hydroxylated Ci-3alkyl, optionally hydroxylated or halogenated Ci-3alkoxy, optionally halogenated Ci-3alkylcarbonyl and optionally halogenated Ci- 3alkoxycarbonyl, any wherein the amino group may be substituted with one or two groups selected from Ci-3alkyl, Ci-3alkylsulfonyl, Ci-3alkylcarbonyl, and Ci-3alkoxycarbonyl , or R10 forms a ring system together with R9, as described herein,

[0060] R1 1 is selected from hydrogen, halogen, cyano, azido, Ci-s alkyl, Ci-s alkoxy, Ci-s

[0061] alkylcarbonyl, C1-6 alkoxycarbonyl, Ci-s alkylsulfonyl, and C1-6 alkylsulfinyl, C2-6 alkenyl, and C2-6 alkynyl, wherein each alkyl or alkoxy can be unsubstituted or substituted with one or more substituents selected from halogen and halogenated preferably fluorinated or unsubstituted C1-3 alkoxy,

[0062] R12, if present, is selected from hydrogen, Ci-s alkyl, Ci-s alkoxy and halogen, wherein each alkyl or alkoxy can be unsubstituted or substituted with one or more substituents selected from halogen and halogenated preferably fluorinated or unsubstituted C1-3 alkoxy, and pharmaceutically acceptable salts, solvates, isotopes and co-crystals thereof.

[0063] In one embodiment, in the compounds of formula I,

[0064] X1 is N or C(R7),

[0065] X2 is NH or O,

[0066] X3 is N or C(R12),

[0067] R4 is selected from hydrogen and fluoro, and is preferably hydrogen,

[0068] R5 is selected from hydrogen, halogen, cyano, Ci-s alkyl, C1-6 alkoxy, C1-3 alkylcarbonyl, Ci-3 alkoxycarbonyl, C1-3 alkylsulfinyl, and Ci-3alkylsulfonyl, wherein each alkyl or alkoxy may optionally be substituted one or more times selected from halogen, C1-3 alkoxy, C2-3 alkynyl, C2-3 alkenyl, cyano, azido, hydroxyl, and optionally C1-3 alkylated amino (with preferred optional substitutions of said alkyl and alkoxy groups being halogen and C1-6 alkoxy), or R5 forms a ring together with R6 as described herein,

[0069] R6 is selected from hydrogen, hydroxy, halogen, cyano, azido, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C3-7 cycloalkyl, C3-6 cycloalkenyl, C3-7 heterocycloalkyl, C3-7

[0070] heterocycloalkenyl, phenyl, C5-10 heteroaryl, Ce-io heterocyclyl , -ORx, -SRx, -SORx, S02Rx, -pentafluorosulfanyl , NRyRzz, -NRyCORx,-NRyC02Rx, -NRxCONRyRz, - - CORx, -C02Rx,-CONRyRz, wherein each alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, heterocycloalkyl, cycloalkenyl, phenyl, heteroaryl or heterocyclyl group in R6 can be unsubstituted or substituted with one or more substituents preferably selected from halogen, hydroxyl, oxo, cyano, azido, nitro, C1-6 alkyl, Ci-6 alkoxy(Ci-3)alkyl , C3-7 cycloalkyl, C3-7 heterocycloalkyl, phenyl, C5-10 (preferably C5-6) heteroaryl, ORx, -SRx, - SORx, S02Rx, -pentafluorosulfanyl, NRyRz, -NRyCORx,-NRyC02Rx, -CORx, -C02Rx,- CONRyRz,

[0071] wherein Rx, Ry, Rz and Rzz are independently selected from hydrogen, Ci-s alkyl, C3-7 cycloalkyl, C3-6 cycloalkenyl, C3-7 cycloalkyl(Ci-6)alkyl, phenyl, phenyl(Ci-6)alkyl, C3-7 heterocycloalkyl, C3-7 heterocycloalkyl(Ci-6)alkyl, C5-6 heteroaryl or heteroaryl(Ci-6)alkyl, any of which groups can be unsubstituted or substituted with one or more substituents, or Ry and Rz, or Ry and Rzz together with the amino atom to which they are both attached may form an aromatic or non aromatic, unsubstituted or substituted C5-6 heterocycle, wherein Rzz is preferably different from hydrogen,

[0072] or R6 forms together with R5 or R7 and the carbon atoms to which they are attached a 5 or 6 membered aromatic or non-aromatic ring which may optionally contain one or more heteroatoms selected from S, O, and N, and wherein said ring can be unsubstituted or substituted with one or more substituents,

[0073] wherein preferably (i) R6 forms together with R7 and the carbon atoms to which R6 and R7 are attached, an unsubstituted or substituted phenyl, unsubstituted or substituted pyridyl, unsubstituted or substituted cyclopentyl or unsubstituted or substituted cyclohexyl, wherein each substitution, if present, is selected from halogen, C1-3 alkyl, C3-7 cycloalkyl, C3-7 cycloalkyl(Ci-3) alkyl, C3-7 heterocycloalkyl(Ci-3)alkyl, C1-3 alkoxy, and Ci-3 alkoxy(Ci-3) alkyl, wherein each alkyl or alkoxy can be unsubstituted or substituted with one or more substituents selected from halogen and C1-3 alkoxy, or (ii) R6 forms together with R5 and the carbon atoms to which R6 and R5 are attached, a 1 ,3-dioxolane which may be unsubstituted or substituted with one or two substituents selected from fluoro and methyl, or

[0074] R7 is selected from H, halogen, cyano, C1-6 alkyl, C1-6 alkoxy, C2-6 alkynyl, C2-6 alkenyl, Ci-6alkylcarbonyl, Ci-6alkoxycarbonyl, Ci-6alkylsulfonyl, C1-6 alkylsulfinyl, C3-7cycloalkyl, C3-7 heterocycloalkyl, phenyl, C5-6 heteroaryl, wherein each alkyl, alkenyl, alkynyl or alkoxy group can be unsubstituted or substituted with one or more substituents selected from halogen, and C1-6 alkoxy,

[0075] R8 is selected from hydrogen, C1-6 alkyl, C1-6 alkoxy, and halogen, wherein each alkyl or alkoxy can be unsubstituted or substituted with one or more substituents selected from halogen and C1-3 alkoxy, or forms a ring system together with R9, as described herein,

[0076] R9 is selected from hydrogen, halogen, cyano, azido, C1-6 alkyl, C1-6 alkoxy, C2-6 alkenyl, C2-6 alkynyl and halogen, wherein each alkyl or alkoxy can be unsubstituted or substituted with one or more substituents selected from halogen and C1-3 alkoxy,

[0077] or R9 forms together with R8 or R10 and the C atoms to which they are attached a 5 or 6 membered ring which can optionally be further substituted and which may contain one or more ring forming heteroatoms selected from N, S, O, and Se;

[0078] wherein the ring formed by R9 together with R8 or R10 and the ring to which they are attached are preferably selected from a bicyclic ring system selected from (a) 2, 1 ,3- benzothiadiazole, (b) 2, 1 ,3-benzoselenadiazole, (c) 2,1 ,3-benzooxadiazole, (d) 1 ,3- benzothiazole, (e)1 ,3-benzoxazole which may be unsubstituted or may be partially hydrogenated and unsubstituted or substituted with oxo, (f) 1 ,3-benzodioxole which may be unsubstituted or substituted with one or two substituents selected from fluoro and methyl, (g) benzothiophene, which may be unsubstituted or may be partially hydrogenated and unsubstituted or substituted with one or two substituents selected from oxo, methyl or fluoro, or (h) benzofuran, which may be unsubstituted or may be partially hydrogenated and unsubstituted or substituted with one or two groups selected from oxo, fluoro and methyl, preferably with one oxo group,

[0079] R10 is selected from hydrogen, halogen, Ci-s alkyl, Ci-6alkoxy, C2-6 alkenyl, C2-6 alkynyl, cyano, cyano(Ci-6) alkyl, Ci-s alkylcarbonyl, Ci-s alkoxycarbonyl, Ci-6 alkylsulfonyl, C1-6 alkylsulfinyl, azido, pentafluorosulfanyl, and nitro, wherein each alkyl, alkenyl, alkynyl or alkoxy can be unsubstituted or substituted with one or more substituents selected from halogen and Ci-s alkoxy, or R10 forms a ring system together with R9, as described herein,

[0080] R1 1 is selected from hydrogen, halogen, cyano, azido, Ci-s alkyl, Ci-s alkoxy, Ci-s

[0081] alkylcarbonyl, C1-6 alkoxycarbonyl, Ci-s alkylsulfonyl, and Ci-s alkylsulfinyl, C2-6 alkenyl, and C2-6 alkynyl, wherein each alkyl or alkoxy can be unsubstituted or substituted with one or more substituents selected from halogen and C1-3 alkoxy,

[0082] R12 is selected from hydrogen, C1-6 alkyl, C1-6 alkoxy and halogen, wherein each alkyl or alkoxy can be unsubstituted or substituted with one or more substituents selected from halogen and C1-3 alkoxy,

[0083] and pharmaceutically acceptable salts, solvates, isotopes and co-crystals thereof.

[0084] In general, in the compounds of the present invention, where R8 and R9 or R9 and R10 together form a bicyclic ring system such as 2,1 ,3-benzothiadiazole, 2,1 ,3- benzoselenadiazole, 2, 1 ,3-benzoxadiazole, dihydro(1 ,3)-benzoxazole, 1 ,3-benzothiazole, dihydrobenzothiophene, dihydrobenzofuran, dihydroisoindole, or 1 ,3-benzodioxole, and the like, as described herein, all phenyl moieties of these bicyclic groups can generally be substituted or unsubstituted as determined by the respective definition of the substituents R8, R10, R1 1 and R12 herein, whereas the annulated moieties of dihydrobenzothiophene, dihydrobenzofuran, dihydrobenzoxazole, or benzodioxole as formed by R8 and R9, or R9 and R10, respectively, may be optionally substituted as expressly defined herein. By way of non-limiting example, when a 1 ,3-dihydro-2-benzofuran formed by R8 and R9 or R9 and R10 and the ring to which they are attached, is said to be optionally substituted with one or two groups selected from oxo, fluoro and methyl, then this particular oxo, fluoro or methyl substitution is a substitution of the ring formed by R8 and R9 or R9 and R10, as the case may be, while the phenyl ring to which R8 and R9 or R9 and R10 are attached may be independently further substituted as defined by the residues R8, R10, R1 1 and R12 herein. Likewise, if, for example, a benzodioxole group would be defined to be unsubstituted, this would refer to the ring formed by R8 and R9 or R9 and R10, whereas the phenyl ring to which they are attached can be substituted in accordance with the definitions of R8, R10, R1 1 and R12 herein.

[0085] In one preferred embodiment, in the compounds of Formula I, if R6 is hydrogen, and X1 is N, then R5 is different from hydrogen; in one preferred embodiment R5 is iodo.

[0086] In one embodiment, R5, R6 and R7, if present, are not all hydrogen at the same time In one embodiment, R4, R5, R6 and R7, if present, are not all hydrogen at the same time

[0087] In one embodiment, R5, R6, R7 (if R7 is present), R8, R9, R10, and R1 1 are not all hydrogen at the same time.

[0088] In one preferred embodiment of the present invention, in a compound of Formula I, either (a) X1 is CR7 and X2 is NH, S or O, or

[0089] (b) X1 is N and X2 is NH,

[0090] In one embodiment of the present invention, in a compound of Formula I, X2 is NH or O. In this embodiment, X1 is preferably CR7. In one embodiment of the present invention, in a compound of Formula I, X2 is S. In this embodiment, X1 is preferably CR7

[0091] In one embodiment of the present invention, in a compound of Formula I, X2 is NH.

[0092] In one embodiment of the present invention, in a compound of Formula I, X2 is O. In this embodiment, X1 is preferably CR7

[0093] In one preferred embodiment of the present invention, in a compound of Formula I, if X1 is N, then X2 is also N. In this embodiment, preferably at least one of R4, R5 and R6 is different from hydrogen.

[0094] In a preferred embodiment, in the compounds of the present invention, at least one of R8, R9, R10 and R1 1 is different from hydrogen. In another preferred embodiment, at least one of R8, R9, R10 and R1 1 is different from hydrogen and unsubstituted alkyl.

[0095] In one aspect, the items of the present invention do not include the compounds N— 3,4- difluorophenyl 1 H-pyrrolo[2,3-b]pyridine-3-sulfonamide, N-(3,5-dimethoxyphenyl 1 H- pyrrolo[2,3-b]pyridine-3-sulfonamide, N-(2,5-difluorophenyl 1 H-pyrrolo[2,3-b]pyridine-3- sulfonamide, and N-(3,5-difluorophenyl 1 H-pyrrolo[2,3-b]pyridine-3-sulfonamide per se, and for use as medicines or as active ingredient in a pharmaceutical composition in general. In one aspect, the invention includes these compounds for use in the prevention and / or treatment of a myelination disorder as further defined herein, in particular in the prevention and / or treatment of multiple sclerosis and / or a method of treating or preventing a GPR17 related disorder, in particular a myelination disorder such as, inter alia, multiple sclerosis .

[0096] In one particular aspect, the compounds of the present invention do not include [N-(4- methylphenyl)-1 H-pyrrolo[2,3-b]pyridine-3-sulfonamide], [N-[4-methoxy-3-(2- methoxyethoxy)phenyl]- 1 H-pyrrolo[2,3-b]pyridine-3-sulfonamide], [N-(4-methoxyphenyl)- 1 H-pyrrolo[2,3-b]pyridine-3-sulfonamide], N-(4-fluoro-2-methylphenyl 1 H-pyrrolo[2,3-b] pyridine-3-sulfonamide], [N-(2-chloro-4-fluorophenyl- 1 H-pyrrolo[2,3-b]pyridine-3- sulfonamide], [N-(6-bromo-2-pyridinyl) 1 H-pyrrolo[2,3-b]pyridine-3-sulfonamide], [N-(5- chloro-2-pyridinyl)1 H-pyrrolo[2,3-b]pyridine-3-sulfonamide], [N-(2,4-dichlorophenyl)-1 H- pyrrolo[2,3-b]pyridine-3-sulfonamide], [N-(3-ethylphenyl)-1 H-pyrrolo[2,3-b]pyridine-3- sulfonamide], N-(2,5-dimethylphenyl)-1 H-pyrrolo[2,3-b]pyridine-3-sulfonamide], [N-[4- (ethylsulfonyl)phenyl]-1 H-pyrrolo[2,3-b]pyridine-3-sulfonamide], [N-(4-fluorophenyl)-1 H- pyrrolo[2,3-b]pyridine-3-sulfonamide], 1 [N-(3-chloro-4-methoxyphenyl)-1 H-pyrrolo[2,3-b] pyridine-3-sulfonamide], [N-(2-ethyl-6-methylphenyl)1 H-pyrrolo[2,3-b]pyridine-3- sulfonamide], [N-(2,4-difluorophenyl)1 H-pyrrolo[2,3-b]pyridine-3-sulfonamide, ], [N-[2- (trifluoromethoxy)phenyl]-1 H-pyrrolo[2,3-b]pyridine-3-sulfonamide], [6-amino-N-(3- bromophenyl)-1 H-lndole-3-sulfonamide], [6-amino-N-(2-fluorophenyl)-1 H-lndole-3- sulfonamide], [6-amino-N-(3-bromo-2-pyridinyl)-1 H-lndole-3-sulfonamide], [N-(4-chloro-2- methylphenyl)-1 H-pyrrolo[2,3-b]pyridine-3-sulfonamide], and [N-(4-propylphenyl)- 1 H- pyrrolo[2,3-b]pyridine-3-sulfonamide per se, while in another aspect, the present invention encompasses these specific compounds for use (a) in therapy and / or diagnosis, (b) in treating or preventing a myelination disorder and / or any other disease or condition associated with a GPR17, such as a GPR17 dysfunction (c) as active ingredient in a pharmaceutical composition along with optional pharmaceutical carriers, and / or (d) in a method of treating or preventing a disorder associated with GPR17, such as a GPR17 dysfunction, in particular a myelination disorder such as, inter alia, multiple sclerosis .

[0097] In a further embodiment, in the compound of Formula I,

[0098] R6 is selected from hydrogen, fluoro, chloro, bromo, iodo, cyano, azido, nitro,

[0099] unsubstituted or substituted C1-3 alkyl, preferably methyl, ethyl, isopropyl, mono-, di-, or trifluoromethyl, unsubstituted or substituted C2-3 alkenyl, unsubstituted or substituted C2-3 alkynyl, unsubstituted or substituted C1-3 alkylcarbonyl, unsubstituted or substituted C1-3 alkoxycarbonyl, unsubstituted or substituted C1-3 alkylsulfinyl preferably methylsulfinyl which may by further substituted with one to three fluoros, unsubstituted or substituted Ci. 3 alkylsulfonyl, preferably methylsulfonyl which may by further substituted with one to three fluoros, unsubstituted or substituted benzylsulfonyl, unsubstituted or substituted benzylsulfinyl, unsubstituted or substituted C3-7 cycloalkyl preferably cyclopropyl, unsubstituted or substituted C3-7 cycloalkyl(Ci-3)alkyl preferably cyclopropylmethyl, unsubstituted or substituted C3-7 cycloalkyl(Ci-3)alkyloxy preferably cyclopropylmethoxy, unsubstituted or substituted C3-7 heterocycloalkyl preferably tetrahydrofuranyl,

[0100] unsubstituted or substituted C3-7 heterocycloalkyl(Ci-3)alkyl, unsubstituted or substituted C3-7 heterocycloalkyl(Ci-3)alkyloxy preferably tetrahydrofuranylmethoxy, unsubstituted or substituted C1-3 alkoxy preferably methoxy or ethoxy, each of which may be optionally substituted with one or more halogens preferably with fluoros, unsubstituted or substituted C3-6 cycloalkoxy, unsubstituted or substituted C3-6 heterocycloalkoxy, unsubstituted or substituted Ci-3alkoxy(Ci-3)alkoxy, preferably methoxyethoxy, unsubstituted or substituted Ci-3alkoxy(Ci-3)alkyl, unsubstituted or substituted (C3-6)cycloalkyl(Ci-3)alkoxy preferably cyclopropylmethoxy, unsubstituted or substituted (C3-6)heterocycloalkyl(Ci-3)alkoxy preferably tetrahydrofuranylmethoxy, unsubstituted or substituted phenyl, unsubstituted or substituted phenyloxy, unsubstituted or substituted thienyl, unsubstituted or substituted pyridyl, preferably unsubstituted pyridyl, unsubstituted or substituted oxazole,

[0101] unsubstituted or substituted thiazole, unsubstituted or substituted isoxazole, unsubstituted or substituted phenyl(Ci-3)alkoxy preferably benzyloxy, wherein each optional substitution in R6 is preferably selected from fluoro, chloro, bromo, unsubstituted or fluorinated methyl , unsubstituted or fluorinated methoxy, hydroxy, and cyano,

[0102] or

[0103] (i) R6 forms together with R7 and the carbon atoms to which R6 and R7 are attached, an unsubstituted or substituted phenyl, unsubstituted or substituted pyridyl, unsubstituted or substituted cyclopentyl or unsubstituted or substituted cyclohexyl,

[0104] wherein each substitution, if present, is selected from halogen, hydroxy, C1-3 alkyl, C3-7 cycloalkyl, C3-7 cycloalkyl(Ci-3) alkyl, C3-7

[0105] heterocycloalkyl(Ci-3)alkyl, C1-3 alkoxy, and Ci-3 alkoxy(Ci-3)alkyl, wherein each alkyl or alkoxy can be unsubstituted or substituted with one or more substituents selected from halogen and C1-3 alkoxy,

[0106] or (ii) R6 forms together with R5 and the carbon atoms to which R6 and R5 are attached, a 1 ,3-dioxolane which may be unsubstituted or substituted with one or two substituents selected from fluoro and methyl,

[0107] wherein, preferably, if R6 is hydrogen, and X1 is N, then R5 is preferably different from hydrogen and is more preferably iodo.

[0108] In a further embodiment, in the compound of Formula I,

[0109] R6 is selected from hydrogen, fluoro, chloro, bromo, iodo, cyano, azido, unsubstituted or substituted C1-3 alkyl, preferably methyl, ethyl, isopropyl, or trifluoromethyl, unsubstituted or substituted C2-3 alkenyl, unsubstituted or substituted C2-3 alkynyl, unsubstituted or substituted C1-3 alkylcarbonyl, unsubstituted or substituted Ci-3 alkoxycarbonyl, unsubstituted or substituted C1-3 alkylsulfinyl preferably methylsulfinyl, unsubstituted or substituted C1-3 alkylsulfonyl, preferably methylsulfonyl, unsubstituted or substituted C3-7 cycloalkyl preferably cyclopropyl, unsubstituted or substituted C3-7 cycloalkyl(Ci-3)alkyl preferably cyclopropylmethyl, unsubstituted or substituted C3-7 heterocycloalkyl preferably tetrahydrofuranyl, unsubstituted or substituted C3-7 heterocycloalkyl(Ci-3)alkyl,

[0110] unsubstituted or substituted C1-3 alkoxy preferably methoxy, unsubstituted or substituted C3-6 cycloalkoxy, unsubstituted or substituted C3-6 heterocycloalkoxy, unsubstituted or substituted Ci-3alkoxy(Ci-3)alkoxy, preferably methoxyethoxy, unsubstituted or substituted (C3-6)cycloalkyl(Ci-3)alkoxy preferably cyclopropylmethoxy, unsubstituted or substituted (C3-6)heterocycloalkyl(Ci-3)alkoxy preferably tetrahydrofuranylmethoxy, unsubstituted or substituted phenyl, unsubstituted or substituted phenyloxy, unsubstituted or substituted thienyl, unsubstituted or substituted pyridyl, preferably unsubstituted pyridyl, unsubstituted or substituted oxazole, unsubstituted or substituted thiazole, unsubstituted or substituted isoxazole, unsubstituted or substituted phenyl(Ci-3)alkoxy preferably benzyloxy, wherein each optional substitution in R6 is preferably selected from fluoro, chloro, bromo, methyl, methoxy and cyano,

[0111] or

[0112] (iii) R6 forms together with R7 and the carbon atoms to which R6 and R7 are attached, an unsubstituted or substituted phenyl, unsubstituted or substituted pyridyl, unsubstituted or substituted cyclopentyl or unsubstituted or substituted cyclohexyl,

[0113] wherein each substitution, if present, is selected from halogen, C1-3 alkyl, C3-7 cycloalkyl, C3-7 cycloalkyl(Ci-3) alkyl, C3-7 heterocycloalkyl(Ci- 3)alkyl, C1-3 alkoxy, and Ci-3 alkoxy(Ci-3)alkyl, wherein each alkyl or alkoxy can be unsubstituted or substituted with one or more substituents selected from halogen and C1-3 alkoxy,

[0114] or

[0115] (iv) R6 forms together with R5 and the carbon atoms to which R6 and R5 are attached, a 1 ,3-dioxolane which may be unsubstituted or substituted with one or two substituents selected from fluoro and methyl,

[0116] wherein, preferably, if R6 is hydrogen, and X1 is N, then R5 is preferably different from hydrogen and is more preferably iodo.

[0117] In each occurance, where the compounds of the present invention contain a R6 and a R7 group, which, together with the ring forming atoms of the bicyclic ring system to which they are attached, form another cycle selected from phenyl, pyridyl, cyclopentyl and cyclohexyl, this cycle together with the bicyclic moiety to which it is annulated forms a tricyclic moiety which is preferably selected from 1 H-benzo[g]indol-3-yl, 1 H-pyrrolo[3,2- h]quinolin-3-yl, 1 ,6,7,8-tetrahydrocyclopenta[g]indol-3yl, and 6,7,8,9-tetrahydro-1 H- benzo[g]indol-3-yl. In one embodiment, any substitution of the 1 H-pyrrolo[3,2-h]quinolin-3- yl moiety is preferably in 8 position such as to result in, for example, in 8-(fluoromethyl)- 1 H-pyrrolo[3,2-h]quinoline.

[0118] In one preferred embodiment, in the compounds of Formula I,

[0119] X1 is N or C(R7),

[0120] X2 is NH, S or O, preferably NH,

[0121] X3 is N or C(R12),

[0122] R4 is selected from hydrogen, methoxy and halogen and is preferably hydrogen or fluoro, most preferably hydrogen,

[0123] R5 is selected from hydrogen, halogen, cyano, C1-3 alkyl, C1-3 alkoxy, C1-3 alkylcarbonyl, Ci-3 alkoxycarbonyl, C1-3 alkylsulfinyl, and C1-3 akylsulfonyl, wherein each alkyl or alkoxy may optionally be substituted one or more times with a substituent selected from halogen, C1-3 alkoxy, cyano, azido, Ci-3alkylamino and di(Ci-3alkyl)amino, preferably with methoxy or halogen, or R5 forms a ring together with R6 as described below,

[0124] R6 is selected from hydrogen, fluoro, chloro, bromo, iodo, cyano, azido, nitro,

[0125] unsubstituted or substituted C1-3 alkyl, preferably methyl, ethyl, isopropyl, or mono-, di- or trifluoromethyl, unsubstituted or substituted C1-3 alkoxy preferably methoxy, ethoxy, mono- , di- or trifluoromethoxy, and mono-, di-or trifluoroethoxy, unsubstituted or substituted C2-3 alkenyl, unsubstituted or substituted C2-3 alkynyl, unsubstituted or substituted C1-3 alkylcarbonyl, unsubstituted or substituted Ci-3 alkoxycarbonyl, unsubstituted or substituted C1-3 alkylsulfinyl preferably methylsulfinyl, unsubstituted or substituted C1-3 alkylsulfonyl, preferably methylsulfonyl, unsubstituted or substituted benzylsulfonyl, unsubstituted or substituted benzylsulfinyl, unsubstituted or substituted C3-7 cycloalkyl preferably cyclopropyl, unsubstituted or substituted C3-7 cycloalkyl(Ci-3)alkyl preferably cyclopropylmethyl, unsubstituted or substituted C3-7 heterocycloalkyl preferably tetrahydrofuranyl and oxetanyl, unsubstituted or substituted C3-7 heterocycloalkyl(Ci- 3)alkyl, unsubstituted or substituted C3-6 cycloalkoxy, unsubstituted or substituted C3-6 heterocycloalkoxy, unsubstituted or substituted Ci-5alkoxy(Ci-5)alkyl, unsubstituted or substituted Ci-3alkoxy(Ci-3)alkoxy, preferably methoxyethoxy, unsubstituted or substituted (C3-6)cycloalkyl(Ci-3)alkoxy preferably cyclopropylmethoxy, unsubstituted or substituted (C3-6)heterocycloalkyl(Ci-3)alkoxy preferably tetrahydrofuranylmethoxy, unsubstituted or substituted phenyl, unsubstituted or substituted phenyloxy, unsubstituted or substituted thienyl, unsubstituted or substituted pyridyl, preferably unsubstituted pyridyl, unsubstituted or substituted oxazole, unsubstituted or substituted thiazole, unsubstituted or substituted isoxazole, unsubstituted or substituted phenyl(Ci-3)alkoxy preferably benzyloxy, wherein each optional substitution in R6 is preferably selected from one or more of the group consisting of fluoro, chloro, bromo, unsubstituted or fluorinated methyl, unsubstituted or fluorinated methoxy, hydroxy, and cyano,

[0126] or

[0127] (i) R6 forms together with R7 and the carbon atoms to which R6 and R7 are attached, an unsubstituted or substituted phenyl, unsubstituted or substituted pyridyl, unsubstituted or substituted cyclopentyl or unsubstituted or substituted cyclohexyl, wherein each substitution, if present, is selected from halogen, hydroxy, cyano, Ci-s alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-7 cycloalkyl, C3-7 cycloalkyl(Ci-3)alkyl, C3-7 heterocycloalkyl(Ci-3)alkyl, C1-6 alkoxy, and Ci-6 alkoxy(Ci-3)alkyl wherein each alkyl or alkoxy can be unsubstituted or substituted with one or more substituents selected from halogen and C1-3 alkoxy,

[0128] wherein each alkyl or alkoxy can be unsubstituted or substituted with one or more substituents selected from halogen and C1-3 alkoxy,

[0129] or (ii) R6 forms together with R5 and the carbon atoms to which R6 and R5 are attached, a 1 ,3-dioxolane which may be unsubstituted or substituted with one or two substituents selected from fluoro and methyl,

[0130] R7 is selected from H, halogen, cyano, C1-3 alkyl, C1-3 alkoxy, C1-3 alkylcarbonyl, C1-3 alkoxycarbonyl, Ci-3 alkylsulfonyl, C1-3 alkylsulfinyl, C5-6 heteroaryl preferably isoxazol, and C5-6 heteroaryl(Ci-3) alkoxy preferably pyridylmethoxy, wherein each alkyl or alkoxy moiety can be substituted with one or more substituents, preferably with halogen, halo(Ci- 6)alkoxy, or C1-3 alkoxy, and wherein each heteroaryl can be substituted with one or more substituents, preferably with halogen, methyl, hydroxy, or methoxy, or R7 forms a ring together with R6 as described herein,

[0131] R8 is selected from hydrogen, C1-3 alkyl, C1-3 alkoxy, cyano, and halogen, wherein each alkyl or alkoxy can be unsubstituted or substituted with one or more substituents selected from halogen, cyano and methoxy, or R8 forms a ring system together with R9, as described herein,

[0132] R9 is selected from hydrogen, C1-3 alkyl, C1-3 alkoxy, fluoro, chloro, bromo and iodo, wherein each alkyl or alkoxy can be unsubstituted or substituted with one or more substituents selected from halogen and methoxy,

[0133] or R9 forms together with R8 or R10 and the ring to which they are attached a bicyclic ring system selected from 2, 1 ,3-benzothiadiazole, 2, 1 ,3-benzoselenadiazole, 2, 1 ,3- benzoxadiazole, 1 ,3-benzothiazole, 1 ,3-benzoxazole which may be unsubstituted or may be partially hydrogenated and substituted with oxo to form 2-oxo-2,3-dihydro-1 ,3- benzoxazol-, 1 ,3-benzodioxole which may be unsubstituted or substituted with one or two substituents selected from fluoro and methyl to preferably form 2,2-difluoro-1 ,3- benzodioxol, 2,3-dihydrobenzothiophene, which may be unsubstituted or substituted with one or two oxo groups to preferably form 1 , 1-dioxido-2,3-dihydro-1-benzothiophen, 1 ,3- dihydro-2-benzofuran, which may be unsubstituted or substituted with one or two groups selected from oxo, fluoro and methyl, preferably with at least one oxo group to preferably form 3-OXO-1 , 3-dihydro-2-benzofuran or 1-methyl-3-oxo-1 ,3-dihydro-2-benzofuran, and dihydroisoindol which may be unsubstituted or substituted with one or more substituents selected from oxo, fluoro and methyl and which preferably is 3-oxo-2,3-dihydro-1 H- isoindol,

[0134] R10 is selected from hydrogen, fluoro, chloro, bromo, iodo, C1-5 alkyl preferably C1-3 alkyl, C1-5 alkoxy preferably C1-3 alkoxy, C2-4 alkenyl, C2-4 alkynyl, C3-4 cycloalkyl, C3-4

[0135] heterocycloalkyl, cyano, cyanomethyl, cyanomethoxy, C1-3 alkylcarbonyl, C1-3

[0136] alkoxycarbonyl, azido, pentafluorosulfanyl, and nitro, wherein each alkyl, alkenyl, alkynyl or alkoxy can be unsubstituted or substituted with one or more substituents selected from halogen, unsubstituted or fluorinated C1-3 alkoxy, unsubstituted or fluorinated C1-3

[0137] alkoxycarbonyl, unsubstituted or fluorinated C1-3 alkylcarbonyl, cyano, hydroxy, cyclopropyl and pyridyl, wherein the pyridyl may be optionally substituted with halogen, unsubstituted or fluorinated methyl and / or unsubstituted or fluorinated methoxy, and wherein any cycloalkyl or heterocycloalkyl can be unsubstituted or substituted with a group selected from halogen, cyano, hydroxy(Ci-2)alkyl, Ci-2alkoxy and Ci- 2alkoxycarbonyl, or R10 forms a ring system together with R8, as described herein,

[0138] R1 1 is selected from hydrogen, C1-3 alkyl, C1-3 alkoxy, fluoro, chloro, bromo, iodo, cyano, C1-3 alkylcarbonyl, C1-3 alkoxycarbonyl, wherein each alkyl and alkoxy can be

[0139] unsubstituted or substituted with one or more substituents selected from fluoro, chloro, bromo, iodo and C1-3 alkoxy,

[0140] R12, if present, is selected from hydrogen, C1-3 alkyl, C1-3 alkoxy, fluoro, chloro, bromo, and iodo, wherein each alkyl and alkoxy can be unsubstituted or substituted with one or more substituents selected from fluoro, chloro, bromo, iodo and C1-3 alkoxy,

[0141] wherein in one preferred embodiment if R6 is hydrogen, and X1 is N, then R5 is different from hydrogen and is particularly preferably iodo,

[0142] wherein, in a preferred embodiment, at least one of R8, R9, R10 and R1 1 is different from hydrogen, and more preferably at least one of R8, R9, R10 and R1 1 is also different from unsubstituted alkyl,

[0143] and wherein in another preferred embodiment, at least one of R5, R6 and R7, if present, is different from hydrogen,

[0144] and pharmaceutically acceptable salts, solvates, isotopes and co-crystals thereof.

[0145] In one preferred embodiment, in the compounds of Formula I,

[0146] X1 is N or C(R7),

[0147] X2 is NH or O, preferably NH,

[0148] X3 is N or C(R12),

[0149] R4 is hydrogen or fluoro, preferably hydrogen,

[0150] R5 is selected from hydrogen, halogen, cyano, C1-3 alkyl, C1-3 alkoxy, C1-3 alkylcarbonyl, C1-3 alkoxycarbonyl, C1-3 alkylsulfinyl, and C1-3 akylsulfonyl, wherein each alkyl or alkoxy may optionally be substituted one or more times with a substituent selected from halogen, C1-3 alkoxy, cyano, azido, and an optionally alkylated amino group, preferably with methoxy or halogen, or R5 forms a ring together with R6 as described below,

[0151] R6 is selected from hydrogen, fluoro, chloro, bromo, iodo, cyano, azido, unsubstituted or substituted C1-3 alkyl, preferably methyl, ethyl, isopropyl, or trifluoromethyl, unsubstituted or substituted C1-3 alkoxy preferably methoxy, unsubstituted or substituted C2-3 alkenyl, unsubstituted or substituted C2-3 alkynyl, unsubstituted or substituted C1-3 alkylcarbonyl, unsubstituted or substituted Ci-3 alkoxycarbonyl, unsubstituted or substituted C1-3 alkylsulfinyl preferably methylsulfinyl, unsubstituted or substituted C1-3 alkylsulfonyl, preferably methylsulfonyl, unsubstituted or substituted C3-7 cycloalkyl preferably cyclopropyl, unsubstituted or substituted C3-7 cycloalkyl(Ci-3)alkyl preferably

[0152] cyclopropylmethyl, unsubstituted or substituted C3-7 heterocycloalkyl preferably tetrahydrofuranyl, unsubstituted or substituted C3-7 heterocycloalkyl(Ci-3)alkyl, unsubstituted or substituted C3-6 cycloalkoxy, unsubstituted or substituted C3-6

[0153] heterocycloalkoxy, unsubstituted or substituted Ci-3alkoxy(Ci-3)alkoxy, preferably methoxyethoxy, unsubstituted or substituted (C3-6)cycloalkyl(Ci-3)alkoxy preferably cyclopropylmethoxy, unsubstituted or substituted (C3-6)heterocycloalkyl(Ci-3)alkoxy preferably tetrahydrofuranylmethoxy, unsubstituted or substituted phenyl, unsubstituted or substituted phenyloxy, unsubstituted or substituted thienyl, unsubstituted or substituted pyridyl, preferably unsubstituted pyridyl, unsubstituted or substituted oxazole,

[0154] unsubstituted or substituted thiazole, unsubstituted or substituted isoxazole, unsubstituted or substituted phenyl(Ci-3)alkoxy preferably benzyloxy, wherein each optional substitution in R6 is preferably selected from fluoro, chloro, bromo, methyl, methoxy and cyano, or

[0155] (i) R6 forms together with R7 and the carbon atoms to which R6 and R7 are attached, an unsubstituted or substituted phenyl, unsubstituted or substituted pyridyl, unsubstituted or substituted cyclopentyl or unsubstituted or substituted cyclohexyl, wherein each substitution, if present, is selected from halogen, C1-3 alkyl, C3-7 cycloalkyl, C3-7 cycloalkyl(Ci-3) alkyl, C3-7 heterocycloalkyl(Ci-3)alkyl, C1-3 alkoxy, and Ci-3 alkoxy(Ci-3)alkyl,

[0156] wherein each alkyl or alkoxy can be unsubstituted or substituted with one or more substituents selected from halogen and C1-3 alkoxy,

[0157] or

[0158] (ii) R6 forms together with R5 and the carbon atoms to which R6 and R5 are attached, a 1 ,3-dioxolane which may be unsubstituted or substituted with one or two substituents selected from fluoro and methyl, R7 is selected from H, halogen, cyano, C1-3 alkyl, C1-3 alkoxy, C1-3 alkylcarbonyl, C1-3 alkoxycarbonyl, Ci-3alkylsulfonyl, and C1-3 alkylsulfinyl, wherein each alkyl or alkoxy moiety can be substituted with one or more substituents, preferably with halogen or C1-3 alkoxy, or R7 forms a ring together with R6 as described herein,

[0159] R8 is selected from hydrogen, C1-3 alkyl, C1-3 alkoxy, and halogen, wherein each alkyl or alkoxy can be unsubstituted or substituted with one or more substituents selected from halogen, cyano and methoxy, or R8 forms a ring system together with R9, as described herein,

[0160] R9 is selected from hydrogen, C1-3 alkyl, C1-3 alkoxy, fluoro, chloro, bromo and iodo, wherein each alkyl or alkoxy can be unsubstituted or substituted with one or more substituents selected from halogen and methoxy,

[0161] or R9 forms together with R8 or R10 and the ring to which they are attached a bicyclic ring system selected from 2, 1 ,3-benzothiadiazole, 2, 1 ,3-benzoselenadiazole, 2, 1 ,3- benzooxadiazole, 1 ,3-benzothiazole, 1 ,3-benzoxazole which may be unsubstituted or may be partially hydrogenated and substituted with oxo, 1 ,3-benzodioxole which may be unsubstituted or substituted with one or two substituents selected from fluoro and methyl, 2,3-dihydrobenzothiophene, which may be unsubstituted or substituted with one or two oxo groups, and 1 ,3-dihydro-2-benzofuran, which may be unsubstituted or substituted with one or two groups selected from oxo, fluoro and methyl, preferably with one oxo group, R10 is selected from hydrogen, fluoro, chloro, bromo, iodo, C1-3 alkyl, C1-3 alkoxy, C2-4 alkenyl, C2-4 alkynyl, cyano, cyanomethyl, C1-3 alkylcarbonyl, C1-3 alkoxycarbonyl, azido, pentafluorosulfanyl, and nitro, wherein each alkyl, alkenyl, alkynyl or alkoxy can be unsubstituted or substituted with one or more substituents selected from halogen and C1-3 alkoxy, or R10 forms a ring system together with R8, as described herein,

[0162] R1 1 is selected from hydrogen, C1-3 alkyl, C1-3 alkoxy, fluoro, chloro, bromo, iodo, C1-3 alkylcarbonyl, C1-3 alkoxycarbonyl, wherein each alkyl and alkoxy can be unsubstituted or substituted with one or more substituents selected from fluoro, chloro, bromo, iodo and Ci- 3 alkoxy,

[0163] R12 is selected from hydrogen, C1-3 alkyl, C1-3 alkoxy, fluoro, chloro, bromo, and iodo, wherein each alkyl and alkoxy can be unsubstituted or substituted with one or more substituents selected from fluoro, chloro, bromo, iodo and C1-3 alkoxy,

[0164] wherein if R6 is hydrogen, and X1 is N, then R5 is preferably different from hydrogen and is particularly preferably iodo, wherein, in a preferred embodiment, at least one of R8, R9, R10 and R1 1 is different from hydrogen, and more preferably at least one of R8, R9, R10 and R11 is also different from unsubstituted alkyl,

[0165] and pharmaceutically acceptable salts, solvates, isotopes and co-crystals thereof.

[0166] A further embodiment relates to compounds of Formula I,

[0167] wherein

[0168] X1 is N or C(R7),

[0169] X2 is NH, S, or O, preferably NH,

[0170] X3 is N or C(R12),

[0171] R4 is hydrogen or fluoro, preferably hydrogen,

[0172] R5 is selected from hydrogen, fluoro, chloro, bromo, iodo, unsubstituted or fluorinated C1-2 alkyl, preferably methyl or trifluoromethyl, unsubstituted or fluorinated C1-2 alkyloxy, unsubstituted or fluorinated C1-2 alkylcarbonyl, unsubstituted or fluorinated C1-2 alkyloxycarbonyl, C1-2 alkylsulfinyl preferably methylsulfinyl, and Ci-2 alkylsulfonyl preferably methylsulfonyl, wherein R5 preferably is preferably selected from hydrogen, methyl, fluoro, chloro, bromo, and iodo, or R5 forms a ring together with R6 as described herein,

[0173] R6 is selected from hydrogen, fluoro, chloro, bromo, iodo, cyano, azido, unsubstituted or substituted C1-3 alkyl, preferably methyl, ethyl, isopropyl, or trifluoromethyl, unsubstituted or fluorinated C1-3 alkylcarbonyl preferably acetyl, unsubstituted or fluorinated C1-3 alkoxycarbonyl preferably methoxycarbonyl, unsubstituted or fluorinated(Ci-3) alkylsulfinyl preferably methylsulfinyl, unsubstituted or fluorinated (Ci-3)alkylsulfonyl preferably methylsulfonyl, unsubstituted or substituted C3-6 cycloalkyl preferably cyclopropyl, unsubstituted or substituted C3-6 preferably cyclopropylmethyl, unsubstituted or substituted C3-6 heterocycloalkyl, unsubstituted or substituted C3-6 cycloalkoxy, unsubstituted or substituted C3-6 heterocycloalkoxy, unsubstituted or substituted C1-3 alkoxy preferably methoxy, ethoxy, fluoromethoxy, and fluoroethoxy, unsubstituted or substituted Ci-3alkoxy(Ci-3) alkoxy, preferably methoxyethoxy, unsubstituted or substituted Ci-3alkoxy(Ci-3)alkyl, unsubstituted or substituted C3-6 cycloalkyl(Ci-3)alkoxy preferably cyclopropylmethoxy, unsubstituted or substituted phenyl, unsubstituted or substituted phenyl(Ci-3)alkoxy preferably benzyloxy, unsubstituted or substituted phenyloxy, unsubstituted or substituted phenyl(Ci-3)alkylsulfonyl preferably benzylsulfonyl, unsubstituted or substituted phenyl(Ci-3)alkylsulfinyl preferably benzylsulfinyl, unsubstituted or substituted thienyl, pyridyl, oxazole, thiazole, and isoxazole, and wherein each optional substitution in R6 is preferably selected from fluoro, chloro, unsubstituted or fluorinated methyl, unsubstituted or fluorinated methoxy, hydroxy, and cyano,

[0174] provided that if R6 is hydrogen, and X1 is N, then R5 is preferably different from hydrogen and is preferably iodo,

[0175] or

[0176] (i) R6 forms together with R7 and the carbon atoms to which R6 and R7 are attached, an unsubstituted or substituted phenyl, an unsubstituted or substituted pyridyl, an unsubstituted or substituted cyclopentyl or an unsubstituted or substituted cyclohexyl,

[0177] wherein each substitution, if present, is selected from halogen, hydroxy, methyl or methoxy, wherein each methyl or methoxy can be unsubstituted or substituted with one or more substituents selected from halogen preferably fluoro, and methoxy, or

[0178] (ii) R6 forms together with R5 and the carbon atoms to which R6 and R5 are attached, a 1 ,3-dioxolane which may be unsubstituted or substituted with one or two substituents selected from fluoro and methyl,

[0179] R7 is selected from hydrogen, fluoro, chloro, bromo, iodo, cyano, Ci-3 alkyl preferably methyl, Ci-3 alkyloxy preferably methoxy, fluoro(Ci-3)alkyl preferably mono-, di-, or trifluoromethyl, fluoro(Ci-3)alkoxy preferably mono-, di- or trifluoromethoxy and mono-, di-, and trifluoroethoxy, unsubstituted or fluorinated C1-3 alkylcarbonyl, unsubstituted or fluorinated Ci-3 alkoxycarbonyl, methylsulfinyl, methylsulfonyl, fluorinated methylsulfinyl, fluorinated methylsulfonyl, substituted or unsubstituted C5-6 heteroaryl, substituted or unsubstituted C5-6 heteroaryloxy, and C5-6 heteroarylmethoxy, wherein the heteroaryl is preferably selected from pyridyl, oxazol and isoxazol, and wherein the heteroaryl may be substituted with one or more substituents selected from halogen, unsubstituted or fluorinated methyl, unsubstituted or fluorinated methoxy, or R7 forms a ring together with R6 as described herein,

[0180] R8 is selected from hydrogen, fluoro, chloro, bromo, iodo, cyano, Ci-3 alkyloxy preferably methoxy, fluoro(Ci-3)alkoxy, C1-3 alkyl preferably methyl, and fluoro(Ci-3)alkyl preferably trifluoromethyl, or R8 forms a ring system together with R10, as described herein, R9 is selected from hydrogen, fluoro, chloro, bromo, iodo, Ci-3 alkyloxy preferably methoxy, fluoro(Ci-3)alkoxy, C1-3 alkyl preferably methyl, cyano, and fluoro(Ci-3)alkyl preferably trifluoromethyl, and is preferably hydrogen, fluoro, chloro, or bromo, or R9 forms together with R8 and the ring to which they are attached a bicyclic ring system selected from 2, 1 ,3-benzothiadiazole, 2,1 ,3-benzoselenadiazole, 2, 1 ,3- benzoxadiazole, 1 ,3-benzoxazole which may be unsubstituted or may be partially hydrogenated and substituted with oxo (to give 2-oxo-2,3-dihydro-1 ,3-benzoxazole) and 1 ,3-benzodioxole, which is optionally substituted with one or two fluoros,

[0181] or R9 forms together with R10 and the ring to which they are attached a bicyclic ring system selected from 2, 1 ,3-benzothiadiazole, 2,1 ,3-benzoselenadiazole, 2, 1 ,3- benzoxadiazole, 1 ,3-benzothiazole, 3-oxo-2,3-dihydro-1 H-isoindol, 2,3-dihydro-1 - benzothiophene, which is substituted with one or two oxo (preferably substituted with two oxo to give 1 ,1 -dioxo-2,3-dihydro-1 -benzothiophene), 3-oxo-1 ,3-dihydro-2-benzofuran, which is optionally substituted with methyl to give 1-methyl-3-oxo-1 ,3-dihydro-2- benzofuran, and 1 ,3-benzodioxole, which is optionally substituted with one or two fluoros,

[0182] R10 is selected from hydrogen, fluoro, chloro, bromo, iodo, C1-3 alkyl, halo(Ci-3)alkyl, preferably fluoro(Ci-3)alkyl, particularly trifluoromethyl, C2-3 alkynyl, C1-3 alkyloxy, halo(Ci-3) alkyloxy, preferably fluoro(Ci-2)alkoxy, cyclopropylcyano, cyanomethyl, cyanoethyl, unsubstituted or fluorinated C1-3 alkylcarbonyl preferably acetyl, unsubstituted or fluorinated C1-3 alkoxycarbonyl preferably methoxycarbonyl, azido, pentafluorosulfanyl, and nitro, wherein each alkyl, cyclopropyl, alkoxy, alkenyl or alkynyl in R10, unless otherwise specified, may be optionally further substituted with one or more substituents selected from fluoro, chloro, cyano, hydroxy, C1-3 alkoxy preferably methoxy, halo C1-3 alkoxy, and unsubstituted or fluorinated C1-3 alkoxycarbonyl, wherein each alkyl and alkoxy may also be substituted with cyclopropyl which can be optionally substituted as defined above, or R10 forms a ring system together with R9, as described herein,

[0183] R1 1 is selected from hydrogen, fluoro, chloro, bromo, iodo, C1-3 alkyl preferably methyl, fluoro(Ci-3)alkyl preferably fluorinated methyl such as trifluoromethyl, C1-3 alkyloxy preferably methoxy, fluoro(Ci-3)alkoxy preferably fluoro(Ci-2)alkoxy, unsubstituted or fluorinated C1-3 alkylcarbonyl preferably acetyl, unsubstituted or fluorinated C1-3

[0184] alkoxycarbonyl preferably methoxycarbonyl, and cyano, and is more preferably hydrogen, fluoro, chloro or bromo,

[0185] R12, if present, is selected from hydrogen, fluoro, chloro, bromo, iodo, C1-3 alkyl preferably methyl, fluoro(Ci-3)alkyl preferably trifluoromethyl, C1-3 alkyloxy preferably methoxy, fluoro(Ci-3) alkoxy preferably fluoro(Ci-2)alkoxy, and cyano and is more preferably hydrogen, fluoro, chloro, or bromo.

[0186] wherein, in a preferred embodiment, at least one of R8, R9, R10 and R1 1 is different from hydrogen, and more preferably at least one of R8, R9, R10 and R1 1 is also different from unsubstituted alkyl,

[0187] and wherein in another preferred embodiment, at least one of R5, R6 and R7, if present, is different from hydrogen, and wherein in one preferred embodiment, if X1 is N, then X2 in NH,

[0188] and pharmaceutically acceptable salts, solvates, isotopes and co-crystals thereof.

[0189] A further embodiment relates to compounds of Formula I,

[0190] wherein

[0191] X1 is N or C(R7),

[0192] X2 is NH or O, preferably NH,

[0193] X3 is N or C(R12),

[0194] R4 is hydrogen,

[0195] R5 is selected from hydrogen, fluoro, chloro, bromo, iodo, unsubstituted or fluorinated C1-2 alkyl, preferably methyl or trifluoromethyl, unsubstituted or fluorinated C1-2 alkyloxy, unsubstituted or fluorinated C1-2 alkylcarbonyl, unsubstituted or fluorinated C1-2

[0196] alkyloxycarbonyl, C1-2 alkylsulfinyl preferably methylsulfinyl, and Ci-2 alkylsulfonyl preferably methylsulfonyl, preferably hydrogen, methyl or iodo, or R5 forms a ring together with R6 as described herein,

[0197] R6 is selected from hydrogen, fluoro, chloro, bromo, iodo, cyano, azido, unsubstituted or substituted C1-3 alkyl, preferably methyl, ethyl, isopropyl, or trifluoromethyl, unsubstituted or fluorinated C1-3 alkylcarbonyl preferably acetyl, unsubstituted or fluorinated C1-3 alkoxycarbonyl preferably methoxycarbonyl, (C1-3) alkylsulfinyl preferably methylsulfinyl, (Ci-3)alkylsulfonyl preferably methylsulfonyl, C3-6 cycloalkyl preferably cyclopropyl, C3-6 cycloalkyl(Ci-3))alkyl preferably cyclopropylmethyl, C3-6 heterocycloalkyl, C3-6 cycloalkoxy, C3-6 heterocycloalkoxy, unsubstituted or substituted C1-3 alkoxy preferably methoxy, unsubstituted or substituted Ci-3alkoxy(Ci-3) alkoxy, preferably methoxyethoxy, C3-6 cycloalkyl(Ci-3)alkoxy preferably cyclopropylmethoxy, unsubstituted or substituted phenyl, unsubstituted or substituted phenyl(Ci-3)alkoxy preferably benzyloxy, unsubstituted or substituted phenyloxy, unsubstituted or substituted thienyl, pyridyl, oxazole, thiazole, and isoxazole, and wherein each optional substitution in R6 is preferably selected from fluoro, chloro, methyl, methoxy, and cyano,

[0198] provided that if R6 is hydrogen, and X1 is N, then R5 is preferably different from hydrogen and is preferably iodo,

[0199] or

[0200] (i) R6 forms together with R7 and the carbon atoms to which R6 and R7 are attached, an unsubstituted or substituted phenyl, an unsubstituted or substituted pyridyl, an unsubstituted or substituted cyclopentyl or an unsubstituted or substituted cyclohexyl,

[0201] wherein each substitution, if present, is selected from halogen, methyl or methoxy, wherein each methyl or methoxy can be unsubstituted or substituted with one or more substituents selected from fluoro and methoxy,

[0202] or

[0203] (ii) R6 forms together with R5 and the carbon atoms to which R6 and R5 are

[0204] attached, a 1 ,3-dioxolane which may be unsubstituted or substituted with one or two substituents selected from fluoro and methyl,

[0205] R7 is selected from hydrogen, fluoro, chloro, bromo, iodo, cyano, C1-3 alkyl, Ci-3 alkyloxy, fluoro(Ci-3)alkyl preferably trifluoromethyl, fluoro(Ci-3)alkoxy preferably trifluoromethoxy, unsubstituted or fluorinated C1-3 alkylcarbonyl, unsubstituted or fluorinated C1-3 alkoxycarbonyl, methylsulfinyl, and methylsulfonyl, or R7 forms a ring together with R6 as described herein,

[0206] R8 is selected from hydrogen, fluoro, chloro, bromo, iodo, Ci-3 alkyloxy preferably methoxy, fluoro(Ci-3)alkoxy, C1-3 alkyl preferably methyl, and fluoro(Ci-3)alkyl preferably trifluoromethyl, or R8 forms a ring system together with R10, as described herein, R9 is selected from hydrogen, fluoro, chloro, bromo, iodo, Ci-3 alkyloxy preferably methoxy, fluoro(Ci-3)alkoxy, C1-3 alkyl preferably methyl, cyano, and fluoro(Ci-3)alkyl preferably trifluoromethyl, and is preferably hydrogen, fluoro, chloro, or bromo, or R9 forms together with R8 and the ring to which they are attached a bicyclic ring system selected from 2,1 ,3-benzothiadiazole, 2,1 ,3-benzoselenadiazole, 2,1 ,3- benzooxadiazole, 1 ,3-benzoxazole which may be unsubstituted or may be partially hydrogenated and substituted with oxo (to give 2-oxo-2,3-dihydro-1 ,3-benzoxazole) and 1 ,3-benzodioxole, which is optionally substituted with one or two fluoros, or R9 forms together with R10 and the ring to which they are attached a bicyclic ring system selected from 2, 1 ,3-benzothiadiazole, 2,1 ,3-benzoselenadiazole, 2, 1 ,3- benzooxadiazole, 1 ,3-benzothiazole, 2,3-dihydro-1 -benzothiophene, which is substituted with one or two oxo (preferably substituted with two oxo to give 1 , 1-dioxo-2,3-dihydro-1 - benzothiophene), 3-oxo-1 ,3-dihydro-2-benzofuran, and 1 ,3-benzodioxole, which is optionally substituted with one or two fluoros,

[0207] R10 is selected from hydrogen, fluoro, chloro, bromo, iodo, C1-3 alkyl, halo(Ci-3)alkyl, preferably fluoro(Ci-3)alkyl, particularly trifluoromethyl, C2-3 alkynyl, C1-3 alkyloxy, halo(Ci-3) alkyloxy, preferably fluoro(Ci-2)alkoxy, cyano, cyanomethyl, unsubstituted or fluorinated C1-3 alkylcarbonyl preferably acetyl, unsubstituted or fluorinated C1-3 alkoxycarbonyl preferably methoxycarbonyl, azido, pentafluorosulfanyl, and nitro, or R10 forms a ring system together with R9, as described herein,

[0208] R1 1 is selected from hydrogen, fluoro, chloro, bromo, iodo, C1-3 alkyl preferably methyl, fluoro(Ci-3)alkyl preferably trifluoromethyl, C1-3 alkyloxy preferably methoxy, fluoro(Ci- 3)alkoxy preferably fluoro(Ci-2)alkoxy, unsubstituted or fluorinated C1-3 alkylcarbonyl preferably acetyl, unsubstituted or fluorinated C1-3 alkoxycarbonyl preferably

[0209] methoxycarbonyl, and cyano, and is more preferably hydrogen, fluoro, chloro or bromo,

[0210] R12 is selected from hydrogen, fluoro, chloro, bromo, iodo, C1-3 alkyl preferably methyl, fluoro(Ci-3)alkyl preferably trifluoromethyl, C1-3 alkyloxy preferably methoxy, fluoro(Ci-3) alkoxy preferably fluoro(Ci-2)alkoxy, and cyano and is more preferably hydrogen, fluoro, chloro, or bromo.

[0211] wherein, in a preferred embodiment, at least one of R8, R9, R10 and R1 1 is different from hydrogen, and more preferably at least one of R8, R9, R10 and R1 1 is also different from unsubstituted alkyl,

[0212] and pharmaceutically acceptable salts, solvates, isotopes and co-crystals thereof.

[0213] In one preferred embodiment, in the compounds of Formula I as described herein, if X2 is O, then X1 is C(R7).

[0214] A further embodiment relates to compounds of Formula I,

[0215] wherein

[0216] X1 is N or C(R7),

[0217] X2 is NH, S or O provided that if X1 is N, then X2 is preferably also N, X3 is N or C(R12),

[0218] R4 is hydrogen or fluoro, preferably hydrogen,

[0219] R5 is selected from hydrogen, methyl, fluoro, chloro and bromo,

[0220] or R5 forms a ring together with R6 as described herein,

[0221] R6 is selected from hydrogen, halogen, cyano, nitro, azido, C1-3 alkyl, Ci-3alkylsulfinyl preferably methylsulfinyl, Ci-3alkylsulfonyl preferably methylsulfonyl, cyclopropyl, cyclopropylmethyl, cyclopropyloxy, C1-3 alkoxy preferably methoxy or ethoxy, phenyl, phenyloxy, benzyl, phenyl(Ci-3)alkoxy preferably benzyloxy, benzylsulfinyl, benzylsulfonyl, tetrahydrofuranyl, and a 5-6 membered heteroaryl, preferably selected from thienyl, pyridyl, oxazole, and isoxazole, and wherein each alkyl, alkoxy, cyclopropyl,

[0222] tetrahydrofuranyl, phenyl or heteroaryl group can be optionally substituted one or more times with substituents selected from fluoro, chloro, hydroxy, unsubstituted or fluorinated C1-2 alkyl, unsubstituted or fluorinated C1-2 alkoxy, and cyano,

[0223] or

[0224] (i) R6 forms together with R7 and the carbon atoms to which R6 and R7 are attached, an unsubstituted or substituted phenyl, an unsubstituted or substituted pyridyl, an unsubstituted or substituted cyclopentyl or an unsubstituted or substituted cyclohexyl,

[0225] wherein each substitution, if present, is selected from halogen, hydroxy, methyl or methoxy, wherein each methyl or methoxy can be unsubstituted or substituted with one or more substituents selected from halogen, preferably fluoro, and methoxy, or

[0226] (ii) R6 forms together with R5 and the carbon atoms to which R6 and R5 are attached, a 1 ,3-dioxolane which may be unsubstituted or substituted with one or two substituents selected from fluoro and methyl,

[0227] R7 is selected from hydrogen, halogen, cyano, C1-3 alkyl, C1-3 alkyloxy, fluoro(Ci-3)alkyl preferably mono-, di-, and trifluoromethyl, fluoro(Ci-3)alkoxy preferably mono-, di-, and trifluoromethoxy or mono-, di-, and trifluoroethoxy, unsubstituted or fluorinated

[0228] methylsulfinyl, unsubstituted or fluorinated methylsulfonyl, C5-6 heteroaryl, C5-6

[0229] heteroaryloxy, C5-6 heteroarylmethyl and C5-6 heteroarylmethoxy, wherein the heteroaryl (in each occurance in R7) is preferably selected from pyridyl, oxazol and isoxazol, and wherein the heteroaryl is unsubstituted or substituted with one or more substituents selected from halogen, cyano, unsubstituted or fluorinated methyl, and unsubstituted or fluorinated methoxy, or R7 forms a ring together with R6 as described herein, R8 is selected from hydrogen, fluoro, chloro, bromo, Ci-3 alkyloxy preferably methoxy, fluoro(Ci-3)alkoxy preferably fluoromethoxy, and unsubstituted or fluorinated Ci-3alkyl preferably fluoromethyl, or R8 forms a ring system together with R10, as described herein,

[0230] R9 is selected from hydrogen, fluoro, chloro, methoxy, fluromethoxy, methyl and fluoromethyl,

[0231] or R9 forms together with R8 and the ring to which they are attached a bicyclic ring system selected from 2,1 ,3-benzothiadiazole, 2,1 ,3-benzoselenadiazole, 2,1 ,3- benzoxadiazole, 1 ,3-benzoxazole which may be unsubstituted or may be partially hydrogenated and substituted with oxo (to give 2-oxo-2,3-dihydro-1 ,3-benzoxazole) and 1 ,3-benzodioxole, which is optionally substituted with one or two fluoros,

[0232] or R9 forms together with R10 and the ring to which they are attached a bicyclic ring system selected from 2,1 ,3-benzothiadiazole, 2,1 ,3-benzoselenadiazole, 2,1 ,3- benzoxadiazole, 1 ,3-benzothiazole, 3-oxo-2,3-dihydro-1 H-isoindol, 2,3-dihydro-1- benzothiophene, which is substituted with one or two oxo (preferably substituted with two oxo to give 1 ,1-dioxo-2,3-dihydro-1 -benzothiophene), 3-oxo-1 ,3-dihydro-2-benzofuran, which is optionally substituted with methyl to give 1-methyl-3-oxo-1 ,3-dihydro-2- benzofuran, and 1 ,3-benzodioxole, which is optionally substituted with one or two fluoros,

[0233] R10 is selected from hydrogen, halogen, cyano, azido, pentafluorosulfanyl, nitro, C1-3 alkyl, C2-3 alkenyl, C2-3 alkynyl, C1-3 alkyloxy, C1-3 alkylcarbonyl preferably acetyl, C3- 6cycloalkyl preferably cycloalkyl, C3-6 cycloalkyloxy preferably cycloalkyloxy, C3-6hetero cycloalkyl, C3-6heterocycloalkyloxy, wherein each cycloalkyl is optionally substituted by one or more substituents selected from fluoro, cyano, unsubstituted or fluorinated Ci- 2alkoxy, and unsubstituted or fluorinated Ci-2alkoxycarbonyl, and wherein each alkyl, alkoxy, alkenyl or alkynyl in R10 may be optionally further substituted with one or more substituents selected from cyclopropyl, halogen preferably fluoro, cyano, hydroxy, C1-3 alkoxy, halo(Ci-3)alkoxy preferably fluoro(Ci-3)alkoxy, unsubstituted or fluorinated C1-3 alkylcarbonyl, and unsubstituted or fluorinated C1-3 alkoxycarbonyl, or R10 forms a ring system together with R9, as described herein,

[0234] R11 is selected from hydrogen, fluoro, chloro, bromo, C1-3 alkyl preferably methyl, fluoro(Ci-3)alkyl preferably fluoromethyl, C1-3 alkyloxy preferably methoxy, fluoro(Ci- 3)alkoxy preferably fluoromethoxy, and cyano,

[0235] R12, if present, is selected from hydrogen, fluoro, chloro, bromo, methyl, fluoromethyl, methoxy and fluoromethoxy, wherein preferably, R12 is hydrogen or fluoro,

[0236] and pharmaceutically acceptable salts, solvates, isotopes and co-crystals thereof; wherein, in a preferred embodiment, at least one, more preferably two of R8, R10 and R1 1 are different from hydrogen, and more preferably at least one of R8, R10 and R1 1 is also different from unsubstituted alkyl,

[0237] and wherein in another preferred embodiment, at least one of R5, R6 and R7, if present, is different from hydrogen,

[0238] A further embodiment relates to compounds of Formula I,

[0239] wherein

[0240] X1 is N or C(R7),

[0241] X2 is NH, S or O, preferably NH or O,

[0242] X3 is N or C(R12),

[0243] R4 is hydrogen,

[0244] R5 is selected from hydrogen, fluoro, chloro and bromo,

[0245] R6 is selected from fluoro, chloro, bromo, iodo, cyano, azido, amino, nitro, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, ethenyl, ethynyl, propargyl, methylsulfinyl,

[0246] methylsulfonyl, cyclopropyl, cyclopropyloxy, cyclopropylmethyl, methoxy, ethoxy, propoxy, methoxyethoxy, ethoxymethoxy, cyclopropylmethoxy, oxetanyl, oxetanylmethoxy, tetrahydrofuranyl, tetrahydrofuranylmethoxy, phenyl, benzyloxy, phenyloxy, benzylsulfinyl, thienyl, pyridyl, oxazole, thiazole, and isoxazole, wherein each phenyl, thienyl, pyridyl, oxazol, thiazole and isoxazol can be optionally substituted one or more times, preferably with a substitution selected from halogen, methoxy, and methyl, and wherein each alkyl, alkenyl, alkynyl and alkoxy group can be substituted one or more times with halogen preferably fluoro, methoxy, fluoromethoxy, and hydroxy,

[0247] or R6 forms together with R7 and the carbon atoms to which R6 and R7 are attached, a ring selected from phenyl, pyridyl, cyclohexyl, and cyclopentyl, each of which can be unsubstituted or further substituted with one or more residues selected from halogen, hydroxy, unsubstituted or fluorinated methyl, and unsubstituted or fluorinated methoxy,

[0248] R7 is selected from hydrogen, fluoro, chloro, bromo, iodo, cyano, methylsulfinyl, methylsulfonyl, methoxy, fluoromethoxy, fluoroethoxy, methyl, fluoromethyl, and fluoroethyl, or R7 forms a ring together with R6 as described herein,

[0249] R8 is selected from hydrogen, fluoro, chloro, bromo, iodo, methoxy, fluoromethoxy, cyano, methyl, and fluoromethyl, or R8 forms a ring system together with R10, as described herein, R9 is selected from hydrogen, fluoro and chloro and is preferably hydrogen,

[0250] or R9 forms together with R8 or R10 and the ring to which they are attached a bicyclic ring system selected from 2,1 ,3-benzothiadiazole, 2,1 ,3-benzoxadiazole, 2-oxo-2,3-dihydro- 1 ,3-benzoxazole and 1 ,3-benzodioxole, which is optionally substituted with two fluoros, or R9 forms together with R10 and the ring to which they are attached a bicyclic ring system selected from 3-oxo-2,3-dihydro-1 H-isoindol, 2,3-dihydro-1-benzothiophene, which is substituted with one or two oxo (preferably substituted with two oxo to give 1 ,1-dioxo- 2,3-dihydro-1-benzothiophene), and optionally methylated 3-oxo-1 ,3-dihydro-2- benzofuran,

[0251] R10 is selected from hydrogen, fluoro, chloro, bromo, iodo, methyl, ethyl, n-propyl, isopropyl, ethenyl, n-propenyl, isopropenyl, ethynyl, propargyl, fluoro(Ci-3)alkyl preferably trifluoromethyl, methoxy, ethoxy, propoxy, fluoro(Ci-3)alkoxy Ci-3alkoxy(Ci-3)alkyl, Ci- 3alkoxy(Ci-3)alkoxy, Ci-3alkoxy(C2-3)alkenyl, Ci-3alkoxy(C2-3)alkynyl, Ci-3alkoxycarbonyl(Ci- 3)alkyl, Ci-3alkylcarbonyl(Ci-3)alkyl, C1-3 alkylcarbonyl(Ci-3)alkyloxy, cyano, acetyl, azido, nitro, pentafluorosulfanyl, cyclopropyl, cyclopropyloxy, cyclopropylmethoxy, and Ci- 3alkoxycarbonyl including methoxycarbonyl, wherein each alkyl, alkenyl, alkynyl and alkoxy group in R10 can be unsubstituted or substituted with one or more residues selected from halogen preferably fluoro, cyano and / or hydroxy, and wherein the cyclopropyl is optionally substituted with one or more residues selected from cyano, optionally fluorinated C1-2 alkoxy and optionally fluorinated Ci-2alkoxycarbonyl, or R10 forms a ring system together with R9, as described herein,

[0252] R11 is selected from hydrogen, fluoro, chloro, bromo, cyano, methyl, fluoromethyl, methoxy and fluoromethoxy,

[0253] R12, if present, is selected from hydrogen, fluoro, chloro, and bromo, and is preferably hydrogen or fluoro.

[0254] wherein, in a preferred embodiment, at least one of R8, R9, R10 and R1 1 , more preferably at least one or at least two, most preferably all of R8, R10 and R11 , are different from hydrogen and at least one, preferably at least two of R8, R10 and R11 , are preferably also different from unsubstituted alkyl,

[0255] and pharmaceutically acceptable salts, solvates, isotopes and co-crystals thereof.

[0256] A further embodiment relates to compounds of Formula I,

[0257] wherein X1 is N or C(R7),

[0258] X2 is NH, S or O, preferably NH or O,

[0259] X3 is N or C(R12),

[0260] R4 is hydrogen,

[0261] R5 is selected from hydrogen, fluoro, chloro and bromo,

[0262] R6 is selected from fluoro, chloro, bromo, azido, nitro, methyl, ethyl, isopropyl, trifluoromethyl, methylsulfinyl, methylsulfonyl, cyclopropyl, methoxy, phenyl, benzyloxy, phenylsulfinyl, benzylsulfinyl, thiophen-2-yl, and thiophen-3-yl, wherein each alkyl and alkoxy group in R6 can be substituted one or more times with fluoro, methoxy, cyano and hydroxy,

[0263] or R6 forms together with R7 and the carbon atoms to which R6 and R7 are attached, a ring selected from phenyl, pyridyl, cyclohexyl, and cyclopentyl, each of which can be optionally substituted one or more times with a group selected from methyl, fluorinated methyl, methoxy, fluorinated methoxy and fluoro,

[0264] R7 is selected from hydrogen, fluoro, chloro, bromo, cyano, methyl, ethyl, methylsulfonyl, methylsulfinyl, methoxy, ethoxy, mono-, di-, and trifluoromethoxy, mono-, di-, and trifluoroethoxy, mono-, di-, and trifluoromethyl, mono-, di-, and trifluoroethyl, or R7 forms a ring together with R6 as described herein,

[0265] R8 is selected from hydrogen, fluoro, chloro, bromo, methoxy, cyano, and mono-, di-, and trifluoromethyl, or R8 forms a ring system together with R10, as described herein,

[0266] R9 is hydrogen or fluoro, preferably hydrogen,

[0267] or R9 forms together with R8 or R10 and the ring to which they are attached a bicyclic ring system selected from 2,1 ,3-benzothiadiazole, 2,1 ,3-benzoxadiazole, 1 ,3-benzodioxole, or 2,2-difluoro-1 ,3-benzodioxole,

[0268] or R9 forms together with R10 and the ring to which they are attached a bicyclic ring system selected from 3-oxo-2,3-dihydro-1 H-isoindol, 3-oxo-1 ,3-dihydro-2-benzofuran, and 1 -methyl-3-oxo-1 , 3-d ihyd ro-2-benzof u ran ,

[0269] R10 is selected from hydrogen, fluoro, chloro, bromo, iodo, methyl, ethyl, propyl, ethenyl, propenyl, ethynyl, propargyl, methoxy, ethoxy, propyloxy, cyano, cyanomethyl, cyanoethyl, cyanomethoxy, fluoro(Ci-3)alkyl including trifluoromethyl, fluorinated and / or hydroxylated Ci-3alkoxy preferably fluoro(Ci-2)alkoxy, unsubstituted or fluorinated and / or hydroxylated Ci-2alkoxy(Ci-3)alkyl preferably methoxypropyl, ethoxyethyl, and

[0270] fluoromethoxymethyl, unsubstituted or fluorinated and / or hydroxylated Ci-2alkoxy(Ci-3)alkoxy preferably fluoromethoxyethoxy, unsubstituted or fluorinated and / or hydroxylated Ci-2alkoxy(C2-3)alkenyl preferably methoxypropenyl and ethoxyethenyl, Ci-2alkoxycyclopropyl, Ci-2alkoxycarbonylcyclopropyl, cyclopropyl(Ci-2)alkoxy, acetyl, azido, and pentafluorosulfanyl, or R10 forms a ring system together with R9, as described herein, and wherein, in a preferred embodiment, R8 and R10 are not both hydrogen,

[0271] R1 1 is selected from hydrogen, fluoro, fluoromethyl, chloro, methoxy and fluoromethoxy,

[0272] R12, if present, is selected from hydrogen and fluoro,

[0273] and pharmaceutically acceptable salts, solvates, isotopes and co-crystals thereof, wherein in one preferred embodiment, if R9 does not form a ring with R8, then R10 is different from hydrogen.

[0274] One embodiment relates to compounds of Formula I,

[0275] wherein

[0276] X1 is N or C(R7),

[0277] X2 is NH, S or O, preferably NH or O, preferably NH,

[0278] R4 is hydrogen,

[0279] R5 is selected from hydrogen, fluoro, chloro and bromo,

[0280] R6 is selected from fluoro, bromo,chloro, nitro, azido, cyano, methyl, fluoromethyl, ethyl, fluoroethyl, isopropyl, cyclopropyl, cyclopropylmethyl, cyclopropylmethoxy, methoxy, ethoxy, fluoromethoxy, fluoroethoxy, methylsulfinyl, methylsulfonyl, benzyloxy, thienyl, and and is preferably chloro,

[0281] R7 is selected from hydrogen, methoxy, fluoro, chloro, bromo, cyano, fluoromethoxy, fluoroethoxy, and mono-, di- and trifluoromethyl,

[0282] X3 is N or C(R12),

[0283] R8 is selected from hydrogen, fluoro, chloro, and methoxy,

[0284] R9 is hydrogen or fluoro, preferably hydrogen,

[0285] R10 is selected from fluoro, chloro, bromo, cyano, cyanomethyl, cyanoethyl,

[0286] cyanomethoxy, azido, methyl, ethyl, propyl, ethenyl, propenyl, ethynyl, propargyl, mono-, di-, and trifluoromethyl, cyclopropylmethoxy, cyclopropylethoxy, methoxycyclopropyl, ethoxycyclopropyl, methoxycarbonylcyclopropyl, ethoxycarbonylcyclopropyl, mono-, di- and trifluoromethoxy, mono-, di-„ and trifluoroethoxy, ethoxymethyl, methoxyethyl, ethoxyethyl, methoxypropyl, fluoroethoxymethyl, fluoromethoxyethyl, fluoroethoxyethyl, fluoromethoxypropyl, ethoxymethoxy, methoxyethoxy, methoxypropoxy,

[0287] fluoroethoxymethoxy, fluoromethoxyethoxy, fluoromethoxypropoxy, methoxyethenyl, methoxypropenyl, fluoromethoxyethenyl, fluoromethoxyethenyl, ethynyl, propargyl, and pentafluorosulfanyl,

[0288] R1 1 is selected from hydrogen, fluoro, chloro, fluoromethyl, methoxy, and fluoromethoxy,

[0289] R12, if present, is hydrogen or fluoro, preferably hydrogen

[0290] wherein, in a preferred embodiment, at least one of R8, and R1 1 is different from hydrogen,

[0291] and pharmaceutically acceptable salts, solvates, isotopes and co-crystals thereof.

[0292] One preferred embodiment relates to compounds of Formula I,

[0293] wherein

[0294] X1 is N, or C(R7),

[0295] X2 is NH, S or O, preferably NH,

[0296] R4 and R5 are both hydrogen,

[0297] R6 is methoxy, chloro or bromo, preferably chloro,

[0298] R7 is hydrogen, methoxy, fluoroor trifluoromethyl,

[0299] X3 is N or C(R12),

[0300] R9 forms together with R8 and the phenyl ring to which R8 and R9 are attached a 2, 1 ,3- benzothiadiazole, a 1 ,3-benzodioxole, or a 2,2-difluoro-1 ,3-benzodioxole,

[0301] R10 is hydrogen or fluoro,

[0302] R1 1 is selected from hydrogen, fluoro, cyano and methoxy, and is preferably hydrogen, R12, if present, is hydrogen or fluoro, preferably hydrogen,

[0303] and pharmaceutically acceptable salts, solvates, isotopes and co-crystals thereof.

[0304] One preferred embodiment relates to compounds of Formula I,

[0305] wherein

[0306] X1 is N or C(R7),

[0307] X2 is NH, S or O, R4 and R5 are both hydrogen,

[0308] R6 is, selected from fluoro, chloro, bromo, cyano, azido, methyl, ethyl, isopropyl, fluoromethyl, cydopropyl, methoxy, fluoromethoxy, methylsulfinyl, methylsulfonyl, thien-2- yl, thien-3-yl, and benzyloxy and is preferably chloro or bromo,

[0309] R7 is selected from hydrogen, methoxy, fluoro, chloro, bromo, cyano, mono-, di-, and trifluoromethyl, methylsulfinyl, methylsulfonyl, and fluoro(Ci-2)alkoxy,

[0310] X3 is N or C(R12),

[0311] R8 is selected from fluoro and methoxy,

[0312] R9 is hydrogen,

[0313] R10 is selected from fluoro, chloro, bromo, azido, cyano, cyanomethyl, cyanoethyl, cyanomethoxy, cyclopropyl(Ci-2)alkyl, cyclopropyl(Ci-2)alkoxy, Ci-2alkoxycyclopropyl, Ci- 2alkoxycarbonylcyclopropyl, unsubstituted or fluorinated C1-3 alkyl, preferably methyl, ethyl and fluoromethyl, unsubstituted or fluorinated C1-3 alkoxy, preferably methoxy,

[0314] difluoromethoxy, difluoroethoxy and trifluoroethoxy, unsubstituted or fluorinated C2-3 alkenyl, unsubstituted or fluorinated C2-3 alkynyl, unsubstituted or fluorinated C1-3 alkoxy(Ci-3)alkyl, preferably methoxypropyl, ethoxyethyl, and fluoromethoxymethyl, unsubstituted or fluorinated C1-3 alkoxy(Ci-3)alkoxy, preferably methoxyethoxy and fluoromethoxyethoxy, unsubstituted or fluorinated C1-3 alkoxy(C2-3)alkenyl, preferably methoxypropenyl, ethoxyethenyl and fluoromethoxypropenyl, and pentafluorosulfanyl, R1 1 is selected from hydrogen, fluoro and methoxy,

[0315] R12, if present, is hydrogen,

[0316] and pharmaceutically acceptable salts, solvates, isotopes and co-crystals thereof.

[0317] A further embodiment relates to compounds of Formula I,

[0318] wherein

[0319] X1 is N or C(R7),

[0320] X2 is NH or O,

[0321] X3 is N or C(R12),

[0322] R4 and R5 are both hydrogen,

[0323] R6 is is selected from fluoro, chloro, bromo, iodo, cyano, azido, methyl, ethyl, isopropyl, trifluoromethyl, methylsulfinyl, methylsulfonyl, cydopropyl, cyclopropylmethyl, methoxy, ethoxy, methoxyethoxy, cyclopropylmethoxy, phenyl, benzyloxy, phenyloxy, thienyl, pyridyl, oxazole, thiazole, and isoxazole,

[0324] or R6 forms together with R7 and the carbon atoms to which R6 and R7 are attached, a ring selected from phenyl, pyridyl, and cyclopentyl,

[0325] R7 is selected from hydrogen, fluoro, chloro, bromo, iodo, methoxy, difluoromethoxy, trifluoromethoxy, methyl, difluoromethyl, and trifluoromethyl, or R7 forms a ring together with R6 as described herein,

[0326] R8 is selected from hydrogen, fluoro, chloro, bromo, iodo, methoxy, methyl, and trifluoromethyl, or R8 forms a ring system together with R10, as described herein, R9 is selected from hydrogen, fluoro and chloro and is preferably hydrogen,

[0327] or R9 forms together with R8 or R10 and the ring to which they are attached a bicyclic ring system selected from 2,1 ,3-benzothiadiazole, 2,1 ,3-benzooxadiazole, 2-oxo-2,3-dihydro- 1 ,3-benzoxazole and 1 ,3-benzodioxole, which is optionally substituted with two fluoros,

[0328] R10 is selected from hydrogen, fluoro, chloro, bromo, iodo, methyl, ethynyl, propargyl, fluoro(Ci-2)alkyl preferably trifluoromethyl, methoxy, fluoro(Ci-2)alkoxy, cyano,

[0329] cyanomethyl, acetyl, azido, pentafluorosulfanyl, and methoxycarbonyl, or R10 forms a ring system together with R9, as described herein,

[0330] R1 1 is selected from hydrogen, fluoro, chloro, bromo, and methoxy,

[0331] R12 is selected from hydrogen, fluoro, chloro, or bromo.

[0332] wherein, in a preferred embodiment, at least one of R8, R9, R10 and R1 1 is different from hydrogen and unsubstituted alkyl,

[0333] and pharmaceutically acceptable salts, solvates, isotopes and co-crystals thereof.

[0334] A further embodiment relates to compounds of Formula I,

[0335] wherein

[0336] X1 is N or C(R7),

[0337] X2 is NH or O,

[0338] X3 is N or C(R12),

[0339] R4 and R5 are both hydrogen,

[0340] R6 is selected from fluoro, chloro, bromo, azido, methyl, isopropyl, trifluoromethyl, methylsulfonyl, cyclopropyl, methoxy, phenyl, benzyloxy, thiophen-2-yl, and thiophen-3-yl, or R6 forms together with R7 and the carbon atoms to which R6 and R7 are attached, a ring selected from phenyl, pyridyl, and cyclopentyl,

[0341] R7 is selected from hydrogen, fluoro, chloro, and methoxy, or R7 forms a ring together with R6 as described herein,

[0342] R8 is selected from hydrogen, fluoro, chloro, bromo, methoxy, and trifluoromethyl, or R8 forms a ring system together with R10, as described herein,

[0343] R9 is hydrogen or fluoro, preferably hydrogen,

[0344] or R9 forms together with R8 or R10 and the ring to which they are attached a bicyclic ring system selected from 2, 1 ,3-benzothiadiazole, 2, 1 ,3-benzooxadiazole, 1 ,3-benzodioxole, or 2,2-difluoro-1 ,3-benzodioxole, R10 is selected from hydrogen, fluoro, chloro, bromo, iodo, ethynyl, propargyl, methoxy, cyano, cyanomethyl, trifluoromethyl, fluoro(Ci-2)alkoxy, acetyl, azido, and pentafluorosulfanyl, or R10 forms a ring system together with R9, as described herein, and wherein, in a preferred embodiment, R8 and R10 are not both hydrogen,

[0345] R1 1 is selected from hydrogen, fluoro, chloro, and methoxy,

[0346] R12 is selected from hydrogen, and fluoro,

[0347] and pharmaceutically acceptable salts, solvates, isotopes and co-crystals thereof.

[0348] One embodiment relates to compounds of Formula I,

[0349] wherein

[0350] X1 is N or C(R7),

[0351] X2 is NH or O, preferably NH,

[0352] R4 and R5 are both hydrogen,

[0353] R6 is bromo or chloro, preferably chloro,

[0354] R7 is hydrogen, methoxy, fluoro or trifluoromethyl,

[0355] X3 is N or C(R12),

[0356] R8 is selected from hydrogen, fluoro, chloro, and methoxy,

[0357] R9 is hydrogen of fluoro, preferably hydrogen,

[0358] R10 is selected from fluoro, chloro, bromo, cyano, cyanomethyl, trifluoromethyl, difluoroethoxy, trifluoroethoxy, and pentafluorosulfanyl,

[0359] R1 1 is selected from hydrogen, fluoro, chloro, and methoxy, R12 is hydrogen or fluoro, preferably hydrogen,

[0360] wherein, in a preferred embodiment, at least one of R8, R9, R10 and R1 1 is different from hydrogen,

[0361] and pharmaceutically acceptable salts, solvates, isotopes and co-crystals thereof.

[0362] One preferred embodiment relates to compounds of Formula I,

[0363] wherein

[0364] X1 is N, or C(R7),

[0365] X2 is NH or O, preferably NH,

[0366] R4 and R5 are both hydrogen,

[0367] R6 is chloro or bromo, preferably chloro,

[0368] R7 is hydrogen, methoxy, fluoro or trifluoromethyl,

[0369] X3 is N or C(R12),

[0370] R9 forms together with R8 and the phenyl ring to which R8 and R9 are attached a 2, 1 ,3- benzothiadiazole or a 2,2-difluoro-1 ,3-benzodioxole,

[0371] R10 is hydrogen, or fluoro,

[0372] R1 1 is selected from hydrogen, fluoro and methoxy,

[0373] R12 is hydrogen or fluoro preferably hydrogen,

[0374] and pharmaceutically acceptable salts, solvates, isotopes and co-crystals thereof.

[0375] One preferred embodiment relates to compounds of Formula I,

[0376] wherein

[0377] X1 is N or C(R7),

[0378] X2 is NH,

[0379] R4 and R5 are both hydrogen,

[0380] R6 is chloro or bromo, preferably chloro,

[0381] R7 is hydrogen, methoxy, fluoro or trifluoromethyl,

[0382] X3 is N or C(R12),

[0383] R8 is selected from fluoro and methoxy, R9 is hydrogen,

[0384] R10 is selected from fluoro, chloro, bromo, cyano, cyanomethyl, trifluoromethyl, difluoroethoxy, trifluoroethoxy, and pentafluorosulfanyl,

[0385] R1 1 is selected from hydrogen, fluoro and methoxy,

[0386] R12 is hydrogen,

[0387] and pharmaceutically acceptable salts, solvates, isotopes and co-crystals thereof.

[0388] One embodiment of the present invention relates to compounds of the general Formula I- 2,

[0389] wherein

[0390] R2 is selected from hydrogen, fluoro, chloro, bromo, iodo and methoxy, preferably from hydrogen and fluoro, and wherein R4, R5, R6, R7 if present, R8, R9, R10, R1 1 , X1 , X2, and X3 are as described for the compounds of Formula I herein.

[0391] One embodiment relates to compounds of Formula I-2,

[0392] wherein

[0393] X1 is N or C(R7),

[0394] X2 is NH, S or O, preferably NH or O, more preferably NH,

[0395] R2 is hydrogen or fluoro,

[0396] R4 is hydrogen or fluoro,

[0397] R5 is selected from hydrogen and halogen,

[0398] R6 is selected from hydrogen, fluoro, chloro, bromo, iodo, cyano, azido, nitro, unsubstituted or fluorinated Ci-3alkyl, unsubstituted or fluorinated Ci-3alkoxy, methylsulfinyl, methylsulfonyl, cyclopropyl, cyclopropylmethyl, cyclopropylmethoxy, benzyloxy, benzylsulfinyl, thienyl and pyridyl, and is preferably chloro or bromo,

[0399] R7 is selected from hydrogen, fluoro, chloro, bromo, cyano, methyl, methoxy,

[0400] fluoromethyl, fluoromethoxy, methylsulfinyl and methylsulfonyl,

[0401] X3 is N or C(R12),

[0402] R8 is selected from hydrogen, fluoro, chloro, cyano, methoxy and fluoromethoxy,

[0403] R9 is hydrogen or fluoro, preferably hydrogen,

[0404] R10 is selected from fluoro, chloro, bromo, iodo, azido, cyano, oxetanyl, cyano(Ci-2)alkyl, cyano(Ci-2)alkoxy, cyclopropyl(Ci-2)alkyl, cyclobutyl(Ci-2)alkyl, cyclopropyl(Ci-2)alkoxy, optionally fluorinated Ci-2alkoxycyclopropyl, optionally fluorinated Ci-

[0405] 2alkoxycarbonylcyclopropyl, unsubstituted or fluorinated C1-3 alkyl, preferably methyl, ethyl and fluoromethyl, unsubstituted or fluorinated C1-3 alkoxy, preferably methoxy,

[0406] difluoromethoxy, difluoroethoxy and trifluoroethoxy, unsubstituted or fluorinated C2-3 alkenyl, unsubstituted or fluorinated C2-3 alkynyl, unsubstituted or fluorinated C1-3 alkoxy(Ci-3)alkyl, preferably methoxypropyl, ethoxyethyl, and fluoromethoxymethyl, unsubstituted or fluorinated C1-3 alkoxy(Ci-3)alkoxy, preferably methoxyethoxy and fluoromethoxyethoxy, unsubstituted or fluorinated Ci-3 alkoxy(C2-3)alkenyl, preferably methoxypropenyl, ethoxyethenyl and fluoromethoxypropenyl, and pentafluorosulfanyl,

[0407] R1 1 is selected from hydrogen, fluoro, chloro, methoxy, fluoromethoxy and fluoromethyl. R12, if present, is hydrogen or fluoro, preferably hydrogen

[0408] wherein, in a preferred embodiment, at least one of R8 and R1 1 is different from hydrogen,

[0409] wherein, in another preferred embodiment, R6 is not hydrogen,

[0410] and pharmaceutically acceptable salts, solvates, isotopes and co-crystals thereof.

[0411] One preferred embodiment relates to compounds of Formula I-2,

[0412] wherein

[0413] X1 is N, or C(R7),

[0414] X2 is NH, S or O, preferably NH,

[0415] R2 is hydrogen,

[0416] R4 is selected from hydrogen and fluoro, R5 is selected from hydrogen, fluoro, chloro, and bromo,

[0417] R6 is selected from halogen, azido, cyano, benzyloxy, thienyl preferably thien-2-yl, unsubstituted or fluorinated C1-3 alkyl preferably isopropyl and fluoromethyl, cyclopropyl, cyclopropylmethyl, cyclopropylmethoxy, unsubstituted or fluorinated C1-3 alkoxy preferably methoxy, fluoromethoxy and fluoroethoxy, methylsulfinyl and methylsulfonyl, wherein R6 is preferably chloro or bromo,

[0418] R7 is selected from hydrogen, fluoro, bromo, chloro, cyano, methyl, fluoromethyl, methoxy, fluoromethoxy, fluoroethoxy, methylsulfinyl and methylsulfonyl,

[0419] X3 is N or C(R12),

[0420] R8 is selected from hydrogen, fluoro, methoxy and fluoromethoxy, and is preferably fluoro or methoxy,

[0421] R9 selected from hydrogen, fluoro and methoxy and is preferably hydrogen,

[0422] R10 is selected from fluoro, chloro, bromo, iodo, cyano, azido, nitro, pentafluorosulfanyl, Ci-3alkyl, Ci-3alkoxy, C2-3alkenyl, C2-3alkynyl, cyclopropyl, cyclopropylmethoxy and cyclopropylethoxy, wherein each alkyl, alkenyl and alkoxy group in R10 can be substituted with one or more residues selected from fluoro, chloro, cyano, Ci-3alkyloxy and fluoro(Ci- 3)alkyloxy, and wherein each cycloalkyi may be unsubstituted or substituted with a residue selected from fluoro, methyl, C1-2 alkoxy, C1-2 alkoxycarbonyl and cyano,

[0423] R1 1 is selected from hydrogen, fluoro, methyl, fluoromethyl, methoxy, and fluoromethoxy, R12, if present, is hydrogen or fluoro, preferably hydrogen,

[0424] and pharmaceutically acceptable salts, solvates, isotopes and co-crystals thereof, wherein in a preferred embodiment, if X1 is N, then X2 is also N, and

[0425] wherein in another preferred embodiment, at least one of R8 and R1 1 is different from hydrogen.

[0426] One preferred embodiment relates to compounds of Formula I-2,

[0427] wherein

[0428] X1 is N or C(R7),

[0429] X2 is NH,

[0430] R2, R4 and R5 are all hydrogen, R6 is selected from fluoro, chloro, bromo, azido, isopropyl, cyclopropyl, methoxy, fluoromethyl, fluormethoxy, methylsulfonyl, methylsulfinyl and benzyloxy and is preferably chloro or bromo,

[0431] R7 is selected from hydrogen, fluoro, chloro, bromo, cyano, methyl, ethyl, fluoromethyl, fluoroethyl, methoxy, fluoromethoxy, fluoroethoxy, methylsulfinyl and methylsulfonyl,

[0432] X3 is N or C(R12),

[0433] R8 is selected from fluoro and methoxy,

[0434] R9 is hydrogen,

[0435] R10 is selected from fluoro, chloro, bromo, iodo, cyano, azido, cyanomethyl, cyanoethyl, cyanomethoxy, cyanoethoxy, methyl, ethyl, propyl, cyclopropyl, cyclopropylmethyl, cyclopropylethyl, methoxymethyl, methoxyethyl, methoxypropyl, ethoxymethyl, ethoxyethyl, methoxy, ethoxy, propoxy, cyclopropylmethoxy, cyclopropylethoxy, methoxymethoxy, methoxyethoxy, methoxypropoxy, ethoxymethoxy, ethoxyethoxy, propoxymethoxy, ethenyl, propenyl, methoxyethenyl, methoxypropenyl, ethynyl, propynyl, methoxycarbonylethyl, ethoxycarbonylethyl, methoxycarbonylethenyl,

[0436] ethoxycarbonylethenyl, and pentafluorosulfanyl, wherein each alkyl or alkoxy group in R10 can be fluorinated and / or hydroxylated, preferably fluorinated, one or more times, and wherein each cyclopropyl group may be substituted with a substituent selected from fluoro, Ci-2 alkoxy and C1-2 alkoxycarbonyl,

[0437] R1 1 is selected from hydrogen, fluoro, chloro, fluoromethyl, methoxy and fluoromethoxy,

[0438] R12, if present, is hydrogen or fluoro,

[0439] and pharmaceutically acceptable salts, solvates, isotopes and co-crystals thereof.

[0440] One embodiment relates to compounds of Formula I or I-2, wherein

[0441] X1 is N or C(R7),

[0442] X2 is NH, S or O and is preferably NH,

[0443] X3 is N or CR12,

[0444] R2, if present, R4, R5 and R9 are all hydrogen,

[0445] R6 is selected from halogen, cyano, Ci-3alkoxy, Ci-3alkyl, C3-6cycloalkyl preferably C3- 4cycloalkyl, C3-6cycloalkyloxy preferably C3-4cycloalkyloxy, C3-6heterocycloalkyl preferably C3-4heterocycloalkyl, and C3-6heterocycloalkyloxy preferably C3-4heterocycloalkyloxy, each of which can be optionally substituted with a residue selected from fluoro and

[0446] unsubstituted or fluorinated Ci-3alkoxy,

[0447] R7 is selected from hydrogen, halogen, cyano, Ci-3alkoxy, Ci-3alkyl, C3-6cycloalkyl preferably C3-4cycloalkyl, C3-6cycloalkyloxy preferably C3-4cycloalkyloxy, C3- 6heterocycloalkyl preferably C3-4heterocycloalkyl, and C3-6heterocycloalkyloxy preferably C3-4heterocycloalkyloxy, each of which can be optionally substituted with a residue selected from fluoro and unsubstituted or fluorinated Ci-3alkoxy,

[0448] R8 is selected from fluoro, methoxy and fluoromethoxy, preferably from fluoro and methoxy,

[0449] R10 is selected from halogen, Ci-4alkoxy, C2-3alkenyl C2-3alkynyl, C3-6cycloalkyl preferably C3-4cycloalkyl, C3-6cycloalkyloxy preferably C3-4cycloalkyloxy, C3- 6heterocycloalkyl preferably C3-4heterocycloalkyl, and C3-6heterocycloalkyloxy preferably C3-4heterocycloalkyloxy, each of which can be optionally substituted with a residue selected from fluoro, cyano and unsubstituted or fluorinated Ci-3alkoxy,

[0450] R1 1 is selected from hydrogen, fluoro, methoxy and fluoromethoxy, preferably from fluoro and methoxy,

[0451] and R12, if present is selected from hydrogen, fluoro, fluoromethyl, methoxy and fluoromethoxy.

[0452] One embodiment of the present invention relates to compounds of Formula I, wherein X1 is CR7 and X2 is NH, thus having the structure of Formula I I

[0453]

[0454] Formula II wherein R4, R5, R6, R7, R8, R9, R10, R1 1 , R12, if present, and X3 are as described as for Formula I herein and pharmaceutically acceptable salts, solvates, isotopes and co- crystals thereof.

[0455] Another embodiment relates to compounds of Formula I, wherein X1 is N and X2 is NH, thus having the structure of Formula III

[0456]

[0457] Formula III wherein R4, R5, R6, R8, R9, R10, R1 1 , R12, if present, and X3 are as described as for Formula I herein and pharmaceutically acceptable salts, solvates, isotopes and co- crystals thereof.

[0458] Another embodiment relates to compounds of Formula I, wherein X2 is O and X1 is C(R7), thus having the structure of Formula IV

[0459] wherein R4, R5, R6, R7, R8, R9, R10, R1 1 , R12, if present, and X3 are as described as for Formula I herein and pharmaceutically acceptable salts, solvates, isotopes and co- crystals thereof.

[0460] Another embodiment relates to compounds of Formula I, wherein X2 is S and X1 is C(R7), thus having the structure of Formula V

[0461]

[0462] wherein R4, R5, R6, R7, R8, R9, R10, R1 1 , R12, if present, and X3 are as described as for Formula I herein and pharmaceutically acceptable salts, solvates, isotopes and co- crystals thereof.

[0463] It is to be understood that subsequently in any definition of the substituents of compounds of Formula II, III, IV and V, the potential reference to R7 only applies to compounds of Formula II, IV and V, whereas the other substitutions apply to compounds of Formula III as well.

[0464] In one embodiment of the compounds of Formula I, II, III, IV and V, X3 is C(R12).

[0465] In one embodiment of the compounds of Formula I, II, III IV and V, X3 is N.

[0466] In one embodiment, in the compounds having Formula III, at least one of R4, R5 and R6 is different from hydrogen, in particular at least one of R5 and R6 is different from hydrogen.

[0467] In one embodiment, in the compounds of Formula III, if R6 is hydrogen, then R5 is halogen; in one particular embodiment, R5 is iodo.

[0468] In one embodiment, in the compounds of Formula I, II, IV and / or V, at least one of R5, R6 and R7 is different from hydrogen. In one embodiment, in the compounds of Formula I, II, III, IV and / or V, if R6 is hydrogen, then R7 is different from hydrogen, and is preferably selected from fluoro, chloro, bromo, cyano, methoxy, unsubstituted or fluorinated Ci-2alkyl, unsubstituted or fluorinated C1-2 alkoxy, unsubstituted or fluorinated methylsulfonyl, and unsubstituted or fluorinated methylsulfinyl, and is preferably selected from fluoro, chloro, bromo, methyl, methoxy, fluoromethyl, fluoromethoxy, fluoroethoxy, methylsulfonyl and methylsulfinyl.

[0469] In one preferred embodiment, in the compounds of Formula I, II, III, IV and V, if R10 is hydrogen, then R8 and R1 1 are both different from hydrogen.

[0470] A further embodiment relates to compounds of Formula II, III, IV or V,

[0471] wherein

[0472] X3 is N or C(R12),

[0473] R4 is hydrogen,

[0474] R5 is selected from hydrogen, fluoro, chloro and bromo,

[0475] R6 is selected from fluoro, chloro, bromo, iodo, cyano, azido, nitro, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, methylsulfinyl, methylsulfonyl, cyclopropyl, cyclopropylmethyl, methoxy, ethoxy, methoxymethoxy, methoxyethoxy, ethoxymethoxy, cyclopropylmethoxy, phenyl, benzyloxy, phenyloxy, benzylsulfinyl, benzylsulfonyl, thienyl, pyridyl, oxazole, thiazole, and isoxazole, wherein wherein each alkyl and alkoxy group in R6 can be substituted with one or more residues selected from fluoro, cyano, and hydroxy and wherein each phenyl, thienyl, pyridyl, oxazol, thiazole and isoxazol can be optionally substituted one or more times, preferably with a substitution selected from halogen, methoxy, fluoromethoxy, methyl and fluoromethyl, or, in the compounds of Formula II, IV or V, in particular in the compounds of formula II, R6 may form together with R7 and the carbon atoms to which R6 and R7 are attached, a ring selected from phenyl, pyridyl, cycloxhexyl and cyclopentyl, each of which can be unsubstituted or substituted one or more times with a group selected from methyl, fluorinated methyl, methoxy, fluorinated methoxy, hydroxy, chloro and fluoro,

[0476] R7 is selected from hydrogen, fluoro, chloro, bromo, iodo, cyano, methoxy, ethoxy, methylsulfinyl, methylsulfonyl, methyl, ethyl, fluoromethyl, fluoroethyl, and fluoro(Ci- 2)alkoxy, or R7 forms a ring together with R6 as described herein,

[0477] R8 is selected from hydrogen, fluoro, chloro, bromo, iodo, methoxy, fluoromethyl and fluoromethoxy, or R8 forms a ring system together with R10, as described herein, R9 is selected from hydrogen, methyl, methoxy, fluoro and chloro and is preferably hydrogen,

[0478] or R9 forms together with R8 or R10 and the ring to which they are attached a bicyclic ring system selected from 2,1 ,3-benzothiadiazole, 2,1 ,3-benzoxadiazole, 2-oxo-2,3-dihydro- 1 ,3-benzoxazole and 1 ,3-benzodioxole, which is optionally substituted with two fluoros, or R9 forms together with R10 and the ring to which they are attached a bicyclic ring system selected from 3-oxo-2,3-dihydro-1 H-isoindol, 1 ,1-dioxo-2,3-dihydro-1- benzothiophene, 3-oxo-1 ,3-dihydro-2-benzofuran which can be optionally methylated in 1 position,

[0479] R10 is selected from hydrogen, fluoro, chloro, bromo, iodo, unsubstituted or fluorinated Ci- 3alkenyl including ethenyl and propenyl, unsubstituted or fluorinated Ci-3alkynyl including ethynyl and propargyl, unsubstituted or fluorinated and / or hydroxylated Ci-3alkyl including methyl, ethyl, isopropyl and trifluoromethyl, unsubstituted or fluorinated and / or

[0480] hydroxylated Ci-3alkoxy including methoxy and fluoro(Ci-2)alkoxy, cyano, cyanomethyl, cyanomethoxy, cyclopropyl, cyclopropylmethoxy, cyclopropylethoxy, acetyl, azido, nitro, pentafluorosulfanyl, unsubstituted or fluorinated and / or hydroxylated Ci-3alkoxy(Ci-3)alkyl, preferably methoxypropyl and ethoxyethyl, unsubstituted or fluorinated and / or

[0481] hydroxylated Ci-3alkoxy(Ci-3)alkoxy, preferably methoxyethoxy and fluoromethoxyethoxy, unsubstituted or fluorinated and / or hydroxylated Ci-3alkoxy(C2-3)alkenyl, preferably methoxypropenyl and ethoxyethenyl, unsubstituted or fluorinated and / or hydroxylated Ci-3alkoxy(C2-3)alkynyl, unsubstituted or fluorinated and / or hydroxylated Ci-3alkoxycarbonyl(Ci-3)alkyl preferably ethoxycarbonylethyl, and unsubstituted or fluorinated and / or hydroxylated Ci-3alkoxycarbonyl(Ci-3)alkenyl preferably ethoxycarbonylethenyl, wherein each cyclopropyl group in R10 may be unsubstituted or further substituted with one or more substituents selected from fluoro, chloro, cyano, optionally fluorinated Ci- 2alkoxy and optionally fluorinated Ci-2alkoxycarbonylor R10 forms a ring system together with R9, as described herein,

[0482] R11 is selected from hydrogen, fluoro, chloro, bromo, unsubstituted or fluorinated methyl, and unsubstituted or fluorinated methoxy,

[0483] R12, if present, is selected from hydrogen, fluoro, chloro, or bromo, and is preferably hydrogen or fluoro;

[0484] wherein, in a preferred embodiment, at least one, preferably two of R8, R10 and R1 1 , are different from hydrogen and unsubstituted alkyl,

[0485] and wherein in one embodiment the residues in R10 are preferably unsubstituted or fluorinated, and pharmaceutically acceptable salts, solvates, isotopes and co-crystals thereof.

[0486] One embodiment relates to compounds of Formula I I, I I I IV and V, wherein

[0487] X3 is N or C(R12),

[0488] R4 is hydrogen,

[0489] R5 is selected from hydrogen, fluoro, chloro and bromo, R6 is selected from fluoro, chloro, bromo, azido, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, methylsulfinyl, methylsulfonyl, cyclopropyl, methoxy, phenyl, benzyloxy, thiophen-2-yl, and thiophen-3-yl, wherein each alkyl and alkoxy group in R6 can be unsubstituted or substituted with one or more residues selected from fluoro, cyclopropyl and methoxy, preferably with fluoro,

[0490] R7 is selected from hydrogen, fluoro, chloro, bromo, cyano, methyl, ethyl, methylsulfinyl, methylsulfonyl, fluoromethyl, fluoroethyl, methoxy, fluoromethoxy, fluoroethoxy, and fluoropropoxy,

[0491] R8 is selected from hydrogen, fluoro, chloro, bromo, methoxy, fluoromethyl and fluoromethoxy, or R8 forms a ring system together with R10, as described herein,

[0492] R9 is hydrogen or fluoro, preferably hydrogen,

[0493] or R9 forms together with R8 or R10 and the ring to which they are attached a bicyclic ring system selected from 2,1 ,3-benzothiadiazole, 2,1 ,3-benzoxadiazole, 2-oxo-2,3-dihydro- 1 ,3-benzoxazole, 1 ,3-benzodioxole, or 2,2-difluoro-1 ,3-benzodioxole,

[0494] or R9 forms together with R10 and the ring to which they are attached a bicyclic ring system selected from 3-oxo- 2,3-dihydro-1 H-isoindol, 1 ,1-dioxo-2,3-dihydro-1- benzothiophene, 3-oxo-1 ,3-dihydro-2-benzofuran and 1-methyl-3-oxo-1 ,3-dihydro-2- benzofuran,

[0495] R10 is selected from hydrogen, fluoro, chloro, bromo, iodo, methyl, ethyl, propyl, ethenyl, propenyl, ethynyl, propargyl, fluoro(Ci-3) alkyl preferably trifluoromethyl, methoxy, ethoxy, fluoro(Ci-3)alkoxy, cyano, cyanomethyl, cyanoethyl, cyanomethoxy, acetyl, azido, unsubstituted or fluorinated Ci-3alkoxy(Ci-3)alkyl, unsubstituted or fluorinated C1-3 alkoxy(Ci-3)alkoxy, unsubstituted or fluorinated Ci-3alkoxy(C2-3)alkenyl, unsubstituted or fluorinated Ci-3alkoxy(C2-3)alkynyl, unsubstituted or fluorinated Ci-3 alkoxycyclopropyl, unsubstituted or fluorinated Ci-3 alkoxycarbonylcyclopropyl, and pentafluorosulfanyl, or R10 forms a ring system together with R9, as described herein, and wherein, in a preferred embodiment, R8 and R10 are not both hydrogen, R1 1 is selected from hydrogen, fluoro, chloro, fluorinated methyl, and unsubstituted or fluorinated methoxy,

[0496] R12, if present, is selected from hydrogen and fluoro,

[0497] and pharmaceutically acceptable salts, solvates, isotopes and co-crystals thereof.

[0498] A further embodiment relates to compounds of Formula II, III or IV,

[0499] wherein

[0500] X3 is N or C(R12),

[0501] R4 and R5 are both hydrogen,

[0502] R6 is is selected from fluoro, chloro, bromo, iodo, cyano, azido, methyl, ethyl, isopropyl, trifluoromethyl, acetyl, methylsulfinyl, methylsulfonyl, cyclopropyl, cyclopropylmethyl, methoxy, ethoxy, methoxyethoxy, cyclopropylmethoxy, phenyl, benzyloxy, phenyloxy, thienyl, pyridyl, oxazole, thiazole, and isoxazole,

[0503] or R6 forms together with R7 and the carbon atoms to which R6 and R7 are attached, a ring selected from phenyl, pyridyl, and cyclopentyl,R7 is selected from hydrogen, fluoro, chloro, bromo, iodo, methoxy, ethoxy, methyl, trifluoromethyl and fluoro(Ci-2)alkoxy, or R7 forms a ring together with R6 as described herein,

[0504] R8 is selected from hydrogen, fluoro, chloro, bromo, iodo, methoxy, methyl, and trifluoromethyl, or R8 forms a ring system together with R10, as described herein, R9 is selected from hydrogen, fluoro and chloro and is preferably hydrogen,

[0505] or R9 forms together with R8 or R10 and the ring to which they are attached a bicyclic ring system selected from 2,1 ,3-benzothiadiazole, 2,1 ,3-benzooxadiazole, 2-oxo-2,3-dihydro- 1 ,3-benzoxazole and 1 ,3-benzodioxole, which is optionally substituted with two fluoros, R10 is selected from hydrogen, fluoro, chloro, bromo, iodo, ethynyl, propargyl, trifluoromethyl, methoxy, fluoro(Ci-2)alkoxy, cyano, cyanomethyl, acetyl, azido, pentafluorosulfanyl, and methoxycarbonyl, or R10 forms a ring system together with R9, as described herein,

[0506] R1 1 is selected from hydrogen, fluoro, chloro, bromo, and methoxy,

[0507] R12 is selected from hydrogen, fluoro, chloro, or bromo.

[0508] wherein, in a preferred embodiment, at least one of R8, R9, R10 and R1 1 is different from hydrogen and unsubstituted alkyl,

[0509] and pharmaceutically acceptable salts, solvates, isotopes and co-crystals thereof. One embodiment relates to compounds of Formula II, II I and IV, wherein

[0510] X3 is N or C(R12),

[0511] R4 and R5 are both hydrogen, R6 is selected from fluoro, chloro, bromo, azido, methyl, isopropyl, trifluoromethyl, methylsulfonyl, cyclopropyl, methoxy, phenyl, benzyloxy, thiophen-2-yl, and thiophen-3-yl,

[0512] R7 is selected from hydrogen, fluoro, chloro, and methoxy,

[0513] R8 is selected from hydrogen, fluoro, chloro, bromo, methoxy, and trifluoromethyl, or R8 forms a ring system together with R10, as described herein,

[0514] R9 is hydrogen or fluoro, preferably hydrogen,

[0515] or R9 forms together with R8 or R10 and the ring to which they are attached a bicyclic ring system selected from 2, 1 ,3-benzothiadiazole, 2, 1 ,3-benzooxadiazole, 2-oxo-2,3-dihydro- 1 ,3-benzoxazole, 1 ,3-benzodioxole, or 2,2-difluoro-1 ,3-benzodioxole,

[0516] R10 is selected from hydrogen, fluoro, chloro, bromo, iodo, methyl, ethynyl,

[0517] trifluoromethyl, methoxy, fluoro(Ci-2)alkoxy, cyano, cyanomethyl, acetyl, azido, and pentafluorosulfanyl, or R10 forms a ring system together with R9, as described herein, and wherein, in a preferred embodiment, R8 and R10 are not both hydrogen,

[0518] R1 1 is selected from hydrogen, fluoro, chloro, and methoxy,

[0519] R12 is selected from hydrogen, and fluoro,

[0520] and pharmaceutically acceptable salts, solvates, isotopes and co-crystals thereof.

[0521] One embodiment relates to compounds of Formula I I, I I I IV or V,

[0522] wherein

[0523] R4 and R5 are both hydrogen,

[0524] R6 is methoxy, trifluoromethyl, bromo or chloro, preferably chloro,

[0525] R7 is hydrogen, fluoro, methoxy, or trifluoromethyl,

[0526] X3 is C(R12),

[0527] R9 forms together with R8 or R10 and the phenyl ring to which R8 and R9, or R9 and R10 are attached, a 2, 1 ,3-benzothiadiazole or 2, 2-difluoro-1 ,3-benzodioxole,

[0528] R10 is selected from hydrogen and fluoro, R1 1 is selected from hydrogen, fluoro and methoxy, and is preferably hydrogen, and R12, if present, is hydrogen or fluoro,

[0529] and pharmaceutically acceptable salts, solvates, isotopes and co-crystals thereof.

[0530] One embodiment relates to compounds of Formula II, III or IV,

[0531] wherein

[0532] R4 and R5 are both hydrogen,

[0533] R6 is bromo or chloro, preferably chloro,

[0534] R7 is hydrogen, fluoro, methoxy, or trifluoromethyl,

[0535] X3 is C(R12),

[0536] R9 forms together with R8 or R10 and the phenyl ring to which R8 and R9, or R9 and R10 are attached, a 2, 1 ,3-benzothiadiazole or 2,2-difluoro-1 ,3-benzodioxole,

[0537] R10 is selected from hydrogen and fluoro,

[0538] R1 1 is selected from hydrogen, fluoro and methoxy, and

[0539] R12 is hydrogen,

[0540] and pharmaceutically acceptable salts, solvates, isotopes and co-crystals thereof.

[0541] One preferred embodiment relates to compounds of Formula I,

[0542] wherein

[0543] R 4 and R5 are both hydrogen,

[0544] R6 is chloro or bromo, preferably chloro,

[0545] R7 is hydrogen, fluoro, methoxy, or trifluoromethyl,

[0546] X3 is N or C(R12),

[0547] R8 is selected from fluoro, chloro and methoxy,

[0548] R9 is hydrogen,

[0549] R10 is selected from fluoro, chloro, bromo, cyano, cyanomethyl, trifluoromethyl and pentafluorosulfanyl,

[0550] R1 1 is selected from hydrogen, fluoro and methoxy,

[0551] R12 is hydrogen and pharmaceutically acceptable salts, solvates, isotopes and co-crystals thereof.

[0552] One preferred embodiment of the present invention relates to compound of Formula II, III IV or V, wherein

[0553] X3 is N or C(R12),

[0554] R4 is hydrogen or fluoro, preferably hydrogen,

[0555] R5 is selected from hydrogen, fluoro, chloro, bromo, iodo, methyl, methoxy, and fluorinated C1-2 alkyl, including trifluoromethyl, preferably hydrogen, methyl, fluoro, chloro, bromo or iodo, or R5 forms a ring together with R6 as described herein,

[0556] R6 is selected from hydrogen, fluoro, chloro, bromo, iodo, cyano, azido, unsubstituted or substituted C1-3 alkyl, preferably methyl, ethyl, isopropyl, difluoromethyl, difluoroethyl, trifluoroethyl and / trifluoromethyl, unsubstituted or substituted C2-3 alkenyl, unsubstituted or substituted C2-3 alkynyl, unsubstituted or unsubstituted or substituted (Ci-3)alkylsulfinyl preferably methylsulfinyl, unsubstituted or unsubstituted or substituted C1-3 alkylsulfonyl preferably methylsulfonyl, unsubstituted or substituted C3-6 cycloalkyl preferably cyclopropyl, unsubstituted or substituted C3-6 cycloalkyl(Ci-3)alkyl preferably

[0557] cyclopropylmethyl, unsubstituted or substituted C3-6 cycloalkyl(Ci-3)alkyloxy preferably cyclopropylmethoxy, unsubstituted or substituted C3-6 heterocycloalkyl, unsubstituted or substituted C3-6 heterocycloalkyl(Ci-3)alkyloxy preferably heterocyclopropylmethoxy unsubstituted or substituted C3-6 cycloalkoxy, unsubstituted or substituted C3-6

[0558] heterocycloalkoxy, unsubstituted or substituted C1-3 alkoxy preferably methoxy, difluoromethoxy, trifluoromethoxy, difluoroethoxy, trifluoroethoxy unsubstituted or substituted Ci-3alkoxy(Ci-3)alkoxy, preferably methoxyethoxy, unsubstituted or substituted Ci-3alkoxy(Ci-3)alkyl, C3-6 cycloalkyl(Ci-3)alkoxy preferably cyclopropylmethoxy, unsubstituted or substituted phenyl, unsubstituted or substituted phenyl(Ci-3)alkyl preferably benzyl, unsubstituted or substituted phenyl(Ci-3)alkoxy preferably benzyloxy, unsubstituted or substituted phenyloxy, unsubstituted or substituted phenyl(Ci- 3)alkylsulfonyl preferably benzylsulfonyl, unsubstituted or substituted phenyl(Ci- 3)alkylsulfinyl preferably benzylsulfinyl, unsubstituted or substituted thienyl, unsubstituted or substituted pyridyl, unsubstituted or substituted oxazole, unsubstituted or substituted thiazole, and unsubstituted or substituted isoxazole, and wherein each optional substitution in R6 is preferably selected from fluoro, chloro, unsubstituted or fluorinated methyl, unsubstituted or fluorinated methoxy, hydroxy, and cyano, provided that in the compounds of Formula I I I, if R6 is hydrogen, then at least one of R5 and R7 is different from hydrogen, wherein R5 is preferably iodo,

[0559] or

[0560] (i) R6 forms together with R7 and the carbon atoms to which R6 and R7 are attached, an unsubstituted or substituted phenyl, an unsubstituted or substituted pyridyl, an unsubstituted or substituted cyclopentyl or an unsubstituted or substituted cyclohexyl,

[0561] wherein each substitution, if present, is selected from halogen, hydroxy, methyl or methoxy, wherein each methyl or methoxy can be unsubstituted or substituted with one or more substituents selected from halogen, preferably fluoro, and methoxy, or

[0562] (ii) R6 forms together with R5 and the carbon atoms to which R6 and R5 are attached, a 1 ,3-dioxolane which may be unsubstituted or substituted with one or two substituents selected from fluoro and methyl,

[0563] R7 is selected hydrogen, fluoro, chloro, bromo, iodo, cyano, C1-3 alkyl, Ci-3 alkyloxy preferably methoxy, fluoro(Ci-3)alkyl preferably difluoromethyl or trifluoromethyl, fluoro(Ci- 3)alkoxy preferably difluoromethoxy, difluoroethoxy, trifluoroethoxy and trifluoromethoxy, methylsulfinyl, methylsulfonyl, fluorinated methylsulfinyl, fluorinated methylsulfonyl, substituted or unsubstituted C3-6 cycloalkyl, substituted or unsubstituted C3-6

[0564] heterocycoalkyl, substituted or unsubstituted C3-6 cycloalkyloxy, substituted or unsubstituted C3-6 heterocycoalkyloxy, substituted or unsubstituted C5-6 heteroaryl, substituted or unsubstituted C5-6 heteroaryloxy, and C5-6 heteroarylmethoxy, wherein the heteroaryl is preferably selected from pyridyl, oxazol and isoxazol, and wherein the heteroaryl may be substituted with one or more substituents selected from halogen, unsubstituted or fluorinated methyl, unsubstituted or fluorinated methoxy, or R7 forms a ring together with R6 as described herein,

[0565] R8 is selected from hydrogen, fluoro, chloro, bromo, iodo, cyano, Ci-3 alkyloxy preferably methoxy, fluoro(Ci-3)alkoxy, C1-3 alkyl preferably methyl, and fluoro(Ci-3)alkyl preferably trifluoromethyl,

[0566] R9 is selected from hydrogen, fluoro, chloro, bromo, iodo, cyano, Ci-3 alkyloxy preferably methoxy, fluoro(Ci-3)alkoxy, C1-3 alkyl preferably methyl, and fluoro(Ci-3)alkyl preferably trifluoromethyl, and is preferably hydrogen, methoxy, or fluoro,

[0567] R10 is selected from hydrogen, fluoro, chloro, bromo, iodo, C1-3 alkyl, halo(Ci-3)alkyl, preferably fluoro(Ci-3)alkyl preferably trifluoromethyl, C2-3 alkenyl, C2-3 alkynyl, C1-3 alkyloxy, halo(Ci-3)alkyloxy preferably fluoro(Ci-3)alkoxy, cyano, cyanomethyl, cyanoethyl, unsubstituted or fluorinated C1-3 alkylcarbonyl preferably acetyl, unsubstituted or fluorinated C1-3 alkoxycarbonyl preferably methoxycarbonyl, cyclopropyl, cyclopropyloxy, azido, pentafluorosulfanyl, and nitro, wherein any cyclopropyl residue is preferably substituted with a group selected from fluoro, cyano, Ci-3alkoxy and Ci-3alkoxycarbonyl, and wherein each alkyl, alkoxy, alkenyl or alkynyl in R10 can be optionally further substituted with one or more substituents selected from cyclopropyl, fluoro, chloro, bromo, iodo, cyano, hydroxy, halo(Ci-3)alkoxy and C1-3 alkoxy, preferably with fluoro, methoxy, fluoromethoxy or fluoroethoxy,

[0568] R1 1 is selected from hydrogen, fluoro, chloro, cyano, C1-3 alkyl preferably methyl, fluoro(Ci-3)alkyl preferably fluoromethyl, C1-3 alkyloxy preferably methoxy, fluoro(Ci- 3)alkoxy preferably fluoro(Ci-2)alkoxy, and is more preferably hydrogen, fluoro, chloro, methoxy, fluoromethoxy or fluoromethyl,

[0569] R12, if present, is selected from hydrogen, fluoro, chloro, bromo, iodo, C1-3 alkyloxy preferably methoxy, fluoro(Ci-3)alkoxy preferably fluoro(Ci-2)alkoxy, C1-3 alkyl preferably methyl, and fluoro(Ci-3)alkyl preferably trifluoromethyl, and is more preferably hydrogen, fluoro, or fluoromethyl,

[0570] wherein, in a preferred embodiment, at least one of R8, R10 and R1 1 is different from hydrogen, and more preferably at least one of R8, R10 and R1 1 is also different from unsubstituted alkyl,

[0571] and wherein, preferably, in the compounds of Formula II, at least one of R5, R6 and R7, if present, is not hydrogen,

[0572] and pharmaceutically acceptable salts, solvates, isotopes and co-crystals thereof.

[0573] One preferred embodiment of the present invention relates to compound of Formula II, III or IV, wherein

[0574] X3 is N or C(R12),

[0575] R4 is hydrogen,

[0576] R5 is selected from hydrogen, fluoro, chloro, bromo, iodo, methyl, methoxy, acetyl, methoxycarbonyl and trifluoromethyl, preferably hydrogen, methyl or iodo, or R5 forms a ring together with R6 as described herein,

[0577] R6 is selected from hydrogen, fluoro, chloro, bromo, iodo, cyano, azido, unsubstituted or substituted C1-3 alkyl, preferably methyl, ethyl, isopropyl, or trifluoromethyl, unsubstituted or fluorinated C1-2 alkylcarbonyl, unsubstituted or fluorinated C1-2 alkoxycarbonyl, (Ci- 3)alkylsulfinyl preferably methylsulfinyl, C1-3 alkylsulfonyl preferably methylsulfonyl, C3-6 cycloalkyl preferably cyclopropyl, C3-6 cycloalkyl(Ci-3)alkyl preferably cyclopropylmethyl, C3-6 heterocycloalkyl, C3-6 cycloalkoxy, C3-6 heterocycloalkoxy, unsubstituted or substituted C1-3 alkoxy preferably methoxy, unsubstituted or substituted Ci-3alkoxy(Ci- 3)alkoxy, preferably methoxyethoxy, C3-6 cycloalkyl(Ci-3)alkoxy preferably

[0578] cyclopropylmethoxy, unsubstituted or substituted phenyl, unsubstituted or substituted phenyl(Ci-3)alkoxy preferably benzyloxy, unsubstituted or substituted phenyloxy, thienyl, pyridyl, oxazole, thiazole, and isoxazole, and wherein each optional substitution in R6 is preferably selected from fluoro, chloro, methyl, methoxy, and cyano,

[0579] provided that in the compounds of Formula III, if R6 is hydrogen, then R5 is different from hydrogen, and is preferably iodo,

[0580] or

[0581] (i) R6 forms together with R7 and the carbon atoms to which R6 and R7 are attached, an unsubstituted or substituted phenyl, an unsubstituted or substituted pyridyl, an unsubstituted or substituted cyclopentyl or an unsubstituted or substituted cyclohexyl,

[0582] wherein each substitution, if present, is selected from halogen, methyl or methoxy, wherein each methyl or methoxy can be unsubstituted or substituted with one or more substituents selected from fluoro and methoxy,

[0583] or

[0584] (ii) R6 forms together with R5 and the carbon atoms to which R6 and R5 are attached, a 1 ,3-dioxolane which may be unsubstituted or substituted with one or two substituents selected from fluoro and methyl,

[0585] R7 is selected hydrogen, fluoro, chloro, bromo, iodo, cyano, C1-3 alkyl, C1-3 alkyloxy, fluoro(Ci-3)alkyl preferably trifluoromethyl, fluoro(Ci-3)alkoxy preferably trifluoromethoxy, unsubstituted or fluorinated C1-2 alkylcarbonyl, unsubstituted or fluorinated C1-2

[0586] alkoxycarbonyl, methylsulfinyl, and methylsulfonyl, or R7 forms a ring together with R6 as described herein,

[0587] R8 is selected from hydrogen, fluoro, chloro, bromo, iodo, C1-3 alkyloxy preferably methoxy, fluoro(Ci-3)alkoxy, C1-3 alkyl preferably methyl, and fluoro(Ci-3)alkyl preferably trifluoromethyl, R9 is selected from hydrogen, fluoro, chloro, bromo, iodo, cyano, Ci-3 alkyloxy preferably methoxy, fluoro(Ci-3)alkoxy, C1-3 alkyl preferably methyl, and fluoro(Ci-3)alkyl preferably trifluoromethyl, and is preferably hydrogen fluoro, chloro, or bromo,

[0588] R10 is selected from hydrogen, fluoro, chloro, bromo, iodo, C1-3 alkyl, halo(Ci-3)alkyl, preferably fluoro(Ci-3)alkyl, particularly trifluoromethyl, C2-3 alkynyl, C1-3 alkyloxy, halo(Ci-3) alkyloxy, preferably fluoro(Ci-2)alkoxy, cyano, cyanomethyl, unsubstituted or fluorinated C1-3 alkylcarbonyl preferably acetyl, unsubstituted or fluorinated C1-3 alkoxycarbonyl preferably methoxycarbonyl, azido, pentafluorosulfanyl, and nitro,

[0589] R11 is selected from hydrogen, fluoro, chloro, bromo, iodo, C1-3 alkyl preferably methyl, fluoro(Ci-3)alkyl preferably trifluoromethyl, C1-3 alkyloxy preferably methoxy, fluoro(Ci- 3)alkoxy, preferably fluoro(Ci-2)alkoxy, unsubstituted or fluorinated C1-3 alkylcarbonyl preferably acetyl, unsubstituted or fluorinated C1-3 alkoxycarbonyl preferably

[0590] methoxycarbonyl and cyano, and, and is more preferably hydrogen, fluoro, chloro or bromo,

[0591] R12 is selected from hydrogen, fluoro, chloro, bromo, iodo, C1-3 alkyloxy preferably methoxy, fluoro(Ci-3)alkoxy preferably fluoro(Ci-2)alkoxy, C1-3 alkyl preferably methyl, and fluoro(Ci-3)alkyl preferably trifluoromethyl, and is more preferably hydrogen, fluoro, chloro, or bromo,

[0592] wherein, in a preferred embodiment, at least one of R8, R9, R10 and R1 1 is different from hydrogen, and more preferably at least one of R8, R9, R10 and R11 is also different from unsubstituted alkyl,

[0593] and pharmaceutically acceptable salts, solvates, isotopes and co-crystals thereof

[0594] One preferred embodiment of the present invention relates to compounds of Formula I I, I I I IV or V, wherein

[0595] R4 is hydrogen or fluoro, more preferably hydrogen,

[0596] R5 is selected from hydrogen, fluoro, bromo, chloro, iodo and methyl,

[0597] R6 is selected from hydrogen, fluoro, chloro, bromo, iodo, methyl, ethyl, propyl preferably isopropyl, acetyl, cyano, nitro, azido, methylsulfonyl, methylsulfinyl, fluoro(Ci-2)alkyl, methoxy, ethoxy, fluoro(Ci-2)alkoxy, Ci-2alkoxymethoxy, fluorinated (Ci-2)alkoxymethoxy, fluorinated (Ci-2)alkoxymethyl, phenyl, phenoxy, benzyloxy, benzylsulfinyl, pyrid-3-yl, thien-2-yl, thien-3-yl, cyclopropyl, cyclopropyloxy, cyclopropylmethyl, and

[0598] cyclopropylmethoxy, wherein each phenyl, thienyl, pyridyl, and cyclopropyl can be optionally substituted one or more times with methoxy, fluoro and / or chloro, and wherein R6 is preferably not hydrogen,

[0599] or, in compounds of Formula II, R6 may form, together with R7 and the carbon atoms to which R6 and R7 are attached a ring selected from an unsubstituted or substituted phenyl, unsubstituted or substituted pyridyl, and unsubstituted or substituted cyclohexyl, and unsubstituted or substituted cyclopentyl, wherein any substitution of such phenyl, pyridyl and cyclopentyl is selected from fluoro, chloro, hydroxy, fluorinated or unsubstituted methoxy and fluorinated or unsubstituted methyl, wherein the ring is preferably selected from unsubstituted phenyl, pyridyl or cyclopentyl,

[0600] R7 is selected from hydrogen, fluoro, chloro, bromo, cyano, methyl, methoxy,

[0601] methylsulfonyl, methylsulfinyl, fluoromethyl, fluoroethyl, fluoromethoxy, fluoroethoxy, and optionally methylated isoxazol which is preferably 3,5-dimethyl-1 ,2-oxazol,

[0602] X3 is N or C(R12), and is preferably C(R12),

[0603] R8 is selected from hydrogen, methoxy, fluoromethoxy, cyano, chloro and fluoro, and is preferably fluoro, methoxy or fluoromethoxy,

[0604] R9 is selected from hydrogen, methoxy, and fluoro,

[0605] R10 is selected from hydrogen, ethenyl, propenyl, ethynyl, propargyl, cyano, cyanomethyl, acetyl, fluoro, chloro, bromo, iodo, azido, nitro,unsubstituted or fluorinated Ci-3alkyl, preferably methyl and trifluoromethyl, hydroxy(Ci-3)alkoxy preferably hydroxyethoxy, cyano(Ci-3)alkoxy preferably cyanomethoxy, cyclopropyl(Ci-2)alkyl, cyclopropyl(Ci-3)alkoxy preferably cyclopropylmethoxy, unsubstituted or fluorinated Ci-3 alkoxy preferably difluoroethoxy and trifluoroethoxy, unsubstituted or fluorinated Ci-2alkoxy(Ci-3)alkyl preferably methoxypropyl and ethoxyethyl, unsubstituted or fluorinated Ci-2alkoxy(Ci- 3)alkoxy preferably methoxyethoxy and fluoromethoxyethoxy, unsubstituted or fluorinated Ci-2alkoxy(C2-3)alkenyl preferably methoxypropenyl, unsubstituted or fluorinated Ci-2alkoxy (C2-3)alkynyl, and pentafluorosulfanyl, Ci-2alkoxycyclopropyl and Ci- 2alkoxycarbonylcyclopropyl,

[0606] R11 is selected from hydrogen, fluoro, chloro, cyano, fluoromethyl, methoxy and fluoromethoxy,

[0607] R12 is hydrogen or fluoro,

[0608] and wherein at least one, pereferably at least two of R8, R10 and R11 are different from hydrogen,

[0609] and pharmaceutically acceptable salts, solvates, isotopes and co-crystals thereof. One preferred embodiment of the present invention relates to compounds of Formula II, III or IV, wherein

[0610] R4 is hydrogen or fluoro, more preferably hydrogen,

[0611] R5 is hydrogen, iodo, or methyl,

[0612] R6 is selected from hydrogen, fluoro, chloro, bromo, iodo, methyl, ethyl, isopropyl, acetyl, trifluoromethyl, methoxy, ethoxy, fluoro(Ci-2)alkoxy, (Ci-2)alkoxymethoxy,

[0613] cyanomethylsulfonyl, phenyl, phenoxy, benzyloxy, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-thienyl, 3-thienyl, cyclopropyl, cyclopropyloxy, and cyclopropylmethoxy,

[0614] or R6 forms, together with R7 and the carbon atoms to which R6 and R7 are attached a ring selected from an unsubstituted or substituted phenyl, unsubstituted or substituted pyridyl, and unsubstituted or substituted cyclopentyl, wherein any substitution is selected from fluoro, methoxy and methyl, wherein the ring is preferably selected from

[0615] unsubstituted phenyl, pyridyl or cyclopentyl,

[0616] and wherein in Formula II, if R6 is hydrogen, then R5 is iodo,

[0617] R7 is selected from hydrogen, methyl, methoxy, trifluoromethyl, fluoro, chloro and bromo,

[0618] X3 is N or C(R12), and is preferably C(R12),

[0619] R8 is selected from hydrogen, methoxy, cyano, chloro and fluoro,

[0620] R9 is selected from hydrogen and fluoro,

[0621] R10 is selected from hydrogen, ethynyl, cyano, cyanomethyl, acetyl, fluoro, chloro, bromo, iodo, azido, nitro, trifluoromethyl, difluoroethoxy, trifluoroethoxy, and pentafluorosulfanyl,

[0622] R1 1 is selected from hydrogen, fluoro, chloro, and methoxy,

[0623] R12 is hydrogen or fluoro

[0624] and wherein at least one of R8, R9, R10 and R1 1 is different from hydrogen

[0625] and pharmaceutically acceptable salts, solvates, isotopes and co-crystals thereof.

[0626] One preferred embodiment of the present invention relates to compound of Formula II, III IV or V, particularly preferably of Formula II or III, wherein

[0627] R4 is hydrogen,

[0628] R5 is selected from hydrogen, fluoro, chloro and bromo, and is preferably hydrogen, R6 is selected from fluoro, chloro, bromo, cyano, methyl, ethyl, propyl preferably isopropyl, methylsulfinyl, methylsulfonyl, cyclopropyl, cyclopropyloxy, benzyloxy, thienyl, methoxy, ethoxy, fluoro(Ci-3 )alkoxy and fluoro(Ci-3)alkyl preferably trifluoromethyl,

[0629] R7 is selected from hydrogen, methoxy, fluoro, chloro, bromo, cyano, methylsulfinyl, methylsulfonyl, Ci-3alkoxy, fluoro(Ci-3 )alkoxy, Ci-3alkyl and fluoro(Ci-3 )alkyl preferably trifluoromethyl,

[0630] or, in compounds of Formula II, R6 and R7, together with the ring-forming C atoms to which they are attached, may form a ring selected from phenyl, cyclopentyl and pyridyl, each of which may be unsubstituted or substituted with one or more residues selected from fluoro, chloro, hydroxy, fluorinated or unsubstituted methoxy and fluorinated or unsubstituted methyl, wherein the phenyl, cyclopentyl and cyclohexyl rings are preferably unsubstituted and wherein the pyroidyl ring is preferably unsubstituted or substituted in 8- position, X3 is -C(R12)- or N,

[0631] R8 is hydrogen, fluoro, methoxy or fluoromethoxy, and is preferably fluoro or methoxy, R9 is hydrogen,

[0632] R10 is selected from halogen, azido, nitro, cyano, Ci-3alkyl, C2-3alkenyl, C2-3alkynyl, C1-3 alkoxy, C3-scycloalkyl preferably cyclopropyl, C3-5cycloalkyloxy and pentafluorosulfanyl, wherein each alkyl, alkenyl, alkynyl and alkoxy can be unsubstituted or substituted with one or more residues selected from halogen preferanly fluoro, cyano, cyclopropyl, Ci- 3alkoxy, and fluoroCi-3alkoxy, and wherein any cycloalkyl moiety can be unsubstituted or substituted with one or more residues selected from fluoro, cyano, unsubstituted or fluorinated Ci-3alkoxy and unsubstituted or fluorinated Ci-3alkoxycarbonyl,

[0633] R1 1 is selected from hydrogen, fluoro, chloro, cyano, methoxy, fluoromethoxy, and fluoromethyl, and

[0634] R12 is selected from hydrogen and fluoro,

[0635] wherein preferably at least one of R8 and R1 1 is different from hydrogen, and wherein preferably at least one of R8 and R1 1 is selected from fluoro, chloro and methoxy, and pharmaceutically acceptable salts, solvates, isotopes and co-crystals thereof.

[0636] One embodiment relates to compounds of Formula II, III IV and V, preferably of Formula II and III;

[0637] wherein

[0638] R4 and R5 are both hydrogen, R6 is selected from methyl, ethyl, propyl, methylsulfonyl, methylsulfinyl, methoxy, mono-, di- and trifluoromethyl, mono-, di- and trifluoroethyl, mono-, di- and trifluoromethoxy, mono-, di- and trifluoroethoxy, cyano, azido, fluoro, bromo and chloro, and is preferably selected from chloro and bromo,

[0639] R7, if present, is selected from hydrogen, fluoro, chloro, bromo, cyano, methoxy, fluoromethoxy, fluoroethoxy, methyl, fluoromethyl, methylsulfinyl and methylsulfonyl,

[0640] X3 is C(R12),

[0641] R8 is selected from hydrogen, fluoro, chloro and methoxy, or forms a ring with R9 as described herein,

[0642] R9 forms together with R8 or R10 and the phenyl ring to which R8 and R9, or R9 and R10 are attached, a 2, 1 ,3-benzothiadiazole or 1 ,3-benzodioxole which is optionally substituted with two fluoros,

[0643] R10 is selected from hydrogen and fluoro, or R10 forms a ring together with R9 as described above,

[0644] R1 1 is selected from hydrogen, fluoro and methoxy,

[0645] R12 is hydrogen

[0646] and pharmaceutically acceptable salts, solvates, isotopes and co-crystals thereof.

[0647] One preferred embodiment of the present invention relates to compound of Formula II, III IV or V, particularly preferably of Formula II or III, wherein

[0648] R4, R5 are both hydrogen,

[0649] R6 is selected from fluoro, chloro, bromo, methoxy, fluoromethoxy and fluoromethyl,

[0650] R7 is selected from hydrogen, methoxy, fluoro, chloro, bromo, fluoromethyl preferably trifluoromethyl, fluoromethoxy, fluoroethoxy, methylsulfinyl and methylsulfonyl,

[0651] X3 is N or CR12,

[0652] R8 is fluoro or methoxy,

[0653] R9 is hydrogen,

[0654] R10 is selected from fluoro, chloro, bromo, cyano, cyanomethyl, cyanoethyl,

[0655] cyanomethoxy, unsubstituted or fluorinated C1-3 alkyl preferably methyl, ethyl and fluoromethyl, unsubstituted or fluorinated C1-3 alkoxy preferably fluoromethoxy and fluoroethoxy, unsubstituted or fluorinated Ci-2alkoxy(Ci-3)alkyl preferably methoxypropyl, fluorinated methoxypropyl, ethoxyethyl, and fluorinated methoxymethyl, unsubstituted or fluorinated Ci-2alkoxy(C2-3)alkenyl including methoxypropenyl and ethoxyethenyl, unsubstituted or fluorinated Ci-2alkoxy(Ci-3)alkoxy preferably methoxyethoxy,

[0656] pentafluorosulfanyl and cycloalkyl, which is substituted with a substituent selected from Ci-2alkoxy, fluoro(Ci-2)alkoxy, Ci-2alkoxycarbonyl and fluoro(Ci-2)alkoxycarbonyl

[0657] R1 1 is selected from hydrogen, methoxy, fluoromethoxy, fluoromethyl, and fluoro,

[0658] R12, if present, is hydrogen or fluoro,

[0659] and pharmaceutically acceptable salts, solvates, isotopes and co-crystals thereof.

[0660] One preferred embodiment of the present invention relates to compound of Formula I I, I I I or IV, particularly preferably of Formula I I or I I I, wherein

[0661] R4 and R5 are both hydrogen,

[0662] R6 is selected from fluoro, chloro, bromo, isopropyl, benzyloxy, and trifluoromethyl,

[0663] R7 is hydrogen, methoxy, fluoro, or bromo, preferably hydrogen,

[0664] or R6 and R7, together with the ring-forming C atoms to which they are attached, form a ring selected from phenyl, cyclopentyl and pyridyl,

[0665] X3 is -C(R12)-,

[0666] R8 is fluoro, hydrogen, or methoxy,

[0667] R9 is hydrogen,

[0668] R10 is ethynyl, trifluoromethyl, difluoroethoxy, cyano, chloro, bromo, or iodo,

[0669] R1 1 is selected from hydrogen and fluoro, and

[0670] R12 is selected from hydrogen and fluoro,

[0671] and pharmaceutically acceptable salts, solvates, isotopes and co-crystals thereof.

[0672] One embodiment relates to compounds of Formula II, II I and IV, preferably of Formula I I and II I;

[0673] wherein

[0674] R4 and R5 are both hydrogen,

[0675] R6 is bromo or chloro, preferably chloro,

[0676] R7 is hydrogen, methoxy, fluoro or trifluoromethyl, X3 is C(R12),

[0677] R8 is selected from hydrogen, fluoro, and methoxy, or forms a ring with R9 as described herein,

[0678] R9 forms together with R8 or R10 and the phenyl ring to which R8 and R9, or R9 and R10 are attached, a 2, 1 ,3-benzothiadiazole or 1 ,3-benzodioxole which is optionally substituted with two fluoros,

[0679] R10 is selected from hydrogen and fluoro, or R10 forms a ring together with R9 as described above,

[0680] R1 1 is selected from hydrogen, fluoro and methoxy,

[0681] R12 is hydrogen

[0682] and pharmaceutically acceptable salts, solvates, isotopes and co-crystals thereof.

[0683] One preferred embodiment of the present invention relates to compound of Formula II, III or IV, particularly preferably of Formula II or III, wherein

[0684] R4, R5 are hydrogen,

[0685] R6 is bromo, chloro, or trifluoromethyl,

[0686] R7 is hydrogen, methoxy, fluoro, or trifluoromethyl,

[0687] R8 is fluoro or methoxy,

[0688] R9 is hydrogen,

[0689] R10 is selected from fluoro, chloro, bromo, cyano, cyanomethyl, trifluoromethyl, difluoroethoxy, and pentafluorosulfanyl,

[0690] R1 1 is selected from hydrogen, methoxy and fluoro,

[0691] and pharmaceutically acceptable salts, solvates, isotopes and co-crystals thereof.

[0692] One embodiment of the present invention relates to compounds of Formula II, III, IV or V, preferably of Formula II or III, wherein

[0693] X3 is C(R12),

[0694] R4 is hydrogen or fluoro, preferably hydrogen,

[0695] R5 is selected from hydrogen, fluoro, chloro, bromo, iodo, methyl, and trifluoromethyl, preferably hydrogen , or R5 forms a ring together with R6 as described herein, R6 is selected from hydrogen, fluoro, chloro, bromo, iodo, cyano, azido, unsubstituted or substituted C1-3 alkyl, preferably methyl, ethyl, isopropyl, or trifluoromethyl, C1-2

[0696] alkylcarbonyl, C1-2 alkoxycarbonyl, (Ci-3)alkylsulfinyl preferably methylsulfinyl, (Ci- 3)alkylsulfonyl, preferably methylsulfonyl, unsubstituted or substituted benzylsulfonyl, unsubstituted or substituted benzylsulfinyl, C3-6 cycloalkyl preferably cyclopropyl, C3-6 cycloalkyl(Ci-3)alkyl preferably cyclopropylmethyl, C3-6 heterocycloalkyl, C3-6 cycloalkoxy, C3-6 heterocycloalkoxy, unsubstituted or substituted C1-3 alkoxy preferably methoxy, mono di- and trifluoroethoxy, unsubstituted or substituted Ci-3alkoxy(Ci-3)alkoxy, preferably methoxyethoxy, unsubstituted or substituted Ci-3alkoxy(Ci-3)alkyl, (C3-6)cycloalkyl(Ci- 3)alkoxy preferably cyclopropylmethoxy, unsubstituted or substituted phenyl, unsubstituted or substituted phenyl(Ci-3)alkoxy preferably benzyloxy, unsubstituted or substituted phenyloxy, thienyl, pyridyl, oxazole, thiazole, and isoxazole, and wherein each optional substitution in R6 is preferably selected from fluoro, chloro, unsubstituted or fluorinated methyl, unsubstituted or fluorinated methoxy, hydroxy, and cyano,

[0697] provided that in the compounds of Formula III, if R6 is hydrogen, then R5 is preferably iodo,

[0698] or

[0699] (i) R6 forms together with R7 and the carbon atoms to which R6 and R7 are attached, an unsubstituted or substituted phenyl, an unsubstituted or substituted pyridyl, an unsubstituted or substituted cyclopentyl or an unsubstituted or substituted cyclohexyl,

[0700] wherein each substitution, if present, is selected from halogen, hydroxy, methyl or methoxy, wherein each methyl or methoxy can be unsubstituted or substituted with one or more substituents selected from halogen, preferably fluoro, and methoxy, or

[0701] (ii) R6 forms together with R5 and the carbon atoms to which R6 and R5 are attached, a 1 ,3-dioxolane which may be unsubstituted or substituted with one or two substituents selected from fluoro and methyl,

[0702] R7 is selected from hydrogen, fluoro, chloro, bromo, iodo, cyano, C1-3 alkyl, Ci-3 alkyloxy, fluoro(Ci-3)alkyl preferably trifluoromethyl, fluoro(Ci-3)alkoxy preferably fluoromethoxy or fluoroethoxy, C1-2 alkylcarbonyl, C1-2 alkoxycarbonyl, methylsulfinyl, and methylsulfonyl, or R7 forms a ring together with R6 as described herein, R8 is selected from hydrogen, fluoro, chloro, bromo, iodo, Ci-3 alkyloxy preferably methoxy, fluoro(Ci-3)alkoxy, C1-3 alkyl preferably methyl, and fluoro(Ci-3)alkyl preferably trifluoromethyl,

[0703] R9 forms together with R10 and the ring to which they are attached a bicyclic ring system selected from 2,1 ,3-benzothiadiazole, 2, 1 ,3-benzoselenadiazole, 2, 1 ,3-benzoxadiazole, 2- oxo-2,3-dihydro-1 ,3-benzoxazole, 1 ,3-benzothiazole, 2,3-dihydro-1-benzothiophene, which is substituted with one or two oxo (preferably substituted with two oxo to give 1 , 1 - dioxo-2,3-dihydro-1-benzothiophene), 3-oxo-1 ,3-dihydro-2-benzofuran-5-yl, which may be unsubstituted or substituted with one or two groups selected from oxo, fluoro and methyl, preferably with at least one oxo group to preferably form 3-oxo-1 ,3-dihydro-2-benzofuran or 1-methyl-3-oxo-1 ,3-dihydro-2-benzofuran, and dihydroisoindol which may be unsubstituted or substituted with one or more substituents selected from oxo, fluoro and methyl and which preferably is 3-oxo-2,3-dihydro-1 H-isoindol,and 1 ,3-benzodioxole, which is optionally substituted with one or two fluoros to preferably form 2,2-difluoro-1 ,3- benzodioxol,

[0704] R1 1 is selected from hydrogen, fluoro, chloro, bromo, iodo, C1-3 alkyl preferably methyl, fluoro(Ci-3)alkyl preferably trifluoromethyl, C1-3 alkyloxy preferably methoxy, fluoro(Ci-3) alkoxy, preferably fluoro(Ci-2)alkoxy, cyano, and, and is more preferably hydrogen, fluoro, chloro or bromo,

[0705] R12 is selected from hydrogen, fluoro, chloro, bromo, iodo, C1-3 alkyloxy

[0706] preferablymethoxy, fluoro(Ci-3)alkoxy preferably fluoro(Ci-2)alkoxy, C1-3 alkyl preferably methyl, and fluoro(Ci-3)alkyl preferably trifluoromethyl, and is more preferably hydrogen, fluoro, chloro, or bromo,

[0707] and pharmaceutically acceptable salts, solvates, isotopes and co-crystals thereof.

[0708] One embodiment of the present invention relates to compounds of Formula II, III, or IV, preferably of Formula II or III, wherein

[0709] X3 is C(R12),

[0710] R4 is hydrogen,

[0711] R5 is selected from hydrogen, fluoro, chloro, bromo, iodo, methyl, and trifluoromethyl, preferably hydrogen or iodo, or R5 forms a ring together with R6 as described herein,

[0712] R6 is selected from hydrogen, fluoro, chloro, bromo, iodo, cyano, azido, unsubstituted or substituted C1-3 alkyl, preferably methyl, ethyl, isopropyl, or trifluoromethyl, C1-2

[0713] alkylcarbonyl, C1-2 alkoxycarbonyl, (Ci-3)alkylsulfinyl preferably methylsulfinyl, (Ci- 3)alkylsulfonyl, preferably methylsulfonyl, C3-6 cycloalkyl preferably cyclopropyl, C3-6 cycloalkyl(Ci-3)alkyl preferably cyclopropylmethyl, C3-6 heterocycloalkyl, C3-6 cycloalkoxy, C3-6 heterocycloalkoxy, unsubstituted or substituted C1-3 alkoxy preferably methoxy, unsubstituted or substituted Ci-3alkoxy(Ci-3)alkoxy, preferably methoxyethoxy, (C3- 6)cycloalkyl(Ci-3)alkoxy preferably cyclopropylmethoxy, unsubstituted or substituted phenyl, unsubstituted or substituted phenyl(Ci-3)alkoxy preferably benzyloxy,

[0714] unsubstituted or substituted phenyloxy, thienyl, pyridyl, oxazole, thiazole, and isoxazole, and wherein each optional substitution in R6 is preferably selected from fluoro, chloro, methyl, methoxy, and cyano,

[0715] provided that in the compounds of Formula I I, if R6 is hydrogen, then R5 is preferably iodo,

[0716] or

[0717] (i) R6 forms together with R7 and the carbon atoms to which R6 and R7 are attached, an unsubstituted or substituted phenyl, an unsubstituted or substituted pyridyl, an unsubstituted or substituted cyclopentyl or an unsubstituted or substituted cyclohexyl,

[0718] wherein each substitution, if present, is selected from halogen, methyl or methoxy, wherein each methyl or methoxy can be unsubstituted or substituted with one or more substituents selected from fluoro and methoxy,

[0719] or

[0720] (ii) R6 forms together with R5 and the carbon atoms to which R6 and R5 are attached, a 1 ,3-dioxolane which may be unsubstituted or substituted with one or two substituents selected from fluoro and methyl,

[0721] R7 is selected from hydrogen, fluoro, chloro, bromo, iodo, cyano, C1-3 alkyl, Ci-3 alkyloxy, fluoro(Ci-3)alkyl preferably trifluoromethyl, fluoro(Ci-3)alkoxy preferably trifluoromethoxy, C1-2 alkylcarbonyl, Ci-2 alkoxycarbonyl, methylsulfinyl, and methylsulfonyl, or R7 forms a ring together with R6 as described herein,

[0722] R8 is selected from hydrogen, fluoro, chloro, bromo, iodo, Ci-3 alkyloxy preferably methoxy, fluoro(Ci-3)alkoxy, C1-3 alkyl preferably methyl, and fluoro(Ci-3)alkyl preferably trifluoromethyl,

[0723] or R9 forms together with R10 and the ring to which they are attached a bicyclic ring system selected from 2,1 ,3-benzothiadiazole, 2,1 ,3-benzoselenadiazole, 2,1 ,3- benzooxadiazole, 2-oxo-2,3-dihydro-1 ,3-benzoxazole, 1 ,3-benzothiazole, 2,3-dihydro-1- benzothiophene, which is substituted with one or two oxo (preferably substituted with two oxo to give 1 ,1 -dioxo-2,3-dihydro-1 -benzothiophene), 3-oxo-1 ,3-dihydro-2-benzofuran-5- yl, and 1 ,3-benzodioxole, which is optionally substituted with one or two fluoros,

[0724] R1 1 is selected from hydrogen, fluoro, chloro, bromo, iodo, C1-3 alkyl preferably methyl, fluoro(Ci-3)alkyl preferably trifluoromethyl, C1-3 alkyloxy preferably methoxy, fluoro(Ci-3) alkoxy, preferably fluoro(Ci-2)alkoxy, cyano, and, and is more preferably hydrogen, fluoro, chloro or bromo,

[0725] R12 is selected from hydrogen, fluoro, chloro, bromo, iodo, C1-3 alkyloxy

[0726] preferablymethoxy, fluoro(Ci-3)alkoxy preferably fluoro(Ci-2)alkoxy, C1-3 alkyl preferably methyl, and fluoro(Ci-3)alkyl preferably trifluoromethyl, and is more preferably hydrogen, fluoro, chloro, or bromo,

[0727] and pharmaceutically acceptable salts, solvates, isotopes and co-crystals thereof.

[0728] One preferred embodiment of the present invention relates to compound of Formula II, III or Formula IV, particularly preferably of Formula II or III, wherein

[0729] X3 is C(R12),

[0730] R4, R5 are both hydrogen,

[0731] R6 is selected from fluoro, chloro, bromo, methoxy, trifluoromethyl, methylsulfonyl, and cyano,

[0732] or R6 forms, together with R7 and the carbon atoms to which R6 and R7 are attached a ring selected from an unsubstituted or substituted phenyl, unsubstituted or substituted pyridyl, unsubstituted or substituted cyclohexyl, and unsubstituted or substituted cyclopentyl, wherein any substitution is selected from fluoro, methoxy and methyl, and wherein the ring is preferably selected from unsubstituted phenyl, pyridyl, cyclohexyl or cyclopentyl,

[0733] R7 is selected from hydrogen, methyl, fluoromethyl preferably trifluoromethyl, methoxy, fluoro, chloro and bromo, preferably from hydrogen, fluoro and trifluoromethyl, or R7 forms a ring together with R6 as described herein,

[0734] R8 is hydrogen or fluoro,

[0735] R9 together with R10 and the C atoms to which they are attached form a ring selected from 2, 1 ,3-benzothiadiazole, 2, 1 ,3-benzoxadiazole, 3-oxo-2,3-dihydro-1 H-isoindol, 3-oxo- 1 ,3-dihydro-2-benzofuran, 1 -methyl-3-oxo-1 ,3-dihydro-2-benzofuran,-and 2,2 difluoro- substituted 1 ,3-benzodioxole, preferably a 2,1 ,3-benzothiadiazole, R1 1 is hydrogen or fluoro, preferably hydrogen, and

[0736] R12 is hydrogen or fluoro,

[0737] and pharmaceutically acceptable salts, solvates, isotopes and co-crystals thereof.

[0738] One preferred embodiment of the present invention relates to compound of Formula II, III or Formula IV, particularly preferably of Formula II or III, wherein

[0739] X3 is C(R12),

[0740] R4, R5 are both hydrogen,

[0741] R6 is fluoro, chloro, bromo, trifluoromethyl, methylsulfonyl, or cyano,

[0742] or R6 forms, together with R7 and the carbon atoms to which R6 and R7 are attached a ring selected from an unsubstituted or substituted phenyl, unsubstituted or substituted pyridyl, and unsubstituted or substituted cyclopentyl, wherein any substitution is selected from fluoro, methoxy and methyl, and wherein the ring is preferably selected from unsubstituted phenyl, pyridyl or cyclopentyl,

[0743] R7 is selected from hydrogen, methyl, trifluoromethyl, methoxy, fluoro, chloro and bromo, preferably from hydrogen and bromo, or R7 forms a ring together with R6 as described herein,

[0744] R8 is hydrogen or fluoro,

[0745] R9 together with R10 and the C atoms to which they are attached form a ring selected from an 2, 1 ,3-benzothiadiazole, 2,1 ,3-benzooxadiazole, and 2,2 difluoro-substituted 1 ,3- benzodioxole, preferably a 2, 1 ,3-benzothiadiazole,

[0746] R1 1 is hydrogen or fluoro, and

[0747] R12 is hydrogen or fluoro,

[0748] and pharmaceutically acceptable salts, solvates, isotopes and co-crystals thereof.

[0749] A further embodiment relates to compounds of Formula II, III IV or V,

[0750] wherein

[0751] X3 is C(R12),

[0752] R4 is hydrogen or fluoro, preferably hydrogen,

[0753] R5 is selected from hydrogen, fluoro, chloro, bromo, iodo, methyl, and fluoromethyl, preferably hydrogen, or R5 forms a ring together with R6 as described herein, R6 is selected from hydrogen, fluoro, chloro, bromo, iodo, cyano, azido, unsubstituted or substituted C1-3 alkyl, preferably methyl, ethyl, propyl, mono-, di- and trifluoromethyl, unsubstituted or substituted C1-2 alkylcarbonyl, unsubstituted or substituted C1-2

[0754] alkoxycarbonyl, (C1-3) alkylsulfinyl preferably methylsulfinyl, (Ci-3)alkylsulfonyl, preferably methylsulfonyl, C3-6 cycloalkyl preferably cyclopropyl, C3-6 cycloalkyl(Ci-3)alkyl preferably cyclopropylmethyl, C3-6 heterocycloalkyl, C3-6 cycloalkoxy, C3-6 heterocycloalkoxy, unsubstituted or substituted C1-3 alkoxy preferably methoxy, mono-, di- and

[0755] trifluoromethoxy, mono-, di- and trifluoroethoxy, unsubstituted or substituted Ci-3alkoxy(Ci- 3) alkoxy, preferably methoxyethoxy, unsubstituted or substituted Ci-3alkoxy(Ci-3)alkyl, (C3- 6)cycloalkyl(Ci-3)alkoxy preferably cyclopropylmethoxy, unsubstituted or substituted phenyl, unsubstituted or substituted phenyl(Ci-3)alkoxy preferably benzyloxy,

[0756] unsubstituted or substituted phenyloxy, thienyl, pyridyl, oxazole, thiazole, and isoxazole, and wherein each optional substitution in R6 is preferably selected from fluoro, chloro, methyl, methoxy, and cyano, provided that in the compounds of Formula III, if R6 is hydrogen, then R5 is preferably iodo,

[0757] or

[0758] (i) R6 forms together with R7 and the carbon atoms to which R6 and R7 are

[0759] attached, an unsubstituted or substituted phenyl, an unsubstituted or substituted pyridyl, an unsubstituted or substituted cyclopentyl or an unsubstituted or substituted cyclohexyl,

[0760] wherein each substitution, if present, is selected from halogen, hydroxy, methyl or methoxy, wherein each methyl or methoxy can be unsubstituted or substituted with one or more substituents selected from fluoro and methoxy,

[0761] or

[0762] (ii) R6 forms together with R5 and the carbon atoms to which R6 and R5 are

[0763] attached, a 1 ,3-dioxolane which may be unsubstituted or substituted with one or two substituents selected from fluoro and methyl,

[0764] R7, if present, is selected from hydrogen, fluoro, chloro, bromo, iodo, cyano, C1-3 alkyl, C1-3 alkyloxy, fluoro(Ci-3)alkyl preferably trifluoromethyl, fluoro(Ci-3)alkoxy preferably fluoromethoxy or fluoroethoxy, unsubstituted or fluorinated C1-2 alkylcarbonyl,

[0765] unsubstituted or fluorinated C1-2 alkoxycarbonyl, methylsulfinyl, pyridylmethoxy, isoxazol and methylsulfonyl, or R7 forms a ring together with R6 as described herein,

[0766] R9 forms together with R8 and the ring to which they are attached a bicyclic ring system selected from 2,1 ,3-benzothiadiazole, 2, 1 ,3-benzoselenadiazole, 2, 1 ,3-benzoxadiazole, 2- oxo-2,3-dihydro-1 ,3-benzoxazole, and 1 ,3-benzodioxole, which is optionally substituted with one or two fluoros,

[0767] R10 is selected from hydrogen, fluoro, chloro, bromo, iodo, C1-3 alkyl, halo(Ci-3)alkyl, preferably fluoro(Ci-2)alkyl, halogenated preferably fluorinated or unsubstituted Ci- 3alkoxy(Ci-3)alkyl, C2-3 alkynyl, halogenated preferably fluorinated or unsubstituted Ci- 3alkoxy(Ci-3)alkenyl, methoxy, ethoxy, halo(Ci-3)alkyloxy preferably fluoro(Ci-2)alkoxy, halogenated preferably fluorinated or unsubstituted Ci-3alkoxy(Ci-3)alkoxy, cyano, cyanomethyl, cyanoethyl, unsubstituted or fluorinated C1-3 alkylcarbonyl preferably acetyl, unsubstituted or fluorinated C1-3 alkoxycarbonyl preferably methoxycarbonyl,

[0768] cyclopropyl methoxy, (Ci-2)alkoxycyclopropyl, (Ci-2)alkoxycarbonylcyclopropyl, azido, pentafluorosulfanyl, and nitro, and wherein in one embodiment, R10 is hydrogen, methoxy or halogen,

[0769] R1 1 is selected from hydrogen, fluoro, chloro, bromo, iodo, C1-3 alkyl preferably methyl, fluoro(Ci-3)alkyl preferably trifluoromethyl, Ci-3 alkyloxy preferably methoxy, fluoro(Ci-3) alkoxy, preferably fluoro(Ci-2)alkoxy, unsubstituted or fluorinated C1-3 alkylcarbonyl preferably acetyl, unsubstituted or fluorinated C1-3 alkoxycarbonyl preferably

[0770] methoxycarbonyl and cyano, and is more preferably hydrogen, fluoro, chloro or bromo,

[0771] R12 is selected from hydrogen, fluoro, chloro, bromo, iodo, Ci-3 alkyloxy preferably methoxy, fluoro(Ci-3)alkoxy preferably fluoro(Ci-2)alkoxy, C1-3 alkyl preferably methyl, and fluoro(Ci-3)alkyl preferably trifluoromethyl, and is more preferably hydrogen, fluoro, chloro, or bromo.

[0772] and pharmaceutically acceptable salts, solvates, isotopes and co-crystals thereof.

[0773] A further embodiment relates to compounds of Formula II, III or IV,

[0774] wherein

[0775] X3 is C(R12),

[0776] R4 is hydrogen,

[0777] R5 is selected from hydrogen, fluoro, chloro, bromo, iodo, methyl, and trifluoromethyl, preferably hydrogen or iodo, or R5 forms a ring together with R6 as described herein, R6 is selected from hydrogen, fluoro, chloro, bromo, iodo, cyano, azido, unsubstituted or substituted C1-3 alkyl, preferably methyl, ethyl, isopropyl, or trifluoromethyl, unsubstituted or substituted C1-2 alkylcarbonyl, unsubstituted or substituted C1-2 alkoxycarbonyl, (C1-3) alkylsulfinyl preferably methylsulfinyl, (Ci-3)alkylsulfonyl, preferably methylsulfonyl, C3-6 cycloalkyl preferably cyclopropyl, C3-6 cycloalkyl(Ci-3)alkyl preferably cyclopropylmethyl, C3-6 heterocycloalkyl, C3-6 cycloalkoxy, C3-6 heterocycloalkoxy, unsubstituted or substituted C1-3 alkoxy preferably methoxy, unsubstituted or substituted Ci-3alkoxy(Ci-3) alkoxy, preferably methoxyethoxy, (C3-6)cycloalkyl(Ci-3)alkoxy preferably cyclopropyl methoxy, unsubstituted or substituted phenyl, unsubstituted or substituted phenyl(Ci-3)alkoxy preferably benzyloxy, unsubstituted or substituted phenyloxy, thienyl, pyridyl, oxazole, thiazole, and isoxazole, and wherein each optional substitution in R6 is preferably selected from fluoro, chloro, methyl, methoxy, and cyano, provided that in the compound of Formula II, if R6 is hydrogen, then R5 is preferably iodo,

[0778] or

[0779] (iii) R6 forms together with R7 and the carbon atoms to which R6 and R7 are attached, an unsubstituted or substituted phenyl, an unsubstituted or substituted pyridyl, an unsubstituted or substituted cyclopentyl or an unsubstituted or substituted cyclohexyl,

[0780] wherein each substitution, if present, is selected from halogen, methyl or methoxy, wherein each methyl or methoxy can be unsubstituted or substituted with one or more substituents selected from fluoro and methoxy,

[0781] or

[0782] (iv) R6 forms together with R5 and the carbon atoms to which R6 and R5 are attached, a 1 ,3-dioxolane which may be unsubstituted or substituted with one or two substituents selected from fluoro and methyl,

[0783] R7 is selected from hydrogen, fluoro, chloro, bromo, iodo, cyano, C1-3 alkyl, Ci-3 alkyloxy, fluoro(Ci-3)alkyl preferably trifluoromethyl, fluoro(Ci-3)alkoxy preferably trifluoromethoxy, unsubstituted or fluorinated C1-2 alkylcarbonyl, unsubstituted or fluorinated C1-2

[0784] alkoxycarbonyl, methylsulfinyl, and methylsulfonyl, or R7 forms a ring together with R6 as described herein,

[0785] R9 forms together with R8 and the ring to which they are attached a bicyclic ring system selected from 2,1 ,3-benzothiadiazole, 2, 1 ,3-benzoselenadiazole, 2, 1 ,3-benzooxadiazole, 2-0X0-2, 3-dihydro-1 ,3-benzoxazole, and 1 ,3-benzodioxole, which is optionally substituted with one or two fluoros,

[0786] R10 is selected from hydrogen, fluoro, chloro, bromo, iodo, C1-3 alkyl, halo(Ci-3)alkyl, preferably fluoro(Ci-2)alkyl, C2-3 alkynyl, methoxy, ethoxy, halo(Ci-3)alkyloxy, preferably fluoro(Ci-2)alkoxy, cyano, cyanomethyl, unsubstituted or fluorinated C1-3 alkylcarbonyl preferably acetyl, unsubstituted or fluorinated C1-3 alkoxycarbonyl preferably methoxycarbonyl, azido, pentafluorosulfanyl, and nitro, and wherein in one embodiment, R10 is hydrogen, methoxy or halogen,

[0787] R1 1 is selected from hydrogen, fluoro, chloro, bromo, iodo, C1-3 alkyl preferably methyl, fluoro(Ci-3)alkyl preferably trifluoromethyl, Ci-3 alkyloxy preferably methoxy, fluoro(Ci-3) alkoxy, preferably fluoro(Ci-2)alkoxy, unsubstituted or fluorinated C1-3 alkylcarbonyl preferably acetyl, unsubstituted or fluorinated C1-3 alkoxycarbonyl preferably

[0788] methoxycarbonyl and cyano, and is more preferably hydrogen, fluoro, chloro or bromo,

[0789] R12 is selected from hydrogen, fluoro, chloro, bromo, iodo, Ci-3 alkyloxy preferably methoxy, fluoro(Ci-3)alkoxy preferably fluoro(Ci-2)alkoxy, C1-3 alkyl preferably methyl, and fluoro(Ci-3)alkyl preferably trifluoromethyl, and is more preferably hydrogen, fluoro, chloro, or bromo.

[0790] and pharmaceutically acceptable salts, solvates, isotopes and co-crystals thereof.

[0791] Another embodiment relates to compounds of Formula II, III IV or V, particularly preferably of Formula II or III, wherein

[0792] X3 is C(R12),

[0793] R4 and R5 are both hydrogen,

[0794] R6 is selected from fluoro, chloro, bromo, methoxy, fluoromethoxy, methylsulfinyl, methylsulfonyl, and fluoromethyl, and is preferably chloro, bromo or fluoromethyl, or R6 forms, together with R7 and the carbon atoms to which R6 and R7 are attached, a ring selected from an unsubstituted or substituted phenyl, unsubstituted or substituted pyridyl, unsubstituted or substituted cyclohexyl, and unsubstituted or substituted cyclopentyl, wherein any substitution is selected from fluoro, fluorinated or unsubstituted methoxy and fluorinated or unsubstituted methyl, and wherein the ring is preferably selected from unsubstituted phenyl, pyridyl, cycloxexyl or cyclopentyl,

[0795] R7 is selected from hydrogen, fluoro, chloro, bromo, methoxy, methyl, acetyl, cyano, fluoromethyl, fluoromethoxy and fluoroethoxy, preferably from hydrogen and

[0796] trifluoromethyl, or R7 forms a ring together with R6 as described herein,

[0797] R8 together with R9 and the C atoms to which they are attached form a ring selected from 2, 1 ,3-benzoselenadiazole, 2, 1 ,3-benzothiadiazole, 2,1 ,3-benzoxadiazole, unsubstituted 1 ,3-benzodioxole, 2-oxo-2,3-dihydro-1 ,3-benzoxazole, and 2,2-difluoro-1 ,3-benzodioxole,

[0798] R10 is selected from hydrogen, fluoro, chloro, bromo and fluoromethyl,

[0799] R1 1 is selected from hydrogen, cyano, fluoro and chloro, and is preferably hydrogen, and R12 is selected from hydrogen, fluoro, chloro and fluoromethyl,

[0800] and pharmaceutically acceptable salts, solvates, isotopes and co-crystals thereof.

[0801] Another embodiment relates to compounds of Formula II, III or IV, particularly preferably of Formula II or III, wherein

[0802] X3 is C(R12),

[0803] R4 and R5 are both hydrogen,

[0804] R6 is selected from fluoro, chloro, bromo, and trifluoromethyl,

[0805] or R6 forms, together with R7 and the carbon atoms to which R6 and R7 are attached a ring selected from an unsubstituted or substituted phenyl, unsubstituted or substituted pyridyl, and unsubstituted or substituted cyclopentyl, wherein any substitution is selected from fluoro, methoxy and methyl, and wherein the ring is preferably selected from unsubstituted phenyl, pyridyl or cyclopentyl,

[0806] R7 is selected from hydrogen, fluoro, chloro, bromo, methoxy, methyl, acetyl and trifluoromethyl, preferably from hydrogen and trifluoromethyl, or R7 forms a ring together with R6 as described herein,

[0807] R8 together with R9 and the C atoms to which they are attached form a ring selected from 2, 1 ,3-benzothiadiazole, 2, 1 ,3-benzooxadiazole, unsubstituted 1 ,3-benzodioxole, 2-oxo- 2,3-dihydro-1 ,3-benzoxazole, and 2,2-difluoro-1 ,3-benzodioxole,

[0808] R10 is hydrogen, or fluoro,

[0809] R1 1 is selected from hydrogen, fluoro, chloro, bromo and cyano, and

[0810] R12 is hydrogen, fluoro, chloro, and trifluoromethyl

[0811] and pharmaceutically acceptable salts, solvates, isotopes and co-crystals thereof.

[0812] Another embodiment relates to compounds of Formula II, III IV or V, particularly preferably of Formula II or III, wherein

[0813] X3 is C(R12),

[0814] R4 and R5 are both hydrogen,

[0815] R6 is selected from fluoro, chloro, bromo, and fluoromethyl,

[0816] or R6 forms, together with R7 and the carbon atoms to which R6 and R7 are attached, a ring selected phenyl, pyridyl, cyclohexyl and cyclopentyl, R7, if present, is selected from hydrogen, fluoro, chloro, bromo, methoxy, methyl, fluoromethyl, fluoromethoxy and fluoroethoxy, preferably from hydrogen, fluoro and trifluoromethyl, or R7 forms a ring together with R6 as described herein,

[0817] R8 together with R9 and the C atoms to which they are attached form a ring selected from 2, 1 ,3-benzothiadiazole, 2, 1 ,3-benzoxadiazole, and 2,2-difluoro-1 ,3-benzodioxole,

[0818] R10 is hydrogen or fluoro,

[0819] R1 1 is selected from hydrogen, fluoro and cyano, and

[0820] R12 is selected from hydrogen, fluoro and fluoromethyl,

[0821] and pharmaceutically acceptable salts, solvates, isotopes and co-crystals thereof.

[0822] One embodiment relates to compounds of the general formula II, III, IV and V which are optionally substituted in 2-position of the upper bicyclic ring, thus having structures according to the general formula II-2, III-2, IV-2 and V-2 as depicted below:

[0823] rmula III-2

[0824]

[0825] Formula IV-2 Formula V-2

[0826] wherein R2 is selected from hydrogen, fluoro, chloro, bromo, iodo and methoxy, and is preferably hydrogen or fluoro, particularly preferably hydrogen,

[0827] and wherein R4, R5, R6, R7, if present, R8, R9, R10, R1 1 and X3 are as described for the respective corresponding comounds of formula II, III, IV and V herein.

[0828] In one preferred embodiment of the present invention, in the compounds of Formula II, II- 2, III, III-2, IV, IV-2, V and V-2,

[0829] X3 is N or CR12,

[0830] R2, if present, R4, R5 and R9 are all hydrogen,

[0831] R6 is selected from halogen, cyano, Ci-3alkoxy, Ci-3alkyl, C3-6cycloalkyl preferably C3- 4cycloalkyl, C3-6cycloalkyloxy preferably C3-4cycloalkyloxy, C3-6heterocycloalkyl preferably C3-4heterocycloalkyl, and C3-6heterocycloalkyloxy preferably C3-4heterocycloalkyloxy, each of which can be optionally substituted with a residue selected from fluoro and

[0832] unsubstituted or fluorinated Ci-3alkoxy,

[0833] R7 is selected from hydrogen, halogen, cyano, Ci-3alkoxy, Ci-3alkyl, C3-6cycloalkyl preferably C3-4cycloalkyl, C3-6cycloalkyloxy preferably C3-4cycloalkyloxy, C3- 6heterocycloalkyl preferably C3-4heterocycloalkyl, and C3-6heterocycloalkyloxy preferably C3-4heterocycloalkyloxy, each of which can be optionally substituted with a residue selected from fluoro and unsubstituted or fluorinated Ci-3alkoxy,

[0834] R8 is selected from fluoro, methoxy and fluoromethoxy, preferably from fluoro and methoxy, R10 is selected from halogen, Ci-4alkoxy, C2-3alkenyl C2-3alkynyl, C3-6cycloalkyl preferably C3-4cycloalkyl, C3-6cycloalkyloxy preferably C3-4cycloalkyloxy, C3-6heterocycloalkyl preferably C3-4heterocycloalkyl, and C3-6heterocycloalkyloxy preferably C3-4heterocycloalkyloxy, each of which can be optionally substituted with a residue selected from fluoro, cyano and unsubstituted or fluorinated Ci-3alkoxy, and

[0835] R1 1 is selected from hydrogen, fluoro, methoxy and fluoromethoxy, preferably from fluoro and methoxy,

[0836] and R12, if present is selected from hydrogen, fluoro, fluoromethyl, methoxy and fluoromethoxy.

[0837] In a further embodiment, the compounds of the present invention are represented by one of the following Form ulae lla - lie:

[0838]

[0839] Formula Ha Form ula lib Formula lie

[0840] wherein

[0841] n is any number from 0 to 4,

[0842] m is 0 or 1 ,

[0843] p is any number from 0 to 3,

[0844] and

[0845] any Y is an independently selected substitution selected from the group consisting of halogen, hydroxy, cyano, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-7 cycloalkyl, C3-7 cycloalkyl(Ci-3)alkyl, C3-7 heterocycloalkyl(Ci-3)alkyl, C1-6 alkoxy, and Ci-6 alkoxy(Ci-3)alkyl wherein each alkyl or alkoxy can be unsubstituted or substituted with one or more substituents selected from halogen and C1-3 alkoxy,

[0846] R4, R5, X3, R8, R9, R10, R1 1 and R12 are as described in the compounds of Formula I, and II herein.

[0847] According to one embodiment, in the compounds of Formula 11 (a) to ll(c)

[0848] m is 0 or 1 , preferably 0,

[0849] n is any number from 0 to 4, preferably from 0 to 2, more preferably 0 or 1 ,

[0850] p is any number from 0 to 3, preferably from 0 to 2, more preferably 0 or 1 ,

[0851] any Y is an independently selected substitution selected from the group of halogen, hydroxy, cyano, C1-3 alkyl, C1-3 alkoxy, and Ci-3alkoxy(Ci-3)alkyl wherein each alkyl or alkoxy can be unsubstituted or substituted with one or more substituents selected from halogen and C1-3 alkoxy,

[0852] R4 is hydrogen or fluoro, preferably hydrogen,

[0853] R5 is selected from hydrogen, halogen, C1-3 alkyl, and C1-3 alkoxy, wherein each alkyl or alkoxy may optionally be substituted one or more times, preferably with methoxy or halogen,

[0854] X3 is N or C(R12),

[0855] R8 is selected from hydrogen, C1-3 alkyl, C1-3 alkoxy, and halogen, wherein each alkyl or alkoxy can be unsubstituted or substituted with one or more substituents selected from halogen, cyano and methoxy, or R8 forms a ring system together with R9, as described herein,

[0856] R9 is selected from hydrogen, C1-3 alkyl, C1-3 alkoxy, fluoro, chloro, bromo and iodo, wherein each alkyl or alkoxy can be unsubstituted or substituted with one or more substituents selected from halogen and methoxy, and wherein R9 is preferably hydrogen, or R9 forms together with R8 or R10 and the ring to which they are attached a bicyclic ring system selected from 2, 1 ,3-benzothiadiazole, 2, 1 ,3-benzoselenadiazole, 2, 1 ,3- benzoxadiazole, 1 ,3-benzoxazole which may optionally be partially hydrogenated and 2- oxo-substituted, 1 ,3-benzodioxole which may be unsubstituted or substituted with one or two substituents selected from fluoro and methyl, 1 ,3-benzothiazole, 2,3-dihydro-1 - benzothiophene, which is substituted with one or two oxo(preferably substituted with two oxo to give 1 ,1 -dioxo-2,3-dihydro-1 -benzothiophene), 3-oxo-2,3-dihydro-1 H-isoindol, or 1 ,3 dihydro-2-benzofuran, which may be unsubstituted or substituted with one or two groups selected from oxo, fluoro and methyl, preferably with one oxo group, or with one oxo and one methyl group,

[0857] R10 is selected from hydrogen, fluoro, chloro, bromo, iodo, C1-3 alkyl, C1-3 alkoxy, C2-4 alkenyl, C2-4 alkynyl, cyano, cyanomethyl, cyanoethyl, cyanomethoxy, C1-3 alkylcarbonyl, Ci-3 alkoxycarbonyl, azido, pentafluorosulfanyl, and nitro, wherein each alkyl, alkenyl, alkynyl or alkoxy can be unsubstituted or substituted with one or more substituents selected from halogen, cyano, hydroxy, fluoro(Ci-3)alkoxy and C1-3 alkoxy, or R8 forms a ring system together with R10, as described herein,

[0858] R1 1 is selected from hydrogen, C1-3 alkyl, C1-3 alkoxy, C1-3 alkylcarbonyl, C1-3

[0859] alkoxycarbonyl, fluoro, chloro, bromo, and iodo, wherein each alkyl and alkoxy can be unsubstituted or substituted with one or more substituents selected from fluoro, chloro, bromo, iodo and C1-3 alkoxy,

[0860] R12, if present, is selected from hydrogen, C1-3 alkyl, C1-3 alkoxy, fluoro, chloro, bromo, and iodo, wherein each alkyl and alkoxy can be unsubstituted or substituted with one or more substituents selected from fluoro, chloro, bromo, iodo and C1-3 alkoxy,

[0861] wherein, in a preferred embodiment, at least one of R8, R10 and R1 1 is different from hydrogen, and more preferably at least one of R8, R9, R10 and R1 1 is also different from unsubstituted alkyl. ,and pharmaceutically acceptable salts, solvates, isotopes and co- crystals thereof.

[0862] In one preferred embodiment, in the compounds having a structure of Formula lla, lib, and lie, Y is selected from hydrogen, halogen, hydroxy, unsubstituted or fluorinated methyl and unsubstituted or fluorinated methoxy. In one embodiment, Y is fluoro, chloro, methoxy or trifluoromethyl. In one preferred embodiment, the values for n and p are independently 0, 1 or 2.

[0863] In another preferred embodiment, in the compounds having a structure of Formula lla, lib, or lie, the values for m, n and p are all 0.

[0864] In a particularly preferred embodiment of the compounds of Formula lla, lib and lie, m is 0 or 1 ,

[0865] n and p are independently 0, 1 or 2,

[0866] Y is selected from halogen, hydroxy, fluorinated methyl and unsubstituted or fluorinated methoxy,

[0867] R4 is hydrogen, R5 is hydrogen, methyl, methoxy, or halogen, preferably hydrogen,

[0868] X3 is N or C(R12),

[0869] R8 is selected from hydrogen, fluoro, chloro, bromo, methoxy, fluoromethoxy, and fluoromethyl, or R8 forms a ring system together with R9, as described herein,

[0870] R9 is hydrogen or fluoro, preferably hydrogen,

[0871] or R9 forms together with R8 or R10 and the ring to which they are attached a bicyclic ring system selected from 2,1 ,3-benzothiadiazole, 2,1 ,3-benzoxadiazole, 1 ,3-benzodioxole, 2- oxo-2,3-dihydro-1 ,3-benzoxazole, 2,2-difluoro-1 ,3-benzodioxole and 4-methyl-2- oxodihydrobenzofuran,

[0872] R10 is selected from hydrogen, fluoro, chloro, bromo, iodo, methyl, cyano, cyanomethyl, cyanoethyl, cyanomethoxy, ethenyl, propenyl, ethynyl, propargyl, pentafluorosulfanyl, unsubstituted, fluorinated or hydroxylated Ci-3alkyloxy including mono-, di- and

[0873] trifluoromethoxy and mono-, di- and trifluoroethoxy, unsubstituted or fluorinated Ci- 3alkyloxy(Ci-3)alkyl, unsubstituted or fluorinated Ci-3alkyloxy(Ci-3)alkyloxy, unsubstituted or fluorinated Ci-3alkyloxy(C2-3)alkenyl, unsubstituted or fluorinated Ci-3alkyloxy(C2-3)alkynyl, unsubstituted or fluorinated Ci-3alkyl including trifluoromethyl, and cyclopropyl which is substituted with a substituent selected from hydroxy, hydroxymethyl, Ci-2 alkoxy and C1-2 alkoxycarbonyl,

[0874] or R10 forms a ring system together with R9, as described herein,

[0875] R11 is selected from hydrogen, fluoro, chloro, and methoxy,

[0876] R12, if present, is selected from hydrogen, and fluoro,

[0877] and pharmaceutically acceptable salts, solvates, isotopes and co-crystals thereof, wherein in one preferred embodiment, if R9 does not form a ring with R8 or R10, then R10 is not hydrogen, and, more preferably, R8 and R10 are both not hydrogen.

[0878] In a particularly preferred embodiment of the compounds of Formula l la, l ib and l ie, the values for m, n and p are all 0,

[0879] R4 is hydrogen,

[0880] R5 is hydrogen, methyl, methoxy, or halogen, preferably hydrogen,

[0881] X3 is N or C(R12), R8 is selected from hydrogen, fluoro, chloro, bromo, methoxy, fluoromethoxy, and mono-, di-, and trifluoromethyl, and is preferably selected from fluoro and methoxy, or R8 forms a ring system together with R9, as described herein,

[0882] R9 is hydrogen or fluoro, preferably hydrogen,

[0883] or R9 forms together with R8 or R10 and the ring to which they are attached a bicyclic ring system selected from 2,1 ,3-benzothiadiazole, 2,1 ,3-benzoxadiazole, 1 ,3-benzodioxole, 2- oxo-2,3-dihydro-1 ,3-benzoxazole, or 2,2-difluoro-1 ,3-benzodioxole,

[0884] R10 is selected from hydrogen, fluoro, chloro, bromo, iodo, cyano, cyanomethyl, cyanoethyl, cyanomethoxy, pentafluorosulfanyl, fluoro(Ci-2)alkoxy preferably

[0885] difluoroethoxy or trifluoroethoxy, and fluoro(Ci-2)alkyl preferably trifluoromethyl, or R10 forms a ring system together with R9, as described herein,

[0886] R1 1 is selected from hydrogen, fluoro, chloro, methoxy and fluoromethoxy, preferably from fluoro and methoxy,

[0887] R12, if present, is selected from hydrogen, methoxy and fluoro,

[0888] and pharmaceutically acceptable salts, solvates, isotopes and co-crystals thereof, wherein in one preferred embodiment, if R9 does not form a ring with R8, then R10 is not hydrogen, and more preferably, R8 and R10 are both not hydrogen.

[0889] In a particularly preferred embodiment of the compounds of Formula lla, lib and lie, the values for m, n and p are all 0,

[0890] R4 is hydrogen,

[0891] R5 is hydrogen, methyl, methoxy, or halogen, preferably hydrogen,

[0892] R8 is selected from hydrogen, fluoro, chloro, bromo, methoxy, and trifluoromethyl, or R8 forms a ring system together with R9, as described herein,

[0893] R9 is hydrogen or fluoro, preferably hydrogen,

[0894] or R9 forms together with R8 or R10 and the ring to which they are attached a bicyclic ring system selected from 2,1 ,3-benzothiadiazole, 2,1 ,3-benzooxadiazole, 1 ,3-benzodioxole, 2-0X0-2, 3-dihydro-1 ,3-benzoxazole, or 2,2-difluoro-1 ,3-benzodioxole,R10 is selected from hydrogen, fluoro, chloro, bromo, cyano, cyanomethyl, pentafluorosulfanyl, difluoroethoxy, trifluoroethoxy, and trifluoromethyl, or R10 forms a ring system together with R9, as described herein, wherein, in a preferred embodiment, R8 and R10 are not both hydrogen, R1 1 is selected from hydrogen, fluoro, chloro, and methoxy,

[0895] R12 is selected from hydrogen, and fluoro,

[0896] and pharmaceutically acceptable salts, solvates, isotopes and co-crystals thereof.

[0897] A further embodiment relates to compounds of Formula I la to lie, wherein

[0898] m is 0 or 1 , preferably 0,

[0899] n is any number from 0 to 3, and is preferably 0 or 1 ,

[0900] p is any number from 0 to 2, and is preferably 0 or 1 ,

[0901] any Y is a substitution independently selected from the group of halogen, hydroxy, C1-3 alkyl, C1-3 alkoxy, wherein each alkyl or alkoxy can be unsubstituted or substituted with one or more substituents selected from halogen and C1-3 alkoxy,

[0902] R4 is hydrogen,

[0903] R5 is selected from hydrogen, fluoro, chloro, bromo, iodo, methyl, methoxy, and trifluoromethyl, and is preferably hydrogen,

[0904] X3 is N or C(R12),

[0905] R8 is selected from hydrogen, fluoro, chloro, bromo, iodo, Ci-3 alkyloxy preferably methoxy, fluoro(Ci-3)alkoxy, C1-3 alkyl preferably methyl, and fluoro(Ci-3)alkyl preferably trifluoromethyl,

[0906] R9 is selected from hydrogen, fluoro, chloro, or bromo, and is preferably hydrogen, R10 is selected from hydrogen, fluoro, chloro, bromo, iodo, C1-3 alkyl, C2-3 alkenyl, C2-3 alkynyl, C1-3 alkyloxy, cyano, unsubstituted or fluorinated C1-3 alkylcarbonyl preferably acetyl, unsubstituted or fluorinated C1-3 alkoxycarbonyl preferably methoxycarbonyl, azido, pentafluorosulfanyl, and nitro, wherein each alkyl, alkoxy, alkenyl or alkynyl can be optionally substituted with one or more substituents selected from halogen, cyano, hydroxy, and unsubstituted or fluorinated and / or hydroxylated C1-3 alkoxy,

[0907] R1 1 is selected from hydrogen, fluoro, chloro, bromo, iodo, C1-3 alkyl preferably methyl, fluoro(Ci-3)alkyl preferably trifluoromethyl, C1-3 alkyloxy preferably methoxy, fluoro(Ci-3) alkoxy preferably fluoro(Ci-2)alkoxy, unsubstituted or fluorinated C1-3 alkylcarbonyl preferably acetyl, unsubstituted or fluorinated C1-3 alkoxycarbonyl preferably

[0908] methoxycarbonyl and cyano, and is more preferably hydrogen, fluoro, chloro or bromo,

[0909] R12, if present, is selected from hydrogen, fluoro, chloro, bromo, iodo, C1-3 alkyloxy preferably methoxy, fluoro(Ci-3)alkoxy preferably fluoro(Ci-2)alkoxy, C1-3 alkyl preferably methyl, and fluoro(Ci-3)alkyl preferably trifluoromethyl, and is more preferably hydrogen, fluoro, chloro, or bromo.

[0910] wherein, in a preferred embodiment, at least one of R8, R10 and R1 1 is different from hydrogen, and preferably at least one of R8, R10 and R1 1 is also different from unsubstituted alkyl,

[0911] wherein, in one preferred embodiment, R10 is different from hydrogen, and in a particularly preferred embodiment R10 and R8 are both not hydrogen,

[0912] and pharmaceutically acceptable salts, solvates, isotopes and co-crystals thereof.

[0913] A further embodiment relates to compounds of Formula I la to lie, wherein

[0914] m is 0 or 1 , preferably 0,

[0915] n is any number from 0 to 3, and is preferably 0 or 1 ,

[0916] p is any number from 0 to 2, and is preferably 0 or 1 ,

[0917] any Y is a substitution independently selected from the group of halogen, C1-3 alkyl, C1-3 alkoxy, wherein each alkyl or alkoxy can be unsubstituted or substituted with one or more substituents selected from halogen and C1-3 alkoxy,

[0918] R4 is hydrogen,

[0919] R5 is selected from hydrogen, fluoro, chloro, bromo, iodo, methyl, methoxy, and trifluoromethyl, preferably hydrogen or iodo, and is preferably hydrogen,

[0920] X3 is N or C(R12),

[0921] R8 is selected from hydrogen, fluoro, chloro, bromo, iodo, Ci-3 alkyloxy preferably methoxy, fluoro(Ci-3)alkoxy, C1-3 alkyl preferably methyl, and fluoro(Ci-3)alkyl preferably trifluoromethyl,

[0922] R9 is selected from hydrogen, fluoro, chloro, bromo, iodo, Ci-3 alkyloxy preferably methoxy, fluoro(Ci-3)alkoxy, C1-3 alkyl preferably methyl, cyano, and fluoro(Ci-3)alkyl preferably trifluoromethyl, and is preferably hydrogen fluoro, chloro, or bromo,

[0923] R10 is selected from hydrogen, fluoro, chloro, bromo, iodo, C1-3 alkyl, halo(Ci-3)alkyl, preferably fluoro(Ci-3)alkyl, particularly trifluoromethyl, C2-3 alkynyl, C1-3 alkyloxy, halo(Ci-3) alkyloxy, preferably fluoro(Ci-2)alkoxy, cyano, cyanomethyl, unsubstituted or fluorinated C1-3 alkylcarbonyl preferably acetyl, unsubstituted or fluorinated C1-3 alkoxycarbonyl preferably methoxycarbonyl, azido, pentafluorosulfanyl, and nitro or R10 forms a ring system together with R9, as described herein, R1 1 is selected from hydrogen, fluoro, chloro, bromo, iodo, C1-3 alkyl preferably methyl, fluoro(Ci-3)alkyl preferably trifluoromethyl, Ci-3 alkyloxy preferably methoxy, fluoro(Ci-3) alkoxy, preferably fluoro(Ci-2)alkoxy, unsubstituted or fluorinated C1-3 alkylcarbonyl preferably acetyl, unsubstituted or fluorinated C1-3 alkoxycarbonyl preferably

[0924] methoxycarbonyl and cyano, and is more preferably hydrogen, fluoro, chloro or bromo,

[0925] R12 is selected from hydrogen, fluoro, chloro, bromo, iodo, Ci-3 alkyloxy preferably methoxy, fluoro(Ci-3)alkoxy preferably fluoro(Ci-2)alkoxy, C1-3 alkyl preferably methyl, and fluoro(Ci-3)alkyl preferably trifluoromethyl, and is more preferably hydrogen, fluoro, chloro, or bromo.

[0926] wherein, in a preferred embodiment, at least one of R8, R9, R10 and R1 1 is different from hydrogen, and more preferably at least one of R8, R9, R10 and R1 1 is also different from unsubstituted alkyl,

[0927] and pharmaceutically acceptable salts, solvates, isotopes and co-crystals thereof.

[0928] Another preferred embodiment relates to compounds having a structure of Formula I la, lib, or lie, wherein

[0929] m is 0 or 1 ,

[0930] n is 0, 1 or 2, and is preferably 0 or 1 ,

[0931] p is 0 or 1

[0932] any Y is selected from hydrogen, halogen, hydroxy, unsubstituted or fluorinated methyl and unsubstituted or fluorinated methoxy,

[0933] R4 and R5 are both hydrogen,

[0934] R8 is selected from hydrogen, methoxy, fluoromethoxy, fluoro, and chloro, and is preferably fluoro,

[0935] X3 is N or C(R12),

[0936] R9 is selected from hydrogen, methoxy, fluoro and chloro, and is preferably hydrogen,

[0937] R10 is selected from hydrogen, ethynyl, cyano, cyanomethyl, cyanoethyl, cyanomethoxy, ethynyl, fluoro, chloro, bromo, iodo, azido, trifluoromethyl, trifluoromethoxy, difluoroethoxy, trifluoroethoxy and pentafluorosulfanyl,

[0938] R1 1 is selected from hydrogen, fluoro, chloro, and methoxy, and

[0939] R12, if present, is hydrogen or fluoro, and wherein at least one of R8, R9, R10 and R1 1 is different from hydrogen, and wherein, in a preferred embodiment, at least R10 is different from hydrogen and wherein in a particularly preferred embodiment, R8 and R10 are both different from hydrogen, and pharmaceutically acceptable salts, solvates, isotopes and co-crystals thereof.

[0940] Another preferred embodiment relates to compounds having a structure of Formula I la, lib, or lie, wherein

[0941] m is 0 or 1 ,

[0942] n is 0, 1 or 2, and is preferably 0 or 1 ,

[0943] p is O, 1 or 2,

[0944] any Y is selected from hydrogen, halogen, hydroxy, unsubstituted or fluorinated methyl and unsubstituted or fluorinated methoxy,

[0945] R4 and R5 are both hydrogen,

[0946] R8 is fluoro or methoxy,

[0947] X3 is N or C(R12),

[0948] R9 is selected from hydrogen, methoxy, fluoro and chloro, and is preferably hydrogen,

[0949] R10 is selected from halogen, ethynyl, propynyl, cyano, cyanomethyl, cyanoethyl, cyanomethoxy, unsubstituted or fluorinated (Ci-3)alkyl, unsubstituted or fluorinated (C2- 3)alkenyl, unsubstituted or fluorinated (C2-3)alkynyl, unsubstituted or fluorinated C1-3 alkyloxy, unsubstituted or fluorinated methoxy(Ci-3)alkyl, unsubstituted or fluorinated methoxy(Ci-3)alkyloxy, unsubstituted or fluorinated methoxy(C2-3)alkenyl, unsubstituted or fluorinated methoxy(C2-3)alkynyl and pentafluorosulfanyl,

[0950] R1 1 is selected from hydrogen, fluoro, and methoxy, and

[0951] R12, if present, is hydrogen or fluoro,

[0952] and pharmaceutically acceptable salts, solvates, isotopes and co-crystals thereof.

[0953] In one preferred embodiment of the compounds of formula lie, p is 1 , and Y is attached to the 8-position of the tricyclic ring system to give a compound of formula Il-c1 , wherein Y is preferably selected from halogen, methyl, fluoromethyl, methoxy, fluoromethoxy and hydroxy, and wherein X3, R4, R5, R8, R9, R10, and R1 1 are as described for the compounds of Formula ll-c herein.

[0954] Formula llc-1 Another preferred embodiment relates to compounds having a structure of Formula I la, lib, or lie, wherein

[0955] m is 0 or 1 ,

[0956] n is 0, 1 or 2, and is preferably 0 or 1 ,

[0957] p is 0 or 1 or 2,

[0958] any Y is selected from hydrogen, halogen, hydroxy, unsubstituted or fluorinated methyl and unsubstituted or fluorinated methoxy,

[0959] R4 and R5 are both selected from hydrogen and fluoro,

[0960] R8 is fluoro or methoxy,

[0961] X3 is N,

[0962] R9 is selected from hydrogen, methoxy, fluoro and chloro, and is preferably hydrogen,

[0963] R10 is selected from fluoro, chloro, bromo, ethynyl, propynyl, cyano, cyanomethyl, cyanoethyl, cyanomethoxy, unsubstituted or fluorinated (Ci-3)alkyl, unsubstituted or fluorinated (C2-3)alkenyl, C2-3alkynyl, unsubstituted or fluorinated Ci-3 alkyloxy, unsubstituted or fluorinated Ci-2alkoxy(Ci-3)alkyl, unsubstituted or fluorinated Ci- 2alkoxy(Ci-3)alkyloxy, unsubstituted or fluorinated Ci-2alkoxy(C2-3)alkenyl and

[0964] pentafluorosulfanyl,

[0965] R11 is selected from hydrogen, fluoro, chloro, methoxy, fluoromethoxy and fluoromethyl, and pharmaceutically acceptable salts, solvates, isotopes and co-crystals thereof, wherein in a preferred embodiment, R10 is selected from chloro, bromo, cyanomethyl, cyanoethyl, cyanomethoxy, unsubstituted or fluorinated (Ci-3)alkyl, unsubstituted or fluorinated Ci-3 alkyloxy, unsubstituted or fluorinated Ci-2alkoxy(Ci-2)alkyloxy and unsubstituted or fluorinated methoxy(Ci-3)alkyl, and is, in another preferred embodiment, chloro.

[0966] Another preferred embodiment relates to compounds having a structure of Formula I la, lib, or lie, wherein R10 is selected from halogen, cyano, cyanomethyl, and cyanoethyl.

[0967] Another preferred embodiment relates to compounds having a structure of Formula I la, lib, or lie, wherein

[0968] m is 0 or 1 ,

[0969] n is any number from 0 to 3, and is preferably 0 or 1 ,

[0970] p is any number from 0 to 2, and is preferably 0 or 1 ,

[0971] any Y is a substitution independently selected from the group of halogen, hydroxy, cyano, Ci-3 alkyl, C1-3 alkoxy, wherein each alkyl or alkoxy can be unsubstituted or substituted with one or more substituents selected from halogen, hydroxy and C1-3 alkoxy,

[0972] X3 is C(R12),

[0973] R4 is hydrogen,

[0974] R5 is selected from hydrogen, fluoro, chloro, bromo, iodo, methyl, methoxy, and trifluoromethyl, preferably hydrogen or iodo,

[0975] R8 is selected from hydrogen, fluoro, chloro, bromo, iodo, C1-3 alkyl, preferably methyl, and C1-3 alkoxy, wherein R8 is preferably selected from fluoro and methoxy,

[0976] or R9 forms together with R10 and the ring to which they are attached a bicyclic ring system selected from 2, 1 ,3-benzothiadiazole, 2,1 ,3-benzoselenadiazole, 2, 1 ,3- benzoxadiazole, 1 ,3-benzothiazole, 2,3-dihydro-1-benzothiophene, which is substituted with one or two oxo (preferably substituted with two oxo to give 1 , 1-dioxo-2,3-dihydro-1 - benzothiophene), optionally methylated 3-oxo-1 ,3-dihydro-2-benzofuran-5-yl, and 1 ,3- benzodioxole, which is optionally substituted with one or two fluoros,

[0977] R1 1 is selected from hydrogen, fluoro, chloro, bromo, iodo and methoxy, and

[0978] R12 is selected from hydrogen, fluoro, chloro, bromo, methoxy, fluoromethoxy, methyl, and fluoromethyl.

[0979] Another preferred embodiment relates to compounds having a structure of Formula I la, lib, or lie, wherein m is 0 or 1 ,

[0980] n is 0, 1 or 2, and is preferably 0,

[0981] p is 0 or 1 , preferably 0,

[0982] any Y is selected from hydrogen, halogen, unsubstituted or fluorinated methyl and unsubstituted or fluorinated methoxy,

[0983] R4, R5 are both hydrogen,

[0984] X3 is C(R12),

[0985] R8 is hydrogen, methoxy or fluoro, and is preferably hydrogen,

[0986] R9 together with R10 and the C atoms to which they are attached form a ring selected from an 2, 1 ,3-benzothiadiazole, 2,1 ,3-benzoxadiazole, and 2,2-difluoro-1 ,3-benzodioxole, preferably 2,1 ,3-benzothiadiazole,

[0987] R1 1 is hydrogen or fluoro, and

[0988] R12 is hydrogen or fluoro

[0989] and pharmaceutically acceptable salts, solvates, isotopes and co-crystals thereof.

[0990] Another preferred embodiment relates to compounds having a structure of Formula I la, lib, or lie, wherein

[0991] m is 0 or 1 ,

[0992] n is any number from 0 to 3, and is preferably 0 or 1 ,

[0993] p is any number from 0 to 2, and is preferably 0 or 1 ,

[0994] any Y is a substitution independently selected from the group of halogen, hydroxy, C1-3 alkyl, C1-3 alkoxy, wherein each alkyl or alkoxy can be unsubstituted or substituted with one or more substituents selected from halogen and C1-3 alkoxy,

[0995] X3 is C(R12),

[0996] R4 is hydrogen,

[0997] R5 is selected from hydrogen, fluoro, chloro, bromo, iodo, methyl, methoxy, and trifluoromethyl, preferably hydrogen or iodo,

[0998] R9 forms together with R8 and the ring to which they are attached a bicyclic ring system selected from 2,1 ,3-benzothiadiazole, 2, 1 ,3-benzoselenadiazole, 2, 1 ,3-benzoxadiazole, 2- oxo-2,3-dihydro-1 ,3-benzoxazole, and 1 ,3-benzodioxole, which is optionally substituted with one or two fluoros, R10 is selected from hydrogen, fluoro, chloro, bromo, iodo, C1-3 alkyl, halo(Ci-3)alkyl, preferably fluoro(Ci-3)alkyl, particularly trifluoromethyl, C2-3 alkynyl, C1-3 alkyloxy, halo(Ci-3) alkyloxy, preferably fluoro(Ci-2)alkoxy, cyano, cyanomethyl, cyanoethyl, cyanomethoxy, unsubstituted or fluorinated C1-3 alkylcarbonyl preferably acetyl, unsubstituted or fluorinated C1-3 alkoxycarbonyl preferably methoxycarbonyl, azido, pentafluorosulfanyl, and nitro, wherein R10 is preferably hydrogen, fluoro, chloro or bromo,

[0999] R1 1 is selected from hydrogen, fluoro, chloro, bromo, iodo, C1-3 alkyl preferably methyl, fluoro(Ci-3)alkyl preferably trifluoromethyl, C1-3 alkyloxy preferably methoxy, fluoro(Ci- 3)alkoxy, preferably fluoro(Ci-2)alkoxy, unsubstituted or fluorinated C1-3 alkylcarbonyl preferably acetyl, unsubstituted or fluorinated C1-3 alkoxycarbonyl preferably

[1000] methoxycarbonyl and cyano, and is more preferably hydrogen, fluoro, chloro or bromo,

[1001] R12 is selected from hydrogen, fluoro, chloro, bromo, iodo, C1-3 alkyloxy preferably methoxy, fluoro(Ci-3)alkoxy preferably fluoro(Ci-2)alkoxy, C1-3 alkyl preferably methyl, and fluoro(Ci-3)alkyl preferably trifluoromethyl, and is more preferably hydrogen, fluoro, chloro, or bromo,

[1002] and pharmaceutically acceptable salts, solvates, isotopes and co-crystals thereof.

[1003] Another preferred embodiment relates to compounds having a structure of Formula I la, lib, or lie, wherein

[1004] m is O oM ,

[1005] n is 0, 1 or 2, and is preferably 0,

[1006] p is 0 or 1 and is preferably 0,

[1007] any Y is selected from hydrogen, halogen, unsubstituted or fluorinated methyl and unsubstituted or fluorinated methoxy

[1008] X3 is C(R12)

[1009] R4 and R5 are both hydrogen,

[1010] R8 together with R9 and the ring to which they are attached form a bicyclic ring system selected from 2, 1 ,3-benzothiadiazole, 2, 1 ,3-benzoxadiazole, 2, 1 ,3-benzoselanadiazole, 2- oxo-2,3-dihydro-1 ,3-benzoxazole, unsubstituted 1 ,3-benzodioxole and 2,2-difluoro-1 ,3- benzodioxole,

[1011] R10 is selected from the group of hydrogen, fluoro, chloro, bromo, trifluoromethyl, trifluoromethoxy, difluoroethoxy, trifluoroethoxy, and cyano, and is preferably hydrogen or fluoro, R11 is selected from hydrogen, methoxy, fluoro, chloro, bromo and cyano, and is preferably hydrogen or fluoro,

[1012] R12 is hydrogen, fluoro, chloro, and trifluoromethyl,

[1013] and pharmaceutically acceptable salts, solvates, isotopes and co-crystals thereof.

[1014] Another preferred embodiment relates to compounds having a structure of Formula II,

[1015] wherein

[1016] R4 and R5 are both hydrogen or fluoro;

[1017] R6 is selected from fluoro, chloro, bromo, amino, nitro, cyano, azido, unsubstituted or fluorinated Ci-3alkyl preferably selected from methyl, ethyl, propyl preferably isopropyl, fluoromethyl preferably trifluoromethyl, unsubstituted or fluorinated methylsulfonyl, unsubstituted or fluorinated methylsulfinyl, unsubstituted or fluorinated Ci-3alkyloxy preferably selected from methoxy, fluoromethoxy and fluoroethoxy, unsubstituted or fluorinated Ci-2alkyloxy(Ci-2)alkyloxy including methoxyethoxy, cyclopropyl,

[1018] cyclopropylmethoxy, phenyl, phenoxy, benzyloxy, benzylsulfinyl, 2-thienyl, 3-thienyl, 3- pyridyl, 4-pyridyl, tetrahydrofuranyl, tetrahydrofuranylmethoxy and dimethyloxazole, wherein each phenyl, phenoxy, benzyloxy, 2-thienyl, 3-thienyl, 3-pyridyl, 4-pyridyl residue may be optionally substituted with one or more of fluoro, chloro, unsubstituted or fluorinated methyl or unsubstituted or fluorinated methoxy,

[1019] X3 is C(R12) or N,

[1020] R7 is selected from hydrogen, methyl, fluoro(Ci-2)alkyl preferably mono-, di- or trifluoromethyl, methylsulfonyl, methylsulfinyl, methoxy, fluoro(Ci-2)alkoxy, cyano, pyridyl, pyridylmethoxy, phenoxy, oxazol, isoxazol, cyano, fluoro, chloro or bromo, and is preferably hydrogen, methoxy, fluoro, or bromo, wherein each pyridyl, isoxazol and phenyl residue may be optionally substituted with one or more of fluoro, chloro, unsubstituted or fluorinated methyl or unsubstituted or fluorinated methoxy;

[1021] R8 and R1 1 are independently selected from hydrogen, fluoro, chloro, and unsubstituted or fluorinated methoxy;

[1022] R9 is hydrogen,

[1023] R10 is selected from fluoro, chloro, bromo, iodo, acetyl, azido, nitro, cyano, cyanomethyl, cyanothyl, cyanomethoxy, unsubstituted or fluorinated Ci-2alkoxycyclopropyl,

[1024] unsubstituted or fluorinated Ci-2alkoxycarbonylcyclopropyl, cyclopropylmethoxy, cyclopropylmethyl, unsubstituted or fluorinated Ci-3alkyl preferably selected from methyl and trifluoromethyl, unsubstituted or fluorinated and / or hydroxylated Ci-3alkoxy preferably selected from methoxy, difluoromethoxy, trifluoromethoxy, difluoroethoxy, and

[1025] trifluoroethoxy, unsubstituted or fluorinated Ci-2 alkoxy(Ci-3)alkyl preferably unsubstituted or fluorinated methoxypropyl, unsubstituted or fluorinated Ci-2 alkoxy(Ci-3)alkoxy including fluoromethoxyethoxy, unsubstituted or fluorinated C2-3alkenyl, unsubstituted or fluorinated C2-3alkynyl, preferably ethynyl unsubstituted or fluorinated C1-2 alkoxy(C2-3)alkenyl preferably methoxypropenyl, unsubstituted or fluorinated Ci-2 alkoxy(C2-3)alkynyl and pentafluorosulfanyl;

[1026] R12, if present, is hydrogen or fluoro,

[1027] and pharmaceutically acceptable salts, solvates, isotopes and co-crystals thereof.

[1028] Another preferred embodiment relates to compounds having a structure of Formula II wherein R4 and R5 are both hydrogen; R6 is selected from fluoro, chloro, bromo, methyl, ethyl, isopropyl, trifluoromethyl, methylsulfonyl, methoxy, cyclopropyl, cyclopropylmethoxy, phenyl, phenoxy, benzyloxy, 2-thienyl, 3-thienyl, 3-pyridyl, 4-pyridyl, tetrahydrofuranyl and dimethyloxazole, X3 is C(R12), R9 is hydrogen; R7 is selected from hydrogen, methyl, trifluoromethyl, methoxy, fluoro, chloro or bromo, and is preferably hydrogen, methoxy, or bromo; R8 and R11 are independently selected from hydrogen, fluoro, chloro, and methoxy; R10 is fluoro, chloro, bromo, iodo, acetyl, azido, ethynyl, cyano, cyanomethyl, trifluoromethyl, difluoroethoxy, trifluoroethoxy, or pentafluorosulfanyl; R12 is hydrogen or fluoro, and pharmaceutically acceptable salts, solvates, isotopes and co-crystals thereof

[1029] Another embodiment relates to compounds of formula II, wherein R4 is hydrogen or fluoro, preferably hydrogen;

[1030] R5 is selected from hydrogen, fluoro, chloro, bromo, methoxy and fluoromethoxy,

[1031] R6 is selected from halogen, cyano, amino, nitro, unsubstituted or fluorinated

[1032] methylsulfonyl, unsubstituted or fluorinated methylsulfinyl, Ci-3alkyl, Ci-3alkyloxy, C2-3 alkenyl, cyclopropyl, phenyl, phenoxy, benzyloxy, benzylsulfinyl, 2-thienyl, 3-thienyl, 3- pyridyl, and 4-pyridyl, wherein each phenyl, phenoxy, benzyloxy, 2-thienyl, 3-thienyl, 3- pyridyl, 4-pyridyl may be optionally substituted with one or more of fluoro, chloro, unsubstituted or fluorinated methyl or unsubstituted or fluorinated methoxy, and wherein each alkyl, alkenyl and alkoxy group can be unsubstituted or substituted with one or more group selected from halogen, methoxy, fluoromethoxy, cyano, cyclopropyl, and halogen,

[1033] X3 is C(R12) or N,

[1034] R7 is selected from hydrogen, cyano, fluoro, chloro, bromo, unsubstituted or fluorinated Ci-3alkyl preferably selected from methyl, fluoromethyl and fluoroethyl, and unsubstituted or fluorinated Ci-3alkyloxy preferably selected from methoxy, fluoromethoxy and fluoroethoxy,

[1035] R8 and R1 1 are independently selected from hydrogen, fluoro, chloro, cyano, methyl, fluoromethyl, methoxy and fluoromethoxy;

[1036] R9 is hydrogen or fluoro, preferably hydrogen,

[1037] R10 is selected from halogen, azido, cyano, cyclopropyl, nitro, Ci-3alkyl, Ci-3alkoxy, C2-3 alkenyl, C2-3alkynyl, Ci-3alkylcarbonyl(Ci-3)alkyl, Ci-3alkoxycarbonyl(Ci-3)alkyl and pentafluorosulfanyl, wherein each alkyl, alkenyl, alkynyl and alkoxy group can be unsubstituted or substituted with one or more residues selected from fluoro, chloro, cyano, cyclopropyl and unsubstituted or fluorinated and / or hydroxylated Ci-3alkoxy, and wherein each cyclopropyl group can be substituted with one or more residues selected from halogen, hydroxy, hydroxymethyl, Ci-3alkoxy, Ci-3alkoxycarbonyl and cyano,

[1038] R12, if present, is hydrogen or fluoro,

[1039] and pharmaceutically acceptable salts, solvates, isotopes and co-crystals thereof.

[1040] Another embodiment relates to compounds of Formula I I wherein

[1041] R4 is hydrogen,

[1042] R5 is selected from hydrogen, fluoro, chloro and bromo, R6 is selected from fluoro, chloro, bromo, iodo, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl preferably trifluoromethyl, fluoroethyl, methoxy, fluoromethoxy, fluoroethoxy, cyano, methylsulfinyl, methylsulfonyl, cydopropyl, phenyl, benzyloxy, 2-thienyl and 3- thienyl, R7 is selected from hydrogen, fluoro, chloro, bromo, cyano, fluoro(Ci-2)alkyl preferably trifluoromethyl, and fluoro(Ci-2)alkoxy, and is preferably selected from hydrogen, fluoro, methoxy, fluoromethoxy and fluoroethoxy,

[1043] X3 is C(R12),

[1044] R8 and R1 1 are independently selected from hydrogen, fluoro, chloro, cyano,

[1045] fluoromethyl, methoxy and fluoromethoxy,

[1046] R9 is hydrogen,

[1047] R10 is selected from fluoro, chloro, bromo, iodo, azido, unsubstituted or fluorinated Ci- 3alkyl preferably trifluoromethyl, unsubstituted or fluorinated Ci-3alkyloxy preferably selected from difluoroethoxy, trifluoromethoxy and trifluoroethoxy, unsubstituted or fluorinated Ci-3alkoxy(Ci-3)alkyl, unsubstituted or fluorinated Ci-3alkoxy(Ci-3)alkoxy, unsubstituted or fluorinated Ci-3alkoxy(C2-3)alkenyl, pentafluorosulfanyl, ethynyl, propynyl, cyano, cyanomethoxy, and cyanomethyl, and

[1048] R12 is hydrogen and fluoro,

[1049] wherein preferably at least one of R8 and R1 1 is fluoro or chloro, preferably fluoro.

[1050] Another embodiment relates to compounds of Formula I I wherein R4 and R5 are both hydrogen, R6 is selected from fluoro, chloro, bromo, iodo, methyl, isopropyl,

[1051] trifluoromethyl, methylsulfonyl, cydopropyl, phenyl, benzyloxy, 2-thienyl and 3-thienyl, X3 is C(R12), R7 is selected from hydrogen, methyl, methoxy, fluoro, chloro, bromo and trifluoromethyl, preferably from hydrogen, fluoro, and bromo, R8 and R1 1 are

[1052] independently selected from hydrogen, fluoro, chloro and methoxy, R9 is hydrogen, R10 is selected from hydrogen, fluoro, chloro, bromo, iodo, azido, trifluoromethyl,

[1053] difluoroethoxy, trifluoromethoxy, trifluoroethoxy, pentafluorosulfanyl, ethynyl, cyano and cyanomethyl, R12 is hydrogen and fluoro, wherein preferably at least one of R8 and R1 1 is fluoro or chloro, preferably fluoro.

[1054] Another embodiment relates to compounds of Formula I I wherein R4 and R5 are both hydrogen, R6 is selected from fluoro, chloro, bromo, isopropyl, trifluoromethyl, cydopropyl, methoxy, fluoromethoxy, fluoroethoxy, methylsulfinyl, and benzyloxy, R7 is hydrogen, methyl, methoxy, fluoromethoxy, fluoroethoxy, fluoromethyl, cyano, bromo, or fluoro, X3 is C(R12), R9 is hydrogen, R10 is selected from fluoro, bromo, chloro, iodo, methyl, fluoromethyl preferably trifluoromethyl, fluoro(Ci-2)alkoxy preferably difluoroethoxy and trifluoromethoxy, pentafluorosulfanyl, cyano, cyanomethoxy, cyanomethyl and cyanoethyl, R12 is hydrogen or fluoro, and R8 and R1 1 are independently selected from hydrogen, fluoro, chloro, methoxy and fluoromethoxy, and are, in one preferred embodiment, both different from hydrogen.

[1055] Another embodiment relates to compounds of Formula I I wherein R4, and R5 are both hydrogen, R6 is selected from fluoro, chloro, bromo, isopropyl, trifluoromethyl,

[1056] cyclopropyl, and benzyloxy, R7 is hydrogen, methoxy, or fluoro, X3 is C(R12), R9 is hydrogen, R10 is selected from fluoro, bromo, chloro, iodo, trifluoromethyl, difluoroethoxy, trifluoromethoxy, pentafluorosulfanyl, cyano, and cyanomethyl, R12 is hydrogen or fluoro, and R8 and R1 1 are both different from hydrogen and are preferably fluoro, chloro, methoxy or cyano, more preferably fluoro.

[1057] Another preferred embodiment relates to compounds of Formula II wherein R4 and R5 are both hydrogen, R6 is selected from fluoro, chloro, bromo, isopropyl, fluoromethyl, methoxy, fluoromethoxy and phenyloxy, R7 is hydrogen, methoxy, fluoromethoxy, fluoroethoxy, cyano, fluoro or chloro, X3 is C(R12), R9 is hydrogen or fluoro, R10 is hydrogen, R12 is hydrogen or fluoro, and R8 and R1 1 are both independently selected from fluoro, chloro and methoxy.

[1058] Another preferred embodiment relates to compounds of Formula II wherein R4, and R5 are both hydrogen, R6 is selected from fluoro, chloro, bromo, isopropyl, trifluoromethyl, and phenyloxy, R7 is hydrogen, methoxy or fluoro, X3 is C(R12), R9 is hydrogen or fluoro, R10 is hydrogen, R12 is hydrogen or fluoro, and R8 and R1 1 are both independently selected from fluoro, chloro and cyano.

[1059] Another preferred embodiment relates to compounds of Formula II wherein R4 and R5 are both hydrogen, R6 is selected from fluoro, chloro, bromo, iodo, methyl, ethyl, isopropyl, fluoromethyl preferably trifluoromethyl, methoxy, methylsulfinyl, methylsulfonyl, cyclopropyl, phenyl, benzyloxy, 2-thienyl and 3-thienyl, and preferably from fluoro, chloro, bromo, and trifluoromethyl, R7 is hydrogen, methoxy or fluoro, preferably hydrogen, X3 is C(R12), R8 is hydrogen, R9 and R10, together with the C atoms to which they are attached form a 2, 1 ,3-benzothiadiazole ,3-oxo-1 ,3-dihydro-2-benzofuran, or 1 -methyl-3- oxo-1 ,3-dihydro-2-benzofuran and R1 1 and R12 are independently selected from hydrogen and fluoro.

[1060] Another embodiment relates to compounds of Formula I I wherein R4, and R5 are both hydrogen, R6 is selected from fluoro, chloro, bromo and methylsulfonyl, R7 is selected from hydrogen, fluoro, bromo, chloro, methoxy, and trifluoromethyl, X3 is C(R12), R8 and R9 together with the ring to which they are attached form a 2, 1 ,3-benzothiadiazole, 2, 1 ,3- benzoselenadiazole, 2,1 ,3-benzoxadiazole or optionally 2,2-fluoro-substituted 1 ,3- benzodioxole, R10 is hydrogen, fluoro, or bromo, R11 is selected from hydrogen, fluoro and cyano, and R12 is hydrogen, fluoro or trifluoromethyl.

[1061] Another embodiment relates to compounds of Formula II wherein R4 is hydrogen, R5 is selected from hydrogen and fluoro, R6 is selected from fluoro, chloro, bromo, methoxy and trifluoromethyl, R7 is selected from hydrogen, halogen, methylsulfonyl, methoxy, fluoromethoxy, fluoroethoxy and fluoromethyl preferably trifluoromethyl, X3 is N, R8 is fluoro, chloro or methoxy, R9 is selected from hydrogen, fluoro, chloro, methyl and methoxy and is preferably hydrogen, R10 is selected from fluoro, chloro, bromo, cyano, cyanomethyl, cyanoethyl, pentafluorosulfanyl, mono-, di- and trifluoromethyl, mono-, di- and trifluoromethoxy, mono-, di- and trifluoroethoxy, unsubstituted or fluorinated Ci- 2alkoxy(Ci-3)alkyl, unsubstituted or fluorinated Ci-2alkoxy(Ci-2)alkoxy, ethynyl and cyanomethyl, and R11 is selected from hydrogen, fluoro, chloro, fluoromethyl, methoxy and fluoromethoxy.

[1062] Another embodiment relates to compounds of Formula II wherein R4, R5 are both hydrogen, R6 is selected from fluoro, chloro, bromo and methoxy, R7 is selected from , hydrogen, fluoro, chloro, bromo, fluorometyl, methoxy and fluoromethoxy, X3 is N, R8 is fluoro or methoxy, R9 is hydrogen, R10 is selected from fluoro, chloro, bromo, cyano, cyanomethyl, acetyl, methyl, ethyl, ethoxyethyl, methoxypropyl, fluorinated methoxypropyl, fluoromethyl, fluoromethoxymethyl, methoxycarbonylcyclopropyl,

[1063] ethoxycarbonylcyclopropyl, ethenyl, ethoxyethenyl, methoxy, fluoromethoxy, fluoroethoxy, fluoropropoxy, methoxyethoxy, fluorinated methoxyethoxy, ethoxyethoxy, fluorinated ethoxyethoxy, methoxypropoxy, fluorinated methoxypropoxy, methoxypropenyl, and fluoromethoxypropenyl, and R11 is hydrogen, methoxy, fluoro or chloro.

[1064] Another embodiment relates to compounds of Formula II wherein R4 and R5 are both hydrogen, R6 is chloro or bromo, R7 is selected from hydrogen, fluoro, chloro, bromo and methoxy, and X3 is C(R12) or N, R8 is fluoro, chloro or methoxy, R9 is hydrogen or fluoro, preferably hydrogen, R10 is selected from fluoro, chloro, bromo, cyano, Ci-3alkyl, C2- 3alkenyl and Ci-3alkoxy, wherein each alkyl, alkenyl and alkoxy can be unsubstituted or substituted with one or more substituents selected from halogen, preferably fluoro, cyano, Ci-2alkoxy and fluoro(Ci-2)alkoxy, and R11 is hydrogen, fluoro or methoxy.

[1065] Another embodiment relates to compounds having Formula l l(d), l l(e), ll(f) and l l(g), wherein R4, R5, R6, R7, R8, R10, R1 1 and R12 are as otherwise described for Formulae I and II herein,

[1066] wherein in Formula ll(d), Q1 is S or O, and

[1067] wherein in Formula ll(e), R13 and R14 are selected from the group of hydrogen, methyl and fluoro and are preferably either both hydrogen or both fluoro,

[1068] wherein in Formula ll(f), Q2 is S or O, preferably S,

[1069] and wherein in Formula II (g), R16 is selected from hydrogen, fluoro, hydroxy, methyl, fluoromethyl, methoxy and fluoromethoxy, and is preferably selected from hydrogen and methyl,

[1070] and pharmaceutically acceptable salts, solvates, isotopes and co-crystals thereof.

[1071] One embodiment relates to compounds according to Formulae ll(d), ll(e), ll(f) and ll(g), wherein

[1072] wherein in Formula 11(d), Q1 is S or O, and

[1073] wherein in Formula ll(e), R13 and R14 are both selected from hydrogen and fluoro, wherein in Formula ll(f), Q2 is S or O, preferably S,

[1074] wherein in Formula ll(g), R16 is selected from hydrogen and methyl,

[1075] R4 is hydrogen,

[1076] R5 is selected from hydrogen, fluoro, chloro and bromo, and is preferably hydrogen,

[1077] R6 is selected from fluoro, chloro, bromo, methyl, methoxy, methylsulfonyl, methylsulfinyl, fluoromethyl, fluoromethoxy, cyano, and benzyloxy, preferably from fluoro, chloro, bromo and fluoromethyl,

[1078] R7 is selected from hydrogen, fluoro, chloro, bromo, methoxy, cyano, methyl, and fluoromethyl, preferably from hydrogen and mono-, di-, and trifluoromethyl,

[1079] R8, if present, is selected from hydrogen and halogen, preferably from hydrogen and fluoro, and is more preferably hydrogen,

[1080] R10, if present, is selected from hydrogen, fluoro, chloro, bromo, and cyano, preferably hydrogen or fluoro,

[1081] R1 1 is selected from hydrogen, halogen, methoxy, fluoromethoxy, fluoromethyl and cyano, and is preferably hydrogen or fluoro,

[1082] R12 is selected from hydrogen, halogen, methoxy, fluoromethyl, preferably from hydrogen, fluoro, and fluoromethyl,

[1083] and pharmaceutically acceptable salts, solvates, isotopes and co-crystals thereof.

[1084] In a preferred embodiment of the compounds of Formula lid and lie,

[1085] R4 and R5 are both hydrogen,

[1086] R6 is selected from fluoro, chloro, bromo, trifluoromethyl, and phenyl,

[1087] R7 is hydrogen, fluoro, bromo, methoxy, or trifluoromethyl, preferably hydrogen or trifluoromethyl,

[1088] R10 is selected from hydrogen and halogen, preferably from hydrogen, fluoro and chloro,

[1089] R1 1 is selected from hydrogen, halogen, trifluoromethyl and cyano, preferably from fluoro and hydrogen, R12 is selected from hydrogen, halogen and trifluoromethyl, preferably from fluoro and hydrogen,

[1090] R13 and R14, in formula lie, are both selected from hydrogen and fluoro,

[1091] and pharmaceutically acceptable salts, solvates, isotopes and co-crystals thereof.

[1092] In a preferred embodiment of the compounds of Formula ll(f),

[1093] R4 and R5 are both hydrogen,

[1094] R6 is selected from fluoro, chloro, bromo, trifluoromethyl and phenyl,

[1095] R7 is selected from hydrogen, methoxy, fluoro, and trifluoromethyl,

[1096] R8 is selected from hydrogen and halogen, preferably from hydrogen and fluoro,

[1097] R1 1 is selected from hydrogen, halogen, trifluoromethyl and cyano, and is preferably hydrogen,

[1098] R12 is selected from hydrogen, halogen and trifluoromethyl, preferably from fluoro and hydrogen,

[1099] and pharmaceutically acceptable salts, solvates, isotopes and co-crystals thereof.

[1100] One embodiment relates to compounds of subformula lla, lib, lie, lid, lie, llf, and llg, which are additionally substituted with a group R2, as depicted for the general Formula II- 2 above, thus leading to the respective corresponding compounds having subformula II- 2a, ll-2b, ll-2c, ll-2d, ll-2e, ll-2f, and ll-2g, wherein R2 is selected from hydrogen, fluoro, chloro, bromo, iodo and methoxy, and wherein R2 is preferably hydrogen or fluoro, and particularly preferably hydrogen, and wherein the other residues are as defined in the formula ll-2a, ll-2b, ll-2c, ll-2d, ll-2e, ll-2f, and ll-2g, herein. By way of non-limiting example, Formula ll-2d and ll-2f are depicted below:

[1101] Another preferred embodiment relates to compounds having a structure of Formula III,

[1102] wherein R4 and R5 are both hydrogen,

[1103] R6 is selected from hydrogen, fluoro, chloro, bromo, fluoromethyl, methoxy,

[1104] fluoromethoxy, and cyclopropyl,

[1105] X3 is C(R12) or N,

[1106] R8 is selected from hydrogen, methoxy, and halogen, particularly preferably from fluoro, chloro, methoxy and hydrogen,

[1107] R9 is hydrogen,

[1108] R10 is selected from fluoro, bromo, chloro, iodo, methyl, fluoro(Ci-3)alkyl preferably trifluoromethyl, unsubstituted or fluorinated methoxy(Ci-3)alkyl, unsubstituted or fluorinated Ci-3alkyloxy preferably mono,- di- and trifluoromethoxy and mono-, di- and trifluoroethoxy, unsubstituted or fluorinated methoxy(Ci-3)alkyloxy, unsubstituted or fluorinated C2-3alkenyl, unsubstituted or fluorinated methoxy(C2-3)alkenyl, ethynyl, propargyl, unsubstituted or fluorinated methoxy(C2-3)alkynyl, azido, pentafluorosulfanyl, cyanomethyl, cyanoethyl, and cyano,

[1109] R1 1 is hydrogen, fluoro, chloro, or methoxy, particularly preferably hydrogen or fluoro, R12, if present, is hydrogen or fluoro,

[1110] and pharmaceutically acceptable salts, solvates, isotopes and co-crystals thereof.

[1111] Another embodiment relates to compounds of Formula III, wherein R4 and R5 are both hydrogen, R6 is chloro or bromo, X3 is C(R12), R12 is hydrogen or fluoro, R8 is selected from hydrogen, methoxy, and halogen, particularly preferably from fluoro and hydrogen, R9 is hydrogen, R10 is selected from fluoro, bromo, chloro, iodo, trifluoromethyl, difluoroethoxy, trifluoromethoxy, trifluoroethoxy, ethynyl, azido, acetyl, pentafluorosulfanyl, cyanomethyl, and cyano, R1 1 is hydrogen, fluoro, chloro, or methoxy, particularly preferably hydrogen or fluoro, and pharmaceutically acceptable salts, solvates, isotopes and co-crystals thereof.

[1112] Another particularly preferred embodiment relates to a compound of Formula III, wherein R4 and R5 are both hydrogen, R6 is selected from methyl, fluoromethyl, methoxy, fluoromethoxy, chloro or bromo, X3 is C(R12), R8 is hydrogen, methoxy, or fluoro and is preferably fluoro, R9 is hydrogen, R10 is selected from fluoro, bromo, chloro, iodo, mono-, di- and trifluoromethyl, mono-, di- and trifluoromethoxy, mono-, di-, and trifluoroethoxy, pentafluorosulfanyl, ethynyl and cyano, and R1 1 and R12 are independently selected from hydrogen and fluoro.

[1113] Another preferred embodiment relates to compounds of Formula III, wherein R4 and R6 are hydrogen, R5 is iodo, X3 is C(R12) or N, R8 and R1 1 are both independently selected from hydrogen or fluoro, R10 is selected from fluoro, bromo, chloro, iodo, mono-, di- and trifluoromethyl, mono-, di-, and trifluoromethoxy, mono-, di-, and trifluoroethoxy, pentafluorosulfanyl, and cyano, R9 is hydrogen, and R12, if present, is hydrogen or fluoro,

[1114] Another preferred embodiment relates to a compound of Formula III, wherein R4 and R5 are both hydrogen, R6 is chloro or bromo, X3 is C(R12), R8 is hydrogen, R9 and R10, together with the phenyl ring to which they are attached, form a 2,1 ,3-benzothiadiazole ring system, R1 1 is hydrogen and R12 is fluoro or hydrogen.

[1115] Another preferred embodiment relates to a compound of Formula III, wherein R4 and R5 are both hydrogen, R6 is chloro or bromo, X3 is C(R12), R8 and R9, together with the phenyl ring to which they are attached, form a 2, 1 ,3-benzothiadiazole, 2,1 ,3- benzoxadiazole, unsubstituted 1 ,3-benzoxolane, or 2,3,-difluoro-1 ,3-benzoxalane group, R10 and R1 1 are independently selected from hydrogen, methoxy, cyano and halogen, preferably from hydrogen and fluoro, and R12 is fluoro, trifluoromethyl or hydrogen.

[1116] Another embodiment relates to compounds of Formula III, wherein R4 and R5 are both hydrogen, R6 is selected from fluoro, chloro, bromo and mono-, di-, and trifluoromethyl, X3 is N, R8 is fluoro, chloro or methoxy, R9 is selected from hydrogen, fluoro, chloro, and methoxy, and is preferably hydrogen, R10 is selected from fluoro, chloro, bromo, iodo, cyano, mono-, di and trifluoromethyl, mono-, di-, and trifluoromethoxy, mono-, di-, and trifluoroethoxy, ethynyl and cyanomethyl, and R1 1 is hydrogen, fluoro or chloro.

[1117] Another embodiment relates to compounds of Formula III, wherein R4 and R5 are both hydrogen, R6 is selected from chloro, bromo, methoxy, mono-, di-, and trifluoromethyl, X3 is C(R12) or N, R8 is selected from hydrogen, fluoro, chloro, methoxy and fluoromethoxy, R9 is hydrogen, R10 is selected from fluoro, chloro, bromo, cyano, cyanomethyl, cyanoethyl, cyanomethoxy, mono-, di-, and trifluoromethyl, mono-, di-, and

[1118] trifluoromethoxy, mono-, di-, and trifluoroethoxy, unsubstituted or fluorinated Ci-2alkoxy(Ci- 3)alkoxy, unsubstituted or fluorinated Ci-2alkoxy(Ci-3)alkyl, unsubstituted or fluorinated C2- 3alkenyl, unsubstituted or fluorinated Ci-2alkoxy(C2-3)alkenyl, and C2-3alkynyl, R1 1 is hydrogen, methoxy. fluoro, or chloro and R12, if present, is hydrogen or fluoro.

[1119] In one embodiment, the compounds have a structure selected from Formula lll(a) to lll(c)

[1120] wherein R4, R5, R6, R8, R10, R1 1 and R12 are as otherwise described for Formulae I and III herein,

[1121] wherein in Formula lll(a), Q1 is S or O, and

[1122] wherein in Formula lll(b), R13 and R14 are selected from the group of hydrogen, methyl and fluoro and are preferably either both hydrogen or both fluoro, and

[1123] wherein in Formula lll(c), Q2 is S or O, preferably S, and pharmaceutically acceptable salts, solvates, isotopes and co-crystals thereof.

[1124] In a preferred embodiment of the compounds of Formula lll(a) to lll(c),

[1125] R4 and R5 are both hydrogen,

[1126] R6 is selected from fluoro, chloro, bromo, mono-, di-, and tnfluoromethyl, methoxy and fluoromethoxy,

[1127] R8, if present, is hydrogen or fluoro, preferably hydrogen,

[1128] R10, if present, is selected from hydrogen and halogen, preferably from hydrogen, fluoro and chloro,

[1129] R1 1 is selected from hydrogen, halogen, tnfluoromethyl and cyano, preferably from fluoro and hydrogen,

[1130] R12 is selected from hydrogen, halogen and tnfluoromethyl, preferably from hydrogen and fluoro.

[1131] One embodiment refers to compounds of Formula lid, lie, Ilia and 1Mb

[1132] wherein R4 and R5 are both hydrogen,

[1133] R6 is selected from fluoro, chloro, bromo, mono-, di-, and tnfluoromethyl, and methoxy,

[1134] R10 is selected from hydrogen and halogen, preferably from hydrogen, fluoro and chloro,

[1135] R1 1 is selected from hydrogen, halogen, tnfluoromethyl and cyano, preferably from fluoro and hydrogen,

[1136] R12 is selected from hydrogen, halogen and tnfluoromethyl,

[1137] wherein in the compounds of Formula ll(d) and lll(a), Q1 is S or O, and

[1138] wherein in Formula ll(e) and lll(b), R13 and R14 are selected from hydrogen and fluoro and are preferably either both hydrogen or both fluoro.

[1139] One embodiment refers to compounds of Formula I If and I lie,

[1140] wherein R4 and R5 are both hydrogen,

[1141] R6 is selected from fluoro, chloro, bromo, methylsulfonyl, mono-, di-, and tnfluoromethyl and phenyl,

[1142] R7, if present, is selected from hydrogen, methoxy, fluoro, and tnfluoromethyl, R8 is selected from hydrogen and halogen, preferably from hydrogen and fluoro,

[1143] R1 1 is selected from hydrogen, halogen, trifluoromethyl and cyano, and is preferably hydrogen,

[1144] R12 is selected from hydrogen, halogen and trifluoromethyl, preferably from fluoro and hydrogen,

[1145] Q2 is O or S, and is preferably S.

[1146] One embodiment relates to compounds of subformula Ilia, lllb, and lllc, which are additionally substituted with a group R2, as depicted for the general Formula III-2 above, thus leading to the respective corresponding compounds having subformula lll-2a, lll-2b, and lll-2c, wherein R2 is selected from hydrogen, fluoro, chloro, bromo, iodo and methoxy, and wherein R2 is preferably hydrogen or fluoro, and particularly preferably hydrogen, and wherein the other residues are as defined in the formula Ilia, lllb, and lllc herein.

[1147] By way of example, if a compound of formula lll-c also carries a R2 group, the resulting compound of Formula lll-2c is as follows:

[1148]

[1149] ormua - c 25

[1150] Another aspect of the present invention relates to compounds having the general formula VI, and pharmaceutically acceptable salts, solvates, isotopes and co-crystals thereof,

[1151] wherein X1 , X2, R2, R4, R5, R6, R8, R9, R10 and R1 1 have the meaning as described for the compounds of formula I-2, II-2, III-2, IV-2 or V-2 hereinbefore, and wherein R2 is selected from hydrogen, fluoro, chloro, bromo, iodo and methoxy, preferably from hydrogen and fluoro; more preferably, R2 is hydrogen.

[1152] One embodiment relates to a compound of Formula VI, wherein

[1153] X1 is C-R7 or N

[1154] X2 is NH, S or O, wherein if X1 is N, then X2 is preferably NH,

[1155] R2 is hydrogen or fluoro, preferably hydrogen,

[1156] R4 is hydrogen or fluoro,

[1157] R5 is selected from hydrogen, halogen, cyano, unsubstituted or fluorinated C1-3 alkyl, unsubstituted or fluorinated C1-3 alkoxy, unsubstituted or fluorinated C1-3 alkylcarbonyl, unsubstituted or fluorinated C1-3 alkylsulfinyl, and unsubstituted or fluorinated C1-3

[1158] alkylsulfonyl, wherein R5 is preferably selected from hydrogen, halogen, cyano, methyl, methoxy, fluoromethyl and fluoromethoxy, and is more preferably selected from hydrogen, fluoro, chloro and bromo,

[1159] or R5 forms a ring together with R6 as described herein,

[1160] R6 is selected from hydrogen, fluoro, chloro, bromo, iodo, cyano, azido, nitro, amino, Ci- 3alkyl, C2-3alkenyl, C2-3alkynyl, Ci-3alkoxy, C3-6 cycloalkyl, C3-6 heterocycloalkyl, phenyl, C5- 6heteroaryl, C3-6 cycloalkyloxy, C3-6 heterocycloalkyloxy, phenyloxy, C5-6heteroaryloxy, Ci- 3alkylsulfinyl, phenylsulfinyl, Ci-3alkylsulfonyl, phenylsulfonyl, benzylsulfonyl, C1-3

[1161] alkylcarbonyl, C1-3 alkoxycarbonyl, C1-3 alkylaminocarbonyl, di(Ci-3)alkylaminocarbonyl, C3-6cycloalkyl(Ci-2)alkyl, heterocycloalkyl(Ci-2)alkyl, phenyl(Ci-2)alkyl, Cs-6 heteroaryl(C1- 2)alkyl, C3-6 cycloalkyl(Ci-3)alkoxy, C3-6 heterocycloalkyl(Ci-2)alkyloxy, phenyl(Ci-2)alkoxy C5-6heteroaryl(Ci-2)alkoxy, phenyl(Ci-2)alkylsulfinyl, phenyl(Ci-2)alkylsulfonyl

[1162] and wherein each group in R6 can be unsubstituted or substituted with one or more groups selected from fluoro, chloro, bromo, fluorinated or unsubstituted Ci-3alkyl, fluorinated or unsubstituted Ci-3alkyloxy, hydroxy, and cyano,

[1163] or

[1164] (i) R6 forms together with R7 and the carbon atoms to which R6 and R7 are attached, an unsubstituted or substituted phenyl, an unsubstituted or substituted pyridyl, an unsubstituted or substituted cyclopentyl or an unsubstituted or substituted cyclohexyl, wherein each substitution, if present, is selected from hydroxy, halogen, methyl or methoxy, wherein each methyl or methoxy can be unsubstituted or substituted with one or more substituents selected from halogen and methoxy,

[1165] or

[1166] (ii) R6 forms together with R5 and the carbon atoms to which R6 and R5 are attached, a 1 ,3-dioxolane which may be unsubstituted or substituted with one or two substituents selected from fluorine and methyl,

[1167] R7, if present, is selected from hydrogen, fluoro, chloro, bromo, iodo, cyano, Ci-3alkyl, Ci- 3alkoxy, C2-3alkynyl, C2-3alkenyl, Ci-3alkylcarbonyl, Ci-3alkoxycarbonyl, Ci-3alkylsulfinyl, Ci-3alkylsulfonyl, Ci-3alkylthio, C3-6cycloalkyl, C3-6 cycloalkyloxy, C3-6heterocycloalkyl, C3- 6heterocycloalkyloxy, phenyl, phenoxy, phenylsulfonyl, phenylsulfinyl, Cs-eheteroaryl, C5-6heteroaryloxy, C5-6heteroaryl(Ci-2)alkyl, and C5-6heteroaryl(Ci-2)alkoxy, C3-6cycloalkyl(Ci- 2)alkyl, C3-6 cycloalkyl(Ci-3)alkoxy, C3-6 heterocycloalkyloxy, C3-6 heterocycloalkyl(Ci- 2)alkyl, heterocycloalkyl(Ci-2)alkyloxy, phenyl(Ci-2)alkyl, phenyl(Ci-2)alkoxy,

[1168] and wherein each group in R7 can be unsubstituted or substituted with one or more groups selected from fluoro, chloro, bromo, fluorinated or unsubstituted Ci-3alkyl, fluorinated or unsubstituted Ci-3alkyloxy, hydroxy, and cyano, or R7 forms a ring together with R6 as described herein,

[1169] R8 is selected from hydrogen, optionally halogenated preferably fluorinated or

[1170] nsubstituted C1-3 alkyl, optionally halogenated preferably fluorinated or unsubstitued C1-3 alkyloxy, cyano and halogen,

[1171] R9 is selected from hydrogen, fluoro, chloro, bromo, iodo, C1-3 alkyl, fluoro(Ci-3)alkyl, C1-3 alkoxy and fluoro(Ci-3)alkoxy, wherein R9 is preferably hydrogen or fluoro, R10 is selected from hydrogen, halogen, Ci-3alkyl, Ci-3alkoxy, C2-3alkenyl, C2-3alkynyl, cyano, Ci-3alkylcarbonyl, Ci-3alkoxycarbonyl, C1-3 alkylsulfinyl, Ci-3alkylsulfonyl, C1-3 alkylthio, C3-6cycloalkyl, C3-6cycloalkyloxy C3-6heterocycloalkyl, C3-6heterocycloalkyloxy, azido, pentafluorosulfanyl, nitro, Ci-3alkylaminocarbonyl, and di(Ci-3)alkylaminocarbonyl, wherein each alkyl, alkenyl, alkynyl or alkoxy in R10 can be unsubstituted or substituted with one or more substituents selected from halogen, unsubstituted or halogenated Ci- 3alkoxy, unsubstituted or halogenated Ci-3alkylthio, unsubstituted or halogenated C1-3 alkylcarbonyl, unsubstituted or halogenated Ci-3 alkyloxycarbonyl, unsubstituted or halogenated Ci-3 alkylaminocarbonyl, unsubstituted or halogenated di(Ci- 3)alkylaminocarbonyl, hydroxy, cyano, C3-6cycloalkyl, C3-6heterocycloalkyl, phenyl, and C5- 6heteroaryl, wherein any cycloalkyl, heterocycloalkyl, phenyl and heteroaryl may be unsubstituted or substituted with one or more residues selected from halogen, hydroxy, hydroxymethyl, cyano, nitro, unsubstituted or halogenated Ci-3alkyl, unsubstituted or halogenated Ci-3alkoxy, unsubstituted or halogenated Ci-3alkylcarbonyl and unsubstituted or halogenated Ci-3alkoxycarbonyl, and wherein any halogenated substituent in R10 is preferably fluorinated and wherein R8 and R10 are preferably not hydrogen,

[1172] R11 is selected from hydrogen, fluoro, chloro, bromo, iodo, cyano, unsubstituted or fluorinated C1-3 alkyl, and unsubstituted or fluorinated Ci-3alkyloxy, and is preferably selected from hydrogen, fluoro, chloro, methyl, fluoromethyl, methoxy and fluoromethoxy, and pharmaceutically acceptable salts, solvates, isotopes and co-crystals thereof.

[1173] One embodiment relates to a compound of formula VI, wherein

[1174] X1 is C-R7 or N,

[1175] X2 is NH, S or O, wherein X2 is preferably NH

[1176] R2 and R4 are both hydrogen,

[1177] R5 is selected from hydrogen, fluoro, chloro and bromo,

[1178] R6 is selected from hydrogen, fluoro, chloro, bromo, cyano, azido, nitro, Ci-3alkyl, Ci- 3alkyloxy, cyclopropyl, cyclopropyloxy, oxetanyl, tetrahydrofuranyl, methylsulfonyl, methylsulfinyl, thienyl, pyridyl, and benzyloxy, wherein each alkyl or alkoxy group in R6 can be unsubstituted or substituted with one or more groups selected from fluoro, chloro, bromo, unsubstituted or fluorinated Ci-2alkyloxy and cyclopropyl and wherein each cyclopropyl, thienyl, pyridyl and phenyl group in R6 can be substituted with one or more groups selected from halogen, methoxy, fluoromethoxy, methyl, fluoromethyl and cyano, or R6 forms together with R7 and the carbon atoms to which R6 and R7 are attached, an unsubstituted or substituted phenyl, an unsubstituted or substituted pyridyl, an

[1179] unsubstituted or substituted cyclopentyl or an unsubstituted or substituted cyclohexyl, wherein each substitution of a ring formed by R6 and R7 is selected from hydroxy, halogen, cyano, methyl or methoxy, wherein each methyl or methoxy can be

[1180] unsubstituted or fluorinated,

[1181] R7, if present, is selected from hydrogen, halogen, cyano, Ci-3alkyl, Ci-3alkoxy, methylsulfinyl and methylsulfonyl, wherein alkyl or alkoxy group in R7 can be

[1182] unsubstituted or substituted with one or more groups selected from fluoro, chloro, cyano, and unsubstituted or fluorinated Ci-2alkyloxy, or R7 forms a ring together with R6 as described herein,

[1183] R8 is selected from hydrogen, fluoro, chloro, unsubstituted or fluorinated methyl, and unsubstituted or fluorinated methoxy,

[1184] R9 is selected from hydrogen, fluoro, methyl, fluoromethyl, methoxy, and fluoromethoxy, and is preferably hydrogen,

[1185] R10 is selected from hydrogen, halogen, Ci-3alkyl, Ci-3alkyloxy, C2-3alkenyl, C2-3alkynyl, Ci-3 alkylcarbonyl, C3-4cycloalkyl and cyano, wherein each alkyl, alkenyl, alkynyl or alkoxy can be unsubstituted or substituted with one or more substituents selected from fluoro, chloro, bromo, fluorinated or unsubstituted Ci-3alkyloxy, fluorinated or unsubstituted Ci-3alkylcarbonyl, fluorinated or unsubstituted Ci-3alkoxycarbonyl, C3-5cycloalkyl, C3-

[1186] 5cycloalkyloxy, Cs-sheterocycloalkyl, Cs-sheterocycloalkyloxy, hydroxy and cyano, wherein any cycloalkyl, heterocycloalkyl, cycloalkyloxy and heterocycloalkyloxy may be

[1187] unsubstituted or substituted with one or more residues selected from halogen, hydroxy, hydroxymethyl, cyano, fluorinated or unsubstituted methyl, fluorinated or unsubstituted Ci- 3alkyloxy, fluorinated or unsubstituted Ci-3alkyloxycarbonyl and fluorinated or

[1188] unsubstituted Ci-3alkyloxy(Ci-3)alkyloxy,

[1189] R11 is selected from hydrogen, fluoro, chloro, bromo, unsubstituted or fluorinated C1-3 alkyl, and unsubstituted or fluorinated C1-3 alkyloxy,

[1190] and pharmaceutically acceptable salts, solvates, isotopes and co-crystals thereof.

[1191] In one preferred embodiment of the compounds of Formula VI, R6 is not hydrogen; in a more preferred embodiment at least one of, preferably two of R8, R10 and R1 1 are also different from hydrogen. In one embodiment, R6 and R10 are both not hydrogen.

[1192] In one preferred embodiment of the present invention, in a compound of Formula VI, either (a) X1 is CR7 and X2 is NH, S or O, or

[1193] (b) X1 is N and X2 is NH,

[1194] Hence, preferred substructures of Formula VI are those of Formula Via, VIb, Vic and VId as follows:

[1195] wherein any R2, R4, R5, R6, R7, if present, R8, R9, R10 and R11 are as described as for compounds of formula I-2, II-2, III-2, IV-2, V-2 and VI herein.

[1196] In one preferred embodiment of the invention, in the compounds of formula VI and Vla-d, R2 is hydrogen or fluoro,

[1197] R4 is selected from hydrogen, methoxy and fluoro, and is preferably hydrogen or fluoro, more preferably hydrogen,

[1198] R5 is selected from hydrogen, halogen, cyano, Ci-3alkoxy, C1-3 alkylcarbonyl, Ci- 3alkoxycarbonyl, Ci-3alkylsulfinyl, and Ci-3alkylsulfonyl, wherein each alkyl or alkoxy may optionally be substituted one or more times with a group selected from halogen, C1-3 alkoxy, halo(Ci-3)alkoxy, cyano, hydroxyl, and C1-3 alkylamino, with preferred optional substitutions of said alkyl and alkoxy groups being halogen and C1-6 alkoxy, or R5 forms a ring together with R6 as described herein,

[1199] R6 is selected from hydrogen, hydroxy, halogen, cyano, azido, nitro, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C3-7 cycloalkyl, C3-6 cycloalkenyl, C3-7 heterocycloalkyl, C3-7 heterocycloalkenyl, phenyl, Cs-ioheteroaryl preferably Cs-eheteroaryl, Ce-io heterocyclyl , -ORx, -SRx, -SORx, S02Rx, -pentafluorosulfanyl , NRyRzz, -NRyCORx,-NRyC02Rx, - NRxCONRyRz, - CORx, -C02Rx,-CONRyRz, wherein each alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, heterocycloalkyl, cycloalkenyl, heterocycloalkenyl, phenyl, heteroaryl or heterocyclyl group in R6 can be unsubstituted or substituted with one or more substituents preferably selected from halogen, hydroxyl, oxo, cyano, azido, nitro, Ci-s alkyl, Ci-s alkoxy(Ci-3)alkyl , C3-7 cycloalkyl, C3-7 heterocycloalkyl, phenyl, C5-10 (preferably C5-6) heteroaryl, ORx, -SRx, -SORx, S02Rx, -pentafluorosulfanyl, NRyRz, -NRyCORx,- NRyC02Rx, -CORx, -C02Rx,-CONRyRz,

[1200] wherein Rx, Ry, Rz and Rzz are independently selected from hydrogen, Ci-s alkyl, C3-7 cycloalkyl, C3-6 cycloalkenyl, C3-7 cycloalkyl(Ci-6)alkyl, phenyl, phenyl(Ci-6)alkyl, C3-7 heterocycloalkyl, C3-7 heterocycloalkyl(Ci-6)alkyl, C5-6 heteroaryl or heteroaryl(Ci-s)alkyl, any of which groups can be unsubstituted or substituted with one or more substituents, or Ry and Rz, or Ry and Rzz together with the amino atom to which they are both attached may form an aromatic or non aromatic, unsubstituted or substituted C5-6 heterocycle, wherein Rzz is preferably different from hydrogen,

[1201] or in the compounds of formula VI, Via, Vlb or Vic R6 may form together with R5 or R7 and the carbon atoms to which they are attached a 5 or 6 membered aromatic or non- aromatic ring which may optionally contain one or more heteroatoms selected from S, O, and N, and wherein said ring can be unsubstituted or substituted with one or more substituents,

[1202] wherein preferably R6 forms together with R7 and the carbon atoms to which R6 and R7 are attached, an unsubstituted or substituted phenyl, unsubstituted or substituted pyridyl, unsubstituted or substituted cyclopentyl or unsubstituted or substituted cyclohexyl, wherein each substitution, if present, is selected from halogen, hydroxy, cyano, C1-3 alkyl, C3-7 cycloalkyl, C3-7 cycloalkyl(Ci-3) alkyl, C3-7 heterocycloalkyl(Ci-3)alkyl, C1-3 alkoxy, and Ci-3 alkoxy(Ci-3) alkyl, wherein each alkyl or alkoxy can be unsubstituted or substituted with one or more substituents selected from halogen and C1-3 alkoxy, or (ii) R6 forms together with R5 and the carbon atoms to which R6 and R5 are attached, a 1 ,3-dioxolane which may be unsubstituted or substituted with one or two substituents selected from fluoro and methyl, or

[1203] R7, if present, is selected from H, halogen, cyano, Ci-s alkyl, Ci-s alkoxy, C2-6 alkynyl, C2-6 alkenyl, Ci-6alkylcarbonyl, Ci-6alkoxycarbonyl, Ci-s alkylcarbonylamino, C1-5

[1204] alkylaminocarbonyl, di(Ci-3)alkylaminocarbonyl, Ci-6 alkylsulfonyl, C1-6 alkylsulfinyl, C3-7 cycloalkyl, C3-7 heterocycloalkyl, phenyl, C5-6 heteroaryl, C5-6 heteroaryl(Ci-3)alkyl and C5-6 heteroaryl(Ci-3) alkoxy, wherein each alkyl, alkenyl, alkynyl or alkoxy group can be unsubstituted or substituted with one or more substituents selected from halogen, halo(Ci- 6)alkoxy preferably fluro(Ci-3)alkoxy and C1-6 alkoxy,

[1205] R8 is selected from hydrogen, Ci-s alkyl, Ci-s alkoxy, and halogen, wherein each alkyl or alkoxy can be unsubstituted or substituted with one or more substituents selected from halogen and optionally fluorinated C1-3 alkoxy,

[1206] R9 is selected from hydrogen, halogen, cyano, azido, C1-6 alkyl, C1-6 alkoxy, C2-6 alkenyl, C2-6 alkynyl and halogen, wherein each alkyl or alkoxy can be unsubstituted or substituted with one or more substituents selected from halogen and C1-3 alkoxy,

[1207] R10 is selected from hydrogen, halogen, Ci-s alkyl, Ci-6alkoxy, C2-6 alkenyl, C2-6 alkynyl, cyano, Ci-6 alkylcarbonyl, C1-6 alkoxycarbonyl, Ci-6 alkylsulfonyl, C1-6 alkylsulfinyl, Ci-s alkylthio, Ci-s alkylcarbonylamino, C1-5 alkylaminocarbonyl, di(Ci-3)alkylaminocarbonyl, C3-6cycloalkyl, hetero(C3-6)cycloalkyl, azido, pentafluorosulfanyl, and nitro, wherein each alkyl, alkenyl, alkynyl or alkoxy can be unsubstituted or substituted with one or more substituents selected from halogen, Ci-s alkoxy, halo(Ci-6)alkoxy, unsubstituted or fluorinated C1-3 alkoxycarbonyl, unsubstituted or fluorinated Ci-3 alkylcarbonyl, C1-6 alkylthio, unsubstituted or fluorinated Ci-3 alkylcarbonylamino, unsubstituted or fluorinated C1-3 alkylaminocarbonyl, unsubstituted or fluorinated di(Ci-3)alkylaminocarbonyl, unsubstituted or fluorinated Ci-3 alkylsulfonyl, unsubstituted or fluorinated C1-3 alkylsulfinyl, hydroxy, cyano, cyclo(C3-6)alkyl, phenyl, and Cs-eheteroaryl, wherein any cycloalkyl, heterocycloalkyl, phenyl and heteroaryl may be unsubstituted or substituted with one or more residues selected from halogen, hydroxy, cyano, unsubstituted or fluorinated C1-3 alkyl, unsubstituted or fluorinated Ci-3alkoxy, and unsubstituted or fluorinated Ci- 3alkoxycarbonyl,

[1208] R1 1 is selected from hydrogen, halogen, cyano, azido, Ci-s alkyl, Ci-s alkoxy, Ci-s

[1209] alkylcarbonyl, C1-6 alkoxycarbonyl, Ci-6 alkylsulfonyl, and C1-6 alkylsulfinyl, C2-6 alkenyl, and C2-6 alkynyl, wherein each alkyl or alkoxy can be unsubstituted or substituted with one or more substituents selected from halogen and C1-3 alkoxy,

[1210] and pharmaceutically acceptable salts, solvates, isotopes and co-crystals thereof. In one embodiment, in the compounds of Formula VI and Vla-d, at least one of the group R5, R6 and R7, if present, and at least one, preferably two of the group R8, R10 and R1 1 are different from hydrogen, wherein more preferably at least one substituent is selected from fluoro, chloro and bromo.

[1211] In one embodiment, in the compounds of Formula VI and Vla-d,

[1212] X1 , if present, is N or CR7,

[1213] X2, if present, is NH, S or O, wherein if X1 is N, then X2 is preferably NH,

[1214] R2 is hydrogen or fluoro, preferably hydrogen,

[1215] R4 is hydrogen or fluoro, preferably hydrogen,

[1216] R5 is selected from hydrogen, halogen, cyano, C1-2 alkyl, and C1-2 alkyloxy, wherein R5 is preferably hydrogen, methyl or halogen, or R5 forms a ring together with R6 as described herein,

[1217] R6 is selected from hydrogen, halogen, cyano, nitro, amino, azido, Ci-3alkyl, C2-3alkenyl, C2-3alkynyl, Ci-3alkyloxy, C1-3 alkylcarbonyl, C1-3 alkoxycarbonyl, Ci-3 alkylcarbonylamino, , Ci-3 alkylaminocarbonyl, di(Ci-3)alkylaminocarbonyl, (Ci-3)alkylsulfinyl, (Ci-3)alkylsulfonyl, C3-6 cycloalkyl, C3-6 cycloalkyloxy, C3-6 cycloalkyl(Ci-2)alkyl, C3-6 cycloalkyl(Ci-3)alkoxy, C3-6 heterocycloalkyl, C3-6 heterocycloalkyloxy, C3-6 heterocycloalkyl(Ci-2)alkyl,

[1218] heterocycloalkyl(Ci-2)alkyloxy, phenyl, phenyloxy, phenyl(Ci-2)alkyl, phenyl(Ci-2)alkoxy, phenylsulfonyl, phenylsulfinyl, phenyl(Ci-2)alkylsulfonyl, phenyl(Ci-2)alkylsulfinyl, C5-

[1219] 6heteroaryl, Cs-eheteroaryloxy, C5-6heteroaryl(Ci-2)alkyl, and C5-6heteroaryl(Ci-2)alkoxy and wherein each group in R6 can be unsubstituted or substituted with one or more groups selected from fluoro, chloro, bromo, fluorinated or unsubstituted Ci-3alkyl, fluorinated or unsubstituted Ci-3alkyloxy, hydroxy, and cyano,

[1220] or

[1221] (i) wherein in the compounds of formula VI, Via, Vlb or Vic R6 may form together with R7 and the carbon atoms to which R6 and R7 are attached, an unsubstituted or substituted phenyl, an unsubstituted or substituted pyridyl, an unsubstituted or substituted cyclopentyl or an unsubstituted or substituted cyclohexyl,

[1222] wherein each substitution, if present, is selected from hydroxy, halogen, methyl or methoxy, wherein each methyl or methoxy can be unsubstituted or substituted with one or more substituents selected from halogen, preferably fluoro, and methoxy, or (ii) R6 forms together with R5 and the carbon atoms to which R6 and R5 are attached, a 1 ,3-dioxolane which may be unsubstituted or substituted with one or two substituents selected from fluoro and methyl,

[1223] R7, if present, is selected from hydrogen, fluoro, chloro, bromo, iodo, cyano, azido, nitro, amino, Ci-3alkyl, C2-3alkenyl, C2-3alkynyl, Ci-3alkyloxy, C1-3 alkylcarbonyl, C1-3

[1224] alkoxycarbonyl, Ci-3 alkylcarbonylamino, Ci-3 alkylaminocarbonyl, di(Ci- 3)alkylaminocarbonyl, Ci-3alkylsulfinyl, Ci-3alkylsulfonyl, Ci-3alkylthio, C3-6 cycloalkyl, C3-6 cycloalkyloxy, C3-6 cycloalkyl(Ci-2)alkyl, C3-6 cycloalkyl(Ci-3)alkoxy, C3-6 heterocycloalkyl, C3-6 heterocycloalkyloxy, C3-6 heterocycloalkyl(Ci-2)alkyl, heterocycloalkyl(Ci-2)alkyloxy, phenyl, phenyloxy, phenyl(Ci-2)alkyl, phenyl(Ci-2)alkoxy, phenylsulfonyl, phenylsulfinyl, C5- 6heteroaryl, Cs-eheteroaryloxy, C5-6heteroaryl(Ci-2)alkyl, and C5-6heteroaryl(Ci-2)alkoxy and wherein each group in R7 can be unsubstituted or substituted with one or more groups selected from fluoro, chloro, bromo, fluorinated or unsubstituted Ci-3alkyl, fluorinated or unsubstituted Ci-3alkyloxy, hydroxy, and cyano, or R7 forms a ring together with R6 as described herein,

[1225] R8 is selected from hydrogen, halogen, cyano, optionally halogenated C1-3 alkyloxy, optionally halogenated C1-3 alkyl, optionally halogenated (Ci-3)alkylsulfinyl, optionally halogenated (Ci-3)alkylsulfonyl and optionally halogenated (Ci-3)alkylthio,

[1226] R9 is selected from hydrogen, fluoro, chloro, bromo, iodo, C1-3 alkyloxy, fluoro(Ci-3)alkoxy, C1-3 alkyl, and fluoro(Ci-3)alkyl, and is preferably hydrogen,

[1227] R10 is selected from hydrogen, fluoro, chloro, bromo, iodo, cyano, nitro, amino, azido, pentafluorosulfanyl, Ci-3alkyl, C2-3alkenyl, C2-3alkynyl, Ci-3alkyloxy, C1-3 alkylcarbonyl, C1-3 alkoxycarbonyl, Ci-3 alkylaminocarbonyl, di(Ci-3)alkylaminocarbonyl, (Ci-3)alkylsulfinyl, (Ci- 3)alkylsulfonyl, (Ci-3>alkylthio, C3-6 cycloalkyl, C3-6 cycloalkyloxy, C3-6 cycloalkyl(Ci-2)alkyl, C3-6 cycloalkyl(Ci-3)alkoxy, C3-6 heterocycloalkyl, C3-6 heterocycloalkyloxy, C3-6

[1228] heterocycloalkyl(Ci-2)alkyl, C3-6 heterocycloalkyl(Ci-2)alkyloxy, and wherein each group in R10 can be unsubstituted or substituted with one or more groups selected from fluoro, chloro, bromo, fluorinated or unsubstituted Ci-3alkyl, fluorinated or unsubstituted Ci- 3alkyloxy, fluorinated or unsubstituted Ci-3alkoxycarbonyl, fluorinated or unsubstituted Ci- 3alkylcarbonyl, Ci-3 alkylaminocarbonyl, di(Ci-3)alkylaminocarbonyl, hydroxy, and cyano,

[1229] R11 is selected from hydrogen, fluoro, chloro, bromo, iodo, C1-3 alkyl, fluoro(Ci-3)alkyl, C1-3 alkyloxy, fluoro(Ci-3)alkoxy, unsubstituted or fluorinated C1-3 alkylcarbonyl, unsubstituted or fluorinated C1-3 alkoxycarbonyl, and cyano,

[1230] and pharmaceutically acceptable salts, solvates, isotopes and co-crystals thereof. In one preferred embodiment, R6 and R10 are both different from hydrogen and are independently selected from a group as further defined herein.

[1231] In one embodiment, in the compounds of Formula VI and Vla-d,

[1232] R2 and R4 are both hydrogen,

[1233] R5 is selected from hydrogen, fluoro, chloro and bromo,

[1234] R6 is selected from fluoro, chloro, bromo, azido, cyano, benzyloxy, methylsulfonyl, methylsulfinyl, Ci-3alkyl, Ci-3alkyloxy, cyclopropyl, cyclopropyloxy and cyclopropylmethoxy, wherein each alkyl, alkoxy and cyclopropyl group in R6 can be unsubstituted or substituted with one or more groups selected from fluoro, chloro, bromo and unsubstituted or fluorinated Ci-2alkyloxy, wherein R6 is preferably selected from fluoro, chloro, bromo, fluorinated methyl, and unsubstituted or fluorinated methoxy,

[1235] or in the compounds of formula VI, Via, VIb or Vic, R6 may form together with R7 and the carbon atoms to which R6 and R7 are attached, an unsubstituted or substituted phenyl, an unsubstituted or substituted pyridyl, an unsubstituted or substituted cyclopentyl or an unsubstituted or substituted cyclohexyl, wherein each substitution in R7, if present, is selected from hydroxy, halogen, cyano, methyl or methoxy, wherein each methyl or methoxy can be unsubstituted or fluorinated and / or hydroxylated,

[1236] R7, if present, is selected from hydrogen, halogen, cyano, Ci-3alkyl, Ci-3alkyloxy, C3-6 cycloalkyl, C3-6cycloalkyloxy, methylsulfinyl and methylsulfonyl, wherein each alkyl, alkoxy or cycloalkyl group in R7 can be unsubstituted or substituted with one or more groups selected from fluoro, chloro, cyano and unsubstituted or fluorinated Ci-2alkyloxy, or R7 forms a ring together with R6 as described herein,

[1237] R8 is selected from hydrogen, fluoro, chloro, unsubstituted or fluorinated methoxy and unsubstituted or fluorinated methyl,

[1238] R9 is selected from hydrogen, fluoro, methyl and methoxy, and is preferably hydrogen,

[1239] R10 is selected from hydrogen, halogen, cyano, Ci-3alkyl, C2-3alkenyl, C2-3alkynyl, Ci- 3alkyloxy, C3-4cycloalkyl, C3-4cycloalkyloxy, C3-4heterocycloalkyl, and C3- 4heterocycloalkyloxy, wherein each alkyl, alkenyl, alkynyl and alkyloxy group in R10 can be unsubstituted or substituted with one or more groups selected from fluoro, chloro, bromo, fluorinated or unsubstituted Ci-3alkyloxy, fluorinated or unsubstituted Ci- 3alkylcarbonyl, fluorinated or unsubstituted Ci-3alkoxycarbonyl, C3-4cycloalkyl, C3- 4cycloalkyloxy, C3-4heterocycloalkyl, C3-4heterocycloalkyloxy, hydroxy, and cyano, and wherein each cycloalkyl and heterocycloalkyl group in R10 can be substituted with a residue selected from fluoro, chloro, bromo, hydroxy, hydroxymethyl, fluorinated or unsubstituted Ci-3alkyl, fluorinated or unsubstituted Ci-3alkyloxy, fluorinated or

[1240] unsubstituted Ci-2alkyloxyCi-2alkyloxy and fluorinated or unsubstituted Ci-3alkoxycarbonyl,

[1241] R11 is selected from hydrogen, fluoro, chloro, bromo, unsubstituted or fluorinated C1-3 alkyl preferably fluoromethyl, and unsubstituted or fluorinated C1-3 alkyloxy preferably methoxy and fluoromethoxy, wherein R1 1 is preferably selected from hydrogen, fluoro, chloro, methoxy and fluoromethyl,

[1242] and pharmaceutically acceptable salts, solvates, isotopes and co-crystals thereof.

[1243] In one preferred embodiment of the compounds of Formula VI, R2 is hydrogen.

[1244] In one preferred embodiment of the compounds of Formula VI and Vla-d, R4 is hydrogen or fluoro, particularly preferably hydrogen.

[1245] In one preferred embodiment of the compounds of Formula VI and Vla-d, R5 is selected from hydrogen, fluoro, chloro, bromo, iodo, and unsubstituted or fluorinated methyl. In a particularly preferred embodiment, R5 is selected from hydrogen, fluoro, chloro, bromo and methyl, and particularly preferably from hydrogen, fluoro, chloro and bromo. In one preferred embodiment of the compounds of Formula VI and Vla-d, if R6 is not hydrogen, then R5 is hydrogen.

[1246] In one embodiment of the compounds of Formula Vla-c, in particular in the compounds of Formula Via, R6 forms a ring together with R7 and the C-atoms atoms to which R6 and R7 are attached, wherein the ring is preferably selected from phenyl, pyridyl, cyclopentyl and cyclohexyl, each of which may be unsubstituted or substituted with one or more substituents selected from halogen, hydrogen, oxo, C1-3 alkyl Ci-3alkoxy, fluoro Ci-3 alkoxy, fluoro C1-3 alkyl, amino, cyano, di(Ci-3 alkyl)amino, acetyl, Ci-3 alkylsulfonyl, C1-3 alkylsulfanyl, C1-3 alkylthio, and wherein the substitution is preferably selected from fluoro, chloro, bromo, cyano, hydroxy, methyl, fluoromethyl, methoxy and fluoromethoxy. In a preferred embodiment, in the compounds of formula Via, R6 and R7 form a ring which, together with the anulated bicyclic ring, give a tricyclic moiety selected from 1 H- benzo[g]indol-3-yl, 1 H-pyrrolo[3,2-h]quinolin-3-yl, 1 ,6,7,8-tetrahydrocyclopenta[g]indol-3- yl, and 6,7,8,9-tetrahydro-1 H-benzo[g]indol-3-yl. In one embodiment, if R6 and R7 form a pyridyl ring to give 1 H-pyrrolo[3,2-h]quinolin-3-yl, the tricycle may be further substituted with a substituent selected from fluoro, chloro, bromo, hydroxy, methoxy, fluoromethyl and fluromethoxy, preferably at the 8-position to give, for example, 8-hydroxy-1 H-pyrrolo[3,2- h]quinoline, 8-(difluoromethyl)-1 H-pyrrolo[3,2-h]quinoline or 8-(trifluoromethoxy)-1 H- pyrrolo[3,2-h]quinoline. In one embodiment of the compounds of Formula Vla-c, in particular in the compounds of Formula Via, R6 forms a ring together with R7 and the C- atoms atoms to which R6 and R7 are attached, wherein the ring is selected from phenyl, pyridyl, cyclopentyl and cyclohexyl, which are unsubstituted or substituted with one or more substituents selected from fluoro, chloro, fluoromethyl and fluoromethoxy, wherein, in one preferred embodiment, the ring is unsubstituted.

[1247] In one preferred embodiment of the compounds of Formula Vla-c, if R6 and R7 form an optionally substituted ring selected from phenyl, pyridyl, cyclopentyl and cyclohexyl, then R4 and R5 are preferably both hydrogen, R8 is hydrogen, halogen or unsubstituted or fluorinated methoxy, preferably fluoro or methoxy, R9 is hydrogen or fluoro preferably hydrogen, R10 is selected from halogen, cyano, cyanomethyl, cyanoethyl, cyanomethoxy, nitro, azido, pentafluorosulfanyl, unsubstituted or fluorinated and / or hydroxylated, preferably unsubstituted or fluorinated C1-3 alkyl, unsubstituted or fluorinated and / or hydroxylated, preferably unsubstituted or fluorinated Ci-3 alkylcarbonyl, unsubstituted or fluorinated and / or hydroxylated, preferably unsubstituted or fluorinated Ci-3 alkoxy, unsubstituted or fluorinated C2-3 alkenyl, C2-3 alkynyl, unsubstituted or fluorinated and / or hydroxylated, preferably unsubstituted or fluorinated Ci-2 alkoxy(Ci-3)alkyl, unsubstituted or fluorinated and / or hydroxylated, preferably unsubstituted or fluorinated Ci-2 alkoxy(Ci- 3)alkoxy, R1 1 is selected from hydrogen, fluoro, chloro, bromo, unsubstituted or fluorinated methoxy and unsubstituted or fluorinated methyl.

[1248] In one embodiment, in the compounds of formula Via, R6 and R7 form a pyridine and the tricyclic ring system formed is optionally substituted 1 H-pyrrolo[3,2-h]quinolin-3-yl, preferably 8-substituted 1 H-pyrrolo[3,2-h]quinoline.

[1249] In one preferred embodiment of the compounds of Formula Via, R6 and R7 form an optionally substituted ring selected from phenyl, pyridyl (to preferably form optionally 8- substituted 1 H-pyrrolo[3,2-h]quinolin-3-yl), cyclopentyl and cyclohexyl, R4 and R5 are both hydrogen, R8 is fluoro or unsubstituted or fluorinated methoxy, R9 is hydrogen or fluoro, preferably hydrogen, R10 is selected from fluoro, chloro, bromo, iodo, cyano, cyanomethyl, cyanoethyl, cyanomethoxy, unsubstituted or fluorinated C1-3 alkyl, unsubstituted or fluorinated Ci-3 alkoxy, unsubstituted or fluorinated C2-3 alkenyl, C2-3 alkynyl, unsubstituted or fluorinated Ci-2 alkoxy(Ci-3)alkyl and unsubstituted or fluorinated Ci-2 alkoxy(Ci-3)alkoxy, R1 1 is selected from hydrogen, fluoro, chloro, bromo,

[1250] unsubstituted or fluorinated methoxy and unsubstituted or fluorinated methyl.

[1251] In one preferred embodiment of the compounds of Formula VI and Vla-d, R6 is selected from fluoro, chloro, bromo, iodo, cyano, azido, amino, nitro, Ci-3alkyl, C2-3alkenyl, C2- 3alkynyl, Ci-3alkyloxy, Ci-3 alkylcarbonylamino, Ci-3 alkylaminocarbonyl, di(Ci- 3)alkylaminocarbonyl, (Ci-3)alkylsulfinyl, (Ci-3)alkylsulfonyl, C3-6 cycloalkyl, C3-6 cycloalkyloxy, C3-6 cycloalkyl(Ci-2)alkyl, C3-6 cycloalkyl(Ci-3)alkoxy, C3-6 heterocycloalkyl, C3-6 heterocycloalkyloxy, C3-6 heterocycloalkyl(Ci-2)alkyl, heterocycloalkyl(Ci-2)alkyloxy, phenyl, phenyloxy, phenyl(Ci-2)alkyl, phenyl(Ci-2)alkoxy, phenylsulfonyl, benzylsulfonyl, phenylsulfinyl, benzylsulfinyl, Cs-eheteroaryl, Cs-6heteroaryloxy, C5-6heteroaryl(Ci-2)alkyl, and C5-6heteroaryl(Ci-2)alkoxy and wherein each group in R6 can be unsubstituted or substituted with one or more groups selected from fluoro, chloro, bromo, fluorinated or unsubstituted fluorinated or unsubstituted Ci-2alkoxy, hydroxy, and cyano.

[1252] In one preferred embodiment of the compounds of Formula VI and Vla-d, R6 is selected from fluoro, chloro, bromo, cyano, cyanomethyl, cyanomethoxy, nitro, azido, cyclopropyl, cyclopropyloxy, cycopropyl methoxy, unsubstituted or substituted Ci-3alkyl, unsubstituted or substituted Ci-3alkyloxy, methylsulfinyl, methylsulfonyl, pyridyl, optionally halogenated thienyl, and benzyloxy, wherein each substitution in R6 is selected from halo, methoxy and fluoromethoxy, and is preferably fluoro. In one preferred embodiment, R6 is selected from chloro, bromo, azido, cyano, cyclopropyl, methylsulfinyl, methylsulfonyl, mono-, di- and trifluoromethyl, methoxy, mono-, di- and trifluoromethoxy, and mono-, di- and trifluoroethoxy. In a particularly preferred embodiment, R6 is selected from fluoro, chloro, bromo, methoxy, fluoromethoxy, fluoroethoxy and fluoromethyl, and most preferably from fluoro, chloro, bromo and methoxy.

[1253] In one preferred embodiment of the compounds of Formula Vla-c, R7 is selected from hydrogen, fluoro, chloro, bromo, iodo, cyano, nitro, Ci-3alkyl, Ci-3alkyloxy, Ci-3alkylsulfinyl, Ci-3alkylsulfonyl, Ci-3alkylthio, C3-6cycloalkyl, C3-6cycloalkyloxy, C3-6heterocycloalkyl, C3-6heterocycloalkyloxy, phenyl, phenyloxy, phenyl(Ci-2)alkyl, phenyl(Ci-2)alkoxy,

[1254] phenylsulfonyl, phenylsulfinyl, Cs-6heteroaryl, Cs-6heteroaryloxy, C5-6heteroaryl(Ci-2)alkyl, and C5-6heteroaryl(Ci-2)alkoxy, wherein each group in R7 can be unsubstituted or substituted with one or more residues selected from fluoro, chloro, bromo, fluorinated or unsubstituted methyl, fluorinated or unsubstituted Ci-3alkyloxy, hydroxy, and cyano, and wherein the Cs-eheteroaryl is preferably selected from pyridyl, oxazol and isoxazol, each of which may be substituted as described above. In one preferred embodiment, R7 is selected from hydrogen, fluoro, chloro, bromo, methyl, fluoromethyl, methoxy,

[1255] fluoromethoxy, fluoroethoxy, methylsulfinyl, methylsulfonyl and optionally substituted isoxazol. In one preferred embodiment, R7 is selected from hydrogen, fluoro, chloro, bromo, methyl, fluoromethyl, methoxy, fluoromethoxy and methylsulfonyl.

[1256] In a preferred embodiment, in the compounds of Formula VI and Vla-d, R8 is selected from hydrogen, halogen, cyano, unsubstituted or fluorinated C1-3 alkyl and unsubstituted or fluorinated Ci-3 alkyloxy, preferably from fluoro, chloro, bromo, methyl, fluoromethyl, methoxy and fluoromethoxy. In one preferred embodiment, R8 is selected from fluoro, methoxy and fluoromethoxy, and in a particularly preferred embodiment, R8 is fluoro or methoxy.

[1257] In one preferred embodiment, in the compounds of Formula VI and Vla-d, R9 is selected from hydrogen, fluoro, chloro, methyl, fluoromethyl, methoxy and fluoromethoxy. In one preferred embodiment, R9 is selected from hydrogen, fluoro, methoxy and fluoromethoxy, and is more preferably hydrogen or fluoro and particularly preferably hydrogen,

[1258] In one embodiment, in the compounds of Formula VI and Vla-d, R10 is selected from hydrogen, fluoro, chloro, bromo, iodo, cyano, nitro, amino, azido, pentafluorosulfanyl, Ci- 3alkyl, C2-3alkenyl, C2-3alkynyl, Ci-3alkyloxy, C1-3 alkylcarbonyl, C1-3 alkoxycarbonyl, C1-3 alkylcarbonylamino, Ci-3 alkylaminocarbonyl, di(Ci-3)alkylaminocarbonyl, (Ci-3)alkylsulfinyl, (Ci-3)alkylsulfonyl, (Ci-3)alkylthio, C3-4 cycloalkyl, C3-4 cycloalkyloxy, C3-4 heterocycloalkyl, C3-4 heterocycloalkyloxy, C3-4 heterocycloalkyl(Ci-2)alkyl, C3-4heterocycloalkyl(Ci-2)alkoxy, C5-6heteroaryl(Ci-2)alkyl, and C5-6heteroaryl(Ci-2)alkoxy and wherein each alkyl, alkenyl, alkynyl and alkoxy group in R10 can be unsubstituted or substituted with one or more groups selected from fluoro, chloro, bromo, fluorinated or unsubstituted Ci-3alkyloxy, Ci- 3alkyloxycarbonyl, phenyl, phenyloxy, C3-6 cycloalkyl, C3-6 cycloalkyloxy, C3-6

[1259] heterocycloalkyl, C3-6 heterocycloalkyloxy, hydroxy, and cyano, and wherein each cyclic group in R10 can be unsubstituted or substituted with one or more residues selected from fluoro, chloro, bromo, fluorinated or unsubstituted Ci-3alkyl, fluorinated or unsubstituted Ci- 3alkyloxy, fluorinated or unsubstituted Ci-3alkyloxycarbonyl, hydroxy, hydroxymethyl, and cyano.

[1260] In one embodiment, in the compounds of Formula VI and Vla-d, R10 is selected from hydrogen, fluoro, chloro, bromo, iodo, cyano, nitro, amino, azido, pentafluorosulfanyl, Ci- 3alkyl, C2-3alkenyl, C2-3alkynyl, Ci-3alkyloxy, C1-3 alkylcarbonyl, C1-3 alkoxycarbonyl, (Ci- 3>alkylsulfinyl, (Ci-3)alkylsulfonyl, (Ci-3>alkylthio, Ci-3alkyloxycyclopropyl and Ci-

[1261] 3alkyloxycarbonylcyclopropyl, wherein each alkyl, alkoxy, alkenyl and alkynyl group in R10 can be unsubstituted or substituted with one or more groups selected from fluoro, chloro, bromo, fluorinated or unsubstituted Ci-3alkyl, fluorinated or unsubstituted Ci-3alkyloxy, fluorinated or unsubstituted Ci-3alkyloxycarbonyl, C3-6 cycloalkyl and cyano.

[1262] In one preferred embodiment, R10 is selected from hydrogen, fluoro, chloro, bromo, iodo, cyano, cyanomethyl, cyanoethyl, cyanomethoxy, cyanoethoxy, nitro, azido,

[1263] pentafluorosulfanyl, Ci-3alkyl, C2-3alkenyl, C2-3alkynyl, Ci-3alkyloxy, Ci-2alkylcarbonyl and substituted cyclopropyl, wherein each group in R10 can be unsubstituted or substituted with one or more groups selected from fluoro, unsubstituted or fluorinated and / or hydroxylated, preferably unsubstituted or fluorinated Ci-2alkyloxy, unsubstituted or fluorinated and / or hydroxylated, preferably unsubstituted or fluorinated Ci-2alkyloxycarbonyl, unsubstituted or substituted cyclopropyl and hydroxy, provided that any substitution of cycopropyl is selected from the group of halogen, cyano, hydroxymethyl, optionally fluorinated Ci-2alkoxy and optionally fluorinated Ci-2alkoxycarbonyl.

[1264] In one preferred embodiment, in the compound of the present invention, including but not limited to the compounds of Formula VI and Vla-d, R10 is selected from hydrogen, fluoro, chloro, bromo, iodo, cyano, cyanomethyl, cyanoethyl, cyanomethoxy, cyanoethoxy, nitro, azido, pentafluorosulfanyl, methyl, ethyl, propyl, fluoromethyl, fluoroethyl, fluoropropyl, methoxymethyl, fluoromethoxymethyl, methoxyethyl, fluoromethoxyethyl, methoxypropyl, fluoromethoxypropyl, ethoxymethyl, fluoroethoxymethyl, ethoxyethyl, fluoroethoxyethyl, propoxymethyl, fluoropropoxymethyl, methoxy, ethoxy, propoxy, fluoromethoxy, fluoroethoxy, fluoropropoxy, methoxymethoxy, fluoromethoxymethoxy, methoxyethoxy, fluoromethoxyethoxy, methoxypropoxy, fluoromethoxypropoxy, ethoxymethoxy, fluoroethoxymethoxy, ethoxyethoxy, fluoroethoxyethoxy, propoxymethoxy,

[1265] fluoropropoxymethoxy, ethenyl, propenyl, fluoroethenyl, fluoropropenyl, methoxyethenyl, fluoromethoxyethenyl, methoxypropenyl, fluoromethoxypropenyl, ethoxyethenyl, fluoroethoxyethenyl, ethynyl, propynyl, methoxyethynyl, fluoromethoxyethynyl, methoxypropynyl, fluoromethoxypropynyl and cyclopropylmethoxy, wherein in one embodiment, each group in R10 may be further suitably substituted with hydroxy.

[1266] In one preferred embodiment, R10 is a cyclic group selected from C3-5 cycloalkyl, C3-5 cycloalkyloxy, C3-5 cycloalkyl(Ci-3)alkyl preferably cycloalkylmethyl, C3-5 cycloalkyl(Ci-

[1267] 3)alkoxy preferably cycloalkylmethoxy, C3-5 heterocycloalkyl, C3-5 heterocycloalkyloxy, C3-5 heterocycloalkyl(Ci-3)alkyl preferably heterocycloalkylmethyl, and C3-5 heterocycloalkyl(Ci- 3)alkoxy preferably heterocycloalkylmethoxy, wherein each cyclic group may be unsubstituted or substituted with one or more substituents selected from halogen preferably fluoro, cyano, hydroxymethyl, optionally fluorinated Ci-3alkoxy, optionally fluorinated Ci-2alkoxy(Ci-2)alkyl, optionally fluorinated Ci-2alkoxy(Ci-2)alkoxy, and optionally fluorinated Ci-2alkoxycarbonyl. In one preferred embodiment, the substitution is preferably selected from fluoro, cyano and optionally fluorinated Ci-3alkoxy, wherein the cyclic group is preferably cyclopropyl.

[1268] In one preferred embodiment, in the compound of the present invention, including but not limited to the compounds of formula VI and Vla-d, R10 is selected from fluoro, chloro, bromo, iodo, cyano, cyanomethyl, cyanoethyl, cyanomethoxy, cyanoethoxy,

[1269] pentafluorosulfanyl, methyl, ethyl, propyl, butyl, fluoromethyl, fluoroethyl, fluoropropyl, methoxymethyl, fluoromethoxymethyl, methoxyethyl, fluoromethoxyethyl, methoxypropyl, fluoromethoxypropyl, ethoxymethyl, fluoroethoxymethyl, ethoxyethyl, fluoroethoxyethyl, methoxy, ethoxy, propoxy, butyloxy, fluoromethoxy, fluoroethoxy, fluoropropoxy, methoxymethoxy, fluoromethoxymethoxy, methoxyethoxy, fluoromethoxyethoxy, methoxypropoxy, fluoromethoxypropoxy, ethoxymethoxy, fluoroethoxymethoxy, ethoxyethoxy, fluoroethoxyethoxy, ethenyl, propenyl, fluoroethenyl, fluoropropenyl, methoxyethenyl, fluoromethoxyethenyl, methoxypropenyl, fluoromethoxypropenyl, ethoxyethenyl, fluoroethoxyethenyl, ethynyl, propynyl, ethoxycyclopropyl,

[1270] ethoxycarbonylcyclopropyl and cyclopropylmethoxy.

[1271] In one preferred embodiment, in the compound of the present invention, including but not limited to the compounds of formula VI and Vla-d, R10 is selected from fluoro, chloro, bromo, cyano, cyanomethyl, cyanoethyl, methyl, mono-, di-, and trifluoromethyl, ethyl, mono-, di-, and trifluoroethyl, propyl, mono-, di-, and trifluoropropyl, methoxy, mono-, di-, and trifluoromethoxy, ethoxy, mono-, di-, and trifluoroethoxy, propyloxy, mono-, di-, and trifluoropropyloxy, methoxymethyl, mono-, di-, and trifluoromethoxymethyl, methoxyethyl, mono-, di-, and trifluoromethoxyethyl, methoxypropyl, mono-, di-, and

[1272] trifluoromethoxypropyl, methoxymethoxy, mono-, di-, and trifluoromethoxymethoxy, methoxyethoxy, mono-, di-, and trifluoromethoxyethoxy, methoxypropyloxy, mono-, di-, and trifluoromethoxypropyloxy ethoxymethoxy, mono-, di-, and trifluoroethoxymethoxy, methoxypropenyl, and mono-, di-, and trifluoromethoxypropenyl.

[1273] In one preferred embodiment, R10 is selected from fluoro, chloro, bromo, iodo, cyano, cyanomethyl, cyanoethyl, cyanomethoxy, cyanoethoxy, unsubstituted or fluorinated Ci- 3alkyl, unsubstituted or fluorinated Ci-3alkoxy, unsubstituted or fluorinated Ci-2alkoxy(Ci- 3)alkyl, unsubstituted or fluorinated Ci-2alkoxy(Ci-3)alkoxy, and unsubstituted or fluorinated Ci-2alkoxy(C2-3)alkenyl.

[1274] In one preferred embodiment, R10 is selected from halogen, Ci-4alkoxy, Ci-4alkyl, C2-4alkenyl, C2-4alkynyl, C3-6cycloalkyl preferably C3-4cycloalkyl, C3-6cycloalkyloxy preferably C3-4cycloalkyloxy, C3-6heterocycloalkyl preferably C3-4heterocycloalkyl, and C3-

[1275] 6heterocycloalkyloxy preferably C3-4cheterocycloalkyloxy, each of which can be optionally substituted with a residue selected from cyano, fluoro and unsubstituted or fluorinated Ci- 3alkoxy.

[1276] In one embodiment, in the compounds of formula VI and Vla-d, R1 1 is selected from hydrogen, fluoro, chloro, bromo, iodo, C1-3 alkyl, fluoro(Ci-3)alkyl, C1-3 alkyloxy, fluoro(Ci- 3)alkoxy, unsubstituted or fluorinated Ci-3 alkylcarbonyl, and cyano. In a preferred embodiment, R1 1 is selected from hydrogen, fluoro, chloro, methyl, fluoromethyl, methoxy, fluoromethoxy and cyano, more preferably from hydrogen, fluoro, floromethyl, methoxy and fluoromethoxy. In one preferred embodiment, in the compounds of Formula VI and Vla-d,

[1277] R2, R4, R5 and R9 are all hydrogen,

[1278] R6 is selected from halogen, cyano, Ci-3alkoxy, Ci-3alkyl, C3-6cycloalkyl preferably C3- 4cycloalkyl, C3-6cycloalkyloxy preferably C3-4cycloalkyloxy, C3-6heterocycloalkyl preferably C3-4heterocycloalkyl, and C3-6heterocycloalkyloxy preferably C3-4heterocycloalkyloxy, each of which can be optionally substituted with a residue selected from fluoro and

[1279] unsubstituted or fluorinated Ci-3alkoxy,

[1280] R7 is selected from hydrogen, halogen, cyano, Ci-3alkoxy, Ci-3alkyl, C3-6cycloalkyl preferably C3-4cycloalkyl, C3-6cycloalkyloxy preferably C3-4cycloalkyloxy, C3- 6heterocycloalkyl preferably C3-4heterocycloalkyl, and C3-6heterocycloalkyloxy preferably C3-4heterocycloalkyloxy, each of which can be optionally substituted with a residue selected from fluoro and unsubstituted or fluorinated Ci-3alkoxy,

[1281] R8 is selected from fluoro, methoxy and fluoromethoxy, preferably from fluoro and methoxy,

[1282] R10 is selected from halogen, Ci-4alkoxy, C2-3alkenyl C2-3alkynyl, C3-6cycloalkyl preferably C3-4cycloalkyl, C3-6cycloalkyloxy preferably C3-4cycloalkyloxy, C3- 6heterocycloalkyl preferably C3-4heterocycloalkyl, and C3-6heterocycloalkyloxy preferably C3-4heterocycloalkyloxy, each of which can be optionally substituted with a residue selected from fluoro, cyano and unsubstituted or fluorinated Ci-3alkoxy, and

[1283] R1 1 is selected from hydrogen, fluoro, methoxy and fluoromethoxy, preferably from fluoro and methoxy.

[1284] In a preferred embodiment, in the compounds of formula VI and Vla-d,

[1285] R2 is hydrogen,

[1286] R4 is hydrogen or fluoro, more preferably hydrogen;

[1287] R5 is selected from hydrogen, fluoro, chloro and bromo;

[1288] R6 is selected from fluoro, chloro, bromo, azido, cyclopropyl, cyclopropyloxy,

[1289] cycopropyl methoxy, unsubstituted or fluorinated Ci-3alkyl, unsubstituted or fluorinated Ci- 3alkyloxy, methylsulfinyl, methylsulfonyl, pyridyl, optionally halogenated thienyl and benzyloxy;

[1290] R7, if present, is selected from hydrogen, fluoro, chloro, bromo, methyl, fluoromethyl, methoxy, fluoromethoxy, fluoroethoxy, methylsulfinyl, and methylsulfonyl; R8 is selected from hydrogen, fluoro, chloro, bromo, methyl, fluoromethyl, methoxy and fluoromethoxy;

[1291] R9 is selected from hydrogen, fluoro, chloro, methyl, fluromethyl, methoxy and

[1292] fluoromethoxy, and is preferably hydrogen,

[1293] R10 is selected from hydrogen, fluoro, chloro, bromo, iodo, cyano, nitro, azido, pentafluorosulfanyl, Ci-3alkyl, C2-3alkenyl, C2-3alkynyl, Ci-3alkyloxy, Ci-3alkylcarbonyl, Ci- 3alkoxycarbonyl and cyclopropyl, wherein the cyclopropyl is optionally substituted with a residue selected from cyano, Ci-2alkoxy, fluoro(Ci-2)alkoxy, Ci-2alkoxy(Ci-2)alkoxy, fluoro(Ci-2)alkoxy(Ci-2)alkoxy, Ci-2alkoxycarbonyl and fluoro(Ci-2)alkoxycarbonyl, and wherein each alkyl, alkoxy, alkenyl and alkynyl group in R10 can be unsubstituted or substituted with one or more groups selected from halogen, fluorinated or unsubstituted Ci-2alkyloxy, cyano, cyclopropyl and hydroxy, wherein such substitution is preferably selected from fluoro, fluorinated or unsubstituted Ci-2alkyloxy and cyano;

[1294] and R11 is selected from hydrogen, fluoro, chloro, methyl, fluoromethyl, methoxy, fluoromethoxy and cyano,

[1295] and pharmaceutically acceptable salts, solvates, isotopes and co-crystals thereof.

[1296] In one preferred embodiment, in the compounds of formula VI and Vla-d, R2, if present, is hydrogen, R4 is hydrogen or fluoro, more preferably hydrogen; R5 is selected from hydrogen, fluoro, chloro and bromo and is preferably hydrogen; R6 is selected from fluoro, chloro, bromo, azido, methylsulfinyl, methylsulfonyl, methyl, mono-, di- and trifluoromethyl, methoxy, mono-, di- and trifluoromethoxy, and mono-, di- and trifluoroethoxy; R7, if present, is selected from hydrogen, fluoro, chloro, bromo, methyl, fluoromethyl, methoxy, fluoromethoxy, fluoroethoxy, methylsulfinyl and methylsulfonyl, R8 is selected from hydrogen, fluoro, chloro, bromo, methyl, fluoromethyl, methoxy and fluoromethoxy and is preferably fluoro or methoxy; R9 is selected from hydrogen, fluoro, methoxy and fluoromethoxy, and is preferably hydrogen; R10 is selected from hydrogen, fluoro, chloro, bromo, iodo, cyano, cyanomethyl, cyanoethyl, cyanomethoxy, cyanoethoxy, unsubstituted or fluorinated Ci-3alkyl, unsubstituted or fluorinated Ci-3alkyloxy, unsubstituted or fluorinated Ci-2alkyloxy(Ci-3)alkyl, unsubstituted or fluorinated Ci-2alkyloxy(Ci-3)alkyloxy, unsubstituted or fluorinated Ci-2alkyloxy(C2-3)alkenyl, cyclopropyl, cyclopropyloxy and cyclopropyl methoxy, wherein any cyclopropyl moiety is optionally substituted with a residue selected from fluoro, cyano, Ci-2alkoxy, fluoro(Ci-2)alkoxy, Ci-2alkoxy(Ci-2)alkoxy, fluoro(Ci-2)alkoxy(Ci-2)alkoxy, Ci-2alkoxycarbonyl, fluoro(Ci-2)alkoxycarbonyl; and R11 is selected from hydrogen, fluoro, chloro, methyl, fluoromethyl, methoxy and fluoromethoxy, wherein preferably at least one, preferably two and more preferably all substituents in R8, R10 and R11 are different from hydrogen, and wherein in one particularly preferred embodiment R8 and R1 1 are both independently selected from fluoro and methoxy.

[1297] Another embodiment relates to compounds of Formula VI and Vla-d, wherein R2, if present, is hydrogen, R4 and R5 are both hydrogen, R6 is selected from fluoro, chloro, bromo, methylsulfinyl, fluoromethyl, methoxy and fluoromethoxy, R7 is selected from hydrogen, fluoro, chloro, bromo, unsubstituted or fluorinated Ci-2alkyl, unsubstituted or fluorinated Ci-2alkoxy, methylsulfinyl, and methylsulfonyl, R8 is selected from hydrogen, fluoro, chloro methoxy and fluoromethoxy, R9 is hydrogen, methoxy or fluoro, preferably hydrogen, R10 is selected from fluoro, chloro, bromo, iodo, cyano, cyanomethyl, cyanoethyl, unsubstituted or fluorinated and / or hydroxylated Ci-3alkyl, unsubstituted or fluorinated and / or hydroxylated Ci-3alkoxy, unsubstituted or fluorinated and / or

[1298] hydroxylated Ci-2alkoxy(Ci-3)alkyl, unsubstituted or fluorinated and / or hydroxylated Ci- 2alkoxy(Ci-3)alkoxy, unsubstituted or fluorinated and / or hydroxylated Ci-2alkoxy(C2- 3)alkenyl and unsubstituted or fluorinated Ci-2alkoxycarbonylcyclopropyl, and is preferably selected from fluoro, chloro, bromo, iodo, cyano, cyanomethyl, cyanoethyl, unsubstituted or fluorinated Ci-3alkyl, unsubstituted or fluorinated Ci-3alkoxy, unsubstituted or fluorinated Ci-2alkoxy(Ci-3)alkyl, unsubstituted or fluorinated Ci-2alkoxy(Ci-3)alkoxy, unsubstituted or fluorinated Ci-2alkoxy(C2-3)alkenyl, unsubstituted or fluorinated Ci- 2alkoxycarbonylcyclopropyl and unsubstituted or fluorinated Ci-3alkoxycyclopropyl, and R11 is selected from hydrogen, fluoro, chloro, fluoromethyl, methoxy, and fluoromethoxy, wherein in a particular preferably embodiment, at least one, more preferably both of R8 and R11 are different from hydrogen.

[1299] A further embodiment relates to compounds of Formula VI and Vla-d,

[1300] wherein

[1301] R2, R4 and R9 are all hydrogen,

[1302] R5 is hydrogen, fluoro, chloro or bromo, and is preferably hydrogen,

[1303] R6 is selected from fluoro, chloro, bromo, methoxy, fluoromethoxy, fluoromethyl and azido,

[1304] or in the compounds of formula VI, Via, VIb or Vic R6 may form together with R7 and the carbon atoms to which R6 and R7 are attached, a ring selected from phenyl, pyridyl, cyclohexyl and cyclopentyl, each of which may be unsubstituted or substituted with one or two substituents selected from fluoro, chloro, hydroxy, cyano, methoxy, fluoromethoxy and fluoromethyl,

[1305] R7 is selected from hydrogen, fluoro, chloro, bromo, unsubstituted or fluorinated methyl, unsubstituted or fluorinated methoxy and methylsulfinyl,

[1306] R8 is selected from fluoro, chloro, methoxy and fluoromethoxy,

[1307] R10 is selected from fluoro, chloro, bromo, iodo, cyano, cyanomethyl, cyanoethyl, cyanomethoxy, unsubstituted or fluorinated Ci-3alkyl, unsubstituted or fluorinated Ci- 3alkoxy, unsubstituted or fluorinated Ci-2alkoxy(Ci-3)alkyl, unsubstituted or fluorinated Ci- 2alkoxy(Ci-3)alkoxy, and unsubstituted or fluorinated Ci-2alkoxy(C2-3)alkenyl, wherein R10 is preferably selected from fluoro, chloro, bromo, cyanomethyl, cyanoethyl, unsubstituted or fluorinated Ci-3alkyl, unsubstituted or fluorinated Ci-3alkoxy, unsubstituted or fluorinated Ci-2alkoxy(Ci-3)alkyl, unsubstituted or fluorinated Ci-2alkoxy(Ci-3)alkoxy, unsubstituted or fluorinated Ci-2alkoxy(C2-3)alkenyl, unsubstituted or fluorinated Ci-3alkoxycycylopropyl, unsubstituted or fluorinated Ci-3alkoxycarbonylcyclopropyl and unsubstituted or fluorinated Ci-2alkoxy(Ci-2)alkoxycycylopropyl,

[1308] R11 is selected from hydrogen, fluoro, chloro, methyl, fluoromethyl, fluoromethoxy and methoxy,

[1309] and pharmaceutically acceptable salts, solvates, isotopes and co-crystals thereof.

[1310] In one preferred embodiment, in the compounds of Formula VI and Vla-d, R6 and R10 are different from hydrogen and are independently selected from a group as further defined herein.

[1311] In one preferred embodiment, in the compounds of Formula VI and Vla-d, R6, R8 and R10 are all different from hydrogen and are independently selected from a group as further defined herein

[1312] In one preferred embodiment, in the compounds of Formula VI and Vla-d, R6, R8, R10 and R11 are all different from hydrogen and are independently selected from a group as further defined herein.

[1313] In one embodiment, in the compounds of Formula VI and Vla-c, R7 is not hydrogen.

[1314] In one preferred embodiment of the compounds of Formula VI and Vla-d, R6, R8 and at least one of R10 and R11 are all different from hydrogen, and are independently selected from a group as further defined herein In one embodiment, in the compounds of Formula VI and Via, R6 and R7 form a ring selected from phenyl, pyridyl, cyclopentyl and cyclohexyl to give the formula Vie to VIg below:

[1315] wherein

[1316] m is 0 or 1 ,

[1317] n is any number from 0 to 4, preferably from 0 to 2, more preferably 0 or 1 ,

[1318] p is any number from 0 to 3, preferably from 0 to 2, more preferably 0 or 1 ,

[1319] Y is selected from hydrogen, fluoro, chloro, bromo, iodo, cyano, hydroxy, methyl and methoxy, wherein the methoxy and methyl group are optionally substituted with one or more substituents selected from fluoro, chloro, bromo, hydroxy, methoxy and fluoromethoxy,

[1320] R2 and R4 are both hydrogen,

[1321] R5 is selected from hydrogen, fluoro, and chloro, more preferably hydrogen,

[1322] R8 is selected from fluoro, fluoromethyl, methoxy and fluoromethoxy,

[1323] R9 is hydrogen or fluoro,

[1324] R10 is selected from hydrogen, fluoro, chloro, bromo, iodo, cyano, cyanomethyl, cyanoethyl, cyanopropyl, cyanomethoxy, cyanoethoxy, nitro, azido, pentafluorosulfanyl, Ci-3alkyl, C2-3alkenyl, C2-3alkynyl, Ci-3alkyloxy, Ci-2alkylcarbonyl, cycylopropyl, cyclopropylmethyl, and cyclopropylmethoxy, wherein each group in R10 can be unsubstituted or substituted with one or more groups selected from fluoro, fluorinated or unsubstituted Ci-2alkyloxy, fluorinated or unsubstituted Ci-2alkyloxycarbonyl and hydroxy,

[1325] R11 is selected from hydrogen, fluoro, chloro, fluoromethyl, methoxy and fluoromethoxy, and pharmaceutically acceptable salts, solvates, isotopes and co-crystals thereof.

[1326] In one preferred embodiment, in the compounds of Formula VI e,

[1327] m is 0 or 1 ,

[1328] n is 0 or 1 , preferably 0,

[1329] Y is selected from fluoro, chloro, cyano, hydroxy, methyl and methoxy, wherein the methoxy and methyl group are optionally substituted with one or more substituents selected from fluoro, chloro, bromo, hydroxy, methoxy and fluoromethoxy,

[1330] R2 and R4 are hydrogen,

[1331] R5 is hydrogen, fluoro, or chloro, preferably hydrogen,

[1332] R8 is selected from fluoro, fluoromethyl, methoxy and fluoromethoxy, preferably from fluoro and methoxy,

[1333] R9 is hydrogen or fluoro, preferably hydrogen,

[1334] R10 is selected from hydrogen, fluoro, chloro, bromo, iodo, cyano, cyanomethyl, cyanoethyl, pentafluorosulfanyl, Ci-3alkyl, C2-3alkenyl, C2-3alkynyl, Ci-3alkyloxy, Ci-2alkylcarbonyl and cyclopropyl, wherein each alkyl, alkenyl, alkynyl, alkyloxy and cyclopropyl group in R10 can be unsubstituted or suitably substituted with one or more groups selected from fluoro, fluorinated or unsubstituted Ci-2alkyloxy, fluorinated or unsubstituted Ci-2alkyloxycarbonyl and hydroxy, wherein said substituent is preferably selected from fluoro and fluorinated or unsubstituted Ci-2alkyloxy,

[1335] R11 is selected from hydrogen, fluoro, chloro, fluoromethyl, methoxy and fluoromethoxy, and pharmaceutically acceptable salts, solvates, isotopes and co-crystals thereof.

[1336] In one preferred embodiment, in the compounds of Formula Vl(f),

[1337] n is 0 or 1 , preferably 0,

[1338] Y is selected from fluoro, chloro, cyano, hydroxy, methyl and methoxy, wherein the methoxy and methyl group are optionally substituted with one or more substituents selected from fluoro, chloro, bromo, hydroxy, methoxy and fluoromethoxy, R2 and R4 are both hydrogen,

[1339] R5 is hydrogen, fluoro, or chloro, preferably hydrogen,

[1340] R8 is selected from fluoro, fluoromethyl, methoxy and fluoromethoxy,

[1341] R9 is hydrogen or fluoro, preferably hydrogen,

[1342] R10 is selected from hydrogen, fluoro, chloro, bromo, iodo, cyano, cyanomethyl, cyanoethyl, pentafluorosulfanyl, Ci-3alkyl, C2-3alkenyl, C2-3alkynyl, Ci-3alkyloxy, Ci- 2alkylcarbonyl and cyclopropyl, wherein each alkyl, alkenyl, alkynyl, alkyloxy and cyclopropyl group in R10 can be unsubstituted or suitably substituted with one or more groups selected from fluoro, fluorinated or unsubstituted Ci-2alkyloxy, fluorinated or unsubstituted Ci-2alkyloxycarbonyl and hydroxy, wherein said substituent is preferably selected from fluoro and fluorinated or unsubstituted Ci-2alkyloxy,

[1343] R11 is selected from hydrogen, fluoro, chloro, fluoromethyl, methoxy and fluoromethoxy, and pharmaceutically acceptable salts, solvates, isotopes and co-crystals thereof.

[1344] In one preferred embodiment, in the compounds of Formula VI g,

[1345] p is 0 or 1 ,

[1346] Y is selected from fluoro, chloro, cyano, hydroxy, methyl and methoxy, wherein the methoxy and methyl group are optionally substituted with one or more substituents selected from fluoro, chloro, bromo, hydroxy, methoxy and fluoromethoxy,

[1347] R4 is hydrogen,

[1348] R5 is hydrogen or fluoro, preferably hydrogen,

[1349] R8 is selected from fluoro, fluoromethyl, methoxy and fluoromethoxy,

[1350] R9 is hydrogen or fluoro,

[1351] R10 is selected from hydrogen, fluoro, chloro, bromo, iodo, cyano, cyanomethyl, cyanoethyl, pentafluorosulfanyl, Ci-3alkyl, C2-3alkenyl, C2-3alkynyl, Ci-3alkyloxy, Ci- 2alkylcarbonyl and cyclopropyl, wherein each alkyl, alkenyl, alkynyl, alkyloxy and cyclopropyl group in R10 can be unsubstituted or suitably substituted with one or more groups selected from fluoro, fluorinated or unsubstituted Ci-2alkyloxy, fluorinated or unsubstituted Ci-2alkyloxycarbonyl and hydroxy, wherein said substituent is preferably selected from fluoro and fluorinated or unsubstituted Ci-2alkyloxy,

[1352] R11 is selected from hydrogen, fluoro, chloro, fluoromethyl, methoxy and fluoromethoxy, and pharmaceutically acceptable salts, solvates, isotopes and co-crystals thereof.

[1353] In one preferred embodiment of the compounds of formula Vle-g, R10 is selected from chloro, cyano, cyanomethyl, cyanoethyl, Ci-3alkyl and Ci-3alkoxy, wherein each alkyl and alkoxy can be unsubstituted or substituted with one or more substituents selected from fluoro, methoxy, fluoromethoxy, ethoxy and fluoroethoxy, wherein in one embodiment R10 is selected from chloro, bromo, unsubstituted or fluorinated Ci-3alkoxy, cyano,

[1354] cyanomethyl and cyanoethyl. In one preferred embodiment of the compounds of formula Vle-g, R10 is chloro.

[1355] In one preferred embodiment of the compounds of formula Vle-g, Y, if present, is selected from fluoro, chloro, cyano, hydroxy, methyl, fluoromethyl, hydroxymethyl, methoxy and fluoromethoxy. In one preferred embodiment of the compounds of formula Vlg, Y is selected from fluoro, hydroxy, fluoromethyl, methoxy and fluoromethoxy.

[1356] In one preferred embodiment, in the compounds or Formula Vie to Vlg, R10 is selected from fluro, chloro, bromo, fluromethyl, fluoroethyl, fluoromethoxy, fluoroethoxy, cyano and cyanomethyl, and is particularly preferably chloro.

[1357] Another preferred embodiment relates to compounds of the present invention including but not limited to those having a structure of Formula I, I-2, II, II-2, lla, ll-2a, lib, ll-2b, lie, ll-2c, lid, ll-2d, lie, ll-2e, llf, ll-2f, llg, ll-2g, III, III-2, Ilia, lll-2a, 1Mb, lll-2b, lllc, lll-2c, IV, IV- 2, V, V-2, VI, Via, Vlb, Vic, Vld, Vie, Vlf, or Vlg, wherein R4 is hydrogen, and the other substitutions are as disclosed herein.

[1358] Another embodiment relates to compounds of the present invention including but not limited to those having a structure of Formula I, 1-2, II, 11-2, lla, ll-2a, lib, ll-2b, lie, ll-2c, lid, ll-2d, lie, ll-2e, llf, ll-2f, llg, ll-2g, III, 111-2, Ilia, lll-2a, 1Mb, lll-2b, lllc, lll-2c, IV, IV-2, V, V-2, VI, Via, Vlb, Vic, Vld, Vie, Vlf, or Vlg, wherein R5 is selected from hydrogen, halogen, cyano, azido, unsubstituted or fluorinated C1-2 alkyl, preferably methyl or trifluoromethyl, unsubstituted or fluorinated C1-2 alkyloxy, unsubstituted or fluorinated C1-2 alkylcarbonyl, unsubstituted or fluorinated C1-2 alkyloxycarbonyl, C1-2 alkylsulfinyl preferably

[1359] methylsulfinyl, and Ci-2 alkylsulfonyl preferably methylsulfonyl, and the other substitutions are as disclosed herein.

[1360] Another preferred embodiment relates to compounds of the present invention including but not limited to those having a structure of Formula I, I-2, II, II-2, lla, ll-2a, lib, ll-2b, lie, ll-2c, lid, ll-2d, lie, ll-2e, llf, ll-2f, llg, ll-2g, III, III-2, Ilia, lll-2a, 1Mb, lll-2b, lllc, lll-2c, IV, IV- 2, V, V-2, VI, Via, Vlb, Vic, Vld, Vie, Vlf, or Vlg, wherein R5 is selected from hydrogen, fluoro, chloro, bromo, iodo, methyl, trifluoromethyl, methoxy and trifluoromethoxy, and is particularly preferably selected from hydrogen, fluoro, chloro and bromo, and the other substitutions are as disclosed herein.

[1361] Another preferred embodiment relates to compounds of the present invention including but not limited to those having a structure of Formula I, I-2, II, II-2, lla, ll-2a, lib, ll-2b, lie, ll-2c, lid, ll-2d, lie, ll-2e, llf, ll-2f, llg, ll-2g, III, III-2, Ilia, lll-2a, 1Mb, lll-2b, lllc, lll-2c, IV, IV- 2, V, V-2, VI, Via, VIb, Vic, Vld, Vie, Vlf, or Vlg, wherein R5 is iodo and R6 is hydrogen, and the other substitutions are as disclosed herein.

[1362] Another preferred embodiment relates to compounds of the present invention including but not limited to those having a structure of Formula I, 1-2, II, 11-2, lla, ll-2a, lib, ll-2b, lie, ll-2c, lid, ll-2d, lie, ll-2e, llf, ll-2f, llg, ll-2g, III, III-2, Ilia, lll-2a, 1Mb, lll-2b, lllc, lll-2c, IV, IV- 2, V, V-2, VI, Via, VIb, Vic, Vld, Vie, Vlf, or Vlg, wherein R5 is hydrogen, and the other substitutions are as disclosed herein

[1363] Another preferred embodiment relates to compounds of the present invention including but not limited to those having a structure of Formula I, 1-2, II, 11-2, lid, ll-2d, lie, ll-2e, llf, ll-2f, llg, ll-2g, IV, IV-2, V, V-2, VI, Via, VIb, or Vic, wherein R7, if present, is hydrogen, and the other substitutions are as disclosed herein.

[1364] Another preferred embodiment relates to compounds of the present invention including but not limited to those having a structure of Formula I I, I-2, II, II-2, lid, ll-2d, lie, ll-2e, llf, ll-2f, llg, ll-2g, IV, IV-2, V, V-2, VI, Via, VIb, or Vic, wherein R7, if present, is fluoro, and the other substitutions are as disclosed herein.

[1365] Another preferred embodiment relates to compounds of the present invention including but not limited to those having a structure of Formula I, I-2, II, II-2, lid, ll-2d, lie, ll-2e, llf, ll-2f, llg, ll-2g, IV, IV-2, V, V-2, VI, Via, VIb, or Vic, wherein R7, if present, is Ci-3alkoxy or fluoro(Ci-3)alkoxy, preferably mono-, di- or trifluoromethoxy, and the other substitutions are as disclosed herein.

[1366] Another preferred embodiment relates to compounds of the present invention including but not limited to those having a structure of Formula I, I-2, II, II-2, lid, ll-2d, lie, ll-2e, llf, ll-2f, llg, ll-2g, IV, IV-2, V, V-2, VI, Via, VIb, or Vic, wherein R7, if present, is methoxy, and the other substitutions are as disclosed herein.

[1367] Another preferred embodiment relates to compounds of the present invention, including but not limited to those having a structure of Formula I, I-2, II, II-2, lid, ll-2d, lie, ll-2e, llf, ll-2f, llg, ll-2g, IV, IV-2, V, V-2, VI, Via, VIb, or Vic wherein R7, if present, is selected from hydrogen, cyano, fluoro, chloro, bromo, methoxy, ethoxy, fluoromethoxy, fluoroethoxy, methyl, ethyl, fluoromethyl, fluoroethyl, methylsulfinyl, fluoromethylsulfinyl, methylsulfonyl and fluoromethylsulfonyl, and the other substitutions are as disclosed herein. Another preferred embodiment relates to compounds of the present invention, including but not limited to those having a structure of Formula I, I-2, II, II-2, lid, ll-2d, lie, ll-2e, llf, ll-2f, llg, ll-2g, IV, IV-2, V, V-2, VI, Via, VIb, or Vic, wherein R7, if present, is

[1368] methylsulfonyl, fluoromethylsulfonyl, methylsulfinyl, or fluoromethylsulfinyl, and the other substitutions are as disclosed herein.

[1369] Another preferred embodiment relates to compounds of the present invention including but not limited to those having a structure of Formula I, I-2, II, II-2, lid, ll-2d, lie, ll-2e, llf, ll-2f, llg, ll-2g, IV, IV-2, V, V-2, VI, Via, VIb, or Vic, wherein R7 is trifluoromethyl, and the other substitutions are as disclosed herein.

[1370] Another preferred embodiment relates to compounds of the present invention, including but not limited to those having a structure of Formula I, I-2, II, II-2, lid, ll-2d, lie, ll-2e, llf, ll-2f, llg, ll-2g, IV, IV-2, V, V-2, VI, Via, VIb, or Vic, wherein R7, if present, is cyano, cyanomethyl, or cyanomethoxy, and the other substitutions are as disclosed herein.

[1371] Another preferred embodiment relates to compounds of the present invention including but not limited to those having a structure of Formula I, I-2, II, II-2, lid, ll-2d, lie, ll-2e, llf, ll-2f, llg, ll-2g, IV, IV-2, V, V-2, VI, Via, VIb, or Vic, wherein R7 is bromo or chloro, preferably bromo, and the other substitutions are as disclosed herein.

[1372] Another preferred embodiment relates to compounds of the present invention including but not limited to those having a structure of Formula I, I-2, II, II-2, lie, ll-2c, lid, ll-2d, lie, ll-2e, llf, ll-2f, llg, ll-2g, III, III-2, IV, IV-2, V, V-2, VI, Via, VIb, Vic, Vld, Vie, Vlf, or Vlg, wherein R8 is selected from hydrogen, fluoro, chloro, bromo, iodo, methoxy, methyl, and trifluoromethyl and the other substitutions are as disclosed herein.

[1373] Another preferred embodiment relates to compounds of the present invention including but not limited to those having a structure of Formula I, I-2, II, II-2, lie, ll-2c, lid, ll-2d, lie, ll-2e, llf, ll-2f, llg, ll-2g, III, III-2, IV, IV-2, V, V-2, VI, Via, VIb, Vic, Vld, Vie, Vlf, or Vlg, wherein R8 is selected from fluoro, chloro, cyano, methoxy and fluoromethoxy, and the other substitutions are as disclosed herein.

[1374] Another preferred embodiment relates to compounds of the present invention including but not limited to those having a structure of Formula I, I-2, II, II-2, lie, ll-2c, lid, ll-2d, lie, ll-2e, III, III-2, IV, IV-2, V, V-2, VI, Via, VIb, Vic, Vld, Vie, Vlf, or Vlg, wherein R9 is selected from hydrogen, fluoro, chloro, bromo, iodo, methoxy, methyl, cyano, and trifluoromethyl, and is preferably hydrogen, fluoro, chloro, or bromo and the other substitutions are as disclosed herein.

[1375] Another preferred embodiment relates to compounds of the present invention including but not limited to those having a structure of Formula I, I-2, II, II-2, lie, ll-2c, lid, ll-2d, lie, ll-2e, III, III-2, IV, IV-2, V, V-2, VI, Via, Vlb, Vic, Vld, Vie, Vlf, or Vlg, wherein R9 is hydrogen, and the other substitutions are as disclosed herein.

[1376] Another preferred embodiment relates to compounds of the present invention including but not limited to those having a structure of Formula I, I-2, II, II-2, lla, ll-2a, lib, ll-2b, lie, ll-2c, lid, ll-2d, lie, ll-2e, llf, ll-2f, llg, ll-2g, III, III-2, Ilia, lll-2a, lllb, lll-2b, lllc, lll-2c, IV, IV- 2, V, V-2, VI, Via, Vlb, Vic, Vld, Vie, Vlf, or Vlg, wherein R1 1 is selected from hydrogen, fluoro, chloro, bromo, iodo, methoxy, fluoromethoxy, methyl, cyano, and fluoromethyl preferably trifluoromethyl, and is more preferably selected from hydrogen, methoxy, fluoromethoxy, fluoromethyl, fluoro, chloro and bromo, and the other substitutions are as disclosed herein.

[1377] Another preferred embodiment relates to compounds of the present invention including but not limited to those having a structure of Formula I, I-2, II, II-2, lla, ll-2a, lib, ll-2b, lie, ll-2c, lid, ll-2d, lie, ll-2e, llf, ll-2f, llg, ll-2g, III, III-2, Ilia, lll-2a, lllb, lll-2b, lllc, lll-2c, IV, IV- 2, V, or V-2, wherein X3 is C-R12 and R12 is selected from hydrogen, fluoro, chloro, bromo, iodo, methoxy, methyl, and fluoro(Ci-3)alkyl preferably trifluoromethyl, and is more preferably hydrogen, fluoro, chloro, or bromo, and the other substitutions are as disclosed herein. In a particularly preferred embodiment, R12 is hydrogen or fluoro.

[1378] Another preferred embodiment relates to compounds of the present invention including but not limited to those having a structure of Formula I, I-2, II, II-2, lid, ll-2d, lie, ll-2e, llf, ll-2f, llg, ll-2g, III, III-2, Ilia, lll-2a, lllb, lll-2b, lllc, lll-2c, IV, IV-2, V, V-2, VI, Via, Vlb, Vic, and Vld, wherein R6 is different from hydrogen, and the other substitutions are as disclosed herein.

[1379] Another preferred embodiment relates to compounds of the present invention including but not limited to those having a structure of Formula I, I-2, II, II-2, lid, ll-2d, lie, ll-2e, llf, ll-2f, llg, ll-2g, III, III-2, Ilia, lll-2a, lllb, lll-2b, lllc, lll-2c, IV, IV-2, V, V-2, VI, Via, Vlb, Vic, and Vld, wherein R6 is selected from the group of halogen, cyclopropyl, cyclopropyloxy, cyclopropylmethyl, unsubstituted or fluorinated C1-3 alkyl, unsubstituted or fluorinated C1-3 alkyloxy, unsubstituted or fluorinated phenyl, benzyloxy, thiophene, methylsulfinyl, methylsulfonyl, and cyclopropyl, and the other substitutions are as disclosed herein. Another preferred embodiment relates to compounds of the present invention including but not limited to those aving a structure of Formula I, I-2, I I, II-2, lid, ll-2d, lie, ll-2e, llf, II- 2f, llg, ll-2g, III, III-2, Ilia, lll-2a, lllb, lll-2b, lllc, lll-2c, IV, IV-2, V, V-2, VI, Via, Vlb, Vic, and Vld, wherein R6 is selected from fluoro, chloro, bromo, methoxy, methyl, ethyl, isopropyl, cyclopropyl, phenyl, benzyloxy, 2-thiophene, 3-thiophene, trifluoromethyl, and the other substitutions are as disclosed herein. Another preferred embodiment relates to compounds of the present invention including but not limited to having a structure of Formula I, I-2, II, II-2, lid, ll-2d, lie, ll-2e, llf, ll-2f, llg, ll-2g, III, III-2, Ilia, lll-2a, 1Mb, lll-2b, lllc, lll-2c, IV, IV-2, V, V-2, VI, Via, Vlb, Vic, and Vld, wherein R6 is chloro or bromo, and the other substitutions are as disclosed herein. Another preferred embodiment relates to compounds of the present invention including but not limited to those having a structure of Formula I, 1-2, II, 11-2, lid, ll-2d, lie, ll-2e, llf, ll-2f, llg, ll-2g, III, 111-2, Ilia, lll-2a, 1Mb, lll-2b, lllc, lll-2c, IV, IV-2, V, V-2, VI, Via, Vlb, Vic and Vld, wherein R6 is chloro, and the other substitutions are as disclosed herein.

[1380] Another preferred embodiment relates to compounds of the present invention including but not limited to those having a structure of Formula I, I-2, II, II-2, lid, ll-2d, lie, ll-2e, llf, ll-2f, llg, ll-2g, IV, IV-2, V, V-2, VI, Via, Vlb, Vic and Vld, wherein R6 is selected from halogen, cyano, Ci-3alkyl, Ci-3alkyloxy, C3-6cycloalkyl and C3-6 cycloalkyloxy, each of which can be optionally substituted with a residue selected from fluoro and unsubstituted or fluorinated Ci-3alkoxy.

[1381] Another preferred embodiment relates to compounds of the present invention including but not limited to those having a structure of Formula I, I-2, II, II-2, lid, ll-2d, lie, ll-2e, llf, ll-2f, llg, ll-2g, IV, IV-2, V, V-2, VI, Via, Vlb, Vic, wherein R7 is selected from hydrogen, halogen, cyano, Ci-3alkyl, Ci-3alkyloxy, C3-6cycloalkyl and C3-6 cycloalkyloxy, each of which can be optionally substituted with a residue selected from fluoro and unsubstituted or fluorinated Ci-3alkoxy.

[1382] Another preferred embodiment relates to compounds of the present invention including but not limited to those having a structure of Formula I, I-2, II, II-2, lla, ll-2a, lib, ll-2b, lie,

[1383] II- 2c, III, III-2, IV, IV-2, V and V-2, wherein X3 is C(R12), and the other substitutions are as disclosed herein.

[1384] Another preferred embodiment relates to compounds of the present invention including but not limited to those structure of Formula I, I-2, II, II-2, lla, ll-2a, lib, ll-2b, lie, ll-2c, III,

[1385] III- 2, IV, IV-2, V and V-2, wherein X3 is N and the other substitutions are as disclosed herein.

[1386] Another preferred embodiment relates to compounds of the present invention including but not limited to those having a structure of Formula I, II, lla, lib, lie, III, or IV, wherein at least one of R8, R10 and R11 is different from hydrogen and unsubstituted alkyl.

[1387] Another preferred embodiment relates to compounds of the present invention including but not limited to those having a structure of Formula I, I-2, II, II-2, lla, ll-2a, lib, ll-2b, lie, ll-2c, lid, ll-2d, lie, ll-2e, III, III-2, Ilia, lll-2a, 1Mb, lll-2b, IV, IV-2, V, V-2, VI, Via, Vlb, Vic, Vld, Vie, Vlf, or Vlg, wherein R10 is selected from hydrogen, fluoro, chloro, bromo, iodo, C1-3 alkyl, halo(Ci-3)alkyl preferably fluoro(Ci-2)alkyl, C2-3 alkynyl, methoxy, ethoxy, propoxy, halo(Ci-3)alkyloxy preferably fluoro(Ci-2)alkyloxy, unsubstituted or fluorinated (Ci- 2)alkoxy(Ci-3)alkoxy, cyano, cyanomethyl, azido, pentafluorosulfanyl, and nitro, , and the other substitutions are as disclosed herein.

[1388] Another preferred embodiment relates to compounds of the present invention including but not limited to those having a structure of Formula I, I-2, II, II-2, lla, ll-2a, lib, ll-2b, lie, ll-2c, lid, ll-2d, lie, ll-2e, III, III-2, Ilia, lll-2a, 1Mb, lll-2b, IV, IV-2, V, V-2, VI, Via, Vlb, Vic, Vld, Vie, Vlf, or Vlg, wherein R10 is selected from halogen, cyano, Ci-3alkyl, C2-3alkenyl, C2-3alkynyl, Ci-3alkyloxy, C3-6 cycloalkyl and C3-6 cycloalkyloxy, each of which can be optionally substituted with a residue selected from fluoro, cyano and optionally fluorinated Ci-3alkoxy.

[1389] Another preferred embodiment relates to compounds of the present invention including but not limited to those having a structure of Formula I, I-2, II, II-2, lla, ll-2a, lib, ll-2b, lie, ll-2c, lid, ll-2d, lie, ll-2e, III, III-2, Ilia, lll-2a, 1Mb, lll-2b, IV, IV-2, V, V-2, VI, Via, Vlb, Vic, Vld, Vie, Vlf, or Vlg, wherein R10 is selected from the group of cyano, cyanomethyl, halogen, azido, ethynyl, pentafluorosulfanyl, acetyl, difluoroethoxy, trifluoroethoxy, trifluoromethoxy and trifluoromethyl, and the other substitutions are as disclosed herein.

[1390] Another preferred embodiment relates to compounds of the present invention including but not limited to those having a structure of Formula I, I-2, II, II-2, lla, ll-2a, lib, ll-2b, lie, ll-2c, lid, ll-2d, lie, ll-2e, III, III-2, Ilia, lll-2a, 1Mb, lll-2b, IV, IV-2, V, V-2, VI, Via, Vlb, Vic, Vld, Vie, Vlf, or Vlg, wherein R10 is cyano, cyanomethyl, cyanoethyl, or cyanomethoxy and the other substitutions are as disclosed herein.

[1391] Another preferred embodiment relates to compounds of the present invention including but not limited to those having a structure of Formula I, I-2, II, II-2, lla, ll-2a, lib, ll-2b, lie, ll-2c, lid, ll-2d, lie, ll-2e, III, III-2, Ilia, lll-2a, 1Mb, lll-2b, IV, IV-2, V, V-2, VI, Via, Vlb, Vic, Vld, Vie, Vlf, or Vlg, wherein R10 is fluoro, and the other substitutions are as disclosed herein.

[1392] Another preferred embodiment relates to compounds of the present invention including but not limited to those having a structure of Formula I, I-2, II, II-2, lla, ll-2a, lib, ll-2b, lie, ll-2c, lid, ll-2d, lie, ll-2e, III, III-2, Ilia, lll-2a, 1Mb, lll-2b, IV, IV-2, V, V-2, VI, Via, Vlb, Vic, Vld, Vie, Vlf, or Vlg wherein R10 is chloro and the other substitutions are as disclosed herein.

[1393] Another preferred embodiment relates to compounds of the present invention including but not limited to those having a structure of Formula I, I-2, II, II-2, lla, ll-2a, lib, ll-2b, lie, ll-2c, lid, ll-2d, lie, ll-2e, III, III-2, Ilia, lll-2a, 1Mb, lll-2b, IV, IV-2, V, V-2, VI, Via, Vlb, Vic, VId, Vie, Vlf, or VIg, wherein R10 is bromo and the other substitutions are as disclosed herein.

[1394] Another preferred embodiment relates to compounds of the present invention including but not limited to those having a structure of Formula I, I-2, II, II-2, lla, ll-2a, lib, ll-2b, lie, ll-2c, lid, ll-2d, lie, ll-2e, III, III-2, Ilia, lll-2a, 1Mb, lll-2b, IV, IV-2, V, V-2, VI, Via, Vlb, Vic, VId, Vie, Vlf, or VIg, wherein R10 is mono-, di- or trifluoromethyl and the other

[1395] substitutions are as disclosed herein.

[1396] Another preferred embodiment relates to compounds of the present invention including but not limited to those having a structure of Formula I, I-2, II, II-2, lla, ll-2a, lib, ll-2b, lie, ll-2c, lid, ll-2d, lie, ll-2e, III, III-2, Ilia, lll-2a, 1Mb, lll-2b, IV, IV-2, V, V-2, VI, Via, Vlb, Vic, VId, Vie, Vlf, or VIg, wherein R10 is difluoroethoxy (-OCH3CHF2) and the other substitutions are as disclosed herein.

[1397] Another preferred embodiment relates to compounds of the present invention including but not limited to those having a structure of Formula I, I-2, II, II-2, lla, ll-2a, lib, ll-2b, lie, ll-2c, lid, ll-2d, lie, ll-2e, III, III-2, Ilia, lll-2a, 1Mb, lll-2b, IV, IV-2, V, V-2, VI, Via, Vlb, Vic, VId, Vie, Vlf, or VIg, wherein R10 is trifluoroethoxy (-OCH3CF3) and the other substitutions are as disclosed herein.

[1398] Another preferred embodiment relates to compounds of the present invention including but not limited to those having a structure of Formula I, I-2, II, II-2, lla, ll-2a, lib, ll-2b, lie, ll-2c, lid, ll-2d, lie, ll-2e, III, III-2, Ilia, lll-2a, 1Mb, lll-2b, IV, IV-2, V, V-2, VI, Via, Vlb, Vic, VId, Vie, Vlf, or VIg, wherein R10 is ethynyl and the other substitutions are as disclosed herein.

[1399] Another preferred embodiment relates to compounds of the present invention, wherein R10 is selected from methoxymethyl, methoxyethyl, methoxypropyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, propoxymethyl, methoxyethenyl, methoxypropenyl,

[1400] ethoxyethenyl, ethoxypropenyl, methoxyethynyl, methoxypropynyl, methoxymethoxy, methoxyethoxy, methoxypropoxy, ethoxymethoxy, ethoxyethoxy, ethoxypropoxy and propoxymethoxy, each of which may be unsubstituted or fluorinated up to three times, and the other substitutions are as disclosed herein.

[1401] Another preferred embodiment relates to compounds of the present invention, wherein R10 is methoxypropyl or fluorinated methoxypropyl, and the other substitutions are as disclosed herein.

[1402] Another particularly preferred embodiment relates to compounds of the present invention, as further described herein, wherein R8, R10 and R1 1 are all different from hydrogen, and the other substitutions are as disclosed herein. Another particularly preferred embodiment relates to compounds of the present invention including but not limited to those having a structure of Formula I, II, III, or IV, as further described herein, wherein R6, R8, and R10 are all different from hydrogen and the other substitutions are as disclosed herein.

[1403] Another particularly preferred embodiment relates to compounds of the present invention including but not limited to those having a structure of Formula I, II, III, or IV, as further described herein, wherein R6, R8, R10 and R1 1 are all different from hydrogen, and the other substitutions are as disclosed herein.

[1404] Another embodiment relates to compounds of the present invention, as further described herein, wherein at least one of R5, R6 and R7 is different from hydrogen and the other substitutions are as disclosed herein.

[1405] Another embodiment relates to compounds of the present invention as further described herein, wherein at least one of R6 and R7 is different from hydrogen and the other substitutions are as disclosed herein.

[1406] Another embodiment relates to compounds having a structure of Formula III, as further described herein, wherein at least one of R6 and R5 is different from hydrogen and the other substitutions are as disclosed herein.

[1407] In one preferred embodiment, in the compounds of the present invention, R...

Claims

Claims1 ) A compound having Formula I-2,whereinX1 is N or C(R7),X2 is NH, S or O,X3 is N or C(R12),R2 is selected from hydrogen, halogen and methoxy,R4 is selected from hydrogen, methoxy and halogen,R5 is selected from hydrogen, halogen, cyano, Ci-s alkyl, C2-3 alkenyl, C2-3 alkynyl, Ci-s alkoxy, C1-3 alkylcarbonyl, Ci-3 alkoxycarbonyl, C1-3 alkylsulfinyl, and Ci-3alkylsulfonyl, wherein each alkyl or alkoxy may optionally be substituted one or more times selected from halogen, C1-3 alkoxy, cyano, azido, hydroxyl, Ci-3alkylamino and di(Ci-3alkyl)amino, or R5 forms a ring together with R6 as described herein,R6 is selected from hydrogen, hydroxy, halogen, cyano, azido, nitro, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C 1-6 alkoxy, C3-7 cycloalkyi, C3-6 cydoalkenyl, C3-7 heterocycloalkyi, C3- 7 heterocycloalkenyl, phenyl, C5-10 heteroaryl, Cs-io heterocyclyl , -ORx, -SRx, -SORx, S02Rx, -pentafluorosulfanyl , NRyRzz, -NRyCORx,-NRyC02Rx, -NRxCONRyRz, - NRySORx,-NRyS02Rx, -CORx, -C02Rx,-CONRyRz, wherein each alkyl, alkenyl, alkynyl, alkoxy, cycloalkyi, heterocycloalkyi, cydoalkenyl, phenyl, heteroaryl or heterocyclyl group in R6 can be unsubstituted or substituted with one or more substituents selected from halogen, hydroxyl, oxo, cyano, azido, nitro, C1-6 alkyl, haloCi-6 alkyl, Ci-6 alkoxy(Ci-3)alkyl , C3-7 cycloalkyi, C3-7 heterocycloalkyi, phenyl, Cs-io heteroaryl, ORx, -SRx, -SORx, SO2RX,■pentafluorosulfanyl, NRyRz, -NRyCORx,-NRyC02Rx, -CORx, -C02Rx,-CONRyRz,wherein Rx, Ry, Rz and Rzz are independently selected from hydrogen, Ci-6 alkyl, C3-7 cycloalkyl, C3-6cycloalkenyl, C3-7 cycloalkyl(Ci-6)alkyl, phenyl, phenyl(Ci-6)alkyl, C3-7 heterocycloalkyl, C3-7 heterocycloalkyl(Ci-6)alkyl, C5-6 heteroaryl or heteroaryl(Ci-6)alkyl, any of which groups can be unsubstituted or substituted with one or more substituents, selected from those described above, and wherein Rzz is different from hydrogen, or Ry and Rz, or Ry and Rzz together with the amino atom to which they are both attached may form an aromatic or non aromatic, unsubstituted or substituted C5-6 heterocycle, wherein any substituent is selected from the substituents described above, or(i) R6 forms together with R7 and the carbon atoms to which R6 and R7 are attached, an unsubstituted or substituted phenyl, unsubstituted or substituted pyridyl, unsubstituted or substituted cyclopentyl or unsubstituted or substituted cyclohexyl,wherein each substitution, if present, of a ring formed by R6 and R7, is selected from halogen, hydroxy, cyano, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-7 cycloalkyl, C3-7 cycloalkyl(Ci-3)alkyl, C3-7 heterocycloalkyl(Ci-3)alkyl and Ci-s alkoxy, wherein each alkyl or alkoxy can be unsubstituted or substituted with one or more substituents selected from halogen, hydroxy, and unsubstituted or fluorinated C1-3 alkoxy, C3-7 cycloalkyl, and C3-7 heterocycloalkyl,or (ii) R6 forms together with R5 and the carbon atoms to which R6 and R5 are attached, a 1 ,3-dioxolane which may be unsubstituted or substituted with one or two substituents selected from fluoro and methyl,R7, if present, is selected from hydrogen, halogen, cyano, azido, nitro, amino Ci-s alkyl, C1-6 alkoxy, C2-6 alkynyl, C2-6 alkenyl, Ci-6 alkylcarbonyl, Ci-6 alkoxycarbonyl, C1-6alkylsulfonyl, C1-6 alkylsulfinyl, C1-6 alkylthio, Ci-3 alkylcarbonylamino, C1-6alkylaminocarbonyl, di(Ci-3)alkylaminocarbonyl, C3-7 cycloalkyl, C3-7 cycloalkyloxy, C3-7 heterocycloalkyl, C3-7 heterocycloalkyloxy, phenyl, phenyloxy, phenyl(Ci-2)alkyl, phenyl(Ci- 2)alkoxy, phenylsulfonyl, phenylsulfinyl, C5-6 heteroaryl, C5-6 heteroaryloxy, C5-6 heteroaryl(Ci-3)alkyl, C5-6 heteroaryl(Ci-3) alkoxy, C3-6cycloalkyl(Ci-2)alkyl, C3-6cycloalkyl(Ci-3)alkoxy, C3-6 heterocycloalkyl(Ci-2)alkyl, heterocycloalkyl(Ci-2)alkyloxy, wherein each group in R7 can be unsubstituted or substituted with one or more substituents selected from halogen, hydroxy, cyano, unsubstituted or halogenated C1-6 alkyl and unsubstituted or halogenated C1-6 alkoxy, or R7 forms a ring together with R6 as described herein,R8 is selected from hydrogen, Ci-s alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, Ci- 3alkylsulfinyl, Ci-3alkylsulfonyl, C1.3alkylt.hio, cyano, and halogen, wherein each alkyl oralkoxy can be unsubstituted or substituted with one or more substituents selected from halogen and unsubstituted or fluorinated C1-3 alkoxy, or forms a ring system together with R9, as described herein,R9 is selected from hydrogen, halogen, cyano, azido, C1-6 alkyl, C1-6 alkoxy, C2-6 alkenyl, C2-6 alkynyl and halogen, wherein each alkyl or alkoxy can be unsubstituted or substituted with one or more substituents selected from halogen and unsubstituted or fluorinated C1-3 alkoxy,or R9 forms together with R8 or R10 and the ring to which they are attached a bicyclic ring system selected from (a) 2, 1 ,3-benzothiadiazole, (b) 2, 1 ,3-benzoselenadiazole, (c) 2, 1 ,3- benzoxadiazole, (d) 1 ,3-benzothiazole, (e)1 ,3-benzoxazole which may be unsubstituted or may be partially hydrogenated and unsubstituted or substituted with oxo, (f) 1 ,3- benzodioxole which may be unsubstituted or substituted with one or two substituents selected from fluorine and methyl, (g) 1 ,3-dihydro-2-benzothiophen, which may be optionally substituted with two oxos to form 1 , 1 -dioxido-2,3-dihydro-1 -benzothiophen (h) 1 ,3-dihydro-2-benzofuran which may be substituted with oxo to form 3-oxo-1 ,3dihydrobenzofuran, and (i) 2,3-dihydro-1 H-isoindol, which is unsubstituted or substituted with oxo to give 3-oxo-2,3-dihydro-1 H-isoindol, which may be optionally further substituted,R10 is selected from hydrogen, halogen, C1-6 alkyl, Ci-6alkoxy, C2-6alkenyl, C2-6alkynyl, cyano, cyano(Ci-6)alkyl, cyano(Ci-6)alkyloxy,Ci-6 alkylcarbonyl, C1-6 alkoxycarbonyl, C1-6 alkylsulfonyl, C1-6 alkylsulfinyl, C1-6 alkylthio, C3-6cycloalkyl, C3-6cycloalkyloxy, C3-6heterocycloalkyl, hetero(C3-6)cycloalkyloxy, amino, azido, pentafluorosulfanyl, nitro, C1-5 alkylcarbonylamino, Ci-3 alkylaminocarbonyl, di(Ci-3)alkylaminocarbonyl, C1-3 alkylsulfinyl and C1-3 alkylsulfonyl, wherein each alkyl, alkenyl, alkynyl or alkoxy can be unsubstituted or substituted with one or more substituents selected from halogen, C1-6 alkoxy, halo(Ci- 6)alkoxy, hydroxy(Ci-6)alkoxy, optionally halogenated C1-6 alkylthio, optionally halogenated C1-3 alkylcarbonyl, optionally halogenated Ci-3 alkyloxycarbonyl, optionally halogenated Ci- 3 alkylsulfonyl, optionally halogenated C1-3 alkylsulfinyl, C1-3 alkylcarbonylamino, C1-3 alkylaminocarbonyl, di(Ci-3)alkylaminocarbonyl, hydroxy, cyano, nitro, oxo, C3-6cycloalkyl, C3-6cycloalkoxy, C3-6heterocycloalkyl, C3-6heterocycloalkoxy, phenyl, phenyloxy, and C5- 6heteroaryl, wherein any C3-6cycloalkyl, C3-6cycloalkoxy, C3-6heterocycloalkyl, C3- 6heterocycloalkoxy, phenyl and heteroaryl may be unsubstituted or substituted with one or more residues selected from halogen, hydroxy, hydroxymethyl, oxo, cyano, nitro, amino, optionally halogenated or hydroxylated Ci-3alkyl, optionally hydroxylated or halogenated Ci-3alkoxy, optionally halogenated Ci-3alkylcarbonyl and optionally halogenated Ci-3alkoxycarbonyl, any wherein the amino group may be substituted with one or two groupsselected from Ci-3alkyl, Ci-3alkylsulfonyl, Ci-3alkylcarbonyl, and Ci-3alkoxycarbonyl , or R10 forms a ring system together with R9, as described herein,R1 1 is selected from hydrogen, halogen, cyano, azido, Ci-s alkyl, Ci-s alkoxy, Ci-s alkylcarbonyl, C1-6 alkoxycarbonyl, Ci-6 alkylsulfonyl, and C1-6 alkylsulfinyl, C2-6 alkenyl, and C2-6 alkynyl, wherein each alkyl or alkoxy can be unsubstituted or substituted with one or more substituents selected from halogen and halogenated or unsubstituted C1-3 alkoxy,R12, if present, is selected from hydrogen, Ci-s alkyl, Ci-s alkoxy and halogen, wherein each alkyl or alkoxy can be unsubstituted or substituted with one or more substituents selected from halogen and halogenated or unsubstituted C1-3 alkoxy,and pharmaceutically acceptable salts, solvates, isotopes and co-crystals thereof.2) A compound according to claim 1 , whereinX1 is N or C(R7),X2 is NH, S or O,X3 is N or C(R12),R2 is hydrogen,R4 is hydrogen or fluoro,R5 is selected from hydrogen, methyl, fluoro, chloro and bromo,or R5 forms a ring together with R6 as described herein,R6 is selected from halogen, cyano, nitro, azido, C1-3 alkyl, Ci-3alkylsulfinyl, Ci- 3alkylsulfonyl, cyclopropyl, cyclopropylmethyl, cyclopropyloxy, C1-3 alkoxy, phenyl, phenyloxy, benzyl, phenyl(Ci-3)alkoxy, benzylsulfinyl, benzylsulfonyl, tetrahydrofuranyl, and a 5-6 membered heteroaryl selected from thienyl, pyridyl, oxazole, and isoxazole, and wherein each alkyl, alkoxy, cyclopropyl, tetrahydrofuranyl, phenyl or heteroaryl group in R6 can be optionally substituted one or more times with substituents selected from fluoro, chloro, hydroxy, unsubstituted or fluorinated C1-2 alkyl, unsubstituted or fluorinated C1-2 alkoxy, and cyano,or(i) R6 forms together with R7 and the carbon atoms to which R6 and R7 are attached, an unsubstituted or substituted phenyl, an unsubstituted orsubstituted pyridyl, an unsubstituted or substituted cyclopentyl or an unsubstituted or substituted cyclohexyl,wherein each substitution, if present, is selected from halogen, hydroxy, methyl or methoxy, wherein each methyl or methoxy can be unsubstituted or substituted with one or more substituents selected from halogen and methoxy,or(ii) R6 forms together with R5 and the carbon atoms to which R6 and R5 are attached, a 1 ,3-dioxolane which is unsubstituted or substituted with one or two substituents selected from fluoro and methyl,R7 is selected from hydrogen, halogen, cyano, C1-3 alkyl, C1-3 alkyloxy, fluoro(Ci-3)alkyl fluoro(Ci-3)alkoxy, unsubstituted or fluorinated methylsulfinyl, unsubstituted or fluorinated methylsulfonyl, C5-6 heteroaryl, C5-6 heteroaryloxy, C5-6 heteroarylmethyl and C5-6 heteroarylmethoxy, wherein the heteroaryl is selected from pyridyl, oxazol and isoxazol, each of which is unsubstituted or substituted with one or more substituents selected from halogen, cyano, unsubstituted or fluorinated methyl, and unsubstituted or fluorinated methoxy, or R7 forms a ring together with R6 as described herein,R8 is selected from hydrogen, fluoro, chloro, bromo, C1-3 alkyloxy, fluoro(Ci-3)alkoxy and and unsubstituted or fluorinated Ci-3alkyl, or R8 forms a ring system together with R10, as described herein,R9 is selected from hydrogen, fluoro, chloro, methoxy, fluromethoxy, methyl and fluoromethyl,or R9 forms together with R8 and the ring to which they are attached a bicyclic ring system selected from 2, 1 ,3-benzothiadiazole, 2,1 ,3-benzoselenadiazole, 2, 1 ,3- benzoxadiazole, 1 ,3-benzoxazole, 2-oxo-2,3-dihydro-1 ,3-benzoxazole, and 1 ,3- benzodioxole, which is optionally substituted with one or two fluoros,or R9 forms together with R10 and the ring to which they are attached a bicyclic ring system selected from 2, 1 ,3-benzothiadiazole, 2,1 ,3-benzoselenadiazole, 2, 1 ,3- benzoxadiazole, 1 ,3-benzothiazole, 3-oxo-2,3-dihydro-1 H-isoindol, 2,3-dihydro-1 - benzothiophene, which is optionally substituted with one or two oxos, 3-oxo-1 ,3-dihydro-2- benzofuran, 1 -methyl-3-oxo-1 ,3-dihydro-2-benzofuran, and 1 ,3-benzodioxole, which is optionally substituted with one or two fluoros,R10 is selected from hydrogen, halogen, cyano, azido, pentafluorosulfanyl, nitro, C1-3 alkyl, C2-3 alkenyl, C2-3 alkynyl, C1-3 alkyloxy, C1-3 alkylcarbonyl, C3-6cycloalkyl, C3-6cycloalkyloxy, C3-6heterocycloalkyl, C3-6heterocycloalkyloxy, wherein each cycloalkyl is optionally substituted by one or more substituents selected from fluoro, cyano, unsubstituted or fluorinated Ci-2alkoxy, and unsubstituted or fluorinated Ci-2alkoxycarbonyl, and wherein each alkyl, alkoxy, alkenyl or alkynyl in R10 may be optionally further substituted with one or more substituents selected from cyclopropyl, halogen, cyano, hydroxy, C1-3 alkoxy, halo(Ci-3)alkoxy, unsubstituted or fluorinated C1-3 alkylcarbonyl, and unsubstituted or fluorinated C1-3 alkoxycarbonyl or R10 forms a ring system together with R9, as described herein,R11 is selected from hydrogen, fluoro, chloro, bromo, C1-3 alkyl, fluoro(Ci-3)alkyl, C1-3 alkyloxy, fluoro(Ci-3)alkoxy and cyano,R12, if present, is selected from hydrogen, fluoro, chloro, bromo, methyl, fluoromethyl, methoxy and fluoromethoxy,wherein at least one of R8, R10 and R11 is different from hydrogen,and pharmaceutically acceptable salts, solvates, isotopes and co-crystals thereof.3) A compound according to anyone of claim 1 to 2, whereinX1 is N or C(R7),X2 is NH, S or O,X3 is N or C(R12),R2 and R4 are both hydrogen,R5 is selected from hydrogen, fluoro, chloro and bromo,R6 is selected from halogen, cyano, azido, amino, nitro, methyl, ethyl, propyl, isopropyl, trifluoromethyl, ethenyl, ethynyl, propargyl, methylsulfinyl, methylsulfonyl, cyclopropyl, cyclopropyloxy, cyclopropylmethyl, methoxy, ethoxy, propoxy, methoxyethoxy, ethoxymethoxy, cyclopropylmethoxy, oxetanyl, oxetanylmethoxy, tetrahydrofuranyl, tetrahydrofuranylmethoxy, phenyl, benzyloxy, phenyloxy, benzylsulfinyl, thienyl, pyridyl, oxazole, thiazole, and isoxazole, wherein each phenyl, thienyl, pyridyl, oxazol, thiazole and isoxazol can be optionally substituted one or more times with a substitution selected from halogen, methoxy, and methyl, and wherein each alkyl, alkenyl, alkynyl, and alkoxy group can be substituted one or more times with fluoro, methoxy, fluoromethoxy, and hydroxy,or R6 forms together with R7 and the carbon atoms to which R6 and R7 are attached, a ring selected from phenyl, pyridyl, cyclohexyl, and cyclopentyl, each of which can beunsubstituted or further substituted with one or more residues selected from halogen, hydroxy, unsubstituted or fluorinated methyl, and unsubstituted or fluorinated methoxy,R7 is selected from hydrogen, halogen, cyano, methylsulfinyl, methylsulfonyl, methoxy, fluoromethoxy, fluoroethoxy, methyl, fluoromethyl, and fluoroethyl, or R7 forms a ring together with R6 as described herein,R8 is selected from hydrogen, halogen, methoxy, fluoromethoxy, cyano, methyl, and fluoromethyl, or R8 forms a ring system together with R10, as described herein,R9 is selected from hydrogen, fluoro and chloro,or R9 forms together with R8 or R10 and the ring to which they are attached a bicyclic ring system selected from 2,1 ,3-benzothiadiazole, 2,1 ,3-benzoxadiazole, 2-oxo-2,3-dihydro- 1 ,3-benzoxazole and 1 ,3-benzodioxole, which is optionally substituted with two fluoros, or R9 forms together with R10 and the ring to which they are attached a bicyclic ring system selected from 3-oxo-2,3-dihydro-1 H-isoindol, 2,3-dihydro-1-benzothiophene, which is substituted with one or two oxo, and optionally methylated 3-oxo-1 ,3-dihydro-2- benzofuran,R10 is selected from hydrogen, halogen, methyl, ethyl, n-propyl, isopropyl, ethenyl, n- propenyl, isopropenyl, ethynyl, propargyl, fluoro(Ci-3)alkyl, methoxy, ethoxy, propoxy, fluoro(Ci-3)alkoxy, Ci-3alkoxy(Ci-3)alkyl, Ci-3alkoxy(Ci-3)alkoxy, Ci-3alkoxy(C2-3)alkenyl, Ci-3alkoxy(C2-3)alkynyl, Ci-3alkoxycarbonyl(Ci-3)alkyl, Ci-3alkylcarbonyl(Ci-3)alkyl, C1-3 alkylcarbonyl(Ci-3)alkyloxy, cyano, acetyl, azido, nitro, pentafluorosulfanyl, cyclopropyl, cyclopropyloxy, cyclopropylmethoxy, and (Ci-3)alkoxycarbonyl, wherein each alkyl, alkenyl, alkynyl and alkoxy group in R10 can be unsubstituted or substituted with one or more residues selected from fluoro, cyano and / or hydroxy, and wherein the cyclopropyl is optionally substituted with one or more residues selected from cyano, optionally fluorinated C1-2 alkoxy and optionally fluorinated Ci-2alkoxycarbonyl, or R10 forms a ring system together with R9, as described herein,R11 is selected from hydrogen, fluoro, chloro, bromo, cyano, methyl, fluoromethyl, methoxy and fluoromethoxy,R12, if present, is selected from hydrogen, fluoro, chloro and bromo,wherein at least two of R8, R10 and R11 are different from hydrogen,and pharmaceutically acceptable salts, solvates, isotopes and co-crystals thereof.4) A compound according to any one of claims 1 or 2, whereinX1 is N or C(R7),X2 is NH,X3 is N or CR12,R2, R4, R5 and R9 are all hydrogen,R6 is selected from halogen, cyano, Ci-3alkoxy, Ci-3alkyl, C3-6cycloalkyl, C3-6cycloalkyloxy, C3-6heterocycloalkyl, and C3-6heterocycloalkyloxy, each of which can be optionally substituted with a residue selected from fluoro and unsubstituted or fluorinated Ci-3alkoxy,R7 is selected from hydrogen, halogen, cyano, Ci-3alkoxy, Ci-3alkyl, C3-6cycloalkyl, C3- 6cycloalkyloxy, C3-6heterocycloalkyl, and C3-6heterocycloalkyloxy, each of which can be optionally substituted with a residue selected from fluoro and unsubstituted or fluorinated Ci-3alkoxy,R8 is selected from fluoro, methoxy and fluoromethoxy,R10 is selected from halogen, Ci-4alkoxy,C2-3alkenyl C2-3alkynyl, C3-6cycloalkyl preferably C3-4cycloalkyl, C3-6cycloalkyloxy, C3-6heterocycloalkyl, and C3- 6heterocycloalkyloxy, each of which can be optionally substituted with a residue selected from fluoro, cyano and unsubstituted or fluorinated Ci-3alkoxy,R1 1 is selected from hydrogen, fluoro, methoxy and fluoromethoxy,and R12, if present, is selected from hydrogen, fluoro, fluoromethyl, methoxy and fluoromethoxy,and pharmaceutically acceptable salts, solvates, isotopes and co-crystals thereof.5) A compound according to any one of the preceding claims, wherein X3 is N, thus having the structure of Formula VI:wherein X1 , X2, R2, R4, R5, R6, R8, R9, R10 and R1 1 have the meaning as described in any one of the previous claims.6) A compound of Formula VI according to claim 5, wherein X1 is C-R7 or NX2 is NH, S or O, provided that if X1 is N, then X2 is NHR2 is hydrogen,R4 is hydrogen or fluoro,R5 is selected from hydrogen, halogen, cyano, unsubstituted or fluorinated C1-3 alkyl, unsubstituted or fluorinated C1-3 alkoxy, unsubstituted or fluorinated C1-3 alkylcarbonyl, unsubstituted or fluorinated C1-3 alkylsulfinyl, and unsubstituted or fluorinated C1-3 alkylsulfonyl,or R5 forms a ring together with R6 as described herein,R6 is selected from halogen, cyano, azido, nitro, amino, Ci-3alkyl, C2-3alkenyl, C2-3alkynyl, Ci-3alkoxy, C3-6 cycloalkyl, C3-6 heterocycloalkyl, phenyl, Cs-6heteroaryl, C3-6 cycloalkyloxy, C3-6 heterocycloalkyloxy, phenyloxy, C5-6heteroaryloxy, Ci-3alkylsulfinyl, phenylsulfinyl, Ci- 3alkylsulfonyl, phenylsulfonyl, benzylsulfonyl, C1-3 alkylcarbonyl, C1-3 alkoxycarbonyl, C1-3 alkylaminocarbonyl, di(Ci-3)alkylaminocarbonyl, C3-6cycloalkyl(Ci-2)alkyl,heterocycloalkyl(Ci-2)alkyl, phenyl(Ci-2)alkyl, C5-6 heteroaryl(C1-2)alkyl, C3-6 cycloalkyl(Ci- 3)alkoxy, C3-6 heterocycloalkyl(Ci-2)alkyloxy, phenyl(Ci-2)alkoxy C5-6heteroaryl(Ci-2)alkoxy, phenyl(Ci-2)alkylsulfinyl, phenyl(Ci-2)alkylsulfonyland wherein each group in R6 can be unsubstituted or substituted with one or more groups selected from fluoro, chloro, bromo, fluorinated or unsubstituted Ci-3alkyl, fluorinated or unsubstituted Ci-3alkyloxy, hydroxy, and cyano,or (i) R6 forms together with R7 and the carbon atoms to which R6 and R7 are attached, an unsubstituted or substituted phenyl, an unsubstituted or substituted pyridyl, an unsubstituted or substituted cyclopentyl or an unsubstituted or substituted cyclohexyl, wherein each substitution, if present, is selected from hydroxy, halogen, methyl or methoxy, wherein each methyl or methoxy can be unsubstituted or substituted with one or more substituents selected from halogen and methoxy,or(ii) R6 forms together with R5 and the carbon atoms to which R6 and R5 are attached, a 1 ,3-dioxolane which may be unsubstituted or substituted with one or two substituents selected from fluorine and methyl,R7, if present, is selected from hydrogen, halogen, cyano, Ci-3alkyl, Ci-3alkoxy, C2- 3alkynyl, C2-3alkenyl, Ci-3alkylcarbonyl, Ci-3alkoxycarbonyl, Ci-3alkylsulfinyl, Ci- 3alkylsulfonyl, Ci-3alkylthio, C3-6cycloalkyl, C3-6 cycloalkyloxy, C3-6heterocycloalkyl, C3- 6heterocycloalkyloxy, phenyl, phenoxy, phenylsulfonyl, phenylsulfinyl, Cs-eheteroaryl, C5-6heteroaryloxy, C5-6heteroaryl(Ci-2)alkyl, and C5-6heteroaryl(Ci-2)alkoxy, C3-6cycloalkyl(Ci- 2)alkyl, C3-6 cycloalkyl(Ci-3)alkoxy, C3-6 heterocycloalkyloxy, C3-6 heterocycloalkyl(Ci- 2)alkyl, heterocycloalkyl(Ci-2)alkyloxy, phenyl(Ci-2)alkyl, phenyl(Ci-2)alkoxy,and wherein each group in R7 can be unsubstituted or substituted with one or more groups selected from fluoro, chloro, bromo, fluorinated or unsubstituted Ci-3alkyl, fluorinated or unsubstituted Ci-3alkyloxy, hydroxy, and cyano, or R7 forms a ring together with R6 as described herein,R8 is selected from hydrogen, optionally halogenated C1-3 alkyl, optionally halogenated Ci- 3 alkyloxy, cyano and halogen,R9 is selected from hydrogen, halogen, C1-3 alkyl, fluoro(Ci-3)alkyl, C1-3 alkoxy and fluoro(Ci-3)alkoxy,R10 is selected from halogen, Ci-3alkyl, Ci-3alkoxy, C2-3alkenyl, C2-3alkynyl, cyano, Ci- 3alkylcarbonyl, Ci-3alkoxycarbonyl, C1-3 alkylsulfinyl, Ci-3 alkylsulfonyl, C1-3 alkylthio, C3- 6cycloalkyl, C3-6cycloalkyloxy C3-6heterocycloalkyl, C3-6heterocycloalkyloxy, azido, pentafluorosulfanyl, nitro, Ci-3alkylaminocarbonyl, and di(Ci-3)alkylaminocarbonyl, wherein each alkyl, alkenyl, alkynyl or alkoxy in R10 can be unsubstituted or substituted with oneor more substituents selected from halogen, unsubstituted or halogenated Ci-3alkoxy, unsubstituted or halogenated Ci-3alkylthio, unsubstituted or halogenated C1-3alkylcarbonyl, unsubstituted or halogenated Ci-3 alkyloxycarbonyl, unsubstituted or halogenated Ci-3 alkylaminocarbonyl, unsubstituted or halogenated di(Ci- 3)alkylaminocarbonyl, hydroxy, cyano, C3-6cycloalkyl, C3-6heterocycloalkyl, phenyl, and C5- 6heteroaryl, wherein any cycloalkyl, heterocycloalkyl, phenyl and heteroaryl may be unsubstituted or substituted with one or more residues selected from halogen, hydroxy, hydroxymethyl, cyano, nitro, unsubstituted or halogenated Ci-3alkyl, unsubstituted or halogenated Ci-3alkoxy, unsubstituted or halogenated Ci-3alkylcarbonyl and unsubstituted or halogenated Ci-3alkoxycarbonyl,R1 1 is selected hydrogen, halogen, cyano, unsubstituted or fluorinated C1-3 alkyl, and unsubstituted or fluorinated Ci-3alkyloxy,and pharmaceutically acceptable salts, solvates, isotopes and co-crystals thereof.7) A compound of formula VI, according to any one of the preceding claims, wherein X1 is C-R7 or N,X2 is NH,R2 and R4 are both hydrogen,R5 is selected from hydrogen, fluoro, chloro and bromo,R6 is selected from fluoro, chloro, bromo, cyano, azido, nitro, Ci-3alkyl, Ci-3alkyloxy, cyclopropyl, cyclopropyloxy, cyclopropyloxy, oxetanyl, tetrahydrofuranyl, methylsulfonyl, methylsulfinyl, thienyl, pyridyl, and benzyloxy, wherein each alkyl or alkoxy group in R6 can be unsubstituted or substituted with one or more groups selected from fluoro, chloro, bromo, unsubstituted or fluorinated Ci-2alkyloxy and cyclopropyl and wherein each cyclopropyl, thienyl, pyridyl and phenyl group in R6 can be substituted with one or more groups selected from halogen, methoxy, fluoromethoxy, methyl, fluoromethyl and cyano, or R6 forms together with R7 and the carbon atoms to which R6 and R7 are attached, an unsubstituted or substituted phenyl, an unsubstituted or substituted pyridyl, anunsubstituted or substituted cyclopentyl or an unsubstituted or substituted cyclohexyl, wherein each substitution in R7, if present, is selected from hydroxy, halogen, methyl or methoxy, wherein each methyl or methoxy can be unsubstituted or fluorinated,R7, if present, is selected from hydrogen, halogen, cyano, Ci-3alkyl, Ci-3alkoxy, methylsulfinyl and methylsulfonyl, wherein alkyl or alkoxy group in R7 can beunsubstituted or substituted with one or more groups selected from fluoro, chloro, cyano, and unsubstituted or fluorinated Ci-2alkyloxy, or R7 forms a ring together with R6 as described herein,R8 is selected from fluoro, chloro, unsubstituted or fluorinated methyl, and unsubstituted or fluorinated methoxy,R9 is selected from hydrogen, fluoro, methyl, fluoromethyl, methoxy, and fluoromethoxy,R10 is selected from halogen, Ci-3alkyl, Ci-3alkyloxy, C2-3alkenyl, C2-3alkynyl, C1-3 alkylcarbonyl, C3-4cycloalkyl, C3-4cycloalkyloxy, C3-4heterocycloalkyl, C3- 4heterocycloalkyloxy and cyano wherein each alkyl, alkenyl, alkynyl or alkoxy can be unsubstituted or substituted with one or more substituents selected from fluoro, chloro, bromo, fluorinated or unsubstituted Ci-3alkyloxy, fluorinated or unsubstituted Ci- 3alkylcarbonyl, Ci-3alkoxycarbonyl, C3-5cycloalkyl, C3-5cycloalkyloxy, Cs-sheterocycloalkyl, C3-5heterocycloalkyloxy, hydroxy and cyano, wherein any C3-scycloalkyl and hetero(C3- 5)cycloalkyl may be unsubstituted or substituted with one or more residues selected from halogen, hydroxy, hydroxymethyl, cyano, fluorinated or unsubstituted methyl, fluorinated or unsubstituted methoxy and fluorinated or unsubstituted Ci-3alkyloxy(Ci-3)alkyloxy,R11 is selected from hydrogen, fluoro, chloro, bromo, unsubstituted or fluorinated C1-3 alkyl, and unsubstituted or fluorinated C1-3 alkyloxy,and pharmaceutically acceptable salts, solvates, isotopes and co-crystals thereof.8) A compound according to anyone of the preceding claims and having one of the following formula Via, Vlb, Vic or Vld:whereinR2 and R4 are both hydrogen,R5 is selected from hydrogen, fluoro, chloro and bromo,R6 is selected from fluoro, chloro, bromo, azido, cyano, benzyloxy, methylsulfonyl, methylsulfinyl, Ci-3alkyl, Ci-3alkyloxy, cyclopropyl, cyclopropyloxy and cyclopropylmethoxy, wherein each alkyl, alkoxy and cyclopropyl group in R6 can be unsubstituted or substituted with one or more groups selected from fluoro, chloro, bromo and unsubstituted or fluorinated Ci-2alkyloxy,wherein in the compounds of formula Via, VIb or Vic, R6 may also form together with R7 and the carbon atoms to which R6 and R7 are attached, an unsubstituted or substituted phenyl, an unsubstituted or substituted pyridyl, an unsubstituted or substituted cyclopentyl or an unsubstituted or substituted cyclohexyl, wherein each substitution in R7, if present, is selected from hydroxy, halogen, cyano, methyl or methoxy, wherein each methyl or methoxy can be unsubstituted or fluorinated and / or hydroxylated,R7, if present, is selected from hydrogen, halogen, cyano, Ci-3alkyl, Ci-3alkyloxy, C3-6 cycloalkyl, C3-6 cycloalkyloxy, methylsulfinyl and methylsulfonyl, wherein alkyl, alkoxy or cycloalkyl group in R7 can be unsubstituted or substituted with one or more groups selected from fluoro, chloro, cyano and unsubstituted or fluorinated Ci-2alkyloxy, or R7 forms a ring together with R6 as described herein,R8 is selected from hydrogen, fluoro, chloro, unsubstituted or fluorinated methoxy and unsubstituted or fluorinated methyl,R9 is selected from hydrogen, fluoro, methyl and methoxy, and is preferably hydrogen,R10 is selected from hydrogen, halogen, cyano, Ci-3alkyl, C2-3alkenyl, C2-3alkynyl, Ci- 3alkyloxy, C3-4cycloalkyl, C3-4cycloalkyloxy, C3-4heterocycloalkyl, and C3-4heterocycloalkyloxy, wherein each alkyl, alkenyl, alkynyl and alkyloxy group in R10 can be unsubstituted or substituted with one or more groups selected from fluoro, chloro, bromo, fluorinated or unsubstituted Ci-3alkyloxy, fluorinated or unsubstituted Ci-3alkylcarbonyl, fluorinated or unsubstituted Ci-3alkoxycarbonyl, Cs^cycloalkyl, C3-4cycloalkyloxy, Cs^heterocycloalkyl, Cs^heterocycloalkyloxy, hydroxy, and cyano, and wherein each cycloalkyi and heterocycloalkyi group in R10 can be substituted with a residue selected from fluoro, chloro, bromo, hydroxy, hydroxymethyl, fluorinated or unsubstituted Ci-3alkyl, fluorinated or unsubstituted Ci-3alkyloxy, fluorinated orunsubstituted Ci-2alkyloxyCi-2alkyloxy and fluorinated or unsubstituted Ci-3alkoxycarbonyl, R1 1 is selected from hydrogen, fluoro, chloro, bromo, unsubstituted or fluorinated methyl, and unsubstituted or fluorinated methoxy,and pharmaceutically acceptable salts, solvates, isotopes and co-crystals thereof.9) A compound according to one of the preceding claims and having one of Formula Via, Vlb, Vic and Vld, whereinR2, R4, R5 and R9 are all hydrogen,R6 is selected from halogen, cyano, Ci-3alkoxy, Ci-3alkyl, C3-6cycloalkyl preferably C3-4cycloalkyl, C3-6cycloalkyloxy preferably Cs^cycloalkyloxy, C3-6heterocycloalkyl preferably Cs^heterocycloalkyl, and C3-6heterocycloalkyloxy preferably Cs^heterocycloalkyloxy, each of which can be optionally substituted with a residue selected from fluoro andunsubstituted or fluorinated Ci-3alkoxy,R7 is selected from hydrogen, halogen, cyano, Ci-3alkoxy, Ci-3alkyl, C3-6cycloalkyl preferably Cs^cycloalkyl, C3-6cycloalkyloxy preferably C3-4cycloalkyloxy, C3- 6heterocycloalkyl preferably C3-4heterocycloalkyl, and C3-6heterocycloalkyloxy preferably Cs^heterocycloalkyloxy, each of which can be optionally substituted with a residue selected from fluoro and unsubstituted or fluorinated Ci-3alkoxy,R8 is selected from fluoro, methoxy and fluoromethoxy, preferably from fluoro and methoxy,R10 is selected from halogen, Ci-4alkoxy, Ci-4alkyl, C2-3alkenyl C2-3alkynyl, C3-6cycloalkyl preferably Cs^cycloalkyl, C3-6cycloalkyloxy preferably C3-4cycloalkyloxy, C3-6heterocycloalkyl preferably C3-4heterocycloalkyl, and C3-6heterocycloalkyloxy preferably Cs^heterocycloalkyloxy, each of which can be optionally substituted with a residue selected from fluoro, cyano and unsubstituted or fluorinated Ci-3alkoxy, andR11 is selected from hydrogen, fluoro, methoxy and fluoromethoxy, preferably from fluoro and methoxy.10) A compound according to any one of the preceding claims and having one of Formula Via, Vlb, Vic and Vld,whereinR2, R4 and R5 are all hydrogen,R6 is selected from fluoro, chloro, bromo, methylsulfinyl, methyl, fluoromethyl, methoxy and fluoromethoxy,R7 is selected from hydrogen, fluoro, chloro, bromo, unsubstituted or fluorinatedunsubstituted or fluorinated Ci-2alkoxy, methylsulfinyl, and methylsulfonyl,R8 is selected from hydrogen, fluoro, chloro, methoxy and fluoromethoxy,R9 is hydrogen, methoxy or fluoro, preferably hydrogen,R10 is selected from is selected from halogen, cyano, cyanomethyl, cyanoethyl, unsubstituted or fluorinated Ci-3alkyl, unsubstituted or fluorinated Ci-3alkoxy, unsubstituted or fluorinated Ci-2alkoxy(Ci-3)alkyl, unsubstituted or fluorinated Ci-2alkoxy(Ci-3)alkoxy, unsubstituted or fluorinated Ci-2alkoxy(C2-3)alkenyl, unsubstituted or fluorinated Ci- 2alkoxycarbonylcyclopropyl and unsubstituted or fluorinated Ci-3alkoxycyclopropyl,R11 is selected from hydrogen, fluoro, chloro, fluoromethyl, methoxy, and fluoromethoxy, wherein at least one of R8 and R10 is different from hydrogen,and pharmaceutically acceptable salts, solvates, isotopes and co-crystals thereof.11 ) A compound according to anyone of claim 1 to 4, having a structure according to one of Formulae II, II I, IV or V,rmulaFormula IIwherein R4, R5, R6, R7, if present, R8, R9, R10, R11 , R12 and X3 are as described as in any one of claims 1 to 4 herein and pharmaceutically acceptable salts, solvates, isotopes and co-crystals thereof.12) A compound according to claim 1 1 whereinX3 is N or C(R12),R4 is hydrogen or fluoro,R5 is selected from hydrogen, halogen, methyl, methoxy, and fluorinated C1-2 alkyl, or R5 forms a ring together with R6 as described herein,R6 is selected from hydrogen, halogen, cyano, azido, Ci-3alkyl, unsubstituted or substituted C2-3alkenyl, unsubstituted or substituted C2-3alkynyl, C1-3 alkylsulfinyl, Ci-3alkylsulfonyl, C3-6cycloalkyl, C3-6cycloalkyl(Ci-3)alkyl, C3-6 cycloalkyl(Ci-3)alkyloxy, C3-6 heterocycloalkyl, C3-6 cycloalkoxy, C3-6 heterocycloalkoxy, C3-6 heterocycloalkyl(Ci- 3)alkyloxy, Ci-3alkoxy, Ci-3alkoxy(Ci-3)alkoxy, Ci-3alkoxy(Ci-3)alkyl, C3-6 cycloalkyl(Ci- 3)alkoxy, phenyl, phenyl(Ci-3)alkyl, phenyl(Ci-3)alkoxy, phenyloxy, phenyl(Ci- 3)alkylsulfonyl, phenyl(Ci-3)alkylsulfinyl, thienyl, pyridyl, oxazole, thiazole, and isoxazole, and wherein group in R6 can be unsubstituted or each suitably substituted with a residue selected from fluoro, chloro, unsubstituted or fluorinated methyl, unsubstituted or fluorinated methoxy, hydroxy, and cyano,provided that in the compounds of Formula III, if R6 is hydrogen, then at least one of R5 and R7 is different from hydrogen,or(i) R6 forms together with R7 and the carbon atoms to which R6 and R7 are attached, an unsubstituted or substituted phenyl, an unsubstituted or substituted pyridyl, an unsubstituted or substituted cyclopentyl or an unsubstituted or substituted cyclohexyl,wherein each substitution, if present, is selected from halogen, hydroxy, methyl or methoxy, wherein each methyl or methoxy can be unsubstituted or substituted with one or more substituents selected from halogen, preferably fluoro, and methoxy,or(ii) R6 forms together with R5 and the carbon atoms to which R6 and R5 are attached, a 1 ,3-dioxolane which may be unsubstituted or substituted with one or two substituents selected from fluoro and methyl,R7 is selected hydrogen, halogen, cyano, C1-3 alkyl, Ci-3 alkoxy, fluoro(Ci-3)alkyl, fluoro(Ci- 3)alkoxy, unsubstituted or fluorinated methylsulfinyl, unsubstituted or fluorinated methylsulfonyl, substituted or unsubstituted C3-6 cycloalkyl, substituted or unsubstituted C3-6 heterocycoalkyl, substituted or unsubstituted C3-6 cycloalkyloxy, substituted or unsubstituted C3-6 heterocycoalkyloxy, substituted or unsubstituted C5-6 heteroaryl, substituted or unsubstituted C5-6 heteroaryloxy, and C5-6 heteroarylmethoxy, wherein the heteroaryl may be substituted with one or more substituents selected from halogen, unsubstituted or fluorinated methyl, unsubstituted or fluorinated methoxy, or R7 forms a ring together with R6 as described herein,R8 is selected from hydrogen, halogen, cyano, Ci-3 alkyloxy, fluoro(Ci-3)alkoxy, C1-3 alkyl, and fluoro(Ci-3)alkyl,R9 is selected from hydrogen, methoxy and fluoro,R10 is selected from hydrogen, halogen, Ci-3alkyl, halo(Ci-3)alkyl, C2-3 alkenyl, C2-3 alkynyl, Ci-3alkyloxy, halo(Ci-3)alkyloxy, cyano, cyanomethyl, cyanoethyl, cyanomethoxy, unsubstituted or fluorinated C1-3 alkylcarbonyl, unsubstituted or fluorinated C1-3alkoxycarbonyl, cyclopropyl, cyclopropyloxy, azido, pentafluorosulfanyl, and nitro, wherein any cyclopropyl residue is preferably substituted with a group selected from fluoro, cyano, Ci-3alkoxy and Ci-3alkoxycarbonyl, and wherein each alkyl, alkoxy, alkenyl or alkynyl in R10 can be optionally further substituted with one or more substituents selected from cyclopropyl, halogen, cyano, hydroxy, halo(Ci-3)alkoxy and C1-3 alkoxy,R1 1 is selected from hydrogen, fluoro, chloro, cyano, C1-3 alkyl, fluoro(Ci-3)alkyl, C1-3 alkyloxy and fluoro(Ci-3)alkoxy,R12, if present, is selected from hydrogen, halogen, Ci-3alkyloxy, fluoro(Ci-3)alkoxy, C1-3 alkyl, and fluoro(Ci-3)alkyl,and pharmaceutically acceptable salts, solvates, isotopes and co-crystals thereof.13) A compound according to claims 1 1-12 whereinR4 is hydrogen,R5 is selected from hydrogen, fluoro, chloro and bromo,R6 is selected from fluoro, chloro, bromo, cyano, methyl, ethyl, propyl, methylsulfonyl, methylsulfinyl, cyclopropyl, cyclopropyloxy, methoxy, ethoxy, benzyloxy, thienyl, fluoro(Ci- 3)alkoxy and fluoro(Ci-3 )alkyl,R7 is selected from hydrogen, methoxy, fluoro, chloro, bromo, cyano, methylsulfinyl, methylsulfonyl, Ci-3alkoxy, fluoro(Ci-3 )alkoxy, Ci-3alkyl and fluoro(Ci-3 )alkyl,or, in compounds of Formula II, R6 and R7, together with the ring-forming C atoms to which they are attached, form a ring selected from phenyl, cyclopentyl and pyridyl, each of which may be unsubstituted or substituted with one or more residues selected from fluoro, chloro, hydroxy, fluorinated or unsubstituted methoxy and fluorinated or unsubstituted methylX3 is -C(R12)- or N,R8 is hydrogen, fluoro, methoxy, or fluoromethoxy,R9 is hydrogen,R10 is selected from halogen, azido, nitro, cyano, Ci-3alkyl, C2-3alkenyl, C2-3alkynyl, C1-3 alkoxy, C3-5cycloalkyl, C3-5cycloalkyloxy and pentafluorosulfanyl, wherein each alkyl, alkenyl, alkynyl and alkoxy can be unsubstituted or substituted with one or more residues selected from halogen preferanly fluoro, cyano, cyclopropyl, Ci-3alkoxy, and fluoroCi-3alkoxy, and wherein any cycloalkyi moiety can be unsubstituted or substituted with one or more residues selected from fluoro, cyano, unsubstituted or fluorinated Ci-3alkoxy and unsubstituted or fluorinated Ci-3alkoxycarbonyl,R1 1 is selected from hydrogen, fluoro, chloro, cyano, methoxy, fluoromethoxy, fluoromethyl andR12, if present, is selected from hydrogen and fluoro,and pharmaceutically acceptable salts, solvates, isotopes and co-crystals thereof14) A compound according to anyone of claims 12 to 13,wherein R4, R5 are both hydrogen,R6 is selected from fluoro, chloro, bromo, methoxy, fluoromethoxy and fluoromethyl,R7 is selected from hydrogen, fluoro, chloro, bromo, methoxy, fluoromethyl,fluoromethoxy, fluoroethoxy, methylsulfinyl and methylsulfonyl,X3 is N or CR12,R8 is fluoro or methoxy,R9 is hydrogen,R10 is selected from fluoro, chloro, bromo, cyano, cyanomethyl, cyanoethyl,cyanomethoxy, unsubstituted or fluorinated C1-3 alkyl, unsubstituted or fluorinated C1-3 alkoxy, unsubstituted or fluorinated Ci-2alkoxy(Ci-3)alkyl, unsubstituted or fluorinated Ci- 2alkoxy(C2-3)alkenyl, unsubstituted or fluorinated Ci-2alkoxy(Ci-3)alkoxy,pentafluorosulfanyl and cycloalkyi, which is substituted with a substituent selected from Ci-2alkoxy, fluoro(Ci-2)alkoxy, Ci-2alkoxycarbonyl and fluoro(Ci-2)alkoxycarbonyl,R1 1 is selected from hydrogen, methoxy, fluoromethoxy, fluoromethyl, and fluoro,R12, if present, is hydrogen or fluoro,and pharmaceutically acceptable salts, solvates, isotopes and co-crystals thereof.15) A compound according to anyone of claims 1 to 3, having a structure of one the following Formulae lla - lie:whereinn is any number from 0 to 4,m is 0 or 1 ,p is any number from 0 to 3,any Y is a substitution independently selected from fluoro, chloro, cyano, hydroxy, methyl, fluoromethyl, methoxy and fluoromethoxy,R4, R5, X3, R8, R9, R10, R1 1 and R12 (if X3 is C-R12) are as described in the compounds of Formula I, and II herein,and pharmaceutically acceptable salts, solvates, isotopes and co-crystals thereof.16) A compound according to claim 15, whereinm is 0 or 1 ,n is 0, 1 or 2,p is 0, 1 or 2,any Y is selected from hydrogen, halogen, hydroxy, unsubstituted or fluorinated methyl and unsubstituted or fluorinated methoxy,R4 and R5 are both hydrogen,R8 is fluoro or methoxy,X3 is N or C(R12),R9 is hydrogen,R10 is selected from halogen, ethynyl, propynyl, cyano, cyanomethyl, cyanoethyl, cyanomethoxy, unsubstituted or fluorinated (Ci-3)alkyl, unsubstituted or fluorinated (C2- 3)alkenyl, unsubstituted or fluorinated (C2-3)alkynyl, unsubstituted or fluorinated C1-3 alkyloxy, unsubstituted or fluorinated methoxy(Ci-3)alkyl, unsubstituted or fluorinated methoxy(Ci-3)alkyloxy, unsubstituted or fluorinated methoxy(C2-3)alkenyl, unsubstituted or fluorinated methoxy(C2-3)alkynyl and pentafluorosulfanyl,R1 1 is selected from hydrogen, fluoro, and methoxy, andR12, if present, is hydrogen or fluoro,and pharmaceutically acceptable salts, solvates, isotopes and co-crystals thereof,wherein R4, R5, R6, R7, R8, R10, R1 1 and R12 are as described for Formulae I and II herein,wherein in the compounds(a) of Formula ll(d), Q1 is S or O,(b) of Formula ll(e), R13 and R14 are selected from the group of hydrogen, methyl and fluoro,(c) of Formula ll(f), Q2 is S or O, and(d) of Formula ll(g), R16 is hydrogen, fluoro, hydroxy, methyl, fluoromethyl, methoxy and fluoromethoxy,and pharmaceutically acceptable salts, solvates, isotopes and co-crystals thereof.18) A compound according to claim 18, wherein(a) in Formula ll(d), Q1 is S or O,(b) in Formula ll(e), R13 and R14 are both selected from hydrogen and fluoro,(c) in Formula ll(f), Q2 is S or O(d) in Formula ll(g), R16 is selected from hydrogen and methyl, andR4 is hydrogen,R5 is selected from hydrogen, fluoro, chloro and bromo,R6 is selected from fluoro, chloro, bromo, methyl, methoxy, methylsulfonyl, methylsulfinyl, fluoromethyl, fluoromethoxy, cyano, and benzyloxy,R7 is selected from hydrogen, fluoro, chloro, bromo, methoxy, cyano, methyl, and fluoromethyl,R8, if present, is selected from hydrogen and halogen,R10, if present, is selected from hydrogen, fluoro, chloro, bromo, fluoromethyl, fluoromethoxy and cyano,R1 1 is selected from hydrogen and fluoro,R12 is selected from hydrogen, halogen, methoxy and fluoromethyl,and pharmaceutically acceptable salts, solvates, isotopes and co-crystals thereof.A compound according to anyone of claims 1 to 3 and 1 1 , having a structure of one of the following Formulae lll(a) to lll(c)wherein R4, R5, R6, R8, R10, R1 1 and R12 are as otherwise described for Formulae I and III herein,wherein in a compound(a) of Formula lll(a), Q1 is S or O,(b) of Formula lll(b), R13 and R14 are selected from the group of hydrogen, methyl and fluoro, and(c) in Formula lll(c), Q2 is S or O, 20) A compound according to claim 19, whereinR4 and R5 are both hydrogen,R6 is selected from fluoro, chloro, bromo, trifluoromethyl, and phenyl,R8, if present, is hydrogen or fluoro,R10, if present, is selected from hydrogen and halogen,R1 1 is selected from hydrogen, halogen, trifluoromethyl and cyano,R12 is selected from hydrogen, halogen and trifluoromethyl,and pharmaceutically acceptable salts, solvates, isotopes and co-crystals thereof.21 ) A compound according to anyone of the preceding claims, wherein(c) at least one of R5, R6 and R7, if R7 is present, and(d) at least one of R8, R10 and R1 1is different from hydrogen. 22) A compound selected from6-chloro-N-(4-ethynylphenyl)-1 H-indole-3-sulfonamide6- chloro-N-(5-cyanopyridin-2-yl)-1 H-indole-3-sulfonamide7- chloro-N-(4-chloro-2,5-difluorophenyl)-6-(methylsulfinyl)-1 H-indole-3-sulfonamide 6-chloro-N-[3-fluoro-5-(methoxymethyl)pyridin-2-yl]-1 H-indole-3-sulfonamide 6-chloro-N-(5-iodo-3-methylpyridin-2-yl)-1 H-indole-3-sulfonamideN-(4-chloro-2-fluorophenyl)-6-(trifluoromethyl)-1 H-indole-3-sulfonamideN-(2,5-difluorophenyl)-6-methyl-1 H-indole-3-sulfonamideN-(4-chloro-2-fluorophenyl)-6-(tetrahydrofuran-3-yl)-1 H-pyrrolo[2,3-b]pyridine-3- sulfonamide6-chloro-N-(4-chloro-2,5-difluorophenyl)-7-(pyridin-3-yl)-1 H-indole-3-sulfonamide N-(2,2,6-trifluoro-1 ,3-benzodioxol-5-yl)-1 H-pyrrolo[3,2-h]quinoline-3-sulfonamide 6-cyano-N-(2,2,6-trifluoro-1 ,3-benzodioxol-5-yl)-1 H-indole-3-sulfonamide6-chloro-N-(7-cyano-2, 1 ,3-benzothiadiazol-4-yl)-1 H-indole-3-sulfonamideN-(2,1 ,3-benzothiadiazol-4-yl)-7-bromo-1 H-indole-3-sulfonamideN-(2,1 ,3-benzothiadiazol-4-yl)-6-methoxy-1 H-indole-3-sulfonamide6-chloro-N-[2,5-difluoro-4-(pyridin-2-ylmethoxy)phenyl]-1 H-indole-3-sulfonamide6-chloro-N-(3-fluoro-5-methylpyridin-2-yl)-1 H-pyrrolo[2,3-b]pyridine-3-sulfonamideN-(4-chloro-2-fluorophenyl)-6-(3-hydroxyprop-1 -en-2-yl)-1 H-pyrrolo[2,3-b]pyridine-3- sulfonamide6-chloro-N-(7-fluoro-2, 1 ,3-benzoxadiazol-4-yl)-1 H-indole-3-sulfonamideN-(2,5-difluorophenyl)-6-(methylsulfonyl)-1 H-indole-3-sulfonamideN-(4-cyano-2,5-difluorophenyl)-6-(2-methoxyethoxy)-1 H-indole-3-sulfonamide N-(4-chloro-2,5-difluorophenyl)-6,7,8,9-tetrahydro-1 H-benzo[g]indole-3-sulfonamide 6-chloro-N-{2-fluoro-4-[(1 E)-3-methoxyprop-1-en-1-yl]phenyl}-1 H-indole-3-sulfonamide N-(2,2-difluoro-1 ,3-benzodioxol-4-yl)-5-iodo-1 H-pyrrolo[2,3-b]pyridine-3-sulfonamide 6-chloro-N-(4,6-dichloropyridin-2-yl)-1 H-indole-3-sulfonamide6-chloro-N-(2,3-difluorophenyl)-1 H-indole-3-sulfonamideN-(2-fluoro-4-iodophenyl)-6-(trifluoromethyl)-1 H-indole-3-sulfonamideN-(1 ,3-benzodioxol-4-yl)-6-methyl-1 H-indole-3-sulfonamide6-chloro-N-(2-chlorophenyl)-1 H-indole-3-sulfonamide5- bromo-N-(4-cyanophenyl)-1 H-indole-3-sulfonamideN-(4-bromo-2,5-difluorophenyl)-6-chloro-1 H-indole-3-sulfonamide6- bromo-N-(4-cyano-2,5-difluorophenyl)-1 H-indole-3-sulfonamide6-chloro-N-[5-(cyanomethyl)-3-fluoro-6-methoxypyridin-2-yl]-1 H-indole-3-sulfonamide N-(4-chloro-2,5-difluorophenyl)-1 H-pyrrolo[3,2-h]quinoline-3-sulfonamideN-(4-bromo-2,5-difluorophenyl)-1 H-pyrrolo[3,2-h]quinoline-3-sulfonamide6-chloro-N-(4-chloro-2,5-difluorophenyl)-1 H-indole-3-sulfonamide6-chloro-N-[4-(difluoromethoxy)-2,5-difluorophenyl]-1 H-indole-3-sulfonamideN-[4-(cyanomethyl)-2,5-difluorophenyl]-1 H-pyrrolo[3,2-h]quinoline-3-sulfonamide 6-bromo-N-[3,6-difluoro-5-(3-methoxypropyl)pyridin-2-yl]-1 H-indole-3-sulfonamide N-(5-bromo-3,6-difluoropyridin-2-yl)-6-chloro-1 H-indole-3-sulfonamideN-(4-bromo-2,5-difluorophenyl)-6-chloro-1 H-pyrrolo[2,3-b]pyridine-3-sulfonamide 6-chloro-N-(5-chloro-3-fluoro-6-methoxypyridin-2-yl)-7-fluoro-1 H-indole-3-sulfonamide N-(4-cyano-2-fluorophenyl)-1 H-benzo[g]indole-3-sulfonamide6-chloro-N-[3,6-difluoro-5-(3-methoxypropyl)pyridin-2-yl]-1 H-indole-3-sulfonamide5-bromo-6-chloro-N-[5-(cyanomethyl)-3-fluoro-6-methoxypyridin-2-yl]-1 H-indole-3- sulfonamide6-chloro-N-(5-chloro-3,6-difluoropyridin-2-yl)-1 H-indole-3-sulfonamide 6-chloro-N-(4-chloro-2,5-difluorophenyl)-7-fluoro-1 H-indole-3-sulfonamideN-(4-cyano-2,5-difluorophenyl)-1 H-benzo[g]indole-3-sulfonamideN-(5-chloro-3-fluoro-6-methoxypyridin-2-yl)-1 H-benzo[g]indole-3-sulfonamide7-bromo-6-chloro-N-(5-chloro-3-fluoro-6-methoxypyridin-2-yl)-1 H-indole-3-sulfonamide 6-chloro-N-[4-(cyanomethoxy)-2,5-difluorophenyl]-1 H-indole-3-sulfonamideN-(5-chloro-3-fluoro-6-methoxypyridin-2-yl)-1 H-pyrrolo[3,2-h]quinoline-3-sulfonamide 6-chloro-N-(4-cyano-5-fluoro-2-methoxyphenyl)-1 H-indole-3-sulfonamide6-chloro-N-(5-chloro-3-fluoro-6-methoxypyridin-2-yl)-1 H-indole-3-sulfonamide6-chloro-N-(5-ethyl-3,6-difluoropyridin-2-yl)-1 H-indole-3-sulfonamide6-chloro-N-{5-[(E)-2-ethoxyethenyl]-3,6-difluoropyridin-2-yl}-1 H-indole-3-sulfonamide 6-chloro-N-(4-chloro-2,5-difluorophenyl)-7-methoxy-1 H-indole-3-sulfonamide6-chloro-N-(4-chloro-2-fluorophenyl)-1 H-indole-3-sulfonamideethyl 3-(6-{[(6-chloro-1 H-indol-3-yl)sulfonyl]amino}-2,5-difluoropyridin-3-yl)propanoate 6-chloro-N-[2,5-difluoro-4-(trifluoromethyl)phenyl]-1 H-indole-3-sulfonamide6-bromo-N-{3,6-difluoro-5-[(1 E)-3-methoxyprop-1 -en-1 -yl]pyridin-2-yl}-1 H-indole-3- sulfonamide6-chloro-N-[5-(cyanomethyl)-3-fluoro-6-methoxypyridin-2-yl]-1 -benzothiophene-3- sulfonamideN-(2,1 ,3-benzothiadiazol-4-yl)-6-bromo-1 H-indole-3-sulfonamide6-chloro-N-[4-(2,2-difluoroethoxy)-2,5-difluorophenyl]-1 H-indole-3-sulfonamide ethyl (2E)-3-(6-{[(6-chloro-1 H-indol-3-yl)sulfonyl]amino}-2,5-difluoropyridin-3-yl)prop-2- enoateN-(5-chloro-3-fluoropyridin-2-yl)-1 H-benzo[g]indole-3-sulfonamideN-(4-chloro-2,5-difluorophenyl)-8-(difluoromethyl)-1 H-pyrrolo[3,2-h]quinoline-3- sulfonamide6-chloro-N-(4-chloro-2,5-difluorophenyl)-1 H-pyrrolo[2,3-b]pyridine-3-sulfonamide 6-chloro-N-(5-chloro-3-fluoro-6-methoxypyridin-2-yl)-7-methoxy-1 H-indole-3-sulfonamide6-chloro-N-[5-(cyanomethyl)-3-fluoro-6-methoxypyridin-2-yl]-7-fluoro-1 H-indole-3- sulfonamide6-chloro-N-(2,5-difluoro-4-iodophenyl)-1 H-indole-3-sulfonamideN-(4-cyano-5-fluoro-2-methoxyphenyl)-1 H-benzo[g]indole-3-sulfonamideN-[4-(cyanomethoxy)-2,5-difluorophenyl]-1 H-pyrrolo[3,2-h]quinoline-3-sulfonamideN-(4-cyano-2,5-difluorophenyl)-6-(trifluoromethyl)-1 H-indole-3-sulfonamide6-chloro-N-(6-fluoro-2, 1 ,3-benzothiadiazol-5-yl)-1 H-indole-3-sulfonamide6-chloro-N-[4-(difluoromethoxy)-2,5-difluorophenyl]-1 H-pyrrolo[2,3-b]pyridine-3- sulfonamideN-(2,1 ,3-benzoselenadiazol-4-yl)-6-chloro-1 H-indole-3-sulfonamide6-chloro-N-[2,5-difluoro-4-(trifluoromethyl)phenyl]-1 H-pyrrolo[2,3-b]pyridine-3-sulfonami6-chloro-N-{3,6-difluoro-5-[(1 E)-3-methoxyprop-1 -en-1 -yl]pyridin-2-yl}-1 H-indole-3- sulfonamide6-chloro-N-(4-cyano-2-fluorophenyl)-1 H-indole-3-sulfonamide6-chloro-N-(2,5-difluoro-4-methylphenyl)-1 H-indole-3-sulfonamide6-chloro-N-[5-(2-ethoxyethyl)-3,6-difluoropyridin-2-yl]-1 H-indole-3-sulfonamide6-chloro-N-(5-chloro-3,6-difluoropyridin-2-yl)-7-methoxy-1 H-indole-3-sulfonamide N-(4-cyano-2-fluorophenyl)-6-(thiophen-2-yl)-1 H-indole-3-sulfonamide6-chloro-N-(4-ethynyl-2 -fluorophenyl )-1 H-indole-3-sulfonamide6-chloro-N-[3-fluoro-5-(trifluoromethyl)pyridin-2-yl]-1 H-indole-3-sulfonamide6- chloro-N-[2-fluoro-4-(trifluoromethyl)phenyl]-1 H-indole-3-sulfonamide7- bromo-6-chloro-N-(4-cyano-2-fluorophenyl)-1 H-indole-3-sulfonamide6-bromo-N-(4-cyano-2-fluorophenyl)-1 H-pyrrolo[2,3-b]pyridine-3-sulfonamide6-chloro-N-(4-cyano-2,5-difluorophenyl)-1 H-indole-3-sulfonamide6-bromo-N-(2-fluoro-4-iodophenyl)-1 H-pyrrolo[2,3-b]pyridine-3-sulfonamideN-(5-bromo-6-fluoro-3-methoxypyridin-2-yl)-6-chloro-1 H-indole-3-sulfonamide6-chloro-N-(2-fluoro-4-iodophenyl)-1 H-indole-3-sulfonamide6-chloro-N-[5-(cyanomethyl)-6-fluoro-3-methoxypyridin-2-yl]-1 H-indole-3-sulfonamide 6-bromo-7-chloro-N-(4-chloro-2,5-difluorophenyl)-1 H-indole-3-sulfonamide6-bromo-N-(6-fluoro-2, 1 ,3-benzothiadiazol-5-yl)-1 H-indole-3-sulfonamideN-(4-bromo-2,5-difluorophenyl)-6-methoxy-1 H-indole-3-sulfonamide6-bromo-N-(4-cyano-2 -fluorophenyl )-1 H-indole-3-sulfonamide6-chloro-N-(4-cyano-2-fluoro-5-methoxyphenyl)-1 H-indole-3-sulfonamideN-(5-chloro-3,6-difluoropyridin-2-yl)-1 H-benzo[g]indole-3-sulfonamide6-azido-N-[5-(cyanomethyl)-3-fluoro-6-methoxypyridin-2-yl]-1 H-indole-3-sulfonamide6-chloro-N-[3,6-difluoro-5-(2-fluoroethoxy)pyridin-2-yl]-1 H-indole-3-sulfonamide6-chloro-N-(6-fluoro-1-methyl-3-oxo-1 ,3-dihydro-2-benzofuran-5-yl)-1 H-indole-3- sulfonamideN-(4-chloro-2,5-difluorophenyl)-5H-[1 ,3]dioxolo[4,5-f]indole-7-sulfonamide6-bromo-N-(5-chloro-3-fluoropyridin-2-yl)-1 H-indole-3-sulfonamideN-[4-(cyanomethoxy)-2,5-difluorophenyl]-6-(difluoromethyl)-1 H-indole-3-sulfonam N-(2,1 ,3-benzothiadiazol-4-yl)-1 H-benzo[g]indole-3-sulfonamide6-bromo-N-(4-chloro-2-fluorophenyl)-1 H-pyrrolo[2,3-b]pyridine-3-sulfonamide6-chloro-N-(4-chloro-2,5-difluorophenyl)-7-(2,2-difluoroethoxy)-1 H-indole-3-sulfonamide 6-bromo-N-(4-cyanophenyl)-1 H-indole-3-sulfonamideN-(2,1 ,3-benzothiadiazol-5-yl)-6-bromo-1 H-indole-3-sulfonamideN-(4-cyano-2-fluorophenyl)-6-(propan-2-yl)-1 H-indole-3-sulfonamideN-(4-cyano-2-fluorophenyl)-6-(trifluoromethyl)-1 H-indole-3-sulfonamideN-(4-cyano-2,5-difluorophenyl)-6-methoxy-1 H-indole-3-sulfonamideN-(4-bromo-2,5-difluorophenyl)-6-methoxy-1 H-pyrrolo[2,3-b]pyridine-3-sulfonamide 6-chloro-N-(5-ethenyl-3,6-difluoropyridin-2-yl)-1 H-indole-3-sulfonamideN-(4-bromo-2,5-difluorophenyl)-6-(methylsulfinyl)-1 H-indole-3-sulfonamideN-(4-bromo-2,5-difluorophenyl)-6-chloro-1-benzofuran-3-sulfonamideN-[4-(difluoromethoxy)-2,5-difluorophenyl]-6-(methylsulfinyl)-1 H-indole-3-sulfonam 6-chloro-N-(2,4,5-trifluorophenyl)-1 H-indole-3-sulfonamideN-(4-chloro-2,5-difluorophenyl)-8-hydroxy-1 H-pyrrolo[3,2-h]quinoline-3-sulfonamide 6-chloro-N-(2,5-difluoro-4-methylphenyl)-1 H-pyrrolo[2,3-b]pyridine-3-sulfonamide6-chloro-N-(4-chloro-2,5-difluorophenyl)-7-cyano-1 H-indole-3-sulfonamide6-chloro-N-[5-(cyanomethyl)-3-methoxypyridin-2-yl]-1 H-indole-3-sulfonamideN-[4-(2-cyanoethyl)-2,5-difluorophenyl]-1 H-pyrrolo[3,2-h]quinoline-3-sulfonamide6-chloro-N-[4-(cyanomethyl)-2-fluorophenyl]-1 H-indole-3-sulfonamideN-(4-cyano-2-fluorophenyl)-1 ,6,7,8-tetrahydrocyclopenta[g]indole-3-sulfonamideN-(2,1 ,3-benzothiadiazol-4-yl)-1 H-pyrrolo[3,2-h]quinoline-3-sulfonamideN-(4-chloro-2,5-difluorophenyl)-6-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridine-3-sulfonamide N-(4-ethynyl-2-fluorophenyl)-1 H-pyrrolo[3,2-h]quinoline-3-sulfonamideN-(4-bromo-2-fluorophenyl)-6-chloro-1 H-indole-3-sulfonamide6-bromo-N-(5-chloro-3-fluoropyridin-2-yl)-7-methyl-1 H-indole-3-sulfonamide6-chloro-N-[4-chloro-5-(difluoromethoxy)-2-fluorophenyl]-1 H-indole-3-sulfonamide N-(2,1 ,3-benzoxadiazol-5-yl)-6-chloro-1 H-indole-3-sulfonamide5- bromo-6-chloro-N-(4-cyano-2-fluorophenyl)-1 H-indole-3-sulfonamide6- (benzyloxy)-N-(4-cyano-2,5-difluorophenyl)-1 H-indole-3-sulfonamideN-(6-fluoro-2, 1 ,3-benzothiadiazol-5-yl)-1 H-benzo[g]indole-3-sulfonamideN-(2,1 ,3-benzothiadiazol-4-yl)-6-chloro-1 H-indole-3-sulfonamide6-chloro-N-(3,6-difluoro-5-methylpyridin-2-yl)-1 H-indole-3-sulfonamide6-chloro-N-(4-cyanophenyl)-1 H-indole-3-sulfonamide6-chloro-N-(5-chloro-3-fluoropyridin-2-yl)-1 H-indole-3-sulfonamideN-(4-chloro-2,5-difluorophenyl)-6-methoxy-1 H-indole-3-sulfonamideN-(4-chloro-2,5-difluorophenyl)-6-(difluoromethyl)-1 H-pyrrolo[2,3-b]pyridine-3-sulfonamide6- chloro-N-(3-chloro-4-cyanophenyl)-1 H-indole-3-sulfonamide7- chloro-N-(5-chloro-3-fluoro-6-methoxypyridin-2-yl)-6-fluoro-1 H-indole-3-sulfonamide6-chloro-N-[2-fluoro-4-(pentafluoro-lambda~6~-sulfanyl)phenyl]-1 H-pyrrolo[2,3-b]pyridine- 3-sulfonamideN-(4-cyanophenyl)-1 H-benzo[g]indole-3-sulfonamideN-(4-chloro-2-fluorophenyl)-1 H-pyrrolo[3,2-h]quinoline-3-sulfonamide6-chloro-N-(5-chloro-3-fluoro-6-methoxypyridin-2-yl)-5J-difluoro-1 H-indole-3-sulfonamideN-[5-(cyanomethyl)-3-fluoro-6-methoxypyridin-2-yl]-6-nitro-1 H-indole-3-sulfonami 6-chloro-N-[2-fluoro-4-(trifluoromethyl)phenyl]-1 H-pyrrolo[2,3-b]pyridine-3-sulfonamide 6-chloro-N-[4-(cyanomethoxy)-2,5-difluorophenyl]-1-benzofuran-3-sulfonamideN-(4-chloro-2,5-difluorophenyl)-6-cyano-1 H-indole-3-sulfonamide6-chloro-N-(2,2-difluoro-1 ,3-benzodioxol-4-yl)-1 H-indole-3-sulfonamide6-chloro-N-(4-chloro-2,5-difluorophenyl)-7-(methylsulfinyl)-1 H-indole-3-sulfonamide 6-chloro-N-[3,6-difluoro-5-(propan-2-yl)pyridin-2-yl]-1 H-indole-3-sulfonamide6- chloro-N-(4-chloro-2,5-difluorophenyl)-1 -benzofuran-3-sulfonamide7- chloro-N-(4-chloro-2,5-difluorophenyl)-6-(methylsulfanyl)-1 H-indole-3-sulfonamide N-(2,1 ,3-benzothiadiazol-4-yl)-6-chloro-1 H-pyrrolo[2,3-b]pyridine-3-sulfonamide6-chloro-N-{5-[(difluoromethoxy)methyl]-3-fluoropyridin-2-yl}-1 H-indole-3-sulfonamide N-(1 ,3-benzodioxol-4-yl)-6-chloro-1 H-indole-3-sulfonamide6-(benzyloxy)-N-(4-cyano-2-fluorophenyl)-1 H-indole-3-sulfonamide6-chloro-N-(3,6-difluoro-5-methylpyridin-2-yl)-7-fluoro-1 H-indole-3-sulfonamideN-(4-cyanophenyl)-6-cyclopropyl-1 H-indole-3-sulfonamide6- chloro-N-(5-chloro-3-fluoro-6-methoxypyridin-2-yl)-5-fluoro-1 H-indole-3-sulfonamide7- chloro-N-(5-chloro-3-fluoro-6-methoxypyridin-2-yl)-6-methoxy-1 H-indole-3-sulfonamide6-chloro-N-(4-cyano-5-fluoro-2-methoxyphenyl)-1 H-pyrrolo[2,3-b]pyridine-3-sulfonamide6-chloro-N-(6-fluoro-3-oxo-1 ,3-dihydro-2-benzofuran-5-yl)-1 H-indole-3-sulfonamide ethyl 2-(6-{[(6-chloro-1 H-indol-3-yl)sulfonyl]amino}-2,5-difluoropyridin-3- yl)cyclopropanecarboxylateN-(2,1 ,3-benzoxadiazol-4-yl)-6-chloro-1 H-indole-3-sulfonamide6-chloro-N-(4-cyanophenyl)-1 H-pyrrolo[2,3-b]pyridine-3-sulfonamide6-chloro-N-(4-chloro-2-fluorophenyl)-1 H-pyrrolo[2,3-b]pyridine-3-sulfonamideN-(2,1 ,3-benzoxadiazol-4-yl)-1 H-pyrrolo[3,2-h]quinoline-3-sulfonamide6-chloro-N-(4-chloro-5-fluoro-2-methoxyphenyl)-1 H-indole-3-sulfonamide6-chloro-N-(4-chloro-2,5-difluorophenyl)-1 -benzothiophene-3-sulfonamide6-chloro-N-[4-(cyanomethoxy)-2,5-difluorophenyl]-1-benzothiophene-3-sulfonamideN-(2 ,3-benzothiadiazol-4-yl)-6-bromo-1 H-pyrrolo[2,3-b]pyridine-3-sulfonamide6-bromo-N-(4-cyanophenyl)-1 H-pyrrolo[2,3-b]pyridine-3-sulfonamide6-chloro-N-(4-cyano-2,6-difluorophenyl)-1 H-indole-3-sulfonamide6-chloro-N-(5-chloro-3-fluoro-6-methoxypyridin-2-yl)-1 H-pyrrolo[2,3-b]pyridine-3- sulfonamideN-(5-bromo-3-fluoropyridin-2-yl)-6-chloro-1 H-indole-3-sulfonamide6-chloro-N-(4-cyano-2-fluorophenyl)-5-fluoro-1 H-indole-3-sulfonamideN-(2,2-difluoro-1 ,3-benzodioxol-4-yl)-1 H-pyrrolo[3,2-h]quinoline-3-sulfonamideN-(5-chloro-3,6-difluoropyridin-2-yl)-1 H-pyrrolo[3,2-h]quinoline-3-sulfonamideN-(4-bromo-2-fluorophenyl)-6-methyl-1 H-indole-3-sulfonamide6-bromo-N-(4-chloro-2,5-difluorophenyl)-4-fluoro-1 H-indole-3-sulfonamideN-(2,1 ,3-benzothiadiazol-5-yl)-6-chloro-1 H-indole-3-sulfonamideN-(4-cyano-2-fluorophenyl)-6-methoxy-1 H-indole-3-sulfonamideN-(4-chloro-2,5-difluorophenyl)-6-methoxy-1 H-pyrrolo[2,3-b]pyridine-3-sulfonamide 6-cyano-N-[4-(difluoromethoxy)-2,5-difluorophenyl]-1 H-indole-3-sulfonamideN-(4-chloro-2,5-difluorophenyl)-6-(methylsulfinyl)-1 H-indole-3-sulfonamide6-chloro-N-(6-fluoro-2, 1 ,3-benzoxadiazol-5-yl)-1 H-indole-3-sulfonamide6-chloro-N-(3,5-difluoro-6-methoxypyridin-2-yl)-1 H-indole-3-sulfonamideN-(4-cyano-5-fluoro-2-methoxyphenyl)-6-methoxy-1 H-indole-3-sulfonamideN-[4-(difluoromethoxy)-2,5-difluorophenyl]-6-(difluoromethyl)-1 H-pyrrolo[2,3-b]pyridine-3- sulfonamideN-(4-cyano-2-fluorophenyl)-6-(thiophen-3-yl)-1 H-indole-3-sulfonamideN-(4-azido-2-fluorophenyl)-6-chloro-1 H-indole-3-sulfonamide6-chloro-N-[2-fluoro-4-(trifluoromethoxy)phenyl]-1 H-pyrrolo[2,3-b]pyridine-3-sulfonamide 6-chloro-N-(2-fluoro-4-iodophenyl)-1 H-pyrrolo[2,3-b]pyridine-3-sulfonamideN-(5-bromo-6-chloropyridin-2-yl)-6-chloro-1 H-indole-3-sulfonamideN-(5-bromo-3-methoxypyridin-2-yl)-6-chloro-1 H-indole-3-sulfonamide6-chloro-N-[3-methoxy-5-(trifluoromethyl)pyridin-2-yl]-1 H-indole-3-sulfonamide6-chloro-N-(2,5-difluorophenyl)-1 H-indole-3-sulfonamide6-chloro-N-(5-chloro-3-fluoro-6-methoxypyridin-2-yl)-1-benzothiophene-3-sulfonamide 6-chloro-N-(4-chloro-2,5-difluorophenyl)-7-(methylsulfonyl)-1 H-indole-3-sulfonamide 6-chloro-N-(4-chloro-2,5-difluorophenyl)-5-fluoro-1 H-indole-3-sulfonamideN-(2-fluoro-4-iodophenyl)-5H-[1 ,3]dioxolo[4,5-f]indole-7-sulfonamideN-[4-(cyanomethoxy)-2,5-difluorophenyl]-6-fluoro-1 H-indole-3-sulfonamideN-[2-fluoro-4-(trifluoromethyl)phenyl]-6-methoxy-1 H-indole-3-sulfonamide6-chloro-N-[2-fluoro-4-(pentafluoro-lambda~6~-sulfanyl)phenyl]-1 H-indole-3-sulfonamide 6-bromo-N-(2,4,5-trifluorophenyl)-1 H-pyrrolo[2,3-b]pyridine-3-sulfonamideN-(2-fluoro-4-iodophenyl)-6-(methylsulfonyl)-1 H-indole-3-sulfonamide6-chloro-N-(7-fluoro-2, 1 ,3-benzothiadiazol-4-yl)-1 H-indole-3-sulfonamide6-chloro-N-(3,6-difluoro-5-methylpyridin-2-yl)-7-(trifluoromethyl)-1 H-indole-3-sulfonamide 6-chloro-N-(3,5-difluoro-6-methoxypyridin-2-yl)-7-fluoro-1 H-indole-3-sulfonamide6-chloro-N-[2-fluoro-4-(trifluoromethoxy)phenyl]-1 H-indole-3-sulfonamide6-chloro-N-(5-chloro-3-fluoro-6-methoxypyridin-2-yl)-1-benzofuran-3-sulfonamide6-chloro-N-(5-chloro-3-fluoro-6-methylpyridin-2-yl)-1 H-indole-3-sulfonamideN-(5-chloro-3-fluoro-6-methoxypyridin-2-yl)-6,7,8,9-tetrahydro-1 H-benzo[g]indole-3- sulfonamide6-bromo-N-(4-ethynylphenyl)-1 H-pyrrolo[2,3-b]pyridine-3-sulfonamide6-chloro-N-(2,2,6-trifluoro-1 ,3-benzodioxol-5-yl)-1 H-indole-3-sulfonamide6-chloro-N-(4-chloro-2,5-difluorophenyl)-7-(3,5-dimethyl-1 ,2-oxazol-4-yl)-1 H-indole-3- sulfonamide6-chloro-N-[5-chloro-3-fluoro-6-(fluoromethyl)pyridin-2-yl]-1 H-indole-3-sulfonamide 6-chloro-N-(3-fluoro-5-methylpyridin-2-yl)-1 H-indole-3-sulfonamide6-chloro-N-(2,5-difluoro-4-methoxyphenyl)-1 H-indole-3-sulfonamideN-(4-chloro-2-fluorophenyl)-6-methyl-1 H-indole-3-sulfonamideN-(5-chloro-3,6-difluoropyridin-2-yl)-1 ,6,7,8-tetrahydrocyclopenta[g]indole-3-sulfonamide5- bromo-6-chloro-N-(4-chloro-2,5-difluorophenyl)-1 H-indole-3-sulfonamide6- chloro-N-(5-chloro-3,6-difluoropyridin-2-yl)-7-(3,5-dimethyl-1 ,2-oxazol-4-yl)-1 H-indole-3- sulfonamide6-bromo-N-(2-chloro-3-fluorophenyl)-1 H-pyrrolo[2,3-b]pyridine-3-sulfonamide6-chloro-N-(5-chloro-3,6-difluoropyridin-2-yl)-1 H-pyrrolo[2,3-b]pyridine-3-sulfonamide6-azido-N-(4-cyano-2-fluorophenyl)-1 H-indole-3-sulfonamide6-(methylsulfonyl)-N-(2,2,6-trifluoro-1 ,3-benzodioxol-5-yl)-1 H-indole-3-sulfonamide 6-chloro-N-[3,6-difluoro-5-(prop-1-en-2-yl)pyridin-2-yl]-1 H-indole-3-sulfonamideN-(5-chloro-3-fluoropyridin-2-yl)-1 H-pyrrolo[3,2-h]quinoline-3-sulfonamideN-(2,1 ,3-benzothiadiazol-4-yl)-6-fluoro-1 H-indole-3-sulfonamide6-chloro-N-(5-chloro-2-fluorophenyl)-1 H-indole-3-sulfonamideN-(4-chloro-5-fluoro-2-methoxyphenyl)-1 H-benzo[g]indole-3-sulfonamide6-chloro-7-(difluoromethoxy)-N-(3,5-difluoro-6-methoxypyridin-2-yl)-1 H-indole-3- sulfonamideN-(4-chloro-2-fluorophenyl)-6-(methylsulfonyl)-1 H-indole-3-sulfonamide6-bromo-N-(2,5-difluorophenyl)-1 H-pyrrolo[2,3-b]pyridine-3-sulfonamideN-(1 ,3-benzodioxol-4-yl)-6-bromo-1 H-pyrrolo[2,3-b]pyridine-3-sulfonamideN-(2,1 ,3-benzothiadiazol-4-yl)-6-(trifluoromethyl)-1 H-indole-3-sulfonamide6-chloro-N-(2-chloro-3,5-difluorophenyl)-1 H-indole-3-sulfonamide6-amino-N-[5-(cyanomethyl)-3-fluoro-6-methoxypyridin-2-yl]-1 H-indole-3-sulfonamide 6-amino-N-[5-(cyanomethyl)-3-fluoro-6-methoxypyridin-2-yl]-1 H-indole-3-sulfonamide 6-(benzylsulfinyl)-N-(4-chloro-2,5-difluorophenyl)-1 H-indole-3-sulfonamide6-chloro-N-(3,6-difluoropyridin-2-yl)-1 H-indole-3-sulfonamide6-chloro-N-(2-fluoro-4-methylphenyl)-1 H-indole-3-sulfonamideN-(4-bromo-2-fluorophenyl)-6-methoxy-1 H-indole-3-sulfonamideN-(4-cyano-2-fluorophenyl)-6-(2,2,2-trifluoroethoxy)-1 H-indole-3-sulfonamide N-(4-cyanophenyl)-6-(methylsulfonyl)-1 H-indole-3-sulfonamideN-(2,4,5-trifluorophenyl)-1 H-pyrrolo[3,2-h]quinoline-3-sulfonamide6-chloro-N-(5-iodopyridin-2-yl)-1 H-indole-3-sulfonamideN-(4-cyano-2-fluorophenyl)-6-(cyclopropylmethoxy)-1 H-indole-3-sulfonamide N-(4-ethynyl-2-fluorophenyl)-6-methoxy-1 H-pyrrolo[2,3-b]pyridine-3-sulfonamide6-fluoro-N-(2-fluoro-4-iodophenyl)-1 H-indole-3-sulfonamide6-chloro-N-(5-chloropyridin-2-yl)-1 H-indole-3-sulfonamide6-chloro-N-(4-cyano-2-fluorophenyl)-1 H-pyrrolo[2,3-b]pyridine-3-sulfonamide6-chloro-N-(4-cyano-2-methoxyphenyl)-1 H-indole-3-sulfonamide6-chloro-N-(3,5-difluoro-6-methoxypyridin-2-yl)-7-(trifluoromethyl)-1 H-indole-3- sulfonamideN-(4-cyano-2-fluorophenyl)-6-(pyridin-3-yl)-1 H-indole-3-sulfonamideN-(2,1 ,3-benzothiadiazol-4-yl)-5-iodo-1 H-pyrrolo[2,3-b]pyridine-3-sulfonamideN-(4-chloro-2,5-difluorophenyl)-6-(2,2,2-trifluoroethoxy)-1 H-indole-3-sulfonamide 6-chloro-N-(2-oxo-2,3-dihydro-1 ,3-benzoxazol-7-yl)-1 H-indole-3-sulfonamide6-chloro-N-(2,2,6-trifluoro-1 ,3-benzodioxol-5-yl)-1 H-pyrrolo[2,3-b]pyridine-3-sulfonamide N-(2,4,5-trifluorophenyl)-1 H-benzo[g]indole-3-sulfonamide6-chloro-N-(6-methoxy-2, 1 ,3-benzoxadiazol-5-yl)-1 H-indole-3-sulfonamideN-(2,1 ,3-benzothiadiazol-5-yl)-6-chloro-1 H-pyrrolo[2,3-b]pyridine-3-sulfonamide N-(4-ethynyl-2-fluorophenyl)-6-methoxy-1 H-indole-3-sulfonamide6-chloro-N-[3,6-difluoro-5-(2-methoxyethoxy)pyridin-2-yl]-1 H-indole-3-sulfonamide 6-chloro-N-[4-(cyclopropylmethoxy)-2,5-difluorophenyl]-1 H-indole-3-sulfonamide N-(4-acetyl-2-fluorophenyl)-6-chloro-1 H-indole-3-sulfonamide6-chloro-N-(4-cyano-3-methoxyphenyl)-1 H-indole-3-sulfonamide6-chloro-N-(3,5-difluoropyridin-2-yl)-1 H-indole-3-sulfonamide6-chloro-N-(6-cyano-2,2-difluoro-1 ,3-benzodioxol-4-yl)-1 H-indole-3-sulfonamide N-(4-chloro-2,5-difluorophenyl)-2-fluoro-6-methoxy-1 H-indole-3-sulfonamideN-(4-chloro-2,5-difluorophenyl)-2-fluoro-6-methoxy-1 H-indole-3-sulfonamide6-chloro-N-(2,2-difluoro-1 ,3-benzodioxol-4-yl)-1 H-pyrrolo[2,3-b]pyridine-3-sulfonamide N-(4-cyano-2-fluorophenyl)-6-phenyl-1 H-indole-3-sulfonamideN-(1 ,3-benzodioxol-4-yl)-6-chloro-1 H-pyrrolo[2,3-b]pyridine-3-sulfonamide6-chloro-N-(4-cyanophenyl)-1-benzothiophene-3-sulfonamide6-chloro-N-(4-nitrophenyl)-1 H-indole-3-sulfonamideN-(4-cyanophenyl)-6-(methylsulfinyl)-1 H-indole-3-sulfonamide6-(methylsulfonyl)-N-(2,4,5-trifluorophenyl)-1 H-indole-3-sulfonamideN-(4-cyanophenyl)-5-iodo-1 H-pyrrolo[2,3-b]pyridine-3-sulfonamide6-chloro-N-(2,4,5-trifluorophenyl)-1 H-pyrrolo[2,3-b]pyridine-3-sulfonamide6-chloro-N-(6-fluoro-3-oxo-1 ,3-dihydro-2-benzofuran-5-yl)-1 H-pyrrolo[2,3-b]pyridine-3- sulfonamide6-chloro-N-(5-fluoro-1 ,3-benzothiazol-6-yl)-1 H-indole-3-sulfonamide6-chloro-N-(7-fluoro-2, 1 ,3-benzothiadiazol-4-yl)-1 H-pyrrolo[2,3-b]pyridine-3-sulfonamideN-(4-chloro-2,5-difluorophenyl)-6-(thiophen-3-yl)-1 H-indole-3-sulfonamide6-chloro-N-(2,4-difluorophenyl)-1 H-indole-3-sulfonamide6-chloro-N-[3,6-difluoro-5-(3-hydroxypropyl)pyridin-2-yl]-1 H-indole-3-sulfonamide6-chloro-N-(2,5-difluorophenyl)-1 H-pyrrolo[2,3-b]pyridine-3-sulfonamideN-(4-chloro-2-fluorophenyl)-6-methoxy-1 H-indole-3-sulfonamide6-chloro-N-(5-fluoro-1 , 1-dioxido-2,3-dihydro-1-benzothiophen-6-yl)-1 H-indole-3- sulfonamideN-(2,2-difluoro-1 ,3-benzodioxol-4-yl)-6-(methylsulfonyl)-1 H-indole-3-sulfonamide 6-bromo-N-(2,4-difluorophenyl)-1 H-pyrrolo[2,3-b]pyridine-3-sulfonamide6-chloro-N-(3,5-dichloropyridin-2-yl)-1 H-indole-3-sulfonamide6-chloro-N-(6-fluoro-3-oxo-2,3-dihydro-1 H-isoindol-5-yl)-1 H-indole-3-sulfonamide N-(5-bromo-3-methoxypyridin-2-yl)-6-chloro-1 H-pyrrolo[2,3-b]pyridine-3-sulfonamide N-(4-chloro-2-fluorophenyl)-6-cyano-1 H-indole-3-sulfonamide6-chloro-N-(2,4,5-trifluorophenyl)-1 -benzofuran-3-sulfonamide6-chloro-N-(2,2-difluoro-1 ,3-benzodioxol-4-yl)-1 -benzofuran-3-sulfonamide6-chloro-N-(4-cyanophenyl)-1 -benzofuran-3-sulfonamide6-chloro-N-(3-oxo-1 ,3-dihydro-2-benzofuran-5-yl)-1 H-indole-3-sulfonamide6-chloro-N-(2-cyano-5-fluorophenyl)-1 H-indole-3-sulfonamide6-chloro-N-(5-chloro-4-methoxypyridin-2-yl)-1 H-indole-3-sulfonamide6-chloro-N-(3,5-dimethoxypyridin-2-yl)-1 H-indole-3-sulfonamide6-chloro-N-[5-(difluoromethoxy)-3,6-difluoropyridin-2-yl]-1 H-indole-3-sulfonamideN-(2,1 ,3-benzothiadiazol-5-yl)-6-(trifluoromethyl)-1 H-indole-3-sulfonamide6- bromo-N-[5-(cyanomethyl)-3-fluoro-6-methoxypyridin-2-yl]-1 H-indole-3-sulfonamide N-(4-cyano-2,5-difluorophenyl)-1 ,6,7,8-tetrahydrocyclopenta[g]indole-3-sulfonamide7- bromo-6-chloro-N-[5-(cyanomethyl)-3-fluoro-6-methoxypyridin-2-yl]-1 H-indole-3- sulfonamideN-(4-cyano-2,5-difluorophenyl)-6-fluoro-1 H-indole-3-sulfonamideN-(4-cyanophenyl)-6-(trifluoromethyl)-1 H-indole-3-sulfonamideN-(4-cyano-2,5-difluorophenyl)-6-methyl-1 H-indole-3-sulfonamide6-bromo-N-(2,2-difluoro-1 ,3-benzodioxol-4-yl)-1 H-pyrrolo[2,3-b]pyridine-3-sulfonamide N-(2,1 ,3-benzoselenadiazol-5-yl)-6-chloro-1 H-indole-3-sulfonamideN-(4-cyanophenyl)-6-methyl-1 H-indole-3-sulfonamide6- chloro-N-(6-fluoro-2, 1 ,3-benzothiadiazol-5-yl)-1 H-pyrrolo[2,3-b]pyridine-3-sulfonamide7- bromo-N-(4-cyano-2,5-difluorophenyl)-1 H-indole-3-sulfonamide6-chloro-N-(3,6-difluoro-5-methylpyridin-2-yl)-1 H-pyrrolo[2,3-b]pyridine-3-sulfonamide N-(2,5-difluoro-4-methylphenyl)-6-(methylsulfinyl)-1 H-indole-3-sulfonamide6-fluoro-N-(6-fluoro-2, 1 ,3-benzothiadiazol-5-yl)-1 H-indole-3-sulfonamide6-chloro-N-(4-cyano-2,5-difluorophenyl)-1 H-pyrrolo[2,3-b]pyridine-3-sulfonamide N-(4-chloro-2-fluorophenyl)-6-cyclopropyl-1 H-pyrrolo[2,3-b]pyridine-3-sulfonamide N-(2 ,3-benzothiadiazol-4-yl)-6-chloro-7-(trifluoromethyl)-1 H-indole-3-sulfonamide N-(2,1 ,3-benzothiadiazol-5-yl)-1 H-benzo[g]indole-3-sulfonamideN-(4-cyano-3-fluorophenyl)-1 ,6,7,8-tetrahydrocyclopenta[g]indole-3-sulfonamide 6-bromo-N-(4-cyanophenyl)-5-methyl-1 H-indole-3-sulfonamideN-(4-cyano-2 -fluorophenyl )-4,6-difluoro-1 H-indole-3-sulfonamideN-(4-cyano-2,5-difluorophenyl)-1 H-indole-3-sulfonamide6-chloro-N-(4-cyano-3-methylphenyl)-1 H-indole-3-sulfonamideN-(4-cyanophenyl)-6-fluoro-1 H-indole-3-sulfonamideN-(2,1 ,3-benzothiadiazol-5-yl)-6-fluoro-1 H-indole-3-sulfonamideN-(2,1 ,3-benzothiadiazol-5-yl)-1 ,6,7,8-tetrahydrocyclopenta[g]indole-3-sulfonamide6- chloro-N-[5-(cyanomethyl)-3-fluoro-6-methylpyridin-2-yl]-1 H-indole-3-sulfonamid7- chloro-N-(4-cyano-2,5-difluorophenyl)-1 H-indole-3-sulfonamide6-chloro-N-(4-chloro-2,5-difluorophenyl)-7-(pyridin-2-ylmethoxy)-1 H-indole-3-sulfonamide N-(4-chloro-2-fluorophenyl)-8-(difluoromethyl)-1 H-pyrrolo[3,2-h]quinoline-3-sulfonamide N-(4-cyanophenyl)-5H-[1 ,3]dioxolo[4,5-f]indole-7-sulfonamideN-(5-bromo-4-chloro-2-fluorophenyl)-6-chloro-1 H-indole-3-sulfonamide6-chloro-N-(4-chloro-2,5-difluorophenyl)-7-phenoxy-1 H-indole-3-sulfonamideN-(4-cyano-2-fluorophenyl)-6-phenoxy-1 H-indole-3-sulfonamide6-chloro-N-[4-(2,2-difluoroethoxy)-2-fluorophenyl]-1 H-indole-3-sulfonamideN-(4-chloro-2-fluorophenyl)-5H-[1 ,3]dioxolo[4,5-f]indole-7-sulfonamideN-(4-bromo-2-fluoro-5-methylphenyl)-6-chloro-1 H-indole-3-sulfonamideN-(4-chloro-2-fluorophenyl)-6-(oxetan-3-yl)-1 H-pyrrolo[2,3-b]pyridine-3-sulfonamide N-(4-cyano-2-fluorophenyl)-6-(3,5-dimethyl-1 ,2-oxazol-4-yl)-1 H-indole-3-sulfonamide N-(4-cyano-2-fluorophenyl)-6-(pyridin-4-yl)-1 H-indole-3-sulfonamideN-(7-bromo-2,2-difluoro-1 ,3-benzodioxol-4-yl)-6-chloro-1 H-indole-3-sulfonamideN-(2,5-difluorophenyl)-5-iodo-1 H-pyrrolo[2,3-b]pyridine-3-sulfonamide6-chloro-N-(2-chloro-3-fluorophenyl)-1 H-indole-3-sulfonamideN-(4-cyano-2,5-difluorophenyl)-4,6-difluoro-1 H-indole-3-sulfonamideN-(4-cyano-2-fluorophenyl)-1 H-indole-3-sulfonamideN-(5-chloro-3-fluoropyridin-2-yl)-6-methoxy-1 H-indole-3-sulfonamideN-(4-chloro-2-fluorophenyl)-8-hydroxy-1 H-pyrrolo[3,2-h]quinoline-3-sulfonamideN-(4-cyano-2-fluorophenyl)-6-(tetrahydrofuran-2-ylmethoxy)-1 H-indole-3-sulfonamide N-(2,2-difluoro-1 ,3-benzodioxol-5-yl)-6-(methylsulfonyl)-1 H-indole-3-sulfonamide 6-(5-chlorothiophen-2-yl)-N-(4-cyano-2 -fluorophenyl )-1 H-indole-3-sulfonamide6-chloro-N-(2,2,7-trifluoro-1 ,3-benzodioxol-4-yl)-1 H-indole-3-sulfonamide6-chloro-7-methoxy-N-(2,4,5-trifluorophenyl)-1 H-indole-3-sulfonamide6-chloro-N-(4-chloro-2-fluoro-5-methylphenyl)-1 H-indole-3-sulfonamideN-(4-chloro-2-fluorophenyl)-6-fluoro-1 H-indole-3-sulfonamideN-(4-ethynylphenyl)-6-(methylsulfonyl)-1 H-indole-3-sulfonamide23) A compound according to one of the preceding claims comprising at least one isotope selected from123l,125l,1311,11C,14C,13N,150,18F,76Br,124l,2H and3H in an amount suitable for PET and / or SPECT imaging.24) A compound according to anyone of the preceding claims, for use in therapy.25) A compound according to anyone of the preceding claims for use in the prevention or treatment of a disorder or syndrome selected from a myelination disorder and a disorder or syndrome associated with brain tissue damage.26) A compound according to claim 25, wherein the syndrome or disorder is selected from the group of multiple sclerosis (MS) including its various subforms, neuromyelitis optica (Devic's disease), chronic relapsing inflammatory optic neuritis, acute disseminated encephalomyelitis, acute haemorrhagic leucoencephalitis (AHL), periventricular leukomalacia, demyelination due to viral or bacterial infections, central pontine and extrapontine myelinolysis, demyelination due to traumatic brain tissue damage, demyelination in response to hypoxia, stroke or ischaemia or other cardiovascular diseases, demyelination due to exposure to carbon dioxide, cyanide, or other CNS toxins, Schilder disease, Balo concentric sclerosis, perinatal encephalopathy, neurodegenerative diseases including amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), multiple system atrophy, Parkinson's Disease, spinocerebellar ataxia (SCA) and Huntington'sDisease, psychiatric disorders such as schizophrenia and bipolar disorder and peripheral myelination diseases including leukodystrophies, peripheral neuropathies, Dejerine-Sottas syndrome or Charcot-Marie-Tooth disease27) A compound according to anyone of the preceding claims for use in the prevention and / or treatment of multiple sclerosis (MS).28) A method for the prevention, and / or treatment of a syndrome or disorder selected from a myelination disorder and a disorder or syndrome associated with a brain tissue damage, which comprises administering to a patient in need thereof a therapeutically effective amount of a compound according to any one of the preceding claims.29) A method according to claim 28, wherein the symptom or disorder is associated with a myelination disorder, selected from the group of multiple sclerosis (MS) including its various subforms, neuromyelitis optica (Devic's disease), chronic relapsing inflammatory optic neuritis, acute disseminated encephalomyelitis, acute haemorrhagicleucoencephalitis (AHL), periventricular leukomalacia, demyelination due to viral infections, central pontine and extrapontine myelinolysis, demyelination due to traumatic brain tissue damage, demyelination in response to hypoxia, stroke or ischaemia or othercardiovascular diseases, demyelination due to exposure to carbon dioxide, cyanide, or other CNS toxins, Schilder's disease, Balo concentric sclerosis, perinatal encephalopathy, neurodegenerative diseases including amyotrophic lateral sclerosis (ALS). Alzheimer's disease (AD), multiple system atrophy, Parkinson's Disease, spinocerebellar ataxia (SCA) and Huntington Disease, psychiatric disorders such as schizophrenia and bipolar disorder and peripheral myelination diseases including leukodystrophies, peripheral neuropathies, Dejerine-Sottas syndrome or Charcot-Marie-Tooth disease.30) A pharmaceutical composition comprising a compound according to anyone of the preceding claims, and a pharmaceutical acceptable carrier.